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“Feiten, waarnemingen en proefnemingen zijn als de bouwmaterialen voor een 
groot bouwwerk; maar als men ze bij elkaar zoekt, moet men voorkomen dat ze 
een ongeordende en hinderlijke puinhoop in de wetenschap worden. In plaats 
daarvan moet men ernaar streven ze in categorieën in te delen, zodat elk deel 
van het bouwwerk nog te onderscheiden is.” 
 
Antoine Laurent Lavoisier, 1777 
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Proteomics research focuses on the study of proteins, their functioning and 
interactions with other biomolecules in the context of complex biological samples. 
Rather than focusing on a single protein, proteomics research takes on large numbers of 
distinct proteins at the same time, in an ideal setting the whole pool of proteins (called 
the proteome) expressed at a given time by an organism or cell type.1,2 In the overall 
study of biological systems proteomics is situated between genomics (study of the 
genome) and metabolomics (study of metabolites produced in cellular processes). The 
ultimate goal in proteomics is the complete understanding of each single protein in all 
physiological processes, which is of great importance in understanding pathological 
states. Since it is extremely difficult to study all proteins and their properties at once, 
proteomic research is usually performed by taking on one specific subset of proteins 
from two or more different biological systems (e.g. healthy cells and infected cells) in a 
comparative study. Traditionally, this is done by separation of the protein subset of 
choice, for example by 1D/2D gel-electrophoresis and immunoprecipitation, followed by 
determination of its level of abundance. An attractive alternative strategy developed for 
proteomics research is activity-based protein profiling (ABPP).3,4 This strategy is based 
on the determination of an enzyme’s activity rather than its levels of expression, which 
is important since an enzyme’s abundance is not necessarily linked to its activity in 
biological processes. A reason for this is that a large number of enzymes is translated as 
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addition, the enzyme’s state can be switched between active and inactive by post-
translational modifications, such as phosphorylation, glycosylation, acetylation, 
ubiquitination and methylation. In the first part of this introduction the general idea of 
 deals with an interesting 
aspe
hes a covalent bond between the 
ABP and enzyme. Depending on the type of enzyme and reactive group this interaction 
can be either reversible or irreversible. The recognition element and the warhead are 
linked, most often via a spacer, to a reporter group or ‘tag’, which allows visualization 
and/or purification of the bound enzyme. The most commonly used tags are 
fluorophores, radioactive labels and biotin, of which the latter can be used for both 
visualization and purification purposes (Figure 1, top). 
 
ABPP will be outlined. The major part of the introduction
ct of this strategy in which a photophore is used to profile specific enzymes or 
enzyme families. The properties of the most commonly applied photophores and their 
use in chemical biology research are discussed. Finally, the aim and outline of this 
Thesis will be described at the end of the introduction. 
1.2 Activity- and affinity-based protein profiling 
Activity-based protein profiling makes use of relatively small organic molecules to 
label a specific enzyme (class) in their active state. These organic molecules are called 
‘activity-based probes’ (ABPs) and comprise three major elements. The recognition unit 
directs the ABP to the target enzyme and is designed to resemble structural and 
functional motives of the natural substrate of the target enzyme. It can often be 
designed such that a number of related enzymes within a family can bind. Closely 
attached to the recognition part is a reactive group (also termed ‘warhead’), which 











Figure 1. Schematic representation of an ABPP experiment. Both the 1-step (top) and the 2-step (bottom) 
labelling strategies are shown. 
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An ingenious extension to ABPP has been developed for those cases in which the 
reporter group hampers the interaction between ABP and enzyme or drastically lowers 
the ability to cross the cell’s membrane, which is especially of interest for labelling in 
living cells. In this approach (referred to as two-step labelling) the ABP’s tag is replaced 
by a ligation handle, which can be connected to the reporter group after the enzyme has 
been captured (Figure 1, bottom).5 A requirement for this ligation handle is that it is 
unreactive towards all functionalities present in a biological sample (bioorthogonal) and 
the most popular ligation handles are the azide and the (terminal) alkyne. The ligation 
reactions used (shown in Figure 2) are the Staudinger-Bertozzi ligation (I)6 and the 
Huisgen 2,3-dipolar cycloaddition or ‘click’ reaction, which can be divided into copper-
catalyzed (II)7,8 and strain-promoted (III).9,10 Recently Boons and co-workers developed a 
new reagent, which allows for a strain-promoted click reaction after irradiation with light 
and is therefore termed the ‘photoclick’ reaction (IV).11 In addition, the use of the Diels-
Alder reaction as alternative ligation reaction is subject to growing attention12 and of the 
different Diels-Alder type reactions, the inverse-electron-demand variation appears the 
most promising for in vivo labelling.13,14 
 
 
Figure 2. Ligation reactions used in 2-step ABPP using the azide functionality as ligation handle. I) Staudinger-
Bertozzi ligation; II) Cu(I) catalyzed click reaction; III) Copper-free click reaction; IV) Photoclick reaction. 
The ABPP strategy as shown in Figure 1 is especially well suited for those enzymes 
that contain a nucleophilic amino acid side chain residue in their active site (e.g. serine, 
cysteine, threonine), which is responsible for the enzyme’s catalytic activity. The ABP 
reactive group which binds the target enzyme is designed such that it reacts with this 
nucleophilic residue to form a covalent bond and is therefore named ‘electrophilic trap’. 
Examples of enzymes targeted with this strategy are cysteine proteases,15-18 serine 
hydrolases19-22 and proteasome subunits.23-25 A difficulty arises for enzymes that do not 
rely on a nucleophilic residue in their active site, which precludes the use of an 
electrophilic trap. Among these are the metalloproteases, histone deacetylases (both of 
which employ a water molecule for their catalytic activity) and kinases. A good 
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alternative for the use of an electrophilic trap is the so-called photoaffinity labelling 
(PAL), in which the probe used is commonly referred to as ‘affinity-based probe’ 
(AfBP).26 The basic principle is shown in Figure 3. In this approach the AfBP binds the 
target enzyme in a reversible manner, either via non-covalent interactions (electrostatic, 
hydrophobic) or via a reversible covalent bond. Although these interactions can be 
relati ly strong, they can not withstand harsh denaturing conditions often applied in 
biochemical protocols. An additional feature of the AfBP is the introduction of a 
photoreactive group (also termed photophore or photocrosslinker), which forms an 
irreversible covalent bond between probe and enzyme upon activation by light. In 
principle, photoaffinity labelling probes do not necessarily label active enzymes, 
however the probe can be designed as such that it has to enter the active site of an 
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Photocrosslinking
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not damage the 
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ns was first described in 1962, where 
o-workers reported on the use of a diazoacetyl group to inactivate 
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Figure 3. Basic principle of photoaffinity labelling (PAL) using an affinity-based probe (AfBP). 
1.3 Photoaffinity labelling 
  In order to use an AfBP for labelling of (active) enzymes in biological 
environments the photoreactive group must meet with certain criteria.27,28 First, the 
photophore has to be stabile towards the various conditions a biological sample may be 
exposed to, as well as the intrinsic reactivity of the sample content, and must only be 
activated upon irradiation with light of a specific wavelength, which may 
gical system (act > 300 nm). Second, the generated reactive species needs to have 
a shorter lifetime compared to the lifetime of the studied enzyme-substrate complex in 
order to limit non-specific labelling. It is important that the activated species reacts with 
any chemical entity in close proximity, regardless of its nature (including relatively 
unreactive C-H bonds), and forms a stabile covalent adduct. Finally, the photoreactive 
moiety must be relatively small, compared to the probe, so that it does not negatively 
influence the binding mode or activity of the AfBP towards the enzyme. 
The use of PAL in enzyme modificatio
Westheimer and c
otrypsin.29 Considerable research on the development of new PAL reagents has 
taken place ever since,27,28,30-36 but only a few number of photophores, which largely 
meet the above-mentioned requirements, are being used nowadays in AfBPs. These are 
aryl azides (first reported use in 1969)37, diazirines (1973)38 and benzophenones (1973).39 
The chemistry of these three photoreactive groups after photolysis as well as their use 
in recently reported AfBPs will be discussed. 
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1.3.1 Aryl azide 
Upon activation of an aryl azide (1, see Scheme 1) by irradiation with light of the 
appropriate wavelength, molecular nitrogen (N2) is expelled and a singlet nitrene (2) is 
formed initially. This high energetic, highly reactive species has a short lifetime (~10-4 s) 
and is quickly converted into other intermediates.35,40 Intersystem crossing (ISC) leads to 
a triplet nitrene (3), which is about 20 kcal/mole lower in energy.41 A major difference 
between the two nitrene states is their nature of reactivity. Singlet nitrenes behave like 
electrophiles and can readily undergo an insertion reaction with C-H bonds, whereas the 
triplet state can be seen as a diradical, which first abstracts a hydrogen radical from a 
nearby C-H followed by coupling to the formed carbon radical. Although they react via 
two different mechanisms the product is the same (4). Singlet nitrenes can also undergo 
rearrange into dehydroazepine (7). Both these species are long-lived electrophiles and 
can react with a nearby nucleophile, which results in compounds 6 and 8 respectively. 
Two observed side-reactions that are not to be ignored when the aryl azide is applied in 
PAL are aerobic oxidation of the triplet nitrene to the corresponding nitro species 1042 
and reduction of the initial aryl azide to the amine 11 by dithiols, such as DTT.43 
Scheme 1. Possible reaction mechanisms of the reactive intermediates formed after photolysis of aryl azides. 






















































Aryl azides can be easily prepared from 
1011
their corresponding amines in one or two 
steps. Three examples are given in Scheme 2A. The most common method is the 
diazotization of the amine with sodium nitrite under acidic conditions, followed by 
addition of sodium azide in an aqueous medium (route a).44 In 2003 the synthetic 
method was improved by application of triflyl azide (TfN3), which allowed a one-step 
conversion and higher yield (route b).45 Recently, the development of imidazole-1-
sulfonyl azide 15 was reported, which proved to be a more stabile reagent and allowed a 
conversion under mild conditions (route c).46  
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A major drawback of phenyl azides that their maximum absorption wavelength 
being below 300 nm, since electromagnetic irradiation at these wavelengths can 
substantially damage the biological system. Consequently, a large number of 
substituted aryl azides have been made and evaluated for their absorption properties. In 
general most substituents ortho to the azide are to be avoided, since they can lead to 
undesired cyclizations after photolysis.30 It has been found that introduction of electron 
withdrawing substituents (e.g. nitro, hydroxyl and acyl groups, for example see 
compound 1647 in Scheme 2B) has the dual effect of increasing the molar absorptivity 
and r
 The 
main advantage of aryl azides is their relatively small size and the possibility to 
ompounds, such as phenylalanine 1850 and 
adenosines 1951 and 20,52 without significant alteration of the original structure. 
Due to the many possible reaction pathways after irradiation (including capturing 
of the reactive intermediates by the solvent) cross-linking yields are often low (<30%). 
Arguably, the popularity of the aryl azide moiety in PAL studies is based on its relative 
ease of preparation and incorporation rather than on its photochemical properties. 
Scheme 2. Preparation and examples of aryl azides. 
ed-shifting the maximum absorption wavelength, both of which positively influence 
the photoactivatable properties.34,48 In addition, it has been found that (per)fluorinated 
aryl azides (such as 17)49 rearrange more slowly from the singlet nitrene species to the 
benzazirine and dehydroazepine, which leads to more efficient insertion reactions.35
incorporate them into natural biological c
 
(A) Three possible routes for the conversion of an aryl amine into its aryl azide: (a) via diazotization,44 (b) by 
the use of triflyl azide45 and (c) with imidazole-1-sulfonyl azide 15.46 (B) Some examples of substituted aryl 
azides. 
An extensive study towards matrix metalloproteinases (MMPs) with the use of an 
aryl azide modified AfBP was recently reported by Dive and co-workers.53 MMPs are 
metallo-proteases which reside in the extracellular matrix and are responsible for 
degradation of extracellular matrix material. Their mode of action depends on a Zn2+ ion 
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in the active site which coordinates the scissile bond carbonyl of the substrate and a 
water molecule. As a result, the carbonyl becomes more electrophilic and is 
subsequently hydrolysed. The fact that there is no formation of a covalent bond 
between enzyme and substrate during the proteolysis makes this class of enzymes an 
interesting target for photo-affinity labelling. The authors describe the use of radio-
labelled compound 21 (Scheme 3A), a potent, subnanomolar MMP inhibitor, to label 
and visualize purified human MMPs.53 The aryl azide photoreactive group is located at 
the P1’ pocket, which leads to a tight interaction with the enzyme’s cavity. A big 
difference in terms of labelling efficiency and sensitivity between several MMPs was 
found, with MMP-12 giving the best results. The estimated crosslinking yield was ~42% 
after two minutes of irradiation, based on silver staining and as little as 2.5 fmol MMP-
 
12 could be detected. In a second study the specifics of photocrosslinking were further 
ometry and site-directed 
mutagenesis.54 Interestingly, the -amine side chain substituent of Lys241 in MMP-12 
appeared to play a crucial role in the photocrosslinking. Two possible covalent 
constructs were proposed (Scheme 3B), but due to the fact that they have the same 
molecular weight it was impossible to distinguish between these using mass 
spectrometry. In theory, some other constructs are possible (see Scheme 1), however 
Scheme 3. Affinity-based probes targeting MMPs from studies by Dive et al. 

































































































(A) Photoreactive AfBP containing a tritium label. (B) Possible constructs formed between hMMP-12 and 21 
after photolysis proposed by Dive et al. (C) Structures of AfBPs with or without a photophore for pull-down of 
active MMPs. 
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they were not mentioned by the authors. The lysine at position 241 is not conserved 
throughout the MMP family and photocrosslinking of 21 to other MMPs was therefore 
further explored.55 MMP-3 (containing His in position 241) and MMP-9 (Arg in position 
241) 
-affinity MMP enrichment from a 
comp x proteome.56 For this, tumor extracts were spiked with hMMP-12 and hMMP-8, 
pounds 22 and 23 were applied followed by streptavidin-coated 
magn
could also be labelled, although with a lower overall efficiency. In addition, labelling 
performed at different pH values indicated that a more basic environment resulted in 
more efficient crosslinking. These results led to the conclusion that the nucleophilicity 
of the residue at position 241 plays a key role in the photoaffinity labelling. This 
conclusion was further substantiated by the finding that mutants of hMMP-12 (Ala241 
and Thr241) gave no labelling whatsoever. 
In addition to the attempts of unravelling the modification site, Dive and co-
workers also constructed two biotinylated AfBPs, 22 and 23 (Scheme 3C) and used 
these to study the difference in affinity- and photo
le
after which com
etic beads for MMP pull-down. Affinity-based labelling with 23 appeared superior 
to photo-affinity-based labelling with 22 in terms of quantity of captured MMPs, 
although it should be noted that the compounds are structurally different and 23 is a 
100 fold more potent MMP-8 and MMP-12 inhibitor. 
 
1.3.2 Diazirine 
One of the greatest advantages of the photolabile diazirine group over aryl azides 
is that all its members absorb most efficiently at a wavelength of 350-380 nm. This is 
well above the 300 nm limit (vide supra) and therefore no significant damage to the 
biological system will occur. The most important reactions that occur after photolysis of 
3-aryl-3H-diazirines are shown in Scheme 4. When a diazirine (such as 24 or 25) is 
irradiated molecular nitrogen is expelled and a singlet carbene is formed (26). 
Competitively, a substantial amount (>30%) of the diazirine is converted into 
diazoisomer 27. This diazo compound can be converted into the singlet carbene under 
the influence of light, however at the wavelengths normally used (360 nm) this process is 
relatively slow. For this reason the diazo species is relatively long-lived and thus has 
time to diffuse resulting in either aspecific labelling or hydrolysis. This problem was 
largely tackled when Brunner and co-workers reported the development of 3-aryl-3-
(trifluoromethyl)-3H-diazirine 25.57 The strong electron-withdrawing properties of the 
trifluoromethyl group stabilize the diazoisomer, which makes it almost completely 
resistant towards undesired ‘dark’ reactions. Singlet carbene 26 is a very short-lived 
species (t1/2 ~1 ns) and can be transformed into triplet carbene 34 via intersystem 
crossing (ISC). Singlet and triplet carbenes display a similar behaviour compared to their 
corresponding nitrenes. A singlet carbene can react as an electrophile, nucleophile or 
ambiphile, depending on the nature of its substituents, whereas triplet carbenes behave 
like diradicals. The formed singlet carbenes can give fast insertion reactions, in which 
they do not discriminate much between different reaction sites. Insertions into hydroxyl 
groups (giving 28) usually do give a higher yield compared to C-H insertions (29).58 
Insertion into a primary or secondary N-H bond (30) can lead to an undesired side 
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reaction. The formed construct easily expels HF, thereby giving enamine 31, which is in 
equilibrium with imine 32. In aqueous environments, such as a physiological sample, 
these species are subsequently hydrolysed into the corresponding ketone, with loss of 
the captured substrate as the result.58 The triplet carbene can react with C-H bonds 
analogues to triplet nitrenes. Initial hydrogen abstraction leads to radical intermediate 
35, which either reacts with the formed carbon radical to give a netto C-H insertion (29) 
or abstracts a second hydrogen from another C-H bond, resulting in a reduction (36). 
ized by 
molecular oxygen (a ‘notorious scavenger of triplet states’) to the corresponding ketone 
37.34 In general, unsubstituted 3-alkyl-3H-diazirines should be avoided since their 
corresponding carbenes are prone to hydride shift, which results in an olefin (see the 
insert in Scheme 4).30 
Scheme 4. Possible reactions of the intermediates formed after photolysis of 3-aryl-3H-diazirines. 
Another undesired side reaction occurs when the triplet carbene is oxid
 
 
Although the diazirine group itself is relatively small, aryl diazirines are quite bulky, 
but they can be incorporated into molecules with a structure similar to naturally 
occurring compounds. Furthermore, they are quite stabile towards a wide variety of 
conditions, including strongly acidic, strongly basic, oxidative and several reducing 
agents, which is a big advantage of diazirines compared to aryl azides. Drawbacks of 
diazirines are the formation of substantial amounts (>30%) of the diazo species after 
photolysis and the intrinsic efficient reactivity of the singlet carbene with O-H bonds, 
which often leads to scavenging of the reactive species by water. Also, the synthesis of 
diazirines is somewhat complicated compared to aryl azides. The synthetic scheme 
often applied for the preparation of 3-aryl-3-(trifluoromethyl)-3H-diazirine nowadays is 
shown in Scheme 5A.59 It starts by lithiation of an aryl bromide (38), which subsequently 
reacts with N-(trifluoroacetyl)piperidine 39 (easily prepared from trifluoroacetic 
anhydride and piperidine) under the formation of trifluoroacetophenone 40. Next, the 
ketone is converted into the corresponding oxime 41, after which the hydroxyl group is 
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conv
ic cell with genetically unmodified translational machinery 
and this methodology was applied in the identification of protein-protein interactions in 
as optimized by Muir and co-workers in 2007, 
who circumvented the enzymatic resolution step and incorporated the unnatural amino 
acid into a protein using solid phase peptide synthesis (SPPS) and expressed protein 
ligation (EPL) strategies.63 
Scheme 5. Preparation and examples of diazirines. 
erted into its tosylate (42). Reaction with liquid ammonia (usually under pressure) 
allows the instalment of the diaziridine group (43). Subsequent oxidation with iodine 
finally results in the diazirine (44). This five-step reaction sequence is especially well 
compatible with acid labile protective groups, which are often used to protect and/or 
install functionalities at the R position. 
Some interesting examples of diazirines used in biologically relevant studies are 
shown in Scheme 5B. Tritium functionalized adamantyl diazirine 45 was used for 
selective labelling of intrinsic membrane proteins in human erythrocytes. Despite the 
presence of -hydrogen atoms, the formed carbene is not prone to hydride shift (see 
Scheme 4) due to the constraints of this caged ring system. However, photolabelling of 
species is reported to be quite inefficient, probably due to its propensity to 
intramolecular C-H insertion reactions and reaction with water.30,34 Among the diazirine 
functionalized amino acids developed, modified L-phenylalanine (Phe(Tmd), 46) is the 
most popular one. Its first stereoselective preparation was reported by Nassal in 198460 
and it has been used extensively ever since.33,36 Recently, the synthesis of its D-
phenylalanine analogue was reported and this compound was used to probe the sweet 
taste receptor.61 In 2005 Thiele and co-workers reported the chemo-enzymatic synthesis 
of diazirinized leucine (47) and methionine (48), which were abbreviated as ‘photo-Leu’ 
and ‘photo-Met’. It was shown that these unnatural amino acids could be incorporated 
into proteins by a eukaryot
living cells.62 The synthesis of photo-Met w
 
(A) Synthetic scheme for preparation of 3-aryl-3-(trifluoromethyl)-3H-diazirines. (B) Some examples of diazirine 
functionalized compounds. 
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Some interesting examples of AfBPs containing the diazirine moiety, which were 
used to target active metalloenzymes, are shown in Figure 4. Yao and co-workers 
reported a library of hydroxamate oligopeptides 49, with varying types of amino acids at 
the P1 position.64 The hydroxamate moiety is a potent zinc binding group (ZBG). The 
oligopeptides were modified with an N-terminal aryl diazirine for covalent modification 
of the target enzyme and a fluorescent label (Cy3) for visualization. They were able to 
selectively label and visualize thermolysin (a Zn2+ dependent metalloprotease found in 
gram
llowed by UV irradiation, click 
reaction and Western blotting revealed labelling of the target enzyme, which could be 
competed away by L288. Interestingly, incubation with one-step probe 51a resulted in 
substantial non-selective labelling, which overwhelmed the MetAP1signal. Apparently, 
the two-step probe is much more selective in this case. 
 
-positive bacteria) spiked in a crude yeast extract after covalent modification by 
irradiation for twenty minutes. In addition, the library of compounds was incorporated in 
a large-scale profiling study, in which the ‘fingerprint’ labelling of twelve yeast 
metalloproteases towards probe library 49 was determined. 
In two other studies photoaffinity labelling of metalloenzymes was combined with 
two-step modification and visualization using the Cu(I) catalyzed click reaction. Qiu et 
al. reported the use of succinylhydroxamate oligopeptide 50 containing an azide 
functionality in labelling MMP-2 (a secreted Zn2+ dependent matrix metalloproteinase) 
both as a purified enzyme and in a mouse melanoma B16-F10 cell culture medium.65 
Visualization of the photocaptured construct was achieved by a click reaction to biotin-
propargylamide and subsequent streptavidin-HRP Western-blotting. The same group 
reported the development of one-step and two-step AfBPs 51a and 51b,66 the design 
of which was based on parent compound L288. The latter is a potent inhibitor (IC50 0.13 
M) of type I methionine aminopeptidase (MetAP1), a cobalt dependent metalloenzyme 
expressed by both prokaryotic and eukaryotic cells, and which removes N-terminal 
(initiator) methionine from polypeptides. The modifications made led to a slight 
decrease in inhibitory potency compared to L288. Incubation of overexpressed E. coli 
MetAP1 in E. coli cell lysate with compound 51b fo
 
Figure 4. Examples of AfBPs containing the diazirine moiety used to study active metalloenzymes. 
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1.3.3 Benzophenone 
A major advantage of benzophenones is that they can be excited at wavelengths 
of 350-360 nm, just like diazirines. The possible reaction pathways of benzophenones 
after photolysis are shown in Scheme 6. Absorption of a photon of the proper 
wavelength by a benzophenone (52) initially results in the formation of a triplet state 
benzhydril diradical (53). The formation of the triplet diradical is reversible and it can 
exist as long as 120 s before relaxing back to its ground state in the case that it is 
unable to find a reaction partner. The first reaction step of the formed reactive species 
is abstraction of a hydrogen and the reaction rate is therefore dependent on the nature 
of a nearby X-H bond.67 In general, the diradical is more reactive towards C-H bonds 
than O-H bonds. Especially those C-H bonds that form relatively stabile carbon radicals 
are prone to react and these include benzylic positions, amino acid -positions, 
hydrogen atoms adjacent to heteroatoms and tertiary carbon centres. Reactions with 
aromatic and vinylic C-H bonds have not been reported. All amino acids can react, 
although it has been shown that there is a preference for the -H in methionine when 
the benzophenone moiety is mobile enough to choose.68 Abstraction of a hydrogen 
from an amino acid -centre (54) by 53 results in the formation of a ketyl (55) and an 
alkyl radical (56), which recombine fast to form a benzhydrol (57). In the case of glycine, 
there is a possibility of elimination of water under the formation of olefin 58. A big 
advantage of the benzophenone group is that its photoactivated counterpart is more 
reactive towards C-H bonds compared to nitrenes and is less prone to intramolecular 
rearrangements than carbenes. Also, when the diradical inserts into water the 
corresponding hydrate (59) is formed. This species quickly dehydrates to form the 
ketone again, which can be recycled under irradiation to the diradical species. This 
 
ability of benzophenones to ‘search’ for a good reaction centre is a big advantage in 
 reactive species is not quenched in time 
there is a big chance of aspecific labelling, especially when a corresponding AfBP is not 
interacting with the target enzyme, but moves around freely in the medium. A possible
Scheme 6. Chemistry of benzophenones after photolysis. 
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AfBP instalment of a benzophenone and an alkyne moiety, which resulted in SAHA-
BPyne (63).70 They showed that the probe can be used for the covalent modification and 
enrichment of several class I and class II HDACs from complex proteomes in an activity-
dependent manner. In addition, they identified several HDAC associated proteins, 
 
reaction which can take place is the homodimerization of ketyl 55 to form 
benzopinacol 60, however due to the relatively big difference in reaction rates of 
hydrogen abstraction and recombination, normally only a very small amount of this is 
formed. 
In contrast to aryl azides and diazirines, the most commonly used benzophenone 
building blocks are commercially available. Benzophenone substituted amino acid 
analogues were also created, similar to what was previously discussed for aryl azides 
and diazirines. Not surprisingly, the most studied amino acid derivative is the one 
derived from phenylalanine, commonly abbreviated as L-Bpa (61 in Scheme 6).69 
Although the benzophenone group may seem like the ideal photocrosslinking reagent, it 
also suffers from some drawbacks. It is relatively bulky, which c
teraction between enzyme and substrate. Also, the resulting steric hindrance can 
give rise to a discrimination between reaction sites and, as a result of that, can lead to a 
non-specific labelling. Finally, irradiation for prolonged times (>30 minutes) is often 
needed in order to obtain a reasonable crosslinking efficiency.27 
In recent literature many examples of AfBPs containing benzophenones can be 
found. A first example concerns the study of histone deacetylases (HDACs). These 
enzymes catalyze the hydrolysis of acetylated lysine amine side chains in histones and 
are thus involved in the regulation of gene expression. There are approximately twenty 
human HDACs which are divided into three classes (I, II and III). Class I and II HDACs are 
zinc-dependent metallohydrolases that do not form a covalent bond with their 
substrates during their catalytic process, which is similar to MMPs. It has been found 
that hydroxamate 62 (SAHA, see Figure 5) is a potent reversible inhibitor of class I and II 


































































Figure 5. Examples of benzophenone modified two-step labelling probes to study HDACs. 
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possibly arising from the tight interaction with HDACs. Also, the probe was used to 
measure differences in HDAC content in human disease models. Later they reported the 
construction of a library of related probes and studied the differences in HDAC 
labelling.71 Their most interesting finding was that the labelling efficiency is not directly 
linked to a compound’s inhibitory potency. For example, compounds 64a, 64b and 65, 
containing Bpa (Figure 5), showed a higher potency (in terms of inhibition of HDAC 
activities) than 63, however the latter compound proved to be superior in HDAC 
labelling. A similar disparancy in inhibitory potential and photo-affinity labelling will be 
addressed in Chapter 4. A similar approach was reported by Xu et al. in 2009, in which 
potent HDAC class I (comprising HDACs 1, 2, 3 and 8) inhibitor 66 was modified with a 
benzophenone-spacer-alkyne moiety (67) to study its binding affinities in more detail.72 
Incub
MMP probe library was constructed, in which the Bpa moiety was incorporated at either 
the P3’ (70a,b) or P2’ (70c) position and the P1’ and P2’ substituents were varied (see 
Figure 6). The library compounds were applied as a ‘cocktail’ to proteomes and instead 
 
ation of FRDA lymphoblast derived nuclear extract with 67 followed by 
photoaffinity crosslinking and a click reaction with either rhodamine azide or biotin 
azide, identified HDAC-3 as the single target of this inhibitor. 
In addition to the aryl azide and diazirine groups, the benzophenone moiety was 
also incorporated in probes that target matrix metalloproteinases (see Figure 6). Potent, 
broad-spectrum succinyl-hydroxamate MMP inhibitor GM6001 (68) was converted into 
photoaffinity probe 69 by incorporation of Bpa (61) and a fluorophore, as reported by 
Cravatt and co-workers in 2004.73 It was shown that this probe can be used to 
covalently label (through photocrosslinking) and visualize several active MMPs in 
complex proteomes. In addition, the authors were able to identify a number of other 
metalloproteases targeted by GM6001, which do not belong to the MMP family. In order 
to address this metalloenzyme’s lack of selectivity towards a single inhibitor, this same 
































































70b R2 = Trp; R1 = Ala, Asp, Leu, s, Phe Lys, Phe  
70a R1 = Leu; R2 = Arg, Asp, Gly, Phe, Pro
Ser, Trp, Lys, Asn, Ala
Ly
R = Ala, Asp, Leu,70c
Figure 6. Examples of benzophenone modified probes to target matrix metalloproteinases. The amino acid 
three letter abbreviations in the R1 (70a,b) and R (70c) substituents refer to their corresponding side chains.  
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of identifying the affinity of each metalloprotease towards a single probe the labelling 
profiles towards the entire library were analyzed collectively. This method proved to be 
powerful in that more than twenty metalloproteases (MMPs and others) could be 
identified from a complex biological mixture. In a later study they showed the use of 
some of the library compounds and related photoaffinity probes as competitive AfBPs 
to s
the synthetically more challenging P1’ Bpa containing biotinylated analogue of 71 
(structure not shown).77 With this probe, they were able to label active -secretase in 
 
tudy the affinity of four MMP-13 inhibitors, for a large number of other 
metalloproteases.75 
A powerful application of the use of benzophenone containing AfBPs to locate the 
active site within a protease complex has been reported for -secretase.76 This multi-
subunit, integral membrane protein complex is responsible for the proteolysis of 
transmembrane proteins. Together with -secretase, it generates the amyloid -protein, 
which is known as the central pathogenic feature in Alzheimer’s disease. Although the 
nature of the -secretase catalytic activity was determined to be of aspartate protease 
type, the exact location of its active site within the complex was unknown. A potent 
inhibitor of -secretase activity is L-685,485 (71, Figure 7), containing a hydroxyethylene 
dipeptide-isostere. This compound mimics the transition state of the aspartate protease 
catalytic process and hence, forms a reversible, non-covalent adduct with the active 
enzyme (the binding of the inhibitor in the enzyme’s active site is shown in Figure 7). Li 
and co-workers reported the modification of the inhibitor’s P2 and P3’ substituents with 
a benzophenone moiety, which led to AfBPs 72a and 72b.76 The modifications did not 
result in a decrease in inhibitory potency towards -secretase activity inhibition 
compared to parent compound 71. The interaction of both probes with -secretase was 
studied by addition of the probes to HeLa cell membranes containing solubilised -
secretase and subsequent photocrosslinking. From the obtained results the authors 
were able to identify membrane-spanning protein presenilin 1 (PS1) as the -secretase 
active site bearing subunit. Four years later the same group reported the preparation of 
 
Figure 7. Examples of AfBPs modified with the benzophenone photophore that target -secretase. 
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living cells and their results demonstrated, for the first time, that active -secretase is 
presented on the cell surface. 
The use of click chemistry has been applied to the synthesis of benzophenone 
modified -secretase probes as well. The group of Yao reported the preparation of a 
compound library built up from Bpa containing alkyne 73 and azide 74 (Figure 7).78 The 
azide part contains a racemic hydroxyethylene moiety and variations were made in its 
aryl sulfonamide domain. The compound library was screened for its potency against -
secretase inhibition and the most potent compounds were used to label active PS1 in a 
cell lysate. In addition, Fuwa and co-workers reported a divergent synthesis of -
secretase AfBPs by means of click chemistry with alkyne 75 and azide 76.79 Variations 
were made in the aryl part of the alkyne (dibenzoazepine or benzodiazepine) and in the 
type of spacer between the benzophenone moiety and biotin in the azide. Photoaffinity 
labelling using these probes provided the authors with evidence that the molecular 
targets of this type of probes are the N-terminal fragment of PS1. 
Another class of enzymes that is especially well suited for PAL is the kinase family. 
These enzymes catalyze the ATP dependent phosphorylation of several substrates, but 
do not form a covalent linkage with either reaction partner and can therefore not be 
caught by means of a suicide trap. Some examples of photoreactive AfBPs targeting 
kinases are shown in Figure 8. In 2003 the group of Sewald reported the preparation of 
fluorescently tagged AfBP 78,80 which was obtained after modification of the potent 
kinase inhibitor H-9 (77), a isoquinolinesulfonamide containing, competitive inhibitor, 
targeting a broad range of kinases by occupying their ATP binding site. The probe 
proved to able of labelling several kinases in a concentration dependent manner and 
could be eliminated by preincubation of the kinase with competing ligands. 
Furthermore, the authors were able to label, although not very selective, creatine kinase 
added to a mixture of isolated thylakoid proteins. 
In 2006 Kawamura and co-workers reported a study towards the photoactivated 
labelling of kinases with compound 79, with Aa being glycine (Figure 8).81 In an initial 
screen towards six different kinases it was shown that this probe selectively labelled one 
 
 
Figure 8. Examples of benzophenone containing AfBPs for labelling of kinases. D-‘pip’ = (R)-piperidine-2-
carboxylic acid; GABA = -aminobutyric acid. 
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kinase, namely leukocyte-specific protein tyrosine kinase (Lck) and that labelling could 
be blocked by adenine. In addition, the probe selectively labelled Lck in an extract of 
Jurkat cells. With the aid of LC-MS/MS after tryptic digest, it was possible to identify the 
labelled fragment within the kinase. Photocrosslinking had taken place in the Ile379-Arg386 
tryptic fragment and, more precisely, to either Gly383 or Leu384. In a later study, the 
influence of target-binding affinity and conformational flexibility on the 
photocrosslinking efficiency was assessed.82 For this, a small library was prepared, in 
which the glycine moiety in 79 was replaced by other (non-proteinogenic) amino acids. 
Variations in length, flexibility and hydrogen bonding capability were made. The results 
corroborated the earlier mentioned finding (see the examples of HDAC inhibitors and 
Chapter 4) that the inhibitor potency does not necessarily correlate with the 
photocrosslinking efficiency. Interestingly, it was found that higher crosslinking yields 
were obtained for the more flexible compounds, while in other cases (for other enzymes) 
crosslinking efficiencies increased upon a more tightly bound probe (see for example 
Chapter 4), however this probably depends on the type of photocrosslinker used as well 
as the class of enzymes studied. 
 
1.3.4 Comparing photocrosslinkers 
As has been pointed out, different photophores can give rise to different labelling 
products. Therefore, the outcome of a photolabelling experiment substantially depends 
on the type of photocrosslinker applied. In order to select the ideal photophore for a 
specific experiment, one should carefully examine the different possibilities. 
Interestingly, there are only a few reports on the comparison of different photophores 
under otherwise identical conditions, especially where all three are taken into account 
or when they are applied in an AfBP. Some representative examples will be given here. 
Weber and Beck-Sickinger reported a study towards the photochemical behaviour 
of the different photophores.83 For this, the synthetic pentapeptide thymopentin, or TP5 
(Arg-Lys-Asp-Val-Thr) was modified with each of the photocrosslinkers (C-terminal Tyr 
was replaced by Phe(Tmd) and Bpa or 4-azidobenzoic acid was coupled to the N-
terminus), thereby obtaining three different photoreactive peptides. The conversion and 
product formation were followed by LC-MS analysis after photolysis in water, n-
propanol and a water/n-propanol mixture (1:1, v/v). It was found that both the diazirine 
and aryl azide were quickly converted into a reactive species, but only the diazirine gave 
a relatively pure product formation resulting from insertion into the solvent, 
predominantly in the O-H bond. The aryl azide also gave a clean O-H insertion reaction 
in water, however when n-propanol was present numerous unidentified products were 
formed, probably arising from intramolecular rearrangements and insertion reactions. 
The benzophenone containing peptide gave clean C-H insertions in the presence of n-
propanol, but the conversion yield was low after fifteen minutes of irradiation (68% and 
82% starting material left in water/n-propanol and n-propanol respectively). In pure 
water the conversion was much higher (94% after fifteen minutes), however due to the 
poor reactivity towards O-H bonds many unidentified products were generated. This led 
to the conclusion that the use of diazirines and aryl azides is preferred over 
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benzophenones, however the latter should be used in case the crosslinking site 
contains many water molecules. 
Another direct comparison between the photophores, however not in an activity-
based setting, was reported by Tate and co-workers.84 They synthesized dUTP analogues 
containing four different photoreactive moieties 80a-d (Figure 9A) and incorporated 
them enzymatically into DNA constructs. With these, the DNA photoaffinity labelling of 
yeast RNA polymerase III transcription complexes was studied. It was shown that 
photolabelling with the diazirine construct rendered many protein-DNA contacts, 
whereas labelling with the other three photoreactive moieties proved only marginal. 
In a recently reported study by Dalhoff and co-workers the aryl azide and diazirine 
photophores were directly compared in an activity-based labelling of methyltransferases 
(MTases).85 This class of enzymes catalyzes the transfer of the activated methyl group in 
S-adenosyl-L-methionine (SAM) to a nucleophilic position in various substrates (DNA, 
RNA, proteins) under the formation of S-adenosyl-L-homocysteine (SAH) as shown in 
the insert in Figure 9B. SAH itself is a general competitive product inhibitor of MTases 
and because of this it was transformed into four AfBPs by attachment of a spacer 
moiety containing biotin and either an aryl azide or aryl diazirine (81a,b, Figure 9B). 
Since the optimal modification site was unknown, the linker moiety was attached to 
either the N6 or C8 position, as indicated in 81. Initially, the compounds were used to 
label and capture (by means of streptavidin-coated magnetic beads) purified DNA 
adenine N6 MTase from Thermus aquatis (M.Taql). All four compounds could be used 
for M.Taql pull-down in a yield of 5-10%, however the capture efficiency of the diazirine-
based probes was slightly higher compared to the aryl azides, as determined from  the 
Western blots. Labelling proved to be activity-based since it could be competed with 
SAH and, in addition, was shown to be light dependent. With these results in hand, the 
authors also tested the N6-aryl azide-derived probe 81a for pull-down of three other 
NTases in there purified form and two other SAH binding proteins in E. coli lysate, which 
were identified by LC-MS/MS analysis. Unfortunately, the diazirine derived probes were 
not further examined, because the authors argued that ‘the small improvement in 
capture yield might not balance the much higher cost of preparation’. 
Up to here it seems that the diazirine-group is the most effective photocrosslinker. 
Interestingly, there are two reports showing that the potency of the applied 
photoreactive group largely depends on the system it is used in. In a study towards 
photoreactive metalloprotease probes by Yao et al.,64 as was outlined in paragraph 
1.3.2, an additional, benzophenone containing, probe was synthesized. In order to 
compare the diazirine and benzophenone moieties, the authors replaced the diazirine 
moiety in compound 82a (Figure 9C, this is the same compound as 49 with P1 = Leu 
(see Figure 4)) with the corresponding benzophenone counterpart (82b). This 
compound proved to label purified thermolysin as well, however no signs of labelling 
were observed when applying the compound to crude yeast extract, spiked with 
thermolysin. In this case the diazirine-based probe appeared superior compared to its 
benzophenone counterpart. In contrast, Fuwa and co-workers obtained the opposite 
results, although in a completely different system.79 In their study towards the 
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development of benzophenone derived photoreactive -secretase probes (see 
paragraph 1.3.3 and Figure 7), they also incorporated the diazirine photophore into their 
probes (83, Figure 9D). These diazirine containing analogues of the compounds 
resulting from a click reaction between 75 and 76 (Figure 7), proved to be completely 
ineffective in the labelling of -secretase active subunits, despite the fact that they 


























































N6 position: n = 2
C8 position: n = 1





























































Figure 9. Structures of compounds used to compare the photoaffinity labelling of different photoreactive 
groups. (A) Photoreactive dUTP analogues 80a-d reported by Tate et al.84 (B) Photoreactive SAH analogues 
81a,b reported by Dalhoff et al.85 The insert shows the transfer of the activated methyl group from SAM to 
nucleophilic positions (Nu) in various substrates by methyltransferases (MTase). A = adenosine. (C) 
Photoreactive metalloprotease probes 82a,b reported by Yao et al.64 (D) Diazirine containing analogue of 
clicked compound 75-76 for labelling of -secretase reported by Fuwa et al.79 
These results show clearly that there is no such thing as the ‘ideal photophore’ 
(yet). Due to the differences in reaction site preferences and the nature of the reactive 
intermediates of each individual moiety, the optimal photophore type needed differs 
from system to system. In most cases it can be worthwhile to spend some time on the 
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optimization of the used photophore in a certain AfBP, in order to obtain the best 
results (an issue that will also be addressed in Chapter 6). In addition, interesting 
information can be obtained when the results derived from different photophores are 
combined.34 
 
1.3.5 Identification of the photocrosslinked sites 
As outlined in paragraph 1.2, the tag incorporated in an ABP or AfBP is used for 
visualization, both in vivo and as read-out after SDS-PAGE, of the bound enzyme. In 
addition, a bifunctional tag, such as biotin, can be used as a pull-down handle for 
purification of the covalently modified complex. Subsequent (tryptic) digestion and LC-
MS/MS analysis allows the identification of the tryptic peptides and hence, the labelled 
enzyme(s). In the case a warhead containing ABP is used, the modified peptide 
fragments can in general be found easily in the LC-MS/MS analysis, since the chemistry 
of modification and hence, the nature of the final construct is known. In photoaffinity 
labelling, the identification of the photolabelled fragment is usually much more difficult. 
This is largely due to the fact that the site of modification is unknown (usually there are 
multiple modification sites) and the photocrosslinking reaction itself can lead to many 
possible products, because of the multiple reactive species involved. In some cases, the 
identification of the photolabelled site is possible (see for instance the labelling of 
hMMP-12 reported by Dive et al. (paragraph 1.3.1) or the labelling of Lck reported by 
Kawamura and colleagues (paragraph 1.3.3)), but this is generally difficult, because of 
complicated mixtures. A possible solution to this problem is the mixed isotope 
photoaffinity labelling strategy, which makes use of so-called ‘MS-friendly’ photoprobes, 
or target identification probes (TIPs).86 The general idea of this strategy is schematically 
shown in Figure 10. A proteome is treated with a 1:1 mixture of two structurally identical 
AfBPs, which only differ in their absolute mass by incorporation of stable isotopes (e.g. 
deuterium, 13C, 18O or 15N). Subsequent photocrosslinking, purification (using the tag) 
and tryptic digestion leads to a mixture of labelled and unlabelled tryptic peptides. It is 
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D7 = Isotope label
 
Figure 10. Mixed isotope photoaffinity labelling strategy for determination of the labelling site. After binding 
and photocrosslinking the target enzyme with a 1:1 mixture of the ‘light’ (D0) and ‘heavy’ (D7) isotopically 
labelled AfBPs, the construct is purified and tryptically digested. LC-MS/MS analysis of the peptide pool allows 
discrimation between the labelled and unlabelled peptides. The modified fragment can easily be retrieved and 
identified by searching for the isotope signature. 
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now possible to discriminate between these two types of peptides in a LC-MS/MS 
analysis because of the double peaks separated by the mass difference between the 
‘light’ and ‘heavy’ isotopically labelled species. Thus, the modified peptide(s) can be 
identified by searching for the unique isotopic pattern, or ‘isotope signature’.Although 
this concept is relatively new in the field of photoaffinity labelling, some examples have 
been recently reported. Lamos and colleagues reported the modification of cyclophilin 
A (CypA) binding immunosuppressive CsA with a benzophenone-D11 and a biotin moiety 
(compound 84, Figure 11).87 As a proof of principle, they used a 1:1 mixture of this TIP 
and its non-deuterated isoster for the selective photoaffinity labelling and pull-down of 
CypA among three other proteins. Subsequent tryptic digestion of the elutes and LC-
MS/MS analysis allowed for the identification of eleven CypA characteristic peptides, 
two of which were modified with the probe as evidenced from the double, 11 Da 
separated, peaks in the mass spectra. The large 11-Da mass difference allowed easy 
visual recognition of labelled peptides in the mass spectra, which makes this a powerful 
method in determination of the modification site after photoaffinity labelling, however 
application in more complex systems still remains to be done. 
  
 
Figure 11. Examples of ‘MS-friendly’ photoreactive compounds used in mixed photoaffinity labelling.  
A second, more extensive, study was recently reported by the group of Heck.88 
These authors describe the application of peptides containing stable isotopes and a 
photoreactive moiety in the localization of cGMP-dependent protein kinase (PKG) 
substrate binding sites. For this, they focussed on oligopeptide DT-2 (Figure 11), a 
potent and selective inhibitor of PKG, which is a construct of a PKG tight binding 
sequence (W45) and a membrane translocating sequence (DT-6). Both of these peptides 
were modified by incorporation of a benzophenone moiety (as Bpa) and an isotopically 
labelled amino acid Leu-13C6/
14N1 or Arg-
13C6/
15N4 (peptides 85-87, notice the difference 
of the Bpa position between the W45 derived peptides). LC-MS/MS analysis was 
performed on photocrosslinked complexes of PKG with each of the peptides. The power 
of the strategy was reflected in their results, which led to the identification of each 
peptide’s binding site. For example, the binding site of compound 87 was located in 
tryptic peptide Gln195-Arg203 and fragmentation of this sequence identified Met201 as the 
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single cross-linked amino acid. Interestingly, the binding site of the highly similar 
peptide 86 was located on a completely differently situated peptide in the PKG 
sequence, namely Phe359-Glu374. In this case the fragmentation did not result in the 
determination of the exact crosslinked amino acid, however it could be pinpointed to 
the residues Thr364-Glu374. With all the obtained results the authors were unfortunately 
unable to determine the exact binding site of DT-2, however they obtained the 
interesting results that both the DT-6 and W45 peptides are targeted to the same pocket 
in the PKG’s catalytic domain and that therefore DT-2 is preferentially bound to dimeric 
PKG. 
Altogether, the mixed isotope photoaffinity labelling strategy is still in 
development, but is believed to become a powerful tool in photoaffinity-based protein 
profiling strategies in the near future. With its aid the photocrosslinking site(s) of an 
AfBP can more easily be identified, which will lead to a better understanding of protein 
structure and function in general. 
1.4 Aim and outline of this Thesis 
The research described in this Thesis aims at the development of chemical biology 
research tools to study proteolytic activities, with the main focus on metalloproteases 
(MMPs and ADAMs) and proteasomes. The first part of Chapter 2 describes the 
synthesis of the enantiomerically pure N,O-diprotected succinyl hydroxamate building 
block 88 (Figure 12) and its use in the construction of peptide hydroxamate-based 
MMP/ADAM inhibitors in a highly efficient, linear SPPS protocol. In addition, 
photoreactive probe 89 was synthesized and used for covalent modification of ADAM-
10. The second part of this chapter deals with the preparation of a library containing 96 
enantiopure peptide hydroxamates with general structure 90 by SPPS using building 
block 88. This compound library was used to study the inhibitor preference of three 
metalloproteases (MMP-9, MMP-12 and ADAM-17) with respect to the substituents at 
the P2’ and P3’ positions (R2 and R1 respectively). 
 
 
Figure 12. Structure of building block 88, used for the construction of photoreactive metalloprotease probe 
89 and a library containing 96 inhibitors with general structure 90. 
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Although the covalent modification of ADAM-10 with compound 89 was shown to 
be possible, the efficiency proved rather modest. Therefore, the effect of moving the 
photophore to the more firmly binding P1’ pocket was studied and is outlined in 
Chapter 3. The synthesis of photoreactive building block 91 (Figure 13) and its 
application in the preparation of activity-based probes 92a-c is described. It is further 
demonstrated that 92a is indeed the more efficient MMP/ADAM AfBP, compared to 89, 




Figure 13. Structure of photoreactive building block 91, used for the synthesis of MMP/ADAM AfBPs 92a-c. 
The research described in Chapter 4 entails a study towards the effect of fluorine 
incorporation into proteasome inhibitors on their specificity towards the different 
proteasome subunits. It was found that fluorine incorporation led to a large decrease in 
potency towards the 1 and 2 subunits and, hence resulted in selectivity for 5. 
Tripeptide epoxyketone 93 (Figure 14) was identified as one of the most 5 selective 
inhibitors known to date. 
 
 
Figure 14. Structures of 5 selective (93) and 2 selective (94) proteasome inhibitors. 
The development of selective inhibitors for the proteasome’s trypsin-like sites (2) 
is discussed in Chapter 5. Selectivity for 2 was achieved by instalment of basic side 
chain residues in the P1 position of tripeptide vinylsulfones. Incorporation of a 4-
aminomethylene benzylamine substituent at this position resulted in compound 94 
(Figure 14), which showed high 2 selectivity both in cell extracts and in living cells. 
Chapter 6 describes the study towards the orientation of extended peptide 
vinylsulfones inside the proteasome’s catalytically active cavity. This study combined 
activity-based modification by means of a warhead with photocrosslinking. A panel of 
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bifunctional two-step probes, comprising of an extended peptide vinylsulfone equipped 
with an N-terminal photophore, was prepared. Of these probes, compound 95 (Figure 
15) was able to establish a crosslink between the active 5 subunit and a neighbouring 
6 subunit which could be identified by subsequent SDS-PAGE and LC-MS/MS analysis. 
 
 
 Figure 15. Structures of photoactivatable proteasome probe 95 and levulinoyl-based cleavable linker 
containing proteasome probe 96. 
The design and preparation of a novel levulinoyl ester-based cleavable linker is 
described in Chapter 7. The cleavable linker was incorporated into potent proteasome 
inhibitor epoxomicin and attachment of biotin resulted in ABP 96 (Figure 15). The 
optimal characteristics, in terms of stability and cleavability, of the cleavable linker were 
reflected by the use of 96 for pull-down of proteasome active subunits from a cell 
lysate. Subsequent treatment with hydrazine allowed a chemoselective release of 96-
derived bound proteins. 
Finally, the research described in this Thesis is summarised in Chapter 8, and 
some future prospects based the presented results are discussed. 
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Matrix metalloproteinases (MMPs) are involved in numerous biological processes 
such as cell migration, wound repair and tissue remodeling. MMPs exert their role by the 
processing of extracellular matrix proteins including gelatin, elastin, and collagen and 
the release of growth factors. ADAMs (a disintegrin and metalloproteinase) are 
metalloproteinases that contain a membrane-spanning and a disintegrin (integrin-
binding) domain. These membrane-bound enzymes are involved in membrane fusion, 
cytokine and growth factor shedding, cell migration, muscle development, fertilization, 
cellular differentiation, cell-cell interactions and cell-matrix interactions.1-3 The best 
known ADAM is ADAM-17, also known as TACE or tumor necrosis factor  (TNF) 
converting enzyme, which was discovered based on its sheddase activity with 
 Leeuwenburgh, P. P. Geurink, T. Klein, H. F. Kauffman, G. A. van der Marel, R. Bischoff, H. S. 
Overkleeft, Org. Lett. 2006, 8, 1705–1708. 
P. Geurink, T. Klein, M. Leeuwenburgh, G. van der Marel, H. Kauffman, R. Bischoff, H. Overkleeft, Org. 
Biomol. Chem. 2008, 6, 1244–1250.
brane-bound TNF.4,5 The expression of MMPs and ADAMs is regulated by 
transcription factors and activity is controlled by natural inhibitors, the tissue inhibitors 
of metalloproteinases (TIMPs). Disturbances in these regulatory mechanisms are 
believed to cause, or be involved in, a wide range of pathological states. These include 
cancer metastasis, rheumatoid arthritis and autoimmune diseases. Deregulation of 
ADAM expression or activity has also been linked to asthma, Alzheimer’s disease, 
bacterial lung infections and allergies of the airways.1,6-12  
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MMPs and ADAMs contain a Zn2+ ion in their active site, which forms a complex 
with the carbonyl group of the scissile amide bond. This complexation enhances the 
reactivity of the carbonyl towards nucleophilic attack of the water molecule, that is 
present in the active site and also coordinated by the Zn2+ ion (see Figure 1A).7,13 As a 
result, a requirement for potent MMP or ADAM inhibitors is that they contain a good 
zinc binding group (ZBG). A large number of MMP and ADAM inhibitors that have 
appeared in the literature consist of an oligopeptide sequence that is equipped with a 
hydroxamate moiety at either the C- or the N-terminus. Notably, commercially available 
members of this type are marimastat, batimastat and TAPI-2 (see Figure 1B), each 
displaying sub- to low-nanomolar, broad MMP/ADAM inhibitory activity. In these 
structures the oligopeptide portion ensures recognition by the metalloproteinases by 
directing the substituents to the corresponding enzyme’s binding pockets. The 
bidentate Zn2+ chelating properties of the hydroxamic acid has the dual effect of a 
strong zinc coordination as well as expulsion of the nucleophilic water molecule from 
the active site, thereby preventing hydrolysis to occur (Figure 1C).  
 
 
Figure 1. (A) Schematic representation of the position of a substrate in an MMP active site and mechanism of 
proteolysis. (B) Structures of some commercially available MMP/ADAM inhibitors. (C) Schematic 
representation of a potent MMP inhibitor 114 containing the hydroxamic acid zinc binding group in an MMP 
active site. P1’ and P2’ refer to the enzyme’s binding pockets.  
C-terminal peptide hydroxamic acids are readily available through modified solid 
phase peptide synthesis (SPPS) protocols.15-20 In contrast, there are very few synthetic 
procedures towards N-terminal peptide hydroxamates,21-23 which obviate a non-SPPS 
step during synthesis.14,24-27 The preparation of compound libraries containing N-
terminal peptide hydroxamates would be greatly facilitated by the existence of suitable, 
complete SPPS methods. For this reason, a building block was devised that can be used 
in a linear SPPS strategy, immediately leading to products as depicted in Figure 1B with 
R1 = . The first part of this chapter describes the synthesis of this enantiomerically 
pure N,O-diprotected succinyl hydroxamate building block 2 (Figure 2) and its use in the 
synthesis of inhibitors and functionalized probes for the study of MMP and ADAM 
 H
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activities. The second part deals with the preparation of a library containing 96 
enantiopure peptide hydroxamates with general structure 3 (Figure 2) by SPPS using 
building block 2. This compound library was used to study the inhibitor preference of 
three metalloproteases (MMP-9, MMP-12 and ADAM-17) with respect to the 




to give compound 
5. Alkylation of di-tert-butyl malonate with bromide 5 gave 6, which was converted into 
 tert-butyl esters followed by thermal 
decarboxylation). Chiral HPLC measurements (see Figure 4 in the Experimental section) 
indicated that compound 7 was formed as a 3.3:1 mixture of stereoisomers. Incubation 
of this compound in TFA for 16 hours did not reduce the enantiomeric excess, proving 
that scrambling of chirality takes place before the deprotection step. 
 2. Structure of chiral succinylhydroxamate building block 2 for SPPS of peptide hydroxamate 
MMP/ADAM inhibitors. General structure 3 represents the library containing 96 compounds made via SPPS 
using building block 2. R1 and R2 are amino acid side chains. 
2.2 Results and Discussion 
2.2.1 Synthesis and application of building block 2 
Retro-synthetically, compound 2 can be prepared from chiral succinate 7 (Scheme 
1) by condensation of the carboxylate with an appropriately protected hydroxylamine 
derivative, followed by transesterification of the benzyl ester. In the first instance, 
compound 7 was synthesized from D-leucine 4 following a modified literature 
procedure28 as depicted in Scheme 1. In short, D-leucine 4 was converted into the 
corresponding bromide, followed by esterification with benzyl alcohol 
7 in a two step procedure (removal of the
Scheme 1. Synthesis of succinate 7 from D-leucine.28 
 
Reagents and conditions: (a) i) NaNO2, HBr, H2O, 90%; ii) BnOH, TsOH, toluene, reflux, 79%; (b) di-tert-butyl 
malonate, KOtBu, DMF, 92%; (c) i) TFA, DCM; ii) toluene, reflux, 83%. 
In order to obtain building block 2 in optically pure form, a second method for the 
synthesis of 7 was investigated (see Scheme 2). Chiral alkylation of known compound 8 
gave enantiopure tert-butyl ester 9.14,29 Removal of the chiral auxiliary using lithium 
benzyl alcoholate gave benzyl ester 10. Partial deprotection led to monoester 7, which 
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was analyzed again by chiral HPLC (see Figure 4 in the Experimental section) and now 
the e.e. was determined to be >99%. Next, the carboxylic acid was converted into its 
acyl chloride derivative and reacted with N-Boc-O-TBS-hydroxylamine30 giving fully 
protected succinyl hydroxamate 11. The benzyl ester was removed by catalytic 
hydrogenation to obtain free acid 12. It was soon discovered that 12 is not only labile 
during storage (even at –20 °C), but also extremely base-sensitive. Attempts to 
precipitate it as several different alkylammonium salts led to complete degradation. 
Also, standard peptide coupling conditions (HCTU/DiPEA) led to complicated reaction 
sation of 12 to the anhydride. Therefore, in order to 
minimize the amount of base encountered by compound 12, it was transformed into an 
active ester derivative, which can, in theory, be coupled without additional base. The 
PFP ester 2, obtained by reaction of 12 with pentafluorophenol under the influence of 
EDC, proved to be far more stable during storage than acid 12. 
Scheme 2. Synthesis of building block 2. 
mixtures, presumably due to cycli
 
Reagents and conditions: (a) LiHMDS, tert-butyl bromoacetate, THF, –78 °C; (b) BnOH, nBuLi, THF, 0 °C, 92%; 
(c) TFA, DCM, 94%; (d) i) (ClCO)2, cat. DMF, DCM; ii) TBSONHBoc, DMAP, ACN, 85%; (e) H2, Pd/C, MeOH; (f) 
PFPOH, EDC, DCM, 55% from 11. 
Next, the potential of PFP-ester 2 in SPPS was evaluated (see Scheme 3). Dipeptide 
13a was synthesized on Rink amide resin using standard SPPS protocols. After removal 
of the Fmoc group, several conditions for the coupling of 2 were investigated.31 The 
optim
ylalanine is replaced by leucine (14b, 
56% yield), tryptophan (14c, 42%) and tyrosine (14d, 71%) were synthesized.  
Enzyme inhibition tests using a fluorogenic substrate revealed IC50 values in the 
2 (catalytic domain) 
and ADAM-17 (ectodomain), as is shown in Table 1, entries 1–4. The observation that 
the aromatic amino acid containing compounds 14acd are more potent inhibitors than 
the aliphatic 14b corroborates earlier findings.7 
 
al conditions proved to be shaking the resin for 2 hours with 5 equivalents of 2 
and 2 equivalents of DiPEA relative to the resin-bound peptide in NMP. The resulting 
product was cleaved from the resin and concomitantly deprotected using 95% aqueous 
TFA, cleanly yielding peptide 14a in 64% after RP-HPLC purification. In the same 
fashion, the analogous peptides in which phen
low nanomolar range for the four compounds against both MMP-1
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Scheme 3. Solid-phase peptide synthesis of succinylhydroxamate peptides using 2. 
 
Reagents and conditions: (a) i) 20% piperidine/DMF; ii) FmocLys(Boc)OH, HCTU, DiPEA, NMP; iii) 20% 
piperidine/DMF; iv) FmocAAOH, HCTU, DiPEA, NMP; (b) i) 20% piperidine/DMF; ii) compound 2, DiPEA, NMP; 
iii) 95% TFA/H2O, RP-HPLC, 14a: 64%, 14b: 56%, 14c: 42%, 14d: 71%. AA = a: Phe, b: Leu, c: Trp, d: Tyr. 
Table 1. Inhibitory a  of the syn P/ADAM i (IC50 value
E  Co  M  AD 7 
ctivities thesized MM nhibitors s in nM). 
ntry mpound MP-12 AM-1
1 14a 5.3 15.1 
2 14b 41.8 58.2 
3 14c 7.8 26.1 
4 14d 4.8 10.7 
5 15 4.1 23.6 
6 16 13.1 42.7 
7 18 3.6 20.6 
 
Functionalization of the free amine in the prepared inhibitors with a fluorescent 
label can readily be accomplished, as is demonstrated in Scheme 4. Compound 15, a 
modified version of 14a with an additional spacer, was obtained via the presented 
method in 53% overall isolated yield. It was established that this spacer does not 
significantly influence the inhibitory activity (see Table 1, entry 5). Reaction of 15 in DMF 
with 1 equivalent of Bodipy(TMR)-Ahx-OSu and DiPEA cleanly furnished labeled 
comp
c group and coupling of 2, the entire construct 
was removed from the resin and concomitantly deprotected, to give 18 in an overall 
ound 16 in 77% isolated yield. Incorporation of the fluorescent label led only to a 
slight drop in inhibitory potency (Table 1, entry 6). 
The usefulness of building block 2 is further demonstrated in the on-resin 
synthesis of the biotinylated inhibitor 18 (Scheme 4), containing a photoactivatable 
group. This compound is designed to bind to the active site of MMPs and ADAMs, after 
which it can be covalently locked by irradiating the photocrosslinker at 366 nm.15,32 The 
biotin moiety can then be used as a handle for affinity purification of the tagged 
enzymes, as well as for visualization by streptavidin after blotting. Rink amide-bound 
FmocLys(Mtt)OH (17) was side-chain deprotected and then coupled to biotin. Next, the 
6-aminohexanoic (Ahx) spacer and the photocrosslinker amino acid FmocPhe(Tmd) were 
coupled. Finally, after removal of the Fmo
yield of 26% after RP-HPLC purification. 
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Scheme 4. Synthesis of fluorescent probe 16 and photocrosllinker containing biotinylated probe 18. 
 
Reage
labeling occurs after approximately 30 minutes of irradiation. These facts make 
compound 18 a promising candidate for activity-based profiling of MMPs and ADAMs. 
 
nts and conditions: (a) Bodipy(Tmr)-Ahx-OSu, DiPEA, DMF, 77%. 
Testing of compound 18 on MMP-12 and ADAM-17 revealed that it is a highly 
potent inhibitor of both enzymes (see Table 1, entry 7), as well as ADAM-10 (IC50 = 114 
nM). In order to validate it as a potential activity-based probe, 18 was incubated with 
recombinant ADAM-10, followed by irradiation at 366 nm, SDS-PAGE and detection 
with streptavidin-alkaline phosphatase. The results of this experiment are shown in 
Figure 3. Clearly, compound 18 is able to irreversibly bind ADAM-10 in an activity-based 
manner, as evidenced by the weak staining after preheating the enzyme (lane 1) in 
comparison with active ADAM-10 (lane 2). The binding efficiency of 18 is shown in lane 
3, where a 40-fold excess of the generic MMP/ADAM inhibitor TAPI-2 only slightly 
decreases the observed staining. Figure 3 also shows that the covalent labeling is light-
dependent, since no labeling is observed without irradiation (lane 8) and the maximum 
1* 2 3 4 5 6 7 8
[18] (M) 2.5 0.5 2.5 2.5 2.5 2.5 2.5 2.5
UV (min.) 60 60 60 60 30 15 5 0





Figure 3. Labeling of ADAM-10 with probe 18. Recombinant ADAM-10 (100 ng) was incubated with probe 18, 
followed by irradiation with UV light (366 nm) for 0-60 min., as indicated. The mixtures were denatured, 
resolved by 10% SDS-PAGE, stained with streptavidin-AP and visualized by Western blotting. *Denatured 
ADAM-10 (preheated with 2% SDS). 
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2.2.2
 and Aa2 (for instance PA 
stands for compound 3 with Aa  = proline and Aa  = alanine). 
Scheme 5. Solid-phase synthesis of the peptide succinyl hydroxamate library. 
 Synthesis and evaluation of a peptide hydroxamate library 
The preparation of the target compound library (see Scheme 5) commenced with 
-NHFmoc-, -NHBoc-protected lysine on Rink amide resin 19. After removal of the 
Fmoc protecting group the first set of amino acids (Aa1) was coupled in a parallel 
fashion under standard SPPS coupling conditions giving 12 different peptides. These 
resin bound peptides were divided into 8 equal portions. Removal of the Fmoc group 
and coupling of the second amino acid (Aa2) gave 96 immobilized peptides with the 
general structure 20. Final Fmoc deprotection and condensation with building block 2 
(see Figure 2) in the presence of 2 equivalents of DiPEA resulted in the immobilized and 
fully protected peptide hydroxamates 21. Acidic cleavage from the resin and 
concomitant removal of all acid labile protecting groups resulted in a 96-membered 
library of crude compounds 3, which were purified by RP-HPLC. The yields of the pure 
peptides based on 19 (purity >95% as determined by LC-MS analysis) varied between 
3% and 40%. The amount of side products formed differed considerably between the 
compounds. Hydrolysis of the hydroxamic acid to the carboxylic acid in the final step 
appeared in most cases to be the major side reaction. The formation of this side 
product was apparent from the LC-MS analyses of the crude mixtures by a 15 Da 
decrease in molecular weight. In some cases condensation with the activated 
hydroxamate ester was incomplete. In general, the best results in terms of yield and side 
product formation were obtained for compounds containing an amino acid with an 
aliphatic side chain at the Aa2 position. All compounds were given a unique two-letter 
code, which resembles the order of coupling of amino acids Aa1
1 2
 
Reagents and conditions: (a) i) 20% piperidine/DMF; ii) FmocAa OH, HCTU, DiPEA, NMP; iii) 20% 
piperidine/DMF; iv) FmocAa
1
2OH, HCTU, DiPEA, NMP; (b) i) 20% piperidine/DMF; ii) compound 2, DiPEA, NMP; 
(c) 95% TFA/H O, RP-HPLC. 2
The results of the single-point (100 nM) inhibitory potential of the 96 compounds 
against MMP-9, MMP-12 and ADAM-17 are depicted in Table 2. This initial screen was 
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performed in order to obtain qualitative insight in the difference in inhibitory potential 
of the 96 peptide hydroxamates. It is apparent that the efficacy of the inhibitors towards 
MMP-12 is generally higher than for the other two enzymes. Introduction of a proline 
residue at the Aa1-position greatly decreases the activity of the inhibitor with respect to 
both MMPs. This effect appears to be strongest for MMP-12 but inhibition of ADAM-17 
appears to be less affected. This observation can be explained by the fact that MMPs 
contain a straight horizontal cleft and therefore a proline would result in a large steric 
hindrance within the active site. ADAMs, however, do not contain such a rigid cleft and 
line.33,34 
Table 2. Remaining enzymatic activity (%) after inhibition.a 
the inhibitor activity is thus less affected by pro
Inhibitor MMP9 MMP12 ADAM17 Inhibitor MMP9 MMP12 ADAM17 Inhibitor MMP9 MMP12 ADAM17
DA 97.3 25.3 90.0 LA 98.7 36.2 73.5 SA 69.2 29.1 42.2
DD 102.3 51.4 105.7 LD 98.2 55.2 92.1 SD 66.2 42.5 96.2
DF 55.8 4.3 92.5 LF 57.0 2.1 25.4 SF 8.6 7.2 11.2
DH 90.8 11.6 97.6 LH 92.5 13.7 69.0 SH 27.9 14.7 33.6
DL 95.2 7.4 98.7 LL 98.3 4.3 41.6 SL 28.4 9.0 11.8
DV 106.0 11.0 100.6 LV 85.6 8.6 30.0 SV 30.1 9.6 8.4
DW 70.4 8.5 108.0 LW 42.6 2.3 36.5 SW 3.4 3.1 14.1
DY 65.3 9.0 101.8 LY 53.7 3.6 32.8 SY 3.7 5.0 8.9
EA 101.2 45.0 92.3 PA 101.8 83.9 64.8 TA 99.3 74.2 86.0
ED 103.2 85.5 91.4 PD 97.8 101.2 94.0 TD 95.4 62.1 94.8
EF 77.8 7.6 86.8 PF 72.9 63.2 49.7 TF 50.8 15.9 41.2
EH 98.2 11.4 99.5 PH 84.9 68.2 50.3 TH 73.2 22.9 66.0
EL 106.2 18.1 92.2 PL 100.2 77.5 43.0 TL 52.7 8.8 26.7
EV 106.8 23.4 96.7 PV 97.4 50.3 48.5 TV 70.0 19.4 26.0
EW 103.3 33.0 103.3 PW 73.1 36.9 63.7 TW 21.2 7.1 35.8
EY 86.8 10.2 99.7 PY 72.5 45.3 63.3 TY 32.7 13.5 33.7
FA 96.7 24.4 47.6 QA 100.0 36.0 68.0 WA 84.6 16.3 56.3
FD 91.8 43.3 92.8 QD 96.6 59.0 90.7 WD 85.0 45.6 96.7
FF 24.6 0.6 16.4 QF 73.3 8.7 57.8 WF 21.6 4.3 23.0
FH 81.4 61.1 67.9 QH 90.8 61.4 87.0 WH 48.5 7.2 58.6
FL 79.7 3.7 33.3 QL 90.0 7.7 53.9 WL 33.6 2.9 21.2
FV 82.6 3.4 19.4 QV 97.1 9.5 53.9 WV 64.6 6.3 20.4
FW 10.4 0.4 40.2 QW 42.7 2.8 58.8 WW 18.5 4.6 48.3
FY 49.8 9.0 55.6 QY 12.8 1.9 16.1 WY 8.1 4.2 13.3
HA 95.1 44.6 78.8 RA 97.6 25.8 23.2 YA 88.4 17.9 60.8
HD 93.8 82.7 89.8 RD 96.2 81.5 87.6 YD 70.5 32.6 81.3
HF 31.3 4.1 35.4 RF 66.5 4.6 6.5 YF 13.2 1.8 16.3
HH 72.2 17.4 67.0 RH 88.1 14.0 14.7 YH 52.7 12.2 64.0
HL 72.1 7.4 43.7 RL 93.8 12.8 8.8 YL 52.1 5.2 25.0
HV 86.4 15.0 49.6 RV 99.5 9.5 5.0 YV 54.8 4.3 17.4
HW 21.0 3.2 53.4 RW 54.1 4.4 9.5 YW 4.9 3.2 28.1
HY 29.2 7.6 56.1 RY 42.8 4.0 7.0 YY 8.1 1.1 18.3
 
a Determined by evaluation of their ability to inhibit proteolytic conversion of a fluorogenic substrate. MMP-12 
catalytic domain, MMP-9 catalytic domain and ADAM-17 ectodomain (5 ng) were incubated with 100 nM final 
concentration of inhibitor. The appropriate fluorogenic substrate was added (2 M final concentration) and 
proteolysis rates were determined by measuring fluorescence (ex 320 nm, em 440 nm) increase. The 
remaining catalytic activity was calculated by comparison with proteolysis rates of equal amounts of 
uninhibited enzyme. Each value is the average of three individual experiments. Each inhibitor is identified by 
its two-letter code, which resembles the order of the coupling of amino acids Aa1–Aa2. For example: 
compound PA means that first proline (Aa1) was coupled, followed by the coupling of alanine (Aa2). 
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It is also obvious that the presence of acidic residues (D and E) in either position 
greatly reduces the efficacy of the inhibitors for MMP-9 and ADAM-17 and to a 
somewhat lesser extend for MMP-12. The inhibitors with the highest efficacy towards 
MMP-12 are those with the aromatic amino acids phenylalanine, tryptophan or tyrosine 
in either position. These results are in line with earlier observations by Lang and co-
workers.34 
The beneficial effect of incorporating aromatic moieties also holds true for MMP-9, 
especially if both positions are occupied by phenylalanine, tryptophan or tyrosine. 
Interestingly, a serine residue in the Aa1 position yields very active MMP-9 inhibitors, 
whereas threonine at Aa1 has a much weaker beneficial effect.  MMP-12 and ADAM-17 
show a similar, albeit not so strong tendency. The presence of an aliphatic amino acid 
(A, L or V) in the Aa2 position decreases the efficacy against MMP-9 in a more 
pronounced way than for the other two enzymes. Netzel-Arnett and co-workers 
reported an extensive study on the substrate preference of MMP-9 towards a set of 
oligopeptides.35 Their findings corroborate our results with respect to a positive effect of 
aromatic moieties in both positions (Aa1 and Aa2) or a serine residue at Aa1 on inhibitory 
potential towards MMP-9. Interestingly, the here presented results are in disagreement 
with their findings that leucine, and to a lesser extent alanine, at Aa2 have a beneficial 
effect on inhibitory potential, since a detrimental effect for both residues at this 
position is observed. Incorporation of arginine in position Aa1 improves efficacy towards 
MMP-12 and ADAM-17 but highly reduces the efficacy towards MMP-9, as was also 
shown by Netzel-Arnett and co-workers.35 The positive effect of aromatic amino acids 
also holds true for ADAM-17 but to a lesser extent than for the tested MMPs. In addition 
it is found that heteroaryl moieties (His and Trp) or a serine at the Aa1 position improves 
the potency towards ADAM-17. These observations are consistent with reports in the 
literature.7,36 
An interesting feature of these inhibitors is that they can be used for solid-phase 
extraction (SPE) of active metalloproteases.37-39 The key element in this is the free amine 
functionality these compounds contain, with which they can be immobilized onto matrix 
material (Sepharose beads). By flushing a biological sample through the modified beads, 
the target active metalloenzymes are captured, which subsequently leads to the 
chemical enrichment of active MMPs and ADAMs. Eight inhibitors (selected on the basis 
of their different potency towards the three enzymes) were studied in more detail. The 
IC50 values of these inhibitors for the target enzymes were determined (see Table 3). 
These values span the entire range from sub-nanomolar to over 10 M (compare for 
instance FF and PD) and some of them show considerable selectivity towards one or two 
of the three tested enzymes (for example YW towards both MMPs and PL towards 
ADAM-17). As can be seen, all values nicely corroborate the results from the single-
point determinations, depicted in Table 2. All eight inhibitors were immobilized on 
Sepharose beads and the extraction efficiency of the three recombinant acitve enzymes 
was determined.40 Experiments showed complete enrichment of MMP-9 and MMP-12, 
however enrichment of ADAM-17 was much more challenging. Of interest is the finding 
that correlation between affinity (IC50 value) of free inhibitor and suitability for SPE is not 
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as obvious as one might expect. One inhibitor in particular (FF) was found to be very 
powerful for SPE and it was therefore only natural to use it for the efficient activity-
based chemical enrichment of ADAM-17 from a complex biological sample (a cell lysate 
from cultured human alveolar carcinoma cell line A549).40 The result from this 
straightforward affinity-based enrichment protocol nicely complements the results from 
Cravatt and co-workers on ADAM-17 enrichment from biological samples in a two-step 
bioorthogonal fashion using a photo-activatable probe and streptavidin-mediated pull-
down.41 
Table 3. IC50 values (in nM) of eight selected inhibitorsa 
 MMP-9 MMP-12 ADAM-17 
DV 905 (221) 10.5 (4.0) 2,241 (250) 
FF 23.2 (3.9) 0.92 (0.22) 16.0 (6.4) 
FW 6.69 (0.66) 2.57 (0.80) 29.6 (9.1) 
PD >10,000b 2,788 (392) 5,998 (2,555) 
PL 3,624 (328) 147 (12) 92.1 (28) 
QY 9.92 (0.79) 0.85 (0.020) 18.9 (2.0) 
SF 9.93 (1.3) 7.70 (1.3) 11.1 (2.3) 
YW 6.71 (0.96) 4.03 (0.95) 36.0 (3.4) 
a Each value represents the mean of three independent inhibition curves. The standard deviation is given in 
parentheses. b Activity of enzyme >50% at 10 M inhibitor. 
2.3 Conclusion 
In summary, a straightforward solid phase synthesis of succinylhydroxamate 
peptides using the readily accessible building block 2 is presented. Potent, free amine 
containing MMP and ADAM inhibitors were conveniently synthesized and could be 
functionalized with a fluorescent label. Photoactivatable inhibitor 18 was efficiently 
synthesized entirely on solid phase and shown to be suited for activity-based covalent 
labeling of a model ADAM. Compound 16 may be used for fluorescent staining of active 
MMPs and ADAMs. Compound 12 nicely complements reported activity-based probes 
for MMPs.15,32 In addition a library of 96 enantiopure peptide hydroxamates was 
prepared and tested with respect to their inhibitory efficacy towards three 
metalloproteases.42 The results show that different amino acids at the P2’ (Aa2) and P3’ 
(Aa1) positions (see Scheme 5) have a substantial influence on inhibitory capacity. This 
is in contrast to reported findings,7 which state that amino acids at the P2’ position have 
‘a modest effect’ on potency. 
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Experimental section 
General  
Tetrahydrofuran (THF) was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane 
(DCM), N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), methanol (MeOH), 
piperidine, diisopropylethylamine (DiPEA) and trifluoroacetic acid (TFA) were of peptide synthesis 
grade, purchased at Biosolve, and used as received. All general chemicals (Fluka, Acros, Merck, 
Aldrich, Sigma) were used as received. Rink amide MBHA resin (0.64 mmol/g) was purchased at 
Novabiochem, as well as all appropriately protected amino acids. O-(1H-6-Chlorobenzotriazolyl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased at Iris Biotech 
(Marktrewitz, Germany). Traces of water were removed from reagents used in reactions that 
require anhydrous conditions by coevaporation with toluene. Solvents that were used in reactions 
were stored over 4Å molecular sieves, except methanol and acetonitrile which were stored over 
3Å molecular sieves. Molecular sieves were flame dried before use. Unless noted otherwise all 
reactions were performed under an argon atmosphere. Column chromatography was performed 
on Silicycle Silia-P Flash Silica Gel, with a particle size of 40-63 m. The eluents toluene, ethyl 
acetate and petroleum ether (40-60 °C boiling range) were distilled prior to use. TLC analysis was 
conducted on Merck aluminium sheets (Silica gel 60 F254). Compounds were visualized by UV 
absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) and 
(NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) 
in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, 
followed by charring at ca. 150 °C. 1H-, 13C- and 19F-NMR spectra were recorded on a Jeol JNM-FX-
200 (200MHz), a Bruker DMX-400 (400 MHz) or a Bruker DMX-600 (600 MHz) spectrometer. 
Chemical shifts are given in ppm () relative to tetramethylsilane (1H-NMR), CDCl3 (13C-NMR) or 
TFA (19F NMR) as internal standard. Mass spectra were recorded on a PE/Sciex API 165 instrument 
equipped with an Electrospray Interface (ESI) (Perkin-Elmer). High resolution MS (HRMS) spectra 
were recorded with a Finnigan LTQ-FT (Thermo Electron). IR spectra were recorded on a Shimadzu 
FTIR-8300 and absorptions are given in cm-1. Optical rotations  were recorded on a Propol 
automatic polarimeter at room temperature. LC-MS analysis was performed on a Jasco HPLC 
system with a Phenomenex Gemini 3 m C18 50  4.6 mm column (detection simultaneously at 
214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI. HPLC gradients were 
10 → 90%, 0 → 50% or 10 → 50% ACN in 0.1% TFA/H2O. Chiral HPLC analysis was performed on 
a Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a 
Chiralcel OD column (150  4.6 mm). The compounds were purified on a Gilson HPLC system 
coupled to a Phenomenex Gemini 5 m 250  10 mm column and a GX281 fraction collector. The 
used gradients were either 0 → 30% or 10 → 40% ACN in 0.1% TFA/water, depending on the 
lipophilicity of the product. Appropriate fractions were pooled, and concentrated in a Christ 





To a cooled solution (–78 °C) of LiHMDS (1.18 mmol, 1.18 mL of a 1M solution in 
THF) in THF (5 mL) was added (S)-4-benzyl-3-(4-methylpentanoyl)oxazolidin-2-one 
(8, 0.39 g, 1.07 mmol) in THF (5 mL) and the mixture was stirred at –78 °C for 30 min. tert-butyl 
bromoacetate (0.58 g, 2.97 mmol) was added and the mixture was allowed to warm to RT. After 3 
h TLC analysis indicated a complete reaction. EtOAc was added and the mixture was extracted 
with sat. aq. NH4Cl. The aqueous layer was extracted with EtOAc (2) and the combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure. The title compound was 
obtained as a colourless solid (yield: 0.32 g, 0.85 mmol, 79%). 1H NMR (200 MHz, CDCl3)  = 7.35-
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3.21 Hz, 1H), 2.82-2.66 (m, 2H), 2.48 (dd, J = 16.60, 4.67 Hz, 1H), 1.62-1.28 (m, 3H), 1.43 (s, 9H), 
0.93 (dd, J = 6.26, 3.56 Hz, 6H) ppm. = +1.5 (c = 1, CHCl3). 23][ D
 
tert-Butyl 3-(R)-benzyloxycarbonyl-5-methylhexanoate (10) 
Benzyl alcohol (1.68 mL, 16.36 mmol) was dissolved in THF (40 mL) and cooled to 
0 °C. nBuLi (6.14 mL, 1.6M in THF, 9.80 mmol) was added dropwise and the 
reaction mixture was stirred for 20 min. A solution of compound 9 (3.10 g, 8.18 
mmol) in THF (5 mL) was added and the reaction was stirred at 0 °C until TLC analysis (10% 
EtOAc/PE) revealed a complete reaction (about 4 h). The reaction mixture was quenched with sat. 
aq. NH4Cl and extracted three times with EtOAc. The combined organic layers were dried over 
MgSO4 and concentrated. The crude material was purified by column chromatography (3% → 10% 
EtOAc/PE) giving the product as a colourless oil (yield: 2.4 g, 7.5 mmol, 92%).  1H-NMR (200 MHz, 
CDCl3):  = 7.40-7.25 (m, 5H), 5.13 (dd, J = 36.6, 12.0 Hz, 2H), 2.98-2.83 (m, 1H), 2.62 (dd, J = 
16.4, 9.1 Hz, 1H), 2.35 (dd, J = 16.1, 5.2 Hz, 1H), 1.63-1.15 (m, 3H), 1.40 (s, 9H), 0.92-0.84 (m, 6H) 
ppm. 13C-NMR (50 MHz, CDCl3):  = 174.92, 170.80, 135.92, 128.31, 127.95, 80.49, 66.05, 40.97, 
39.61, 37.70, 27.84, 25.63, 22.51, 22.05 ppm. = +1.5 (c = 1, CHCl3). IR (thin film): 2962.5, 
1728.1, 1365.5, 1249.8, 1141.8. HRMS: calcd. for C19H28O4 [M + H]







3-(R)-Benzyloxycarbonyl-5-methylhexanoic acid (7) 
To a stirred solution of 10 (2.4 g, 7.5 mmol) in DCM (20 mL) was added TFA (20 mL) 
and the reaction was stirred until TLC analysis indicated complete consumption of 
starting material (after 30 min.). Toluene was added and the mixture was 
concentrated under reduced pressure. In order to remove all traces of TFA the product was 
coevaporated with toluene three times. The title compound was obtained as a colourless oil 
(yield: 1.98 g, 7.5 mmol, quant.) 1H-NMR (200 MHz, CDCl3):  = 7.36-7.29 (m, 5H), 5.14 (s, 2H), 
3.00-2.85 (m, 1H), 2.76 (dd, J = 16.8, 9.12 Hz, 1H), 2.48 (dd, J = 16.8, 4.9 Hz, 1H), 1.65-1.29 (m, 
3H), 0.93-0.86 (2d, 6H) ppm. 13C-NMR (50 MHz, CDCl3):  = 178.04, 174.86, 135.71, 128.37, 
128.01, 127.95, 66.36, 40.91, 39.12, 36.03, 25.60, 22.35, 22.05 ppm. = +10.6 (c = 1, 
CHCl3). IR (thin film): 2954.7, 1705.0, 1450.4, 1388.7, 1157.2. HRMS: calcd. for C15H20O4 [M + H]
+: 






Synthesis from D-leucine 4: Compounds 5 and 6 were prepared according to a procedure 
described in literature.28 Compound 6 (15.5 g, 36.9 mmol) was treated with a 1:1 mixture of 
DCM/TFA (100 mL) for 2 h, after which TLC analysis indicated complete consumption of starting 
material. Toluene was added and the mixture was concentrated under reduced pressure, followed 
by coevaporating the mixture with toluene twice. The resulting material was dissolved in toluene 
(100 mL) and refluxed for 2 h, after which the mixture was concentrated to dryness under reduced 
pressure. The product was obtained as a colourless oil (yield: 8.09 g, 30.6 mmol, 83%). NMR data 
corresponded to the data shown above. = +6.4 (c = 1, CHCl3). 23][ D
Verification of the chiral purity of compound 7 
As a reference compound, the racemic form of 7 was synthesized.43 NMR data and purities were 
identical for 7 and its racemate. Chiral HPLC chromatograms are depicted in Figure 4. Based on 
the relative intensities of the peaks (depicted under the peaks) in chromatogram B, the e.e. of 7 
was determined to be >99%. Chromatogram D shows the chiral HPLC run for compound 7 
synthesized from D-leucine as depicted in Scheme 1. Based on the relative intensities of the peaks 
this compound was determined to be a ~3.3:1 mixture of stereoisomers. 
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A B C D
 
Figure 4. Results from the chiral HPLC analyses of (R)-2-isobutylmonobenzylsuccinate 7 and the racemate 
synthesized by the method of Chatterjee et al.43 Measurements were done with a Chiral OD column; eluent: 
hexane:isopropanol 95:5 (v/v) + 0,25% AcOH; flow: 1 mL/min.; UV detection at  = 254 nm. Retention times 
and relative integrals are given. (A) racemate; (B) compound 7; (C) racemate; (D) compound 7 synthesized from 




Carboxylic acid 7 (2.11 g, 8.0 mmol) was dissolved in DCM (30 mL) and DMF (2 
drops) was added. The solution was cooled to 0 °C and oxalyl chloride (40 
mmol, 3.4 mL) was added dropwise. The solution was warmed to room temperature and stirred 
until gas evolution ceased (about 30 min.). Toluene (30 mL) was added and the mixture was 
concentrated. Residual reagent was removed by repeated coevaporation with toluene. The 
intermediate acid choride was obtained as a yellowish oil and used without further purification. 
The crude acid chloride was redissolved in ACN (15 mL) and cooled to 0 °C. To this, a mixture of 
N-Boc-O-TBS-hydroxylamine30 (8.8 mmol, 2.17 g) and DMAP (16 mmol, 1.95 g) in ACN (15 mL) was 
added. The reaction mixture was slowly warmed to room temperature and stirred until TLC (10% 
EtOAc/PE) revealed a complete reaction (approx. 2 h). The mixture was diluted with Et2O (200 mL) 
and extracted subsequently with 1M aq. HCl and brine. The organic layer was dried over MgSO4 
and concentrated under reduced pressure. The residue was purified by column chromatography 
(5% EtOAc/PE), and the product was obtained as a colourless oil (yield: 3.36 g, 6.8 mmol, 85%). 
1H-NMR (200 MHz, CDCl3):  = 7.35-7.29 (m, 5H), 5.18-5.03 (dd, 2H, J = 36.5, 12.8 Hz), 3.24 (dd, J 
= 17.1, 9.7 Hz, 1H), 3.10-3.00 (m, 1H), 2.88 (dd, J = 17.1, 3.6 Hz, 1H), 1.60-1.10 (m, 3H), 1.53 (s, 
9H), 0.98 (s, 9H), 0.92-0.83 (m, 6H), 0.12 (s, 3H), 0.10 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 
175.28, 170.43, 151.93, 136.04, 128.22, 127.79, 84.13, 65.93, 41.06, 39.67, 39.15, 27.78, 25.60, 
22.29, 17.96, -5.21 ppm. = +16.5 (c = 1, CHCl3). IR (thin film): 2954.7, 1728.1, 1465.8, 
1303.8, 1141.8. HRMS: calcd. for C26H43NO6Si [M+H]





dimethylsilyloxy)carbamoyl)propionic acid (12) 
To a solution of compound 11 (3.16 g, 6.40 mmol) in methanol (50 mL) Pd/C 
(10% w/w, 150 mg) was added. Hydrogen gas was then bubbled through the 
mixture until TLC analysis (10% EtOAc/PE) revealed a complete reaction (approx. 1.5 h). The 
reaction mixture was filtered over Celite and concentrated to obtain the product as a sticky syrup 
(2.6 g, 6.40 mmol, quant.). The compound was used without further purification. 1H-NMR (200 
MHz, CDCl3):  = 10.47 (bs, 1H), 3.12 (dd, J = 16.8, 8.7 Hz, 1H), 3.00-2.70 (m, 2H), 1.70-1.15 (m, 
3H), 1.47 (s, 9H), 0.91 (s, 9H), 0.88-0.81 (m, 6H), 0.06 (s, 3H), 0.04 (s, 3H) ppm. 13C-NMR (50 MHz, 
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ppm. = +12.4 (c = 1, CHCl3). IR (thin film): 2954.7, 1705.0, 1465.8, 1249.8, 1145.5. ESI-MS 
(m/z): 404.2 (M + H+), 426.1 (M + Na+), 442.4 (M + K+), 829.5 (2M + Na+), 304.1 (M – Boc + 





A mixture of crude compound 12 (1.15 g, ~2.85 mmol) and pentafluorophenol 
(5.6 mmol, 1.03 g) in DCM (15 mL) was treated with EDC (5.6 mmol, 1.07 g). 
After stirring the mixture at room temperature overnight, Et2O (100 mL) was added and the 
mixture was extracted with 1M aq. HCl and brine, dried over MgSO4 and concentrated. The 
residue was purified by column chromatography (2% EtOAc/PE) and the product was obtained as 
a colourless oil (yield: 0.87 g, 1.53 mmol, 55%).  1H-NMR (600 MHz, CDCl3):  = 3.33-3.28 (m, 2H), 
3.09-3.04 (m, 1H), 1.80-1.71 (m, 2H), 1.56 (s, 9H), 1.52-1.47 (m, 1H), 1.00 (d, 3H, J = 6.6 Hz), 0.99 
(s, 9H), 0.95 (d, 3H, J = 6.6 Hz), 0.13, (s, 3H), 0.12 (s, 3H) ppm. 13C-NMR (150 MHz, CDCl3):  = 
171.82, 169.85, 152.03, 141.16 (dd, J = 250, 9.0 Hz), 139.31 (dt, J = 264, 13.5 Hz), 137.71 (dt, J = 
249, 13.5 Hz), 125.16 (t, J = 12.8 Hz), 84.49, 41.02, 39.91, 39.01, 27.75, 25.67, 25.55, 22.24, 
22.01, 18.03, –5.31, –5.39. 19F NMR (376 MHz, CDCl3):  = –155.72 (d, J = 17.6 Hz, 2F), –162.46 (t, 
J = 21.6 Hz, 1F), –166.77 (dd, J = 21.4, 17.3 Hz, 2F). = +10.9 (c = 1, CHCl3). IR (thin film): 









General procedure A: solid phase peptide synthesis 
Prior to first use, the Fmoc Rink Amide MBHA resin was washed twice with DMF, twice with 
methanol and twice with DCM. Fmoc deprotection was performed by shaking the resin in a 20% 
piperidine/DMF stock solution for 20 min. The resin was washed twice with DMF and twice with 
DCM after every coupling and deprotection step. The first amino acid was loaded by reacting the 
resin with 5 eq. of HCTU, 5 eq. of amino acid and 10 eq. DiPEA (0.45 M stock solution in NMP). 
The amino acid was pre-activated in solution (5 min.) before adding it to the resin and shaking the 
resin for 1 h (standard coupling protocol). Loading was determined by UV spectroscopy at 300 nm 
of a freshly prepared Fmoc-deprotected resin sample. A capping step was performed by shaking 
the resin for 10 min. with 0.45 M acetic anhydride and 0.45 M DiPEA/NMP solution. Mtt 
deprotection was done by shaking repeatedly in a 1% TFA/DCM solution until the characteristic 
yellow colour of Mtt cation did no longer appear (7-12 times, 2 min. each). After Mtt-cleavage, 
immediately before the following coupling step, the resin was washed with a 0.45 M DiPEA stock 
solution in NMP. The coupling and deprotection reactions were checked on the presence of free 
amines by performing a Kaiser test. Before cleaving the peptide from the resin, it was washed 5 
times alternatingly with DCM and MeOH. Cleavage from the solid support was done by shaking 
the resin in a 95% v/v TFA/H2O solution for two hours, followed by filtration and rinsing the resin 
with a small portion of 95% v/v TFA/H2O. The filtrates were immediately poured into cold Et2O/PE 
(1:1 approx. 20 volume eq.) and stored overnight at –20 ºC. Centrifugation, followed by 
decantation of the supernatant afforded the crude product. 
 
Hydroxamic acid Phe-Lys-NH2 (14a)  
This compound was synthesized on solid support on 25 mol scale (based on the loading of 
Fmoc-Lys(Boc)) following the General procedure A. Coupling of Fmoc-Phe-OH gave the precursor 
13a. The final coupling step involved the addition of compound 2 (125 mol, 71 mg) and DiPEA 
(50.0 mol, 0.11 mL 0.45 M in NMP) with NMP (0.40 mL) to the resin and shaking for 2 hours. 
Cleavage from the resin, precipitation (see General Procedure) and purification by RP-HPLC gave 
pure 14a (yield: 7.4 mg, 16.0 mol, 64%). LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt 
(min): 4.54. HRMS: calcd. for C23H37N5O5 [M + H]
+: 464.28675; found: 464.28674. 
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Hydroxamic acid Leu-Lys-NH2 (14b) 
Synthesized in the same way as described for 14a, using Fmoc-Leu-OH in the second coupling 
(yield: 6.1 mg, 14.0 mol, 56%). LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 4.09. 
HRMS: calcd. for C20H39N5O5 [M + H]
+: 430.30240; found: 430.30239. 
 
Hydroxamic acid Trp-Lys-NH2 (14c) 
Synthesized in the same way as described for 14a, using Fmoc-Trp(Boc)-OH in the second 
coupling (yield: 5.3 mg, 11.0 mol, 42%). LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt 
(min): 3.94. HRMS: calcd. for C25H38N6O5 [M + H]
+: 503.29764; found: 503.29768. 
 
Hydroxamic acid Tyr-Lys-NH2 (14d) 
Synthesized in the same way as described for 14a, using Fmoc-Tyr(tBu)-OH in the second 
coupling (yield: 8.5 mg, 18.0 mol, 71%). LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt 
(min): 3.57. HRMS: calcd. for C23H37N5O6 [M + H]
+: 480.28166; found: 480.28163. 
 
Hydroxamic acid Phe-Ahx-Lys-NH2 (15) 
This compound was prepared as described in General procedure A on 50 mol scale (based on 
the loading of Fmoc-Lys(Boc)). Sequential coupling of Fmoc-Ahx-OH, Fmoc-Phe-OH and 
compound 2 (see for the last coupling, compound 14a). Cleavage from the resin followed by RP-
HPLC purification afforded pure 15 (yield: 13.6 mg, 23.6 mol, 47%). LC-MS: gradient 10% → 90% 
ACN/(0.1% TFA/H2O): Rt (min): 4.67. HRMS: calcd. for C29H48N6O6 [M + H]
+: 577.37081; found: 
577.37088. 
 
Hydroxamic acid Phe-Ahx-Lys(Ahx-BODIPY(TMR))-NH2 (16) 
To a solution of 15 (2.2 mg, 3.8 mol) in DMF (250 L) were added DiPEA (7.6 mol, 1.3 L) and 
BODIPY(TMR)-Ahx-OSu (3.8 mol, 2.3 mg). The solution was agitated overnight in the dark. 
Evaporation of the solvent, followed by RP-HPLC purification yielded 16 as a purple solid (3.2 mg, 
2.9 mol, 77%). LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 8.33. HRMS: calcd. for 
C56H78BF2N9O9 [M + H]
+: 1070.60564; found: 1070.60518. 
 
Hydroxamic acid Phe(Tmd)-Ahx-Lys(Biotin)-NH2 (18) 
This compound was synthesized on 50 mol scale (based on the loading of Fmoc-Lys(Mtt)) 
following General procedure A. A slight modification was made for the coupling of Fmoc-
Phe(Tmd)-OH. Because of its high price, only 1 eq. of Fmoc-Phe(Tmd)-OH was used, along with 
HCTU (1 eq.) and DIPEA (2 eq.) in NMP and shaking for 16 h. After rinsing the resin, this step was 
repeated. The final coupling included the addition of compound 2 (5 eq.) and DiPEA (2 eq.) in 
NMP to the resin and shaking for 2 h. After cleavage and purification by RP-HPLC the product was 
obtained as white solid (yield: 11.7 mg, 12.9 mol, 26%). LC-MS: gradient 10% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 6.60. HRMS: calcd. for C41H61F3N10O8S [M + H]
+: 911.4419; found: 911.4391. 
Synthesis of the compound library (3) 
Rink amide resin was rinsed with DCM, MeOH and DMF (2 each), then deprotected by shaking 
with 20% piperidine in DMF for 10 min. (2) and rinsed with DMF and DCM (2 each). Loading of 
the resin was effected by shaking with FmocLys(Boc)OH (5 eq. relative to the stated loading), 
HCTU (5 eq.) and 0.45 M DIPEA (10 eq.) in NMP for 2 h. The resin was filtered, then rinsed with 
DMF and DCM (2 each). Any non-reacted amines were capped by shaking the resin with Ac2O (5 
eq.) in 0.45 M DIPEA (10 eq.) in NMP for 5 min. After rinsing the resin with DMF, DCM and Et2O 
(2 each) and drying in vacuo, Fmoc determination (UV measurement at 300 nm) gave a loading of 
0.47 mmol/g. Twelve portions of 80 mol (170 mg resin) were rinsed with DCM and DMF (2 each), 
deprotected using 20% piperidine in DMF (10 min) and shaken with preactivated solutions of the 
appropriate Fmoc-amino acids Aa1 (400 mol), HCTU (400 mol, 165 mg) and DIPEA (800 mol, 
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1.8 mL 0.45 M in NMP) for 1 h. After rinsing with DMF, DCM and Et2O (2 each), and drying in 
vacuo, each portion was in turn divided into eight equal portions. Every portion (~ 10 mol) was 
respectively reacted with preactivated solutions of the eight amino acids Aa2 (50 mol each), 
HCTU (50 mol) and DIPEA (100 mol as a 0.45 M solution in NMP) and shaken for 1 h. After 
rinsing the resins with DMF and DCM (2 each), all portions were deprotected using 20% 
piperidine in DMF for 10 min., then filtered and rinsed with DMF and DCM (2 each). Finally, to all 
96 resins was added compound 2 (250 L 0.2 M in NMP) and DIPEA (44 L 0.45 M in NMP). After 
shaking for 2 h, the resins were filtered, rinsed with DMF, MeOH and DCM (2 each) and treated 
with 95% v/v TFA/water (0.5 mL) for 1 h (with the exception of resins containing Arg(Pmc), these 
were reacted 2.5 h). The filtrates, as well as small portions of 95% TFA/water used for rinsing the 
resins, were collected in tubes containing chilled Et2O/petroleum ether (1/1, ~5 mL) and left 
overnight at –20 ºC. The tubes were then centrifuged, and the filtrates were decanted. The crude 




Recombinant human MMP-12 catalytic domain and MMP-9 catalytic domain (without fibronectin 
type II inserts) were a gift from AstraZeneca R&D (Lund & Moelndal, Sweden) and were produced 
in E. coli (Parkar 2000, Shipley 1996). Recombinant human ADAM-17 ectodomain was obtained 
from R&D systems. The fluorogenic MMP substrate Mca-PLGL-Dpa-AR-NH2 (where Mca = (7-
methoxycoumarin-4-yl)acetyl and Dpa = dinitrophenyl)-L-2,3-diaminopropionyl) was obtained 
from Bachem, the ADAM substrate Mca-PLAQAV-Dpa-RSSSR-NH2 was obtained from R&D 
systems. Ultra-pure water was produced in-house by an Elga water purifying system and used for 
all mobile phase and buffer preparations. 
Determination of IC50 values shown in Table 1 
The compounds were tested for efficacy by determining their ability to inhibit conversion of a 
fluorogenic peptide substrate by recombinant metalloproteinases. IC50 values for MMP-12 were 
determined using recombinant catalytic domain (a kind gift by AstraZeneca R&D, Lund and 
Moelndal, Sweden) and substrate Mca-PLGL-Dpa-AR-NH2 (Bachem). IC50 values for ADAM-17 were 
determined using recombinant ectodomain (R&D Systems) and substrate Mca-PLAQAV-Dpa-
RSSSR-NH2 (R&D Systems). Proteolysis rates of the substrates were determined at 25 °C by 
measuring increase in fluorescence (ex,em = 320, 440 nm) for 15 min. in 96-well plates (Costar 
White) using a Fluorostar Optima plate reader (BMG Labtech). Each well (final volume 100 L) 
contained 10 ng enzyme and a final concentration of 4 mol/L substrate in assay buffer (MMP-12: 
50 mM Tris pH 7.4, 0.1 M NaCl, 10 mM CaCl2, 0.05% w/v Brij-35. ADAM-17: 25 mM Tris pH 9.0, 2.5 
M ZnCl2, 0.005% w/v Brij-35). Inhibition curves were plotted in Origin 7.0 (Micronal) and IC50 
values were determined by sigmoidal fitting. 
Determination of covalent labeling of active ADAM-10 by probe 18 (Figure 3) 
Recombinant ADAM-10 ectodomain (R&D systems) was incubated with probe 18 in 96-well plates 
(Costar White). Each well (final volume 50 L) contained 100 ng protein and 2.5 M inhibitor in 
assay buffer (25 mM Tris pH 9.0, 2.5 M ZnCl2, 0.005% w/v Brij-35). One well also contained 100 
M ADAM inhibitor TAPI-2 (Calbiochem). In one well ADAM-10 was denatured prior to incubation 
by boiling for 5 min. in assay buffer with 2% w/v SDS. The plate was irradiated by UV light under a 
Camag universal UV lamp with a 366 nm filter for different times. The reaction was stopped by 
adding 10 L 5 non-reducing SDS-PAGE sample buffer (Pierce). Samples were analyzed by SDS-
PAGE by loading 20 l of each sample on an 8% polyacrylamide Precise Protein gel (Pierce) and 
running in a mini-Protean III electrophoresis system (Bio-Rad) at 100 V for 45 min. The protein was 
transferred to an Immun-Blot PVDF membrane (Bio-Rad) by wet Western blotting in a mini Trans-
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blot cell (Bio-Rad) at 350 mA for 90 min. in 25 mM Tris, 190 mM glycine with 20% v/v methanol. 
The membrane was blocked for 30 min. in TBS-Tween supplemented with 5% w/v non-fat dried 
milk and incubated for 1 h in TBS-Tween with 1:1500 streptavidin-alkaline phosphatase (Sigma-
Aldrich). Staining was performed with NBT/BCIP (Duchefa). 
Determination of inhibitor efficacy (Table 2) 
The efficacy of the inhibitors was tested by evaluating their ability to inhibit proteolytic conversion 
of a fluorogenic substrate by recombinant metalloproteases. A fixed concentration of each 
inhibitor (final concentration 100 nM) was incubated with 5 ng of either MMP-9 catalytic domain, 
MMP-12 catalytic domain or ADAM-17 ectodomain in assay buffer (for MMP-9 and -12: 50 mM 
Tris pH 7.4, 0,1 M NaCl, 10 mM CaCl2, 0.05 % w/v Brij-35; for ADAM-17: 25 mM Tris pH 9.0, 2.5 M 
ZnCl2, 0.005% w/v Brij-35) in 96-well plates (Costar White). The appropriate fluorogenic substrate 
was added to a final concentration of 2 M and proteolysis rates were determined by measuring 
fluorescence (ex,em = 320, 440 nm) increase using a Fluostar Optima plate reader (BMG Labtech) 
at 28 °C. The remaining catalytic activity was calculated by comparing with proteolysis rates of 5 
ng uninhibited enzyme. 
Determination of IC50 values shown in Table 3 
The IC50 values of eight selected inhibitors were determined in a competitive enzyme activity assay 
monitoring conversion of the same fluorogenic substrates by recombinant metalloproteinases in 
presence of increasing concentrations inhibitor. Measurements were performed in 96-well plates 
(Costar white), where each well contained 5 ng of either MMP-9 catalytic domain, MMP-12 
catalytic domain or ADAM-17 and a final concentration of  2 M of the appropriate substrate in a 
final volume of 100 L assay buffer.  Proteolysis rates were determined by measuring fluorescence 
increase like above. Seven-point inhibition curves (0-10 M) were plotted in Origin 7.0 (Micronal) 
and IC50 values were determined by sigmoidal fitting.  
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Photoreactive Probes of Zinc-
Dependent Metalloproteases 








As outlined in Chapter 2 MMPs and ADAMs are an important class of proteases 
that fulfil a significant role in (extra-cellular) physiological processes1-10 and, as a 
consequence, deregulation of metalloprotease catalytic activity can lead to several 
inflammatory processes.6,11-15 Conventional proteomics approaches to determine the 
relation of metalloproteases to disease states are limited by the fact that they take the 
total protein amount into account, whereas in many cases the functionality, that is the 
catalytic activity, is the relevant parameter. Several elegant methods to determine 
proteolytic activity in biological samples have been developed, such as zymography and 
activity-based ELISA.16,17 Although these approaches visualise and quantify active 
proteases, application to a family-wide proteomics approach is difficult. Substrate 
specificity in zymography (for instance, gelatinases in gelatin zymography) and antibody 
specificity in ELISA make that both techniques are inherently limited to specific 
enzymes. Due to these limitations, there is a growing interest in the development of 
family-wide functional proteomics probes. Considerable progress have been made in the 
development and application of activity-based probes targeting cysteine proteases,18-21 
serine hydrolases22-25 and proteasome subunits.26-28 In these proteases a side chain 
residue (serine, cysteine or threonine) acts as the nucleophilic species involved in amide 
bond cleavage that is amenable to covalent and irreversible modification by instalment 
of an appropriate electrophilic trap in the activity-based probes. MMPs and ADAMs 
employ a water molecule as the nucleophile in their active site, which precludes the use 
P. P. Geurink, T. Klein, L. Prèly, K. Paal, M. A. Leeuwenburgh, G. A. van der Marel, H. F. Kauffman, 
H. S. Overkleeft, R. Bischoff, Eur. J. Org. Chem. 2010, 2100–2112. 
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of such an electrophilic trap. Photoaffinity labeling represents an alternative way to 
introduce tags into the active site of metalloproteases.29-36 In this context, peptide 
hydroxamate 1 featuring both a biotin and a trifluoromethyldiazirine moiety (Figure 1B) 
was developed (Chapter 2).37 Upon incubation of purified recombinant ADAM-10 and 
subsequent irradiation with UV light (366 nm) the metalloprotease was covalently and 
irreversibly modified, as was evidenced by SDS PAGE of the denatured protein followed 
by streptavidin blotting. The efficiency of the photoaffinity labeling however proved 
rather modest. This raised the question whether the photoactivatable group would be 
better directed towards the P1’ pocket, rather than the P2’ pocket (see Figure 1A for a 
general picture of the binding mode of N-terminal peptide hydroxamate-based 
metalloprotease inhibitors). Examination of the available 3-dimensional structures of 
metalloprotease-inhibitor complexes indicates that the P1’ pocket in general should be 
able to accommodate rather bulky hydrophobic groups at this position.38-41 It was 
decided to address this issue by the synthesis of peptide hydroxamate 2a (Figure 1C) 
with the photoactivatable group at the P1’ position, and compare its MMP/ADAM 
label g efficiency to that of probe 1 having the photoactivatable group at the P2’ 
position. This chapter describes an efficient synthesis of the required diazirine-modified 
succinyl hydroxamate building block and its application in the synthesis of activity-
based probe 2a along with a pair of fluorescent analogues 2b and 2c. It is further 
demonstrated that 2a indeed is the more efficient photoactivatable MMP/ADAM 
activity-based probe compared to 1 in a head to head comparison towards a range of 




Figure 1. (A) Generic binding mode of N-terminal peptide hydroxamates to metalloprotease active sites. (B) 
Peptide hydroxamate-based activity-based metalloprotease probe from previous studies with the 
photoactivatable group at the P2’ position.37 (C) Compounds targeted in this study and featuring the 
photoactivatable group at the P1’ site. 
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3.2 Results and Discussion 
In the work described in Chapter 237 on the synthesis of ABP 1, a chiral, L-leucine 
mimetic succinyl hydroxamate was employed in which the hydroxamic acid moiety was 
protected with acid-labile protective groups (O(TBS)-N(Boc)-R) and the carboxylate 
activated as the pentafluorophenyl ester. This buidling block can be readily incorporated 
in Fmoc-based solid-phase peptide synthesis protocols as the final building block after 
which the immobilized peptide hydroxamate is in one step cleaved from the resin and 
concomitantly deprotected. This strategy appeared of general use as was demonstrated 
by the construction of a peptide hydroxamate library (Chapter 2)42 and it was therefore 
decided to apply a similar strategy for the construction of the target compounds (2a-c). 
This required the synthesis of trifluoromethylphenyldiazirine functionalised analogue of 
compound 2 in Chapter 2. The synthesis of this compound (24, Scheme 2) starts with 
the construction of the P1’-trifluoromethylphenyldiazirine side chain, shown in Scheme 
1, which was prepared as follows. Reduction of 4-bromophenylpropionic acid 3 with 
LiAlH4 provided alcohol 4 that was transformed into TBS ether 5. At this stage the 
trifluoroacetyl moiety was introduced by first lithiation and subsequent addition of 1-
trifluoroacetyl piperidine. Refluxing the resulting ketone 6 and hydroxylamine in pyridine 
afforded oxime 7 as an E/Z mixture (~3:1). The hydroxyl in 7 was converted into the 
tosylate 8 after which reaction with liquid ammonia under 8 bar at room temperature led 
to the formation of diaziridine 9.  
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Reagents and conditions: (a) LiAlH4, Et2O, 0 °C, quant.; (b) TBSCl, imidazole, DMF, quant.; (c) nBuLi, 1-
trifluoroacetyl piperidine, Et2O, –78 °C → RT, 76%; (d) HONH2·HCl, pyridine, , 93%; (e) TsCl, Et3N, DMAP, 
DCM, 97%; (f) NH3, Et2O, 8 bar, 95%; (g) I2, Et3N, MeOH, 94%; (h) HCl, H2O, MeOH, 97%; (i) TEMPO, BAIB, 
DCM, H2O, 96%; (j) i) (ClCO)2, DMF, DCM; ii) 13, nBuLi, THF, 0 °C, 82%; (k) LiHMDS, tert-butyl bromoacetate, 
THF, –78 °C, 70%. 
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Oxidation of the diaziridine using iodine provided diazirine 10. Acidolysis of the 
TBS ether followed by biphasic TEMPO/BAIB oxidation of the resulting alcohol 1143 
provided carboxylic acid 12 in 57% overall yield over the nine steps. The route of 
synthesis continued by condensation of 12, via its acyl chloride, with the lithium salt of 
chiral auxilliary 13. Deprotonation of the resulting intermediate 14 followed by 
enantioselective alkylation with tert-butyl bromoacetate afforded succinate 15 as the 
single observed diastereomer in 57% yield over the two steps. 
In line with previous studies37 the Evans template was substituted with lithium 
benzyl alcoholate to give diester 16 (see Scheme 2). Selective acidic removal of the tert-
butyl group gave carboxylic acid 17 which was transformed into fully protected succinyl 
hydroxamate 18 by first transformation into the corresponding acyl chloride and next 
reaction with the lithiate of N-Boc-O-TBS-hydroxylamine.44 It was previously found 
(Chapter 2)37 that condensation of N-Boc-O-TBS-hydroxylamine with related acyl 
chlorides proceeded well under the agency of two equivalents of 4-
dimethylaminopyridine (DMAP) as the base. However, this procedure proved less 
efficient in the transformation aimed for here, and optimal results were obtained by 
adding dropwise the lithiate of N-Boc-O-TBS-hydroxylamine to a THF solution of the 
acyl chloride. Unfortunately deprotection of the benzyl ester to carboxylic acid 19 failed 
under the conditions attempted (Pd/C, H2 or Pd(OAc)2, Et3SiH, Et3N), either because the 
hydrogenation of the benzyl proceeded sluggishly or the diazirine was reduced 
concomitantly to the diaziridine.  
Scheme 2. Construction of photocrosslinker containing building block 24. 
 
Reagents and conditions: (a) BnOH, nBuLi, THF, 0 °C, 82%; (b) TFA, DCM, 97%; (c) i) (ClCO)2, DMF, DCM; ii) 
TBSONHBoc, nBuLi, THF, 27% for 18 and 77% for 22; (d) several conditions, no yield; (e) PFPOH, EDC, DCM, 
88% over 2 steps; (f) allyl alcohol, nBuLi, THF, 0 °C, 65%; (g) 23, Pd(PPh)4, THF. 
Rather than searching for a protocol in which the diaziridine is oxidised back to the 
diazirine after hydrogenation, it was opted to adapt the protective group scheme, as 
follows. Reaction of compound 15 with the lithium salt of allyl alcohol afforded allyl 
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ester 20.45 Partial deprotection and condensation with the protected hydroxylamine as 
described before gave succinyl hydroxamate 22. Now, the allyl ester was removed by 
reaction with tetrakis(triphenylphosphine)palladium in the presence of N,N’-
dimethylbarbaturic acid 23 as the allyl scavenger, providing carboxylate 19. The latter 
was converted into the key intermediate, pentafluorophenyl ester 24, in 88% yield over 
the last two steps. The choice for chiral alkylation by means of Evans template 
chemistry was based on previous work in which it was shown that alkylation and 
substitution of the Evans template, both of which entail strong basic conditions, gave 
optically pure products.37 Indeed, in the here presented synthesis no signs of any kind 
of epimerization were observed. The chiral outcome of these steps however can vary 
with the type of side chain used and the use of a different kind of chiral auxiliary, for 
example the thiazolidinethione derivatives which are known to display a better leaving 
group ability,46,47 may then prove necessary. 
The construction of peptide hydroxamates incorporating the chiral succinic acid 
derivative is depicted in Scheme 3. In the first instance pentafluorophenyl ester 24 was 
reacted with L-phenylalanine methylamide 2548 in DMF to give bisamide 26, which was 
finally deprotected (TFA/H2O, 95:5 (v:v)) to the free hydroxamic acid 27 in 30% yield over 
the two steps.49 This experiment at once established that building block 24 is 
compatible with the peptide coupling/global deprotection conditions envisioned and 
delivered a tag-free analogue of the target compounds for control experiments (vide 
infra). The target compound 2a was prepared by Fmoc-based solid-phase peptide 
synthesis starting with RINK amide-bound Fmoc-biocytin 28. Standard Fmoc-based 
solid-phase peptide synthesis afforded immobilized tripeptide 29, which was 
transformed in three steps (first Fmoc removal, then condensation with 
pentafluorophenyl ester 24 and finally removal from the solid support with concomitant 
global deprotection) into peptide hydroxamate 2a in 30% overall yield after RP-HPLC 
purification and based on 28. In a similar fashion, but employing FmocLys(Boc) instead 
of Fmoc-biocytin, peptide hydroxamate 30 was prepared. Treatment of 30 with either 
Bodipy(Tmr)-OSu50 or Bodipy(FL)-OSu51 gave compounds 2b and 2c in a yield of 31% 
and 55% respectively.  
Next, the labeling efficiencies of probes 1 and 2a against a panel of MMPs and 
ADAMs were compared. In a first experiment the inhibitory potency of the two probes 
against MMP-9, MMP-12, ADAM-10 and ADAM-17 were assessed (Table 1). Although the 
four enzymes are inhibited in the nanomolar range by both compounds, there are some 
differences in potency. The values differ especially for ADAM-17, for which hydroxamate 
1 appeared about 25 fold more potent compared to 2a. Interestingly, both compounds 
appear equally efficient in labeling ADAM-17, as is evidenced from Figure 2. In this 
experiment, recombinant and purified ADAM-17 was exposed to either 1 or 2a and UV 
light prior to denaturation, SDS PAGE and streptavidin blotting. It seems that inhibitory 
efficiency is not directly correlated to photoaffinity labelling, a phenomenon that may 
be explained by the mechanism by which the trifluoromethyldiazirine dissociates and 
reacts upon irradiation. Upon photoexcitation nitrogen is expulsed with concomitant 
formation of a highly reactive carbene that will insert in the first available X-H (where X 
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= C, N, O, S) bond (Chapter 1).52 In case an (active site) amino acid is nearby effective 
photoaffinity labeling is the expected result, whereas poor labelling will occur in case 
the photoreactive group is solvent (water) exposed. 
Scheme 3. Application of building block 24 in both solution-phase and solid-phase peptide chemistry. The 
construction of target compounds 2a-c. 
 
Reagents and conditions: (a) DMF, 45%; (b) TFA/H2O, 95:5 (v:v), RP-HPLC, 67%; (c) i) 20% piperidine/DMF; ii) 
Fmoc-Ahx-OH, HCTU, DiPEA, NMP; iii) 20% piperidine/DMF; iv) Fmoc-Phe-OH, HCTU, DiPEA, NMP; (d) i) 20% 
piperidine/DMF; ii) 24, DiPEA, NMP; iii) TFA/H2O/TIS 95:2.5:2.5 (v:v:v), 30% from 28; (e) Bodipy(Tmr)-OSu, 
DiPEA, DMF,RP-HPLC, 31%; (f) Bodipy(FL)-OSu, DiPEA, DMF, RP-HPLC, 55%. 
Table 1. IC50 values (in nM) of compounds 1 and 2a. 
 MMP-9 MMP-12 ADAM-10 ADAM-17 
1 25.1 3.60a 114a 20.6a 
2a 24.2 12.5 54.1 490 
a From reference.37 
A plausible hypothesis may be that the diazirine moiety in compound 2a is bound 
more tightly to ADAM-17 than the one in compound 1, even though the latter 
compound is the more potent inhibitor. Perusal of a panel of ten recombinant and 
purified MMPs and three more ADAMs reveals that, in general, peptide hydroxamate 2a 
is the more effective affinity label (Figure 2). In each case compound 2a is at least as 
effective (compare the data obtained for ADAM-9 and ADAM-10) and often in fact 
provides a signal where compound 1 does not (see for instance the results obtained for 
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MMP-8 and MMP-13). Interestingly, multiple bands appear for some of the MMP labeling 
experiments (see for instance, MMP-1 and MMP-8 treated with 2a), with the band 
corresponding to the highest molecular weight in each case corresponding to the 
molecular weight of the full-length MMP at hand. These bands in all likelihood are the 
result of auto-degradation, in which unmodified MMP processes its photoaffinity labeled 
counterpart. From these experiments it can be concluded that positioning the 
photoactivatable group at P1’ as in 2a indeed gives a comparatively more potent 
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Figure 2. Photoaffinity labeling of MMPs (A) and ADAMs (B) using probe 1 (upper panels) and probe 2a (lower 
panels) at 1 M. The modified proteins were visualized by anti-biotin Western blots with streptavidin-alkaline 
phosphatase. Ten recombinant MMP and four recombinant ADAM proteases (4 pmol each; numbers above 
the lanes correspond to the respective protease) were studied. Multiple biotinylated bands in the recombinant 
MMPs indicate auto-degradation. M: molecular weight marker. 
In order to prove that labeling is activity-dependent, aliquots of MMP-9 and MMP-
12 were incubated with either the natural inhibitor, TIMP-153 or the non-biotinylated 
inhibitor 27 (see Figure 3). In the presence of equimolar amounts (relative to 2a) of 
TIMP-1 neither MMP-9 nor MMP-12 were detectably labeled. Preincubation of MMP-9 or 
MMP-12 with two-fold molar excess, relative to 2a, of the non-biotinylated inhibitor 27 
also effectively abolished labeling. Taken together, these data provide strong evidence 
that photoaffinity labeling is activity-dependent and that labelling occurs most likely in 
the active site of the enzymes. 
3.3 Conclusion 
In summary, the development of an efficient photoactivatable activity-based probe 
with which a broad panel of MMPs and ADAMs can be covalently and irreversibly 
modified in an activity-dependent fashion has been described. This work demonstrates 
that the enantioselective synthesis strategy previously reported37,42 for the preparation 
of an enantiomerically pure, alkylated succinyl hydroxamate is also effective, in adapted 
form, for the synthesis of the functionally more challenging key building block 24. 
Further, the hypothesis that placing the photoactivatable trifluoromethyldiazirine in the 
P1’ position would lead to more effective activity-based probes proved to be valid. The 
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next  challenge would be to detect MMPs and ADAMs in their natural environment and 
at natural abundance levels in a photoactivatable activity-based proteomics profiling 
experimental setting. The ability to prepare, with relative ease, peptide hydroxamates 
analoguous to compounds 1 and 2a such as Bodipy derivatives 2b,c may well be 
indispensable in reaching this research objective. 
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Figure 3. Activity-dependence of photoaffinity labeling of MMP-9 and MMP-12 (4 pmol each) with probe 2a 
(200 nM final concentration) as shown by competition with (A) an equimolar amount of the endogenous MMP 




Tetrahydrofuran was distilled over LiAlH4 prior to use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), N-methyl-2-pyrrolidone (NMP), methanol (MeOH), piperidine, 
diisopropylethylamine (DiPEA) and trifluoroacetic acid (TFA) were of peptide synthesis grade, 
purchased at Biosolve, and used as received. All general chemicals were used as received. Rink 
amide MBHA resin (0.64 mmol/g) was purchased at Novabiochem, as well as all appropriately 
protected amino acids. O-(1H-6-Chlorobenzotriazolyl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HCTU) was purchased at Iris Biotech (Marktrewitz, Germany). Traces of 
water were removed from reagents used in reactions that require anhydrous conditions by co-
evaporation with toluene. Solvents that were used in reactions were stored over 4 Å molecular 
sieves, except methanol and acetonitrile which were stored over 3 Å molecular sieves. Molecular 
sieves were flame dried before use. Unless noted otherwise all reactions were performed under an 
argon atmosphere. Column chromatography was performed on Screening Devices b.v. Silica Gel, 
with a particle size of 40-63 m and pore diameter of 60 Å. The eluents toluene, EtOAc and PE 
(40-60 ºC boiling range) were distilled prior to use. TLC analysis was conducted on Merck 
aluminium sheets (Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by 
spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% 
sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and 
acetic acid (12.5 mL/L) in ethanol, where appropriate, followed by charring at ca. 150 °C. 1H- and 
13C-NMR spectra were recorded on a Bruker AV-400 (400 MHz), a Bruker AV-500 (500 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. 19F NMR spectra were recorded on a Bruker AV-200 (200 
MHz) or a Bruker DMX-400 (400 MHz). Chemical shifts are given in ppm () relative to 
tetramethylsilane, CD3OD, DMSO-d6, CDCl3 or CFCl3 as internal standard. High resolution mass 
spectra were recorded by direct injection (2 L of a 2 M solution in water/acetonitrile 50/50 (v/v) 
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and 0.1% formic acid) on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an 
electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary 
temperature 250 °C) with resolution R = 60,000 at m/z = 400 (mass range m/z = 150-2000) and 
dioctylpthalate (m/z = 391.28428) as a “lock mass”. The high resolution mass spectrometer was 
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). Optical rotations 
 were recorded on a Propol automatic polarimeter. LC-MS analysis was performed on a 
Finnigan Surveyor HPLC system with a Gemini C18 50 × 4.60 mm column (detection at 200-600 
nm), coupled to a Finnigan LCQ Advantage Max mass spectrometer with ESI. The applied buffers 
were H2O, ACN and 1.0% aq. TFA. RP-HPLC purifications were performed on a Gilson HPLC 
system coupled to a Phenomenex Gemini 5 m 250 × 10 mm column and a GX281 fraction 
collector. The applied buffers were: 0.1% aq. TFA and ACN. Appropriate fractions were pooled, 
and concentrated in a Christ rotary vacuum concentrator overnight at room temperature at 0.1 
mbar. 
23][ D
General procedure A: solid-phase peptide synthesis 
Fmoc Rink Amide MBHA resin (0.64 mmol/g) was used as received. Prior to first use, it was washed 
twice with DMF, twice with MeOH and twice with DCM. Fmoc deprotection was performed by 
shaking the resin in a 20% piperidine/DMF (v/v) stock solution for 20 min. The resin was washed 
twice with DMF and twice with DCM after every coupling and deprotection step. The first amino 
acid was loaded by reacting the resin with 4 equivalents of HCTU, 4 equivalents of amino acid and 
8 equivalents DiPEA (0.45 M stock solution in NMP). The amino acid was pre-activated in solution 
(5 min.) before adding it to the resin and shaking the resin for 1 h (standard coupling protocol). 
Loading was determined by UV spectroscopy at 300 nm of a freshly prepared Fmoc-deprotected 
resin sample. A capping step was performed by shaking the resin for 10 min. with 0.45 M acetic 
anhydride and 0.45 M DiPEA/NMP solution. Mtt deprotection was done by shaking repeatedly in a 
1% TFA/DCM solution until the characteristic yellow colour of the Mtt cation did no longer appear 
(7-12 times, 2 min. each). After Mtt-cleavage, immediately before the following coupling step, the 
resin was washed with a 0.45 M DiPEA stock solution in NMP. The coupling and deprotection 
reactions were checked on the presence of free amines by performing a Kaiser test. Before 
cleaving the peptide from the resin, it was washed 5 times alternatingly with DCM and MeOH. 
Cleavage from the solid support was done by shaking the resin in a  TFA:H2O:TIS, 95:2.5:2.5 (v/v/v) 
solution for 2 h, followed by filtration and rinsing the resin with a small portion of TFA:H2O:TIS, 
95:2.5:2.5 (v/v/v). The resulting filtrate was concentrated under reduced pressure and the product 
was purified by RP-HPLC. 
 
3-(4-bromophenyl)propanol (4) 
Commercially available 3-(4-bromophenyl)propanoic acid (3, 10.8 g, 46.22 mmol) 
was dissolved in Et2O (250 mL) and cooled to 0 °C. To this solution was carefully 
added LiAlH4 (1.3 eq., 60 mmol, 2.28 g) in portions. The reaction was slowly warmed to room 
temperature in 1 h after which TLC analysis indicated a completed reaction. 1M aq. HCl (200 mL) 
was slowly added and the layers were separated. The organic layer was extracted with 1M aq. HCl 
(200 mL), saturated aq. NaHCO3 (2 × 200 mL) and brine (200 mL), dried over MgSO4 and 
concentrated under reduced pressure. The product was obtained as a colourless oil (yield: 9.9 g, 





To a solution of alcohol 4 (9.9 g, 46.2 mmol) in DMF (80 mL) were added 
imidazole (4.77 g, 69.3 mmol) and tert-butylchlorodimethylsilane (TBS-Cl) (7.82 
g, 50.8 mmol). The reaction was stirred for 2 h after which TLC analysis indicated complete 
conversion. Deionised H2O (300 mL) was added and the mixture was extracted 3 times with PE 




66       Chapter 3  
(200 mL), dried over MgSO4 and concentrated under reduced pressure. The product was obtained 
as a colourless oil (yield: 15.2 g, 46.2 mmol, quant.) and subjected to the next step without further 
purification. The spectroscopic data correspond with those reported in literature.55 
 
1-(4-(3-(tert-butyldimethylsilyloxy)propyl)phenyl)-2,2,2-
trifluoroethanone  (6) 
Bromide 5 (7.03 g, 21.36 mmol) was dissolved in Et2O (100 mL) and cooled to 
–78 °C. nBuLi (26.7 mmol, 16.7 mL, 1.6 M in THF) was added dropwise and the 
solution was slowly warmed up to room temperature at which it was stirred for 1 h. Then the 
mixture was cooled again to –78 °C and a solution of 1-trifluoroacetyl piperidine (4.2 g, 23.2 
mmol) in Et2O (5 mL) was added dropwise. The solution was slowly warmed to 0 °C in 2 h after 
which TLC analysis indicated a complete conversion. The reaction was quenched with saturated 
aq. NH4Cl (100 mL) and the layers were separated. The organic layer was extracted with saturated 
aq. NH4Cl, deionised water and brine (100 mL each), dried over MgSO4 and concentrated under 
reduced pressure. The crude material was purified by column chromatography (10% → 30% 
toluene/PE) and the product was obtained as a colourless oil (yield: 5.63 g, 16.3 mmol, 76%). 1H 
NMR (400 MHz, CDCl3):  = 8.00 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 3.64 (t, J = 6.4 Hz, 
2H), 2.79 (t, J = 7.6 Hz, 2H), 1.89-1.84 (m, 2H), 0.91 (s, 9H), 0.06 (s, 6H) ppm. 13C NMR (100 MHz, 
CDCl3):  = 151.3, 130.2, 129.3, 127.7, 116.8 (q, J = 290 Hz), 61.4, 33.9, 32.4, 25.9, 18.2, –5.4 
ppm. HRMS: calcd. for C17H25F3O2Si [M + H]






trifluoroethanone oxime (7) 
Ketone 6 (9.43 g, 27.2 mmol) was dissolved in pyridine (30 mL) and 
hydroxylamine hydrochloride (5.68 mmol, 81.7 mmol) was added. The mixture was stirred at reflux 
for 2 h after which TLC analysis indicated a complete conversion. The mixture was concentrated 
under reduced pressure and dissolved in EtOAc (100 mL) and 0.2 M aq. citric acid (100 mL). The 
layers were separated and the organic layer was extracted with 0.2 M aq. citric acid, deionised 
water and brine (100 mL each), dried over MgSO4 and concentrated under reduced pressure. The 
crude product was obtained as a colourless oil (yield: 9.13 g, 25.3 mmol, 93%) as a Z/E mixture. A 
small amount was purified by column chromatography (5% → 10% EtOAc/PE) for characterization. 
1H NMR (400 MHz, CDCl3):  = 8.51 (bs, 1H), 8.25 (bs, 1H), 7.44-7.39 (m, 2H), 7.31-7.23 (m, 2H), 
3.67-3.62 (m, 2H), 2.74-2.69 (m, 2H), 1.89-1.82 (m, 2H), 0.91 (s, 9H), 0.06 (s, 6H) ppm. 13C NMR 
(100 MHz, CDCl3):  = 147.4-146.5 (m), 144.9, 144.5, 129.2, 128.9, 128.9, 128.7, 128.6, 128.6, 
128.4, 128.3, 128.2, 127.9, 123.7, 120.9 (q, J = 273 Hz), 118.6 (q, J = 281 Hz), 63.0, 62.8, 34.0, 









trifluoroethanone O-tosyl oxime (8) 
Oxime 7 (9.13 g, 25.3 mmol) was dissolved in DCM (20 mL). To this solution 
were added Et3N (5.26 mL, 37.95 mmol) and DMAP (60 mg, 0.5 mmol) after which TsCl (4.84 g, 
25.3 mmol) in DCM (20 mL) was added dropwise over 1 h. After stirring the mixture at room 
temperature for 30 min. TLC analysis indicated a complete conversion. Aqueous citric acid (0.2 M, 
100 mL) was added and the layers were separated. The organic layer was extracted with 0.2 M aq. 
citric acid (100 mL) and brine, dried over MgSO4 and concentrated under reduced pressure 
yielding the crude product (Z/E mixture) as a colourless oil (yield: 12.59 g, 24.4 mmol, 97%). A 
small amount was purified by column chromatography (1.5% → 7.5% EtOAc/PE) for 
characterization. 1H NMR (400 MHz, CDCl3):  = 7.91-7.88 (m, 2H), 7.39-7.25 (m, 6H), 3.66-3.62 
(m, 2H), 2.73 (t, J = 7.8 Hz, 2H), 2.48 (s, 3H), 2.46 (s, 3H), 1.88-1.83 (m, 2H), 0.91 (s, 9H), 0.90 (s, 
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146.6, 146.0, 145.9, 131.5, 131.2, 129.7, 129.1, 128.9, 129.8, 128.7, 128.4, 121.8, 119.7 (q, J = 
276 Hz), 61.9, 61.8, 33.8, 33.8, 32.0, 31.9, 25.8, 21.5, 18.1, –5.5 ppm. HRMS: calculated for 
C24H32F3NO4SSi [M + H]




Tosylate 8 (12.6 g, 24.4 mmol) was dissolved in Et2O (30 mL) in an autoclave 
and cooled to –78 °C. Freshly condensed ammonia (~5 mL) was added and the autoclave was 
closed and warmed to room temperature. The pressure inside increased to 8 bar. After 5 h the 
autoclave was cooled to –78 °C and opened. Deionised water (40 mL) was carefully added and the 
mixture was warmed to room temperature. The layers were separated and the organic layer was 
extracted with deionised water (3 × 50 mL)) and brine, dried over MgSO4 and concentrated under 
reduced pressure. The crude diaziridine was obtained as a colourless oil (yield: 8.32 g, 23.1 mmol, 
95%). A small amount was purified by column chromatography (2% → 11% EtOAc/PE) for 
characterization. 1H NMR (400 MHz, CDCl3):  = 7.51 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 
3.63 (t, J = 6.2 Hz, 2H), 2.77 (d, J = 8.8 Hz, 1H), 2.71 (t, J = 7.8 Hz, 2H), 2.20 (d, J = 8.8 Hz, 1H), 
1.86-1.81 (m, 2H), 0.90 (s, 9H), 0.05 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3):  = 144.3, 129.1, 
128.8, 127.9, 123.6 (q, J = 277 Hz), 61.9, 57.7 (q, J = 35.7 Hz), 34.0, 31.7, 25.7, 18.1, –5.6 ppm. 
HRMS: calcd. for C17H27F3N2OSi [M + H]









Et3N (46.2 mmol, 6.4 mL) was added to a solution of crude diaziridine 9 (8.32 
g, 23.1 mmol) in MeOH (25 mL). Then iodine (23.1 mmol, 5.86 g) was added in portions, letting the 
mixture decolorize after every portion. Eventually the reaction mixture did not decolorize anymore 
and the mixture was stirred for another 30 min. TLC analysis indicated a completed reaction and a 
10% w/w aq. citric acid solution (100 mL) was added. The mixture was extracted twice with Et2O 
(150 mL) and the combined organic layers were extracted with 10% w/w aq. citric acid (100 mL), a 
saturated aq. NaHSO3 solution (100 mL), deionised water (100 mL) and brine (100 mL), dried over 
MgSO4 and concentrated under reduced pressure. The crude diazirine was obtained as a 
colourless oil (yield: 7.77 g, 21.7 mmol, 94%). A small amount was purified by column 
chromatography (1% → 2.5% EtOAc/PE) for characterization. 1H NMR (600 MHz, CDCl3):  = 7.22 
(d, J = 8.4 Hz, 2H), 7.10 (d, J = 7.8 Hz, 2H), 3.61 (t, J = 6.3 Hz, 2H), 2.69 (t, J = 7.5 Hz, 2H), 1.82-
1.79 (m, 2H), 0.90 (s, 9H), 0.05 (s, 6H) ppm. 13C NMR (150 MHz, CDCl3):  = 144.2, 129.0, 126.6, 
126.5, 122.4 (q, J = 273 Hz), 61.9, 34.2, 31.8, 28.4 (q, J = 40 Hz), 25.9, 18.3, –5.5 ppm. HRMS: 
calcd. for C17H25F3N2OSi [M + H]







Compound 10 (7.78 g, 21.7 mmol) was dissolved in MeOH (50 mL) and 
concentrated HCl (37% (w/v), 3 mL) was added. The reaction mixture was stirred 
at room temperature until TLC analysis revealed a completed reaction after 2 h. 
The solvent was evaporated under reduced pressure and the residue was dissolved in Et2O (200 
mL). The resulting solution was extracted twice with a saturated aq. NaHCO3 solution (150 mL) 
and brine (100 mL), dried over MgSO4 and concentrated under reduced pressure. The crude 
mixture was purified by column chromatography (10% → 60% EtOAc/PE) and the pure alcohol 11 
was obtained as a colourless oil (yield: 5.13 g, 21.0 mmol, 97%). 1H NMR (400 MHz, CDCl3):  = 
7.25 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 3.66 (t, J = 6.4 Hz, 2H), 2.72 (d, J = 7.8 Hz, 2H), 
1.90-1.83 (m, 2H), 1.43 (bs, 1H) ppm. 13C NMR (100 MHz, CDCl3):  = 143.7, 129.1, 126.5, 126.4, 
122.2 (q, J = 263 Hz), 61.4, 33.7, 31.6, 28.2 (q, J = 40.2 Hz) ppm. HRMS: calcd. for C11H11F3N2O [M 
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3-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)propanoic acid (12) 
Alcohol 11 (2.1 g, 8.6 mmol) was dissolved in a mixture of DCM (25 mL) and 
deionised H2O (12.5 mL). To this mixture were added 2,2,6,6-
tetramethylpiperidinooxy (TEMPO) (0.1 eq., 0.86 mmol, 134 mg) and 
(bis(acetoxy)iodo)benzene (BAIB) (2.5 eq., 21.5 mmol, 6.92 g). The reaction was stirred overnight 
at room temperature after which TLC analysis revealed a completed reaction. A saturated aq. 
Na2S2O3 solution (100 mL) was added and the mixture was vigorously stirred for 5 min. EtOAc (150 
mL) was added and the layers were separated. The organic layer was extracted with 1 M aq. HCl 
and brine (100 mL), dried over MgSO4 and concentrated under reduced pressure. The crude 
material was purified by column chromatography (10% → 30% EtOAc/PE) and the product was 
obtained as a colourless solid (yield: 2.13 g, 8.23 mmol, 96%). 1H NMR (600 MHz, CDCl3):  = 
11.81 (bs, 1H), 7.22 (d, J = 9.0 Hz, 2H), 7.11 (d, J = 9.6 Hz, 2H), 2.94 (t, J = 8.1 Hz, 2H), 2.65 (t, J 
= 8.1 Hz, 2H) ppm. 13C NMR (150 MHz, CDCl3):  = 179.4, 142.0, 128.8, 127.2, 126.6, 122.2 (q, J 
= 273 Hz), 35.2, 30.1, 28.4 (q, J = 40.5 Hz) ppm. HRMS: calcd. for C11H9F3N2O2 [M + H]+ 









Carboxylic acid 12 (1.04 g, 4.03 mmol) was dissolved in DCM (25 mL) and 
DMF (1 drop) was added. The mixture was cooled to 0 °C and oxalyl chloride 
(1.7 mL, 20 mmol) was added dropwise. The reaction was warmed to room temperature and 
stirred for 30 min. after which gas formation ceased. Toluene was added and the mixture was 
concentrated in vacuo followed by coevaporation with toluene (twice). The crude product was 
subjected to the next step without further purification. nBuLi (2.75 mL of a 1.6 M solution in THF, 
4.4 mmol) was put into a flask under an argon atmosphere and cooled to 0 °C. To this was added 
dropwise a solution of (S)-4-benzyloxazolidin-2-one (13, 0.78 g, 4.43 mmol) in THF (15 mL) and 
the mixture was stirred at 0 °C for 15 min., thereby forming a white precipitant. Then the freshly 
prepared acyl chloride in THF (10 mL) was added to the reaction mixture dropwise and the mixture 
was slowly warmed to room temperature. After 2 h at room temperature, TLC analysis showed 
complete consumption of the starting material. To the mixture was added deionised water (50 mL) 
and it was extracted twice with EtOAc (50 mL). The combined organic layers were extracted with a 
saturated aq. solution of NaHCO3 (2 × 50 mL) and brine (50 mL), dried over MgSO4 and 
concentrated under reduced pressure. The obtained material was purified by column 
chromatography (10% → 30% EtOAc/PE) and the product was obtained as a colourless solid 
(yield: 1.38 g, 3.31 mmol, 82%). 1H NMR (600 MHz, CDCl3):  = 7.32-7.25 (m, 5H), 7.16 (d, J = 7.2 
Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 4.67-4.63 (m, 1H), 4.18-4.14 (m, 2H), 3.32-3.19 (m, 3H), 3.04-
3.01 (m, 2H), 2.75 (dd, J = 13.8, 9.6 Hz, 1H) ppm. 13C NMR (150 MHz, CDCl3):  = 171.9, 153.4, 
142.4, 135.0, 129.3, 129.1, 128.9, 127.3, 127.0, 126.6, 122.1 (q, J = 273 Hz), 66.2, 55.0, 37.7, 36.7, 
29.7, 28.3 (q, J = 40.0 Hz) ppm.  = +48.5 (c = 1, CHCl3). HRMS: calcd. for C21H18F3N3O3 [M 













LiHMDS (5.5 mL of a 1 M solution, 5.5 mmol) was put into a flask under an 
argon atmosphere and cooled to –78 °C. To this was added a solution of 
compound 14 (2.0 g, 5.0 mmol) in THF (25 mL) over 15 min. The reaction was stirred for 1 h at –78 
°C after which tert-butyl bromoacetate (2.2 mL, 15 mmol) was added. Then the mixture was slowly 
warmed to –10 °C in 4 h after which TLC analysis showed a completed reaction. A saturated aq. 
NH4Cl solution (50 mL) was added and the mixture was extracted with EtOAc (3 × 30 mL). The 
combined organic layers were dried over MgSO4 and concentrated under reduced pressure. The 
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product was obtained as a colourless solid (yield: 1.86 g, 3.50 mmol, 70%). 1H NMR (600 MHz, 
CDCl3):  = 7.30-7.25 (m, 4H), 7.21-7.18 (m, 3H), 7.05 (d, J = 9.0 Hz, 2H), 4.55-4.52 (m, 1H), 4.42-
4.38 (m, 1H), 4.05 (dd, J = 9.0, 1.8 Hz, 1H), 3.92 (t, J = 8.4 Hz, 1H), 3.23 (dd, J = 13.5, 2.7 Hz, 1H), 
3.00 (dd, J = 13.2, 6.0 Hz, 1H), 2.79-2.70 (m, 2H), 2.57 (dd, J = 13.2, 9.6 Hz, 1H), 2.25 (dd, J = 
16.8, 4.2 Hz, 1H), 1.34 (s, 9H) ppm. 13C NMR (150 MHz, CDCl3):  = 174.5, 170.8, 152.8, 139.9, 
135.3, 129.6, 129.3, 128.7, 127.3, 127.1, 126.4, 121.9 (q, J = 273 Hz), 80.6, 65.7, 55.2, 41.0, 37.3, 
36.2, 28.1 (q, J = 39.8 Hz), 27.2 ppm.  = +72.8 (c = 1, CHCl3). HRMS: calcd. for 
C27H28F3N3O5 [M + H]





Benzyl alcohol (350 L, 3.40 mmol) was dissolved in THF (8 mL) and cooled 
to 0 °C. To this mixture was added nBuLi (1.10 mL of a 1.6 M solution, 1.76 
mmol) and the reaction was stirred at 0 °C for 30 min. Then a solution of 
compound 15 (784 mg, 1.47 mmol) in THF (4 mL) was added and the reaction mixture was stirred 
for 1 h at 0 °C and then warmed to room temperature. After 30 min. TLC analysis indicated 
complete conversion of the starting material. A saturated aq. NH4Cl solution (20 mL) was added 
and the mixture was extracted twice with EtOAc (20 mL). The combined organic layers were dried 
over MgSO4 and concentrated under reduced pressure. After purification of the crude mixture by 
column chromatography (3% → 10% EtOAc/PE) the product was obtained as a colourless oil 
(yield: 558 mg, 1.21 mmol, 82%). 1H NMR (600 MHz, CDCl3):  = 7.37 (t, J = 7.2 Hz, 1H), 7.33 (d, J 
= 4.8 Hz, 2H), 7.22 (t, J = 3.6 Hz, 2H), 7.14 (d, J = 7.8 Hz, 2H), 7.05 (d, J = 7.8 Hz, 2H), 5.06 (dd, J 
= 36.6, 12.0 Hz, 2H), 3.13-3.10 (m, 1H), 2.99 (dd, J = 13.2, 7.2 Hz, 1H), 2.82 (dd, J =13.8, 7.8 Hz, 
1H), 2.60 (dd, J = 16.2, 8.4 Hz, 1H), 2.34 (dd, J = 16.8, 5.4 Hz, 1H), 1.40 (s, 9H) ppm. 13C NMR 
(150 MHz, CDCl3):  = 173.4, 170.3, 140.0, 135.5, 129.3, 128.1, 128.0, 127.1, 126.4, 126.3, 122.0 











yl)benzyl)butanoic acid (17) 
Tert-butyl ester 16 (550 mg, 1.19 mmol) was dissolved in DCM (4 mL). To this 
was added TFA (3 mL) and the reaction was stirred at room temperature. 
After 1 h TLC analysis indicated a completed reaction. Toluene was added 
and the mixture was concentrated under reduced pressure. Coevaporating the mixture twice with 
toluene resulted in a yellowish oil. This crude product was purified by column chromatography 
(10% → 60% EtOAc/PE) and the free carboxylic acid was obtained as a colourless solid (yield: 1.09 
g, 3.07 mmol, 97%). 1H NMR (600 MHz, CDCl3):  = 11.15 (bs, 1H), 7.35 (t, J = 7.2 Hz, 1H), 7.32 (d, 
J = 4.8 Hz, 2H), 7.21 (t, J = 3.6 Hz, 2H), 7.11 (d, J = 7.8 Hz, 2H), 7.04 (d, J = 7.8 Hz, 2H), 5.06 (dd, 
J = 36.6, 12.0 Hz, 2H), 3.17-3.12 (m, 1H), 3.00 (dd, J = 13.8, 7.2 Hz, 1H), 2.81 (dd, J =13.8, 7.8 Hz, 
1H), 2.74 (dd, J = 17.4, 9.0 Hz, 1H), 2.43 (dd, J = 17.4, 5.4 Hz, 1H) ppm. 13C NMR (150 MHz, 
CDCl3):  = 177.7, 173.4, 139.6, 135.3, 129.4, 128.5, 128.5, 128.4, 127.5, 126.5, 122.0 (q, J = 273 











Carboxylic acid 17 (71 mg, 0.18 mmol) was dissolved in DCM (1.5 mL) and 
DMF (1 drop) was added. This mixture was cooled to 0 °C and oxalyl 
chloride (4 eq., 0.70 mmol, 60 L) was added dropwise. The reaction was warmed to room 
temperature and stirred for 30 min. after which gas formation ceased. Toluene was added and the 
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protected hydroxylamine44 (1.2 eq., 0.19 mmol, 48 mg) was dissolved in THF (2 mL) and the 
solution was cooled to 0 °C. nBuLi (1.05 eq., 0.185 mmol, 0.11 mL of a 1.6 M solution in hexane) 
was added dropwise and the reaction mixture was stirred at 0 °C for 30 min. In a separate flask the 
freshly prepared crude acyl chloride was dissolved in THF (2 mL) and cooled to 0 °C. To this the 
lithiated hydroxylamine mixture was added dropwise and the reaction was stirred at 0 °C for 2.5 h 
after which TLC analysis indicated complete conversion of compound 17. A 0.1 M aq. HCl 
solution (10 mL) was added and the mixture was extracted twice with EtOAc (10 mL). The 
combined organic layers were extracted with 0.1 M aq. HCl (10 mL) and brine, dried over MgSO4 
and concentrated under reduced pressure. The crude mixture was purified by column 
chromatography (toluene → 3% EtOAc/toluene) and the product was obtained as a colourless oil 
(yield: 30 mg, 47 mol, 27%). 1H NMR (600 MHz, CDCl3):  = 7.34-7.31 (m, 3H), 7.20 (t, J = 3.6 Hz, 
2H), 7.15 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 7.8 Hz, 2H), 5.06-5.01 (m, 2H), 3.27-3.21 (m, 2H), 2.98 
(dd, J = 13.2, 6.6 Hz, 1H), 2.90-2.84 (m, 2H), 1.53 (s, 9H), 0.98 (s, 9H), 0.12 (s, 3H), 0.085 (s, 3H) 
ppm. 13C NMR (150 MHz, CDCl3):  = 174.1, 170.3, 151.8, 140.0, 135.5, 129.4, 128.4, 128.2, 128.1, 
127.3, 126.4, 122.1 (q, J = 273 Hz), 84.6, 66.4, 42.7, 38.8, 37.4, 28.2 (q, J = 40 Hz), 27.9, 25.6, 




Allyl alcohol (190 L, 2.75 mmol) was dissolved in THF (5 mL) and cooled to 
0 °C. To this mixture was added nBuLi (812 L of a 1.6 M solution, 1.3 mmol) 
and the reaction was stirred at 0 °C for 30 min. Then a solution of compound 
15 (586 mg, 1.10 mmol) in THF (4 mL) was added and the reaction mixture was stirred for 1 h at 0 
°C and then warmed to room temperature. After 2.5 h TLC analysis indicated complete conversion 
of the starting material. A saturated aq. NH4Cl solution (20 mL) was added and the mixture was 
extracted twice with EtOAc (20 mL). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. After purification of the crude mixture by column 
chromatography (2.5% → 5% EtOAc/PE) the product was obtained as a colourless oil (yield: 293 
mg, 0.71 mmol, 65%). 1H NMR (600 MHz, CDCl3):  = 7.21 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 7.8 Hz, 
2H), 5.83-5.77 (m, 1H), 5.22 (d, J = 16.8 Hz, 1H), 5.18 (d, J = 10.8 Hz, 1H), 4.57-4.50 (m, 2H), 
3.11-3.07 (m, 1H), 3.02 (dd, J = 13.8, 7.2 Hz, 1H), 2.82 (dd, J = 13.8, 7.8 Hz, 1H), 2.59 (dd, J = 
16.2, 8.4 Hz, 1H), 2.33 (dd, J = 16.8, 5.4 Hz, 1H), 1.42 (s, 9H) ppm. 13C NMR (150 MHz, CDCl3):  = 
173.5, 170.6, 140.2, 131.7, 129.5, 127.4, 126.5, 122.1 (q, J = 273 Hz), 118.3, 80.9, 65.3, 43.0, 37.2, 
36.4, 28.2 (q, J = 40.5 Hz), 27.9 ppm.  = +9.9 (c = 1, CHCl3). HRMS: calcd. for C20H23F3N2O4 










yl)benzyl)butanoic acid (21) 
Tert-butyl ester 20 (1.31 g, 3.17 mmol) was dissolved in DCM (10 mL). To this 
was added TFA (10 mL) and the reaction was stirred at room temperature. 
After 1 h TLC analysis indicated a completed reaction. Toluene was added and 
the mixture was concentrated under reduced pressure. Coevaporating the mixture twice with 
toluene resulted in yellowish oil. This crude product was purified by column chromatography (10% 
→ 50% EtOAc/PE) and the free acid was obtained as a colourless solid (yield: 1.09 g, 3.07 mmol, 
97%). 1H NMR (600 MHz, CDCl3):  = 10.80 (bs, 1H), 7.20 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 
2H), 5.82-5.76 (m, 1H), 5.22 (dd, J = 15.6, 1.8 Hz, 1H), 5.19 (dd, J = 10.8, 1.2 Hz, 1H), 4.57-4.52 
(m, 2H), 3.15-3.10 (m, 1H), 3.05 (dd, J = 13.8, 7.2 Hz, 1H), 2.83 (dd, J = 13.8, 7.8 Hz, 1H), 2.73 
(dd, J = 17.4, 9.0 Hz, 1H), 2.44 (dd, J = 17.4, 5.4 Hz, 1H) ppm. 13C NMR (150 MHz, CDCl3):  = 
177.7, 173.3, 139.8, 131.5, 129.5, 127.6, 126.6, 122.0 (q, J = 273 Hz), 118.5, 65.5, 42.5, 37.1, 34.8, 
28.2 (q, J = 40.0 Hz) ppm 23]D  = +13.2 (c = 1, CHCl3). HRMS: calcd. for C16H15F3N2O4 [M + H]
+ 













Carboxylic acid 21 (1.22 g, 3.42 mmol) was dissolved in DCM (15 mL) and 
DMF (2 drops) were added. This mixture was cooled to 0 °C and oxalyl 
chloride (4 eq., 13.68 mmol, 1.20 mL) was added dropwise. The reaction was warmed to room 
temperature and stirred for 30 min. after which gas formation ceased. Toluene was added and the 
mixture was concentrated in vacuo followed by coevaporation with toluene (2×). The crude 
product was subjected to the next step without further purification. O(TBS)-N(Boc) protected 
hydroxylamine44 (1.2 eq., 4.1 mmol, 1.01 g) was dissolved in THF (10 mL) and the solution was 
cooled to 0 °C. nBuLi (1.05 eq., 3.59 mmol, 2.25 mL of a 1.6 M solution in hexane) was added 
dropwise and the reaction mixture was stirred at 0 °C for 30 min. In a separate flask the freshly 
prepared crude acyl chloride was dissolved in THF (15 mL) and cooled to 0 °C. To this the lithiated 
hydroxylamine mixture was added dropwise and the reaction was stirred at 0 °C for 2.5 h after 
which TLC analysis indicated complete conversion of compound 21. A 0.1 M aq. HCl solution (30 
mL) was added and the mixture was extracted twice with EtOAc (30 mL). The combined organic 
layers were extracted with 0.1 M aq. HCl (30 mL) and brine, dried over MgSO4 and concentrated 
under reduced pressure. The crude mixture was purified by column chromatography (100% 
toluene → 2.5% EtOAc/toluene) and the product was obtained as a yellowish oil (yield: 1.54 g, 
2.63 mmol, 77%). 1H NMR (600 MHz, CDCl3):  = 7.22 (d, J = 8.4 Hz, 2H), 7.11 (d, J = 8.4 Hz, 2H), 
5.80-5.75 (m, 1H), 5.21 (d, J = 17.4 Hz, 1H), 5.16 (d, J = 10.2 Hz, 1H), 4.51 (d, J = 6.0 Hz, 2H), 
3.24-3.20 (m, 2H), 3.03 (dd, J = 13.8, 6.6 Hz, 1H), 2.89-2.85 (m, 2H), 1.53 (s, 9H), 0.99 (s, 9H), 0.13 
(s, 3H), 0.10 (s, 3H) ppm. 13C NMR (150 MHz, CDCl3):  = 173.7, 170.2, 151.8, 140.3, 131.8, 129.4, 
127.3, 126.5, 122.0 (q, J = 273 Hz), 118.1, 84.5, 65 42.7, 38.6, 37.3, 28.2 (q, J = 40.5 Hz), 27.8, 










RMS: calcd. for C27H38F3N3O6Si [M + H]
+ 
86.25547; found 586 . 
2-(4-(3-(trifluoromethyl)-3H-
(s, 3F








Allyl ester 22 (1.53 g, 2.63 mmol) was dissolved in THF (15 mL). To this 
solution were added N,N’-dimethylbarbaturic acid (23, 0.5 eq., 1.32 mmol, 
210 mg) and tetrakis(triphenylphosphine)palladium (cat.). The reaction was stirred for 1 h at RT 
after which TLC analysis indicated complete consumption of the starting compound. The mixture 
was concentrated under reduced pressure and dissolved again in DCM (15 mL) without further 
purification (19). To this mixture were added pentafluorophenol (2 eq., 5.26 mmol, 556 L) and 
EDC (2 eq., 5.26 mmol, 1.00 g) and the reaction was stirred for 12 h at RT. Et2O (50 mL) was added 
and the mixture was extracted twice with 0.1 M aq. HCl (50 mL) and brine, dried over MgSO4 and 
concentrated under reduced pressure. The resulting mixture was purified by column 
chromatography (1.5% EtOAc/PE) and the product was obtained as a yellow solid (yield: 1.65 g, 
2.31 mmol, 88%). 1H NMR (500 MHz, CDCl3):  = 7.30 (d, J = 8.5 Hz, 2H), 7.16 (d, J = 8.0 Hz, 2H), 
3.62-3.56 (m, 1H), 3.33 (dd, J = 18.5, 9.5 Hz, 1H), 2.23 (dd, J = 13.5, 6.5 Hz, 1H), 3.07-2.99 (m, 
2H), 1.54 (s, 9H), 0.99 (s, 9H), 0.14 (s, 3H), 0.12 (s, 3H) ppm. 13C NMR (125 MHz, CDCl3):  = 
170.5, 169.6, 151.9, 141.1 (dd, J = 250, 9.0 Hz), 139.5 (dt, J = 264, 13.5 Hz), 139.3, 137.8 (dt, J = 
249, 13.5 Hz), 129.5, 127.9, 126.8, 125.0 (t, J = 12.8 Hz), 122.1 (q, J = 273 Hz), 84.9, 42.4, 38.7, 
37.1, 28.3 (q, J = 40.1 Hz), 27.8, 25.6, 18.1, –5.2, –5.3 ppm. 19F NMR (188 MHz, CDCl3):  = –65.8 
), –152.4 (d, J = 18.6 Hz, 2F), –158.6 (t, J = 21.1 Hz, 1F), –163.0 (t, J = 21.4 Hz, 2F) ppm. 















 (M + H+)). HRMS: 
lcd. for C23H24F3N5O4 [M + H]
+ 492.18532; found 492.18494. 
9H), 1.40-1.22 (m, 6H), 1.20-1.12 (m, 2H) ppm. LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): 
L-phenylalanine methylamide48 (25, 21 mg, 120 mol) was added to a 
solution of compound 24 (85 mg, 120 mol) in DMF (2 mL). The reaction 
was stirred at RT for 24 h after which no more starting material was 
consumed (followed by LC-MS analysis). Et2O (10 mL) and 0.1 M aq. HCl solution (10 mL) were 
added and the layers were separated. The aqueous layer was extracted with Et2O (10 mL) and the 
combined organic layers were extracted with a 0.1 M aq. HCl solution (2 × 10 mL) and brine, dried 
over MgSO4 and concentrated under reduced pressure. The resulting mixture was purified by 
column chromatography (10% → 50% EtOAc/PE) and the product was obtained as a colourless oil 
(yield: 38 mg, 54.0 mol, 45%). 1H NMR (400 MHz, CDCl3):  = 7.29-7.17 (m, 7H), 7.06 (d, J = 8.0 
Hz, 2H), 6.14 (d, J = 8.0 Hz, 1H), 5.29-5.28 (m, 1H), 4.50 (q, J = 6.9 Hz, 1H), 3.21-3.11 (m, 2H), 
2.97-2.85 (m, 4H), 2.77-2.69 (m, 1H), 2.57 (d, J = 4.8 Hz, 3H), 1.54 (s, 9H), 0.99 (s, 9H), 0.14 (s, 
3H), 0.11 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3):  = 173.6, 170.8, 170.7, 151.8, 140.7, 136.7, 
129.5, 128.6, 127.5, 126.9, 126.5, 122.1 (q, J = 273 Hz), 84.8, 54.4, 44.5, 39.9, 37.9, 37.6, 29.7, 
28.3 (q, J = 40.1 Hz), 28.0, 26.0, 25.7, 18.1, –4.9 ppm.  = +5.6 (c = 1, CHCl3). LC-MS: 
gradient 50% → 90% ACN/(0.1% TFA/H2O): Rt (min): 9.81 (ESI-MS (m/z): 705.87 (M + H+)). HRMS: 
calcd. for C34H46F3N5O6Si [M + H]


















TFA (1 mL) and deionised H2O (50 L) were added to a solution of 
compound 26 (21 mg, 30 mol) in DCM (1 mL). After 1 h LC-MS and TLC 
analysis indicated complete conversion of the starting material. Toluene was 
added and the mixture was concentrated under reduced pressure. In order to remove excess TFA 
the mixture was coevaporated twice with toluene. The resulting mixture was purified by RP-HPLC 
(gradient 40% → 65% ACN/(0.1% TFA/H2O)). The title compound was obtained as a colourless 
solid (yield: 10.2 mg, 21 mol, 69%). 1H NMR (400 MHz, DMSO-d6):  = 10.44 (s, 1H), 8.78 (bs, 
1H), 8.17 (d, J = 8.0 Hz, 1H), 7.65-7.58 (m, 1H), 7.30-7.21 (m, 7H), 7.14 (d, J = 8.0 Hz, 2H), 4.38-
4.36 (m, 1H), 3.00 (dd, J = 13.6, 5.2 Hz, 1H), 2.98-2.92 (m, 1H), 2.82-2.75 (m, 2H), 2.62 (dd, J = 
13.6, 5.6 Hz, 1H), 2.57 (d, 3H), 2.11 (dd, J = 14.8, 7.2 Hz, 1H), 1.94 (dd, J = 14.6, 7.4 Hz, 1H) ppm. 
13C NMR (100 MHz, DMSO-d6):  = 173.7, 172.0, 168.3, 142.8, 139.0, 130. 0.0, 129.0, 127.1, 
127.0, 126.2, 55.0, 44.1, 38.2, 37.8, 35.1, 26.4 ppm. 23][ D  = –10.8 (c = 1, DMSO). LC-MS: 
















This compound was synthesized on solid support on a 20 mol scale (based on the loading of 
Fmoc-Lys(Biotin)) following the General procedure A. The final coupling step involved the addition 
of compound 24 (70 mol, 50 mg) and DiPEA (40 mol, 90 L 0.45 M in NMP) in NMP (0.40 mL) 
to the resin and shaking for 2 h. The compound was purified by RP-HPLC (gradient 10% → 90% 
ACN/(0.1% TFA/H2O)) and was obtained as a colourless solid (yield: 4.3 mg, 6.0 mol, 30% after 3 
coupling steps). 1H NMR (400 MHz, DMSO-d6):  = 10.38 (s, 1H), 8.25 (bs, 1H), 8.13 (t, J = 8.72 
Hz, 1H), 7.80-7.72 (m, 4H), 7.65 (t, J = 5.58 Hz, 1H), 7.37-7.13 (m, 8H), 7.10 (t, J = 7.74 Hz, 2H), 
6.94 (bs, 1H), 6.42 (bs, 1H), 6.36 (bs, 1H), 4.35-4.32 (m, 2H), 4.18-4.09 (m, 2H), 3.09 (dd, J = 
12.83, 6.04 Hz, 1H), 3.03-2.87 (m, 6H), 2.82 (dd, J = 12.40, 5.07 Hz, 1H), 2.78-2.72 (m, 1H), 2.68-
2.66 (m, 1H), 2.64-2.60 (m, 1H), 2.60 (d, J = 12.4 Hz, 1H), 2.13 (t, J = 7.35 Hz, 2H), 2.07 (t, J = 
7.60 Hz, 2H), 2.02-1.96 (m, 1H) 1.91 (dd, J = 13.98, 7.50 Hz, 1H), 1.65-1.56 (m, 1H), 1.52-1.40 (m, 
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Rt (min): 6.45 (ESI-MS (m/z): 945.53 (M + H+)). HRMS: calcd. for C44H59F3N10O8S [M + H]+ 




yl)benzyl)succinamide or (HA-succ(Tmd)-Phe-Ahx-Lys-NH2 (30) 
This compound was synthesized on solid support on a 175 mol scale (based on the loading of 
Fmoc-Lys(Boc)) following the General procedure A. The final coupling step involved the addition 
of compound 24 (1.12 mmol, 800 mg) and DiPEA (750 mol, 124 L 0.45 M in NMP) in NMP (10 
mL) to the resin and shaking for 2 h. The compound was purified by RP-HPLC (gradient 10% → 
90% ACN/(0.1% TFA/H2O)) and was obtained as a colourless solid (yield: 45 mg, 54 mol, 30% 
after 3 coupling steps). 1H NMR (400 MHz, CD3OD):  = 7.69 (t, J = 5.62 Hz, 1H), 7.38-7.34 (m, 
1H), 7.29-7.16 (m, 9H), 7.10 (d, J = 8.03 Hz, 2H), 4.43 (t, J = 7.49 Hz, 1H), 4.35 (dd, J = 8.89, 5.32 
Hz, 1H), 3.15-3.05 (m, 3H), 3.04-2.99 (m, 1H), 2.98-2.83 (m, 4H), 2.70 (dd, J = 13.62, 6.17 Hz, 1H), 
2.33-2.24 (m, 3H), 2.11 (dd, J = 14.82, 6.37 Hz, 1H), 1.87 (ddd, J = 14.60, 7.64, 4.70 Hz, 1H), 1.78-
1.68 (m, 3H), 1.57 (dd, J = 14.95, 7.45 Hz, 2H), 1.55-1.45 (m, 2H), 1.44-1.36 (m, 2H),  1.30-1.18 (m, 
2H) ppm. 13C NMR (100 MHz, CD3OD):  = 177.0, 176.5, 173.8, 173.7, 171.2, 143.4, 139.5, 131.8, 
131.3, 130.3, 128.9, 128.6, 128.4, 57.2, 54.9, 46.5, 41.4, 41.0, 39.4, 39.4, 37.4, 36.5, 33.4, 30.7, 
28.9, 28.2, 27.2, 24.7 ppm. LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 5.92 (ESI-




Compound 30 (9.1 mg, 11 mol) and Bodipy(Tmr)-OSu (4.6 mg, 12 mol) were dissolved in DMF 
(0.5 mL). DiPEA (4.5 L, 27 mol) was added and the reaction was stirred for 24 h after which the 
solvent was evaporated under reduced pressure. The resulting mixture was purified by RP-HPLC 
(gradient 10% → 90% ACN/(0.1% TFA/H2O)) and the title compound was obtained as a brown solid 
(yield: 3.4 mg, 3.4 mol, 31%). 1H NMR (400 MHz, DMSO-d6):  = 10.38 (s, 1H), 8.73 (s, 1H), 8.15 
(d, J = 8.0 Hz, 1H), 7.86 (d, J = 8.87 Hz, 2H), 7.85 (t, J = 5.20 Hz, 1H), 7.81 (d, J = 8.40 Hz, 1H) 
7.67 (s, 1H), 7.68 (t, J = 5.49 Hz, 1H), 7.32 (s, 1H), 7.30-7.11 (m, 10H), 7.02 (d, J = 8.91 Hz, 2H), 
6.93 (s, 1H), 6.70 (d, J = 4.02 Hz, 1H), 4.41-4.30 (m, 1H), 4.13 (dt, J = 8.80, 5.79 Hz, 1H), 3.82 (s, 
3H), 3.04-2.83 (m, 6H), 2.82-2.70 (m, 2H), 2.64-2.58 (m, 3H), 2.48 (s, 3H), 2.24 (s, 3H), 2.23 (t, J = 
6.8 Hz, 2H), 2.14-2.07 (m, 3H), 1.88 (dd, J = 15.01, 7.43 Hz, 1H), 1.68-1.58 (m, 1H), 1.54-1.42 (m, 
3H), 1.39-1.11 (m, 8H) ppm. 19F NMR (376 MHz, DMSO-d6):  = –64.09 (s, 3F), –136.82 (q, J = 
32.8 Hz, 2F) ppm. LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 8.84 (ESI-MS (m/z): 
1099.40 (M + H+)). HRMS: calcd. for C55H64BF5N10O8 [M + H]
+ 1099.49946; found 1099.50039. 
 
HA-succ(Tmd)-Phe-Ahx-Lys(Bodipy(FL))-NH2 (2c) 
Compound 30 (9.1 mg, 11 mol) and Bodipy(FL)-OSu (4.6 mg, 12 mol) were dissolved in DMF 
(0.5 mL). DiPEA (4.5 L, 27 mol) was added and the reaction was stirred for 24 h after which the 
solvent was evaporated under reduced pressure. The resulting mixture was purified by RP-HPLC 
(gradient 10% → 90% ACN/(0.1% TFA/H2O)) and the title compound was obtained as an orange 
solid (yield: 5.9 mg, 6.0 mol, 55%). 1H NMR (400 MHz, DMSO-d6):  = 10.38 (s, 1H), 8.73 (s, 1H), 
8.12 (d, J = 8.23 Hz, 1H), 7.91 (t, J = 5.35 Hz, 1H), 7.80 (d, J = 8.15 Hz, 1H), 7.68 (s, 1H), 7.65 (t, J 
= 5.49 Hz, 1H), 7.31 (s, 1H), 7.27-7.13 (m, 7H), 7.11-7.07 (m, 3H), 6.95 (s, 1H), 6.34 (d, J = 3.99 
Hz, 1H), 6.29 (s, 1H), 4.34 (dd, J = 14.65, 8.31 Hz, 1H), 4.15 (dt, J = 8.29, 5.47 Hz, 1H), 3.15-3.03 
(m, 4H), 3.01-2.90 (m, 4H), 2.83-2.77 (m, 2H), 2.62 (dd, J = 13.6, 6.0 Hz, 1H), 2.50 (s, 3H), 2.49 
(signal under DMSO signal, 3H) 2.29 (s, 3H), 2.18-2.06 (m, 3H), 1.88 (dd, J = 15.00, 7.51 Hz, 1H), 
1.70-1.60 (m, 1H), 1.57-1.38 (m, 5H), 1.37-1.23 (m, 4H), 1.22-1.11 (m, 2H) ppm. 19F NMR (376 
MHz, DMSO-d6):  = –64.09 (s, 3F), –142.77 (q, J = 33.2 Hz, 2F) ppm. LC-MS: gradient 10% → 
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90% ACN/(0.1% TFA/H2O): Rt (min): 8.13 (ESI-MS (m/z): 993.33 (M + H+)). HRMS: calcd. for 
C48H58BF5N10O7 [M + H]
+ 993.45759; found 993.45864. 
 
Biological evaluation 
Inhibition and labeling studies 
Recombinant ADAM-8 (Catalog Number 1031-AD, catalytic domain of human ADAM-8 Glu158-
Pro497, Murine myeloma cell line, NS0 derived), ADAM-9 (Catalog Number 939-AD, catalytic 
domain of human ADAM-9 Ala206-Asp697, Murine myeloma cell line, NS0 derived), ADAM-10 
(Catalog Number 936-AD, catalytic domain of human ADAM-10 Thr214-Glu672, Spodoptera 
frugiperda, Sf 21 (baculovirus) derived) and ADAM-17 (ectodomain, Catalog Number 930-ADB, 
catalytic domain of human ADAM-17 Arg215-Asn671, Spodoptera frugiperda, Sf 21 (baculovirus) 
derived) were purchased from R&D systems (Minneapolis, MN, USA). ADAM-8 was 
autocatalytically activated by incubation at 37 °C for 5 days according to the manufacturer’s 
instructions. Recombinant catalytic domains (CD) of human MMP-1 (Catalog Number BML-SE180-
0010, catalytic domain of human MMP-1 Phe100-Gln268), MMP-2 (Catalog Number BML-SE237-
0010, catalytic domain of human MMP-2 Tyr110-Asp452), MMP-3 (Catalog Number BML-SE109-
0010, catalytic domain of human MMP-3 Phe100-Thr272), MMP-7 (Catalog Number BML-SE181-
0010, catalytic domain of human MMP-7 Tyr95-Lys267), MMP-8 (Catalog Number BML-SE255-0010, 
catalytic domain of human MMP-8 Phe99-Gln269), MMP-10 (Catalog Number BML-SE329-0010, 
catalytic domain of human MMP-10 Phe99-Glu271), MMP-11 (Catalog Number BML-SE282-0010, 
catalytic domain of human MMP-11 Phe98-Ser266) and MMP-13 (Catalog Number BML-SE246-0010, 
catalytic domain of human MMP-13 Tyr104-Asn274) were from Biomol International (Butler Pike, PA, 
USA). All hrMMPs were expressed in E. coli. Recombinant human MMP-12 CD and recombinant 
human MMP-9 CD without fibronectin type II inserts (expressed in E. coli as described56,57) were a 
kind gift from AstraZeneca R&D (Lund & Moelndal, Sweden). TIMP-1 from human neutrophil 
granulocytes was from Calbiochem (La Jolla, CA, USA). Alkaline phosphatase conjugated 
streptavidin was from Sigma-Aldrich (Zwijndrecht, The Netherlands). 5-bromo-4-chloro-3-indoyl 
phosphate (BCIP) and nitro blue tetrazolium (NBT) were from Duchefa (Haarlem, The Netherlands). 
Unless mentioned otherwise all other biochemicals were purchased from Sigma-Aldrich. 
Determination of IC50 values 
The affinity of the photoactivatable probes for ADAM and MMP proteases was determined in a 
competitive enzyme activity assay monitoring conversion of the fluorogenic substrate Mca-
PLAQAV-Dpa-RSSSR-NH2 (R&D Systems) by recombinant ADAM-9, -10 and -17 in the presence of 
increasing concentrations photoactivatable probe. For MMP-9 and MMP-12 inhibition of the 
conversion of fluorogenic substrate Mca-PLGL-Dpa-AR-NH2 (Bachem, Bubendorf, Switserland) was 
determined. Measurements were performed in Costar White 96-well plates (Corning, Schiphol-Rijk, 
The Netherlands), where each well contained either 10 ng ADAM-17, 100 ng ADAM-10 or 200 ng 
ADAM-9 and a final concentration of 10 M substrate in a final volume of 100 L ADAM assay 
buffer (25 mM Tris pH 9.0, 2.5 M ZnCl2, 0.005% w/v Brij-35). Inhibition of MMP proteolytic activity 
was determined with 10 ng of MMP-9 or MMP-12 per well with a final concentration of 2 M 
substrate in 100 L MMP assay buffer (50 mM Tris pH 7.4, 0.2 M NaCl, 10 mM CaCl2, 2.5 M 
ZnCl2, 0.05 % (v/v) Brij-35). Proteolysis rates were followed by measuring fluorescence (ex,em = 
320, 440 nm) increase using a Fluostar Optima plate reader (BMG Labtech, Offenburg, Germany) 
at 37 °C. Six-point inhibition curves (0-10 M) were plotted in Origin 7.0 (Micronal) and IC50 values 
were determined by sigmoidal fitting. 
Labeling of active recombinant metalloproteases  
Recombinant MMP catalytic domains and recombinant ADAM ectodomains were incubated with 
photoactivatable inhibitor probes in 96-well plates (Costar White). Each well (final volume 30 L) 
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contained 4 pmol enzyme and a final concentration of 1 M inhibitor probe in MMP or ADAM 
assay buffer. The plate was irradiated at 366 nm using a Camag universal UV lamp (20W, distance 
to plate 4 cm) for 30 min. For subsequent analysis by Western blotting, the reaction was stopped 
by adding 10 L 5× non-reducing SDS-PAGE sample buffer.  
Western blotting 
Samples were analyzed by SDS-PAGE on 0.75 mm thick 12.5% polyacrylamide gels. 
Electrophoresis was carried out at 20 mA per gel using a mini-Protean III electrophoresis system 
(Bio-Rad, Veenendal, The Netherlands). The proteins were transferred to an Immun-Blot PVDF 
membrane by wet Western blotting in a mini Trans-blot cell at 350 mA for 60 min. in 25 mM Tris, 
190 mM glycine with 20% (v/v) methanol (BioRad). Membranes were blocked overnight at 4 °C in 
TBST (25 mM Tris buffer pH 7.5 containing 150 mM NaCl, 0.05% (v/v) Tween-20) supplemented 
with 5% (w/v) non-fat dried milk (Protifar Plus, Nutricia, Zoetermeer, The Netherlands) and 
incubated for 1 h in a 1:1500 dilution of streptavidin-alkaline phosphatase (0.67 g/mL) in TBST 
supplemented with 1% non-fat dried milk. Biotinylated proteins were visualized by staining with an 
NBT/BCIP substrate solution (0.1 M Tris buffer, pH 9.5 containing 5 mM MgCl2, 0.15 mg/mL BCIP 
and 0.30 mg/mL NBT). 
Competition experiments with TIMPs and compound 27 
Aliquots of 4 pmol of MMP-9 and MMP-12 were incubated overnight with equimolar equivalents of 
TIMP-1. Control aliquots were kept at 4 °C overnight without TIMPs. Photoactivatable inhibitor 2a 
was added to a final concentration of 200 nM. Labeling and analysis were performed as described 
above. 
Aliquots of 4 pmol MMP-9 and MMP-12 (both catalytic domains) in assay buffer were 
preincubated for 15 min. with 400 nM control inhibitor 27 and irradiated with UV light. Positive 
controls were treated the same, but without control inhibitor 27 added to the solution. Next, 
photoactivatable probe 2a was added to a final concentration of 200 nM. Labeling and analysis 
were performed as described above. 
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The majority of all cytosolic and nuclear proteins in eukaryotic cells are degraded 
by the ubiquitin-proteasome pathway. In this system, proteins destined for degradation 
are modified with a poly-ubiquitin chain, which serves as a recognition tag for the 26S 
proteasome where proteolysis occurs. The 26S proteasome contains one or two 19S 
regulatory caps together with the proteolytically active, cylindrical 20S core (see Figure 
1A). Within the mammalian constitutive 20S core three pairs of proteolytically active 
sites are present displaying different substrate specificity. Of these, the 1 subunits 
(caspase-like) cleave after acidic residues, the 2 subunits (trypsin-like) cleave after 
basic residues and the 5 subunits (chymotrypsin-like) cleave after bulky, hydrophobic 
residues.1,2 Next to the constitutive proteasome some specific mammalian cells also 
express the so-called immunoproteasome, in which the active subunits are replaced by 
their immuno counterparts 1i, 2i and 5i. The peptidyl bo
P. P. Geurink, N. Liu, M. P. Spaans, S. L. Downey, A. M. C. H. van den Nieuwendijk, G. A. van der 
Marel, A. F. Kisselev, B. I. Florea, H. S. Overkleeft, J. Med. Chem. 2010, 53, 2319–2323. 
itor Bortezomib (also known as PS-341 or Velcade, see Figure 1B)3 is used for the 
treatment of multiple myeloma and targets the 5(i) and 1(i) subunits. In order to study 
the role of the individual active subunits, inhibitors that specifically target one active 
subunit are imperative. Inhibitors with moderate to good selectivity for either one of the 
subunits have been developed.4 There remains, however, room for improvements, for 
instance in the direction of inhibitors that can distinguish between a constitutive 
proteasome active site and its immunoproteasome counterpart. 
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The search for subunit selective inhibitors is predominantly conducted by either 
screening of natural products,5 rational design6 or compound library building.4b,7 
Interestingly, in these studies the effect of fluorine functionality in proteasome 
inhibitors is relatively uncharted.8 In contrast, fluorine has found wide interest in 
bioorganic and structural chemistry over the past decade and has become an important 
featu  in drug design.9 This is predominantly due to the typical characteristics of 
fluorine (when bound to carbon), such as its comparable size to hydrogen, its electron 
withdrawing ability, superhydrophobicity of fluorocarbons and self-association between 
fluorinated moieties. In protein structure design introduction of fluorine can mimic 
functional groups, alter structural properties and thereby (de)stabilize protein structures 
or function as recognition motifs.10 In addition, the beneficial 19F nuclear magnetic 
characteristics have found their use in structure analysis by (solid state) 19F NMR 






































Figure 1. (A) Schematic representation of the 26S proteasome. (B) Structures of potent proteasome 
inhibitors. 
The set of fluorinated proteasome inhibitors prepared in the context of the here 
presented studies are depicted in Figure 2. Compounds 2a and 2b containing penta-
fluoroPhe (Phe(F5)) and 3,5-bis(trifluoromethyl)Phe (Phe(m-CF3)2) respectively, are based 
on Bortezomib derivative 1 (having a comparable potency towards the 1 and 5 
proteasome subunits with respect to Bortezomib)12 and differ in that the phenylalanine 
in 1 is replaced by the corresponding fluorinated analogue. In addition, incorporation of 
fluorinated phenylalanines at different positions in tripeptide epoxyketones2 led to 
compounds 3-6 in which systematically either one or both of the P2 and P3 positions 
were altered. Fluorinated amino acids Phe(m-CF3)2 and Phe(F5) were used for the dual 
reason that these are readily available and that hydrophobic amino acids (that is the 
non-fluorinated analogues) are in principle accepted by all proteasome active sites. The 
epoxyketone electrophilic trap was selected based on the natural product epoxomicin 
(see Figure 1B). The epoxyketone warhead featured by epoxomicin displays a specific 
and selective reactivity towards the N-terminal threonine residue that makes up the 
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proteasome catalytic active sites.2,5 For this reason synthetic peptide epoxyketones are 
now much studied leads in medicinal chemistry studies in which the proteasome plays a 
role.13 The tripeptide epoxyketones 3-6 feature an azide moiety at the N-terminal end 
for future modifications (for instance, coupling to a fluorophore or biotin in either one- 
or two-step labeling experiments).14 
 
 
Figure 2. Synthesized fluorinated proteasome inhibitors. Indicated are the enzyme pockets (P1, P2, P3). 
4.2 Results and Discussion 
The C-terminally modified oligopeptides were produced via solution phase peptide 
chemistry following reported protocols.7 The fluorinated amino acids used were 
prepared according to the procedure outlined in Scheme 1. In this procedure fully 
protected glycine 7 was alkylated with the appropriate fluorinated benzyl bromide and 
hiral phase-transfer catalyst.15 The 
alkylation products 8a,b were obtained in high yields with an e.e. of >98% (as 
determined by chiral HPLC). Removal of the two acid labile protecting groups and 
introduction of a Boc protecting group on the amine led to fluorinated amino acids 
10a,b, which were now ready for use in peptide synthesis schemes. 
Scheme 1. Synthesis of fluorinated phenylalanine derivatives. 
chirality was introduced by application of a c
 
Reagents and conditions: (a) RFBnBr, KOH, 2,7-bis[O(9)-allylhydrocinchonidinium-N-methyl]naphthalene 
dibromide, H2O, CHCl3, toluene, –20 ºC, quant., e.e. >98%; (b) citric acid, H2O, THF, 95%; (c) TFA, DCM; (d) 
Boc2O, Na2CO3, H2O, 1,4-dioxane, 96%; (e) HOSu, DIC, DCM; (f) TMSCHN2, MeOH, toluene, quant. 
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Boronic ester 2a was constructed from chloride 13 (see Scheme 2).12 First, the 
chloride was substituted with LiHMDS, giving the corresponding doubly silylated amine. 
Acidic removal of the silyl groups resulted in the free amine, which was coupled to the 
N-hydroxysuccinimide ester 11a (made from 10a, Scheme 1). The resulting protected 
dipeptide 14 was debocylated and coupled to 2-pyrazine carboxylic acid using HCTU 
and DiPEA, which resulted in inhibitor 2a (compound 2b was created by the same 
strategy from 11b). Peptide epoxyketone 6a was constructed in three peptide couplings 
starting from methyl ester 12a (obtained by esterification of 10a) as shown in Scheme 
g to compound 16, the methyl ester 
was converted into its hydrazide 17 and an ‘azide-coupling’ was performed in which 
amine 1816 was reacted to the C-terminus of the tripeptide, thereby facilitating an 
epimerization free product formation.7 All other peptide epoxyketones were constructed 
in the same fashion. 
Scheme 2. Synthesis of the fluorinated proteasome inhibitors. 
2. After two peptide couplings (HCTU, DiPEA) leadin
 
Reagents and conditions: (a) i) LiHMDS, THF, –78 ºC; ii) HCl; iii) 11a,b, DiPEA; (b) i) TFA, DCM; ii) PyrOH, 
HCTU, DiPEA, DCM, 16% from 13 after RP-HPLC; (c) i) TFA, DCM; ii) 10a,b, HCTU, DiPEA, DCM, 79-95%; (d) i) 
TFA, DCM; ii) N3PheOH, HCTU, DiPEA, DCM, 48-93%; (e) NH2NH2·H2O, MeOH, reflux, quant.; (f) i) tBuONO, 
HCl, DCM, DMF, –30 ºC; ii) 18, DiPEA, –30 ºC  RT, 7-99%. 
The inhibition potential of compounds 2a and 2b, in comparison with their non-
fluorinated analogue boronic ester 1 (the pinanediol analogue of the clinical drug 
Bortezomib), was assessed in a competition assay employing cell lysates from human 
embryonic kidney cells (HEK-293T) and mouse lymphoma cells (EL4) in combination 
with the fluorescent broad spectrum proteasome probe MV151.12 Cell lysates were 
incubated with each of the three compounds at 0.05, 0.1 and 1 M final concentrations, 
prior to treatment with 0.5 M final concentration of MV151. The samples were 
denatured, resolved by SDS-PAGE and the wet gel slabs were scanned on a fluorescence 
scanner. The gel images are shown in Figure 3. HEK-293T lysates treated with the 
fluorescent probe display three bands that correspond to the three active subunits (1, 
2 and 5) as depicted in Figure 3A lane 1. The ability of a compound to inhibit the 
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proteasome active sites is reflected by disappearance of the bands. As apparent from 
this image the fluorinated compounds 2a and 2b are at least as potent as their non-
fluorinated counterpart 1, since they show complete inhibition of the 1 and 5 
subunits between 0.1 and 1 M. In addition, incorporation of fluorinated Phe leaves the 
selectivity of 1 and 5 over 2 subunits for this type of inhibitor unchanged. The 
experiments in EL4 cell lysate (Figure 3B) show a similar selectivity for these three 
compounds towards the 1(i) and 5(i) subunits. This result is also apparent from the 
activity (IC50) measurements of the inhibitors towards the different subunits in purified 
rabbit 26S proteasome as shown in Table 1.  
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Figure 3. Characteriza of the specificity he fluorinated dip ptide boronate n assay in (A) 
HEK-293T lysate and (B) EL4 lysate. Lysate  incubated for r with com  1, 2a and 2b at the 
indicated final concen Residual pr me activity was labeled with 0.5  r one hour. 
Table 1. Activity (IC50 f 2-5 agains three active co tive 26S prote units.a 
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pou nLPnL  (RLR  (LLVY
2a 0.44 >15 0.031 
2b 0.16 11 0.0030 
3 >15 1.8 0.0010 
4a >15 >15 0.0020 
4b >15 >15 0.10 
5a >15 >15 0.20 
5b >15 >15 0.13 
a Determined with the indicated subunit specific fluorogenic peptide substrates. All values are averages of two 
experiments. 
Next, the inhibition properties of the seven epoxyketone containing compounds 
were determined in a similar competition assay against MV151 at 1 and 100 M final 
concentrations employing HEK-293T cell lysates (Figure 4) and by measuring inhibition 
of purified proteasomes for the most active compounds (Table 1). When comparing non-
fluorinated compound 3 to the fluorinated ones (4-6), it becomes apparent that none 
of these compounds inhibit the 1 subunit at concentrations up to 100 M and that 
introducing fluorines (in either position) leads to a decrease in the inhibition of the 2 
subunit and hence to an increase in 5 specificity. When comparing Table 1 with Figure 
4 it appears that the results from the two independent assays deviate in places. For 
example, the 2-IC50 value for 4a is >15 M (Table 1), whereas the majority of the 
corresponding band in Figure 4 is gone at 1 M. Intrinsic differences in both assays, 
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neither of which deliver ki values, are at the basis of these small but distinct differences. 
The complementary assays however both show similar trends. For instance, in Figure 4 
there appears to be almost no difference in inhibition potential of 5 between the non-
fluorinated compound 3 and either P2 or P3 fluorinated compounds 4a,b and 5a,b. 
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as well).17 Having an IC50 value of 2 nM for 
the 
read-out at 520 nm visualizing the appearance of one band: labeling of the 5 subunit 
 
Figure 4. Characterization of the specificity of fluorinated peptide epoxyketones. Competition assay in HEK-
293T lysate. Lysates were incubated for one hour with compounds 3, 4a,b, 5a,b or 6a,b at the indicated final 
concentrations. Residual proteasome activity was labeled with 0.5 M MV151 for one hour. 
Interestingly, the presence of fluorine substituents at both P2 and P3 positions 
(6a,b, Figure 4) has a dramatic effect on the inhibition. This effect is most pronounced 
for the Phe(m-CF3)2 analogues (b series). In general the Phe(F5) compounds (a series) are 
more active against the 5 subunit than their hexafluoro-Phe analogues (b series). Thus, 
it appears that introduction of Phe(F5) in the P2 position generates a highly specific 
inhibitor of the 5 site. This most potent and 5 selective inhibitor (compound 4a) was 
further investigated. The inhibitory potential at much lower concentrations (1 nM to 1 
M) is shown in Figure 5 (competition assay against MV151). Inhibition of 5 is already 
apparent at 5 nm and between 100 and 250 nM all 5 subunits are saturated, while 1 
and 2 are unaffected or even upregulated (a phenomenon which is not fully 
understood, but has been observed by others 
5 subunit against >15 M for 1 and 2, this compound is one of the most 5 
selective inhibitors known to date. For instance, this compound compares well with 
NC005, a 5 selective inhibitor recently discovered.6 Comparison of non-fluorinated 
compound 3 with 4a reveals that both compounds are equally active towards the 5 
subunit. Enhanced selectivity for 5 arises by the dramatic drop in activity for the 2 
subunit when fluorine is introduced, as in 4a. 
For the direct labeling of 5 a new fluorescent probe was made by reacting 
compound 4a with a Bodipy-alkyne18 in a Cu(I) mediated Huisgen 1,3-dipolar 
cycloaddition giving green fluorescent probe 19 (Figure 6A). The potential of this probe 
to label the 5 subunit was explored in a competition assay against MV151 as explained 
before. The gel was scanned on a fluorescence scanner at two different wavelengths 
allowing visualization of one of the two fluorescent dyes at a time. Figure 6B shows the 
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by compound 19. The labeling is already visible at a concentration of 1 nM and the 
subunit appears to be saturated (no more increase in the bands intensity) between 50 
and 100 nM. At this point only a faint 2 band is visible. The fluorescence read-out at 
560 nm in Figure 6C (displaying labeling with MV151 of remaining activities) reveals that 
the 5 band disappears while leaving the remaining subunit-bands intact. The IC50 
values of compound 19 towards each active subunit were determined in the same 
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Figure  Characterization of the specificity of compound 4a. (A) Competition assay in HEK-293T lysate. 
Lysates were incubated for one hour with compound 4a at the indicated final concentrations. Residual 
proteasome activity was labeled with 0.5 M MV151 for one hour. (B) Remaining subunit activity after 
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Figure 6. (A) Construction of a novel probe for the 5 site. Reagents and conditions: a) Bodipy-alkyne,18 10 
mol% CuSO4, 15 mol% sodium ascorbate, toluene/H2O/tBuOH 1:1:1, 80 ºC, 87%. (B,C) Competition assay in 
HEK-293T cell lysate. Lysates were incubated for one hour with compound 19 at the indicated final 
concentrations. Residual proteasome activity was labeled with 0.5 M MV151 for one hour. Fluorescence read-
out at (B) ex 488 nm, em 520 nm (compound 19) and (C) ex 532 nm, em 560 nm (MV151).  
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4.3 Conclusion 
In summary, the effect of incorporation of fluorinated Phe in proteasome inhibitors 
was studied. It was found that substitution of non-fluorinated Phe in Bortezomib 
analogue 1 with fluorinated versions does not affect its selectivity for the different active 
subunits whereas the potency is slightly increased for the Phe(m-CF3)2 version. In 
addition, the effect of incorporation of fluorinated Phe in peptide epoxyketone 
proteasome inhibitors appeared to depend on the site of substitution. Fluorination of 
both the P2 and P3 sites decreases potency dramatically, however fluorinated Phe at the 
P2 position hardly affects the potency, but instead yields much more 5 selective 
inhibitors. Comparison of the results obtained with the boronic esters with those from 
the epoxyketone studies invites the tentative conclusion that 2 is most sensitive 
towards fluorine substituents. Compound 1 is ineffective towards 2 and introduction of 
fluorines into this sequence has no apparent effect. When comparing epoxyketone 3 
with 4-6, however, the major difference is that the latter, fluorinated analogues leave 2 
largely intact. Further studies, for instance making use of different fluorine amino acids, 
are needed to substantiate this finding. Finally, compound 4a was identified as one of 
the most 5 selective inhibitors known to date and was converted to a 5 selective 




Tetrahydrofuran was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH), diisopropylethylamine (DiPEA) and 
trifluoroacetic acid (TFA) were of peptide synthesis grade, purchased at Biosolve, and used as 
received. All general chemicals (Fluka, Fischer, Merck, Sigma-Aldrich) were used as received. O-
(1H-6-Chlorobenzotriazolyl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was 
purchased at Iris Biotech (Marktrewitz, Germany). Traces of water were removed from reagents 
used in reactions that require anhydrous conditions by coevaporation with toluene. Solvents that 
were used in reactions were stored over 4 Å molecular sieves, except methanol and acetonitrile, 
which were stored over 3 Å molecular sieves. Molecular sieves were flame dried before use. Unless 
noted otherwise all reactions were performed under an argon atmosphere. Column 
chromatography was performed on silicagel (Screening Devices b.v.) with a particle size of 40-63 
m and a pore size of 60 Å. The eluents toluene, ethyl acetate and petroleum ether (40-60 ºC 
boiling range) were distilled prior to use. TLC analysis was conducted on Merck aluminium sheets 
(Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by spraying with a 
solution of (NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a 
solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid 
(12.5 ml/L) in ethanol, where appropriate, followed by charring at ca. 150 ºC. 1H- and 13C-NMR 
spectra were recorded on a Bruker AV-400 (400 MHz) or a Bruker DMX-600 (600 MHz) 
spectrometer. Chemical shifts are given in ppm () relative to tetramethylsilane, CDCl3 or CD3OD 
as internal standard. High resolution mass spectra were recorded by direct injection (2 L of a 2 
M solution in water/acetonitrile; 1/1; v/v and 0.1% formic acid) on a mass spectrometer (Thermo 
Finnigan LTQ Orbitrap) equipped with an electrospray ion source in positive mode (source voltage 
3.5 kV, sheath gas flow 10, capillary temperature 250 C) with resolution R = 60,000 at m/z = 400 
(mass range m/z = 150-2,000) and dioctylpthalate (m/z = 391.28428) as a “lock mass”. The high 
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resolution mass spectrometer was calibrated prior to measurements with a calibration mixture 
(Thermo Finnigan). Optical rotations  were recorded on a Propol automatic polarimeter at 
room temperature. LC-MS analysis was performed on a Jasco HPLC system with a Phenomenex 
Gemini 3 m C18 50 × 4.60 mm column (detection simultaneously at 214 and 254 nm), coupled 
to a PE Sciex API 165 mass spectrometer with ESI (system A) or on a Finnigan Surveyor HPLC 
system with a Gemini C18 50 × 4.60 mm column (detection at 200-600 nm), coupled to a 
Finnigan LCQ Advantage Max mass spectrometer with ESI (system B). Chiral HPLC analysis was 
performed on a Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) 
equipped with a Chiralcel OD column (150  4.6 mm). RP-HPLC purification was performed on a 
Gilson HPLC system coupled to a Phenomenex Gemini 5 m 250  10 mm column and a GX281 
fraction collector. Chiral HPLC analysis was performed on a Spectroflow 757 system (ABI 






To a solution of tert-butyl 2-(diphenylmethyleneamino)acetate (7, 5.10 g, 17.3 
mmol) in toluene/CHCl3 (7/3 v/v, 80 mL) 2,3,4,5,6-pentafluorobenzylbromide (3.6 
mL, 25.6 mmol, 1.5 eq.) and 2,7-bis[O(9)-allylhydrocinchonidinium-N-methyl]naphthalene 
dibromide (0.045 g, 0.045 mmol, 0.003 eq.) were added. The mixture was stirred at –20 °C for 30 
min.. Hereafter, a precooled 50% aqueous solution of KOH (30 mL) was added and the resulting 
mixture was stirred at –20 °C for 3.5 days. Diethyl ether (150 mL) was added and the mixture was 
washed with H2O (2×) and brine before being dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash chromatography (100% PE → 9% EtOAc/PE) to give the 
title compound (yield: 8.22 g, 17.3 mmol, quant.) as a yellowish oil. Using chiral HPLC the e.e. was 
determined >98%. 1H NMR (400 MHz, CDCl3):  = 7.57 (d, J = 1.2 Hz, 2H), 7.42-7.28 (m, 6H), 6.88 
(d, J = 6.4 Hz, 2H), 4.26 (dd, J = 8.8, 5.2 Hz, 1H), 3.37-3.31 (m, 1H), 3.27-3.22 (m, 1H), 1.46 (s, 9H) 
ppm. 13C NMR (100 MHz, CDCl3):  = 171.41, 169.63, 146.53, 144.08 (t, J = 9.00 Hz), 140.96, 
139.01, 138.51, 135.88, 135.65, 129.95, 128.18, 127.97, 127.76, 127.45, 111.76 (t, J = 24.0 Hz), 
81.78, 64.33, 27.84, 26.10 ppm. = –155.6 (c = 1 in CHCl3). HRMS: calcd. for C26H22F5NO2 [M 











This compound was prepared by the same method described for compound 8a, 
using 2,4-trifluoromethylbenzylbromide as alkylating agent. The product was 
obtained as a colourless oil (yield: 2.21 g, 4.23 mmol, quant.). Using chiral HPLC 
the e.e. was determined >98%. 1H NMR (400 MHz, CDCl3):  = 7.70 (s, 1H), 7.58 (s, 2H), 7.54 (d, J 
= 7.22 Hz, 2H), 7.40-7.27 (m, 6H), 6.68 (d, J = 6.95 Hz, 2H), 4.16 (dd, J = 8.32, 4.87 Hz, 1H), 3.38-
3.27 (m, 2H), 1.45 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 169.87, 140.94, 130.50, 130.20, 
131.2 (q, J = 33.14 Hz), 128.67, 128.34, 127.99, 127.32, 123.31 (q, J = 272.51 Hz), 120.20, 81.82, 
66.66, 39.11, 27.99 ppm. = –165.7° (c = 1 in CHCl3). HRMS: calcd. for C28H25F6NO2 [M + H]+ 










(S)-tert-butyl 2-amino-3-(perfluorophenyl)propanoate (9a) 
Aqueous citric acid (15% w/w, 110 mL) was added to a solution of compound 8a 
(8.22 g, 17.3 mmol) in THF (90 mL) and the mixture was stirred overnight at RT. 
Aqueous K2CO3 (sat.) and EtOAc were added and the layers were separated before 
the aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over 
MgSO4 and concentrated. The product (yield: 4.92 g, 15.8 mmol, 91%) was obtained as a yellowish 
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3.58 (dd, J = 8.4, 6.4 Hz, 1H), 3.10 (dd, J = 13.6, 6.0 Hz, 1H), 2.90 (dd, J = 14.0, 8.8 Hz, 1H), 1.63 
(bs, 1H), 1.45 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 173.39, 146.57-146.38 (m), 144.13-
143.94 (m), 141.21-141.02 (m), 138.70-138.37 (m), 135.99 (t, J = 17.0 Hz), 111.70 (t, J = 20.0 Hz), 
81.57, 54.38, 27.75, 27.60 ppm. = +12.1 (c = 1 in CHCl3). HRMS: calcd. for C13H14F5NO4 [M 
+ H]+ 312.10175; found 312.10182. 
23][ D
 
(S)-tert-butyl 2-amino-3-(3,5-bis(trifluoromethyl)phenyl)propanoate (9b) 
This compound was prepared by the same method described for compound 9a. 
The product was obtained as a colourless oil (yield: 1.37 g, 3.83 mmol, quant.). 1H 
NMR (400 MHz, CDCl3):  = 7.76 (s, 1H), 7.73 (s, 2H), 3.66 (t, J = 6.61, 6.61 Hz, 
1H), 3.07 (ddd, J = 20.92, 13.78, 6.62 Hz, 2H), 1.57 (s, 1H), 1.42 (s, 9H) ppm. 13C 
NMR (100 MHz, CDCl3):  = 173.62, 140.34, 131.43 (q, J = 33.16 Hz), 129.58, 123.28 (q, J = 
272.53 Hz), 120.55, 81.66, 55.75, 40.51, 2  ppm. 23][ D = +12.6° (c = 1 in CHCl3). HRMS: 
calcd. for C15H17F6NO2 [M + H]











(S)-2-(tert-butoxycarbonylamino)-3-(perfluorophenyl)propanoic acid (10a) 
Compound 9a (1.25 g, 4.0 mmol) was treated with TFA (15 mL) for 30 min., after 
which the mixture was coevaporated three times with toluene. The resulting 
product was dissolved in water (40 mL) containing Na2CO3 (1.61 g, 15.2 mmol) and 
cooled to 0 °C. A solution of di-tert-butyldicarbonate (0.96 g, 4.43 mmol) in 1,4-dioxane (25 mL) 
was slowly added and the resulting mixture was stirred for 12 h slowly warming up to RT. Next, 
water was added followed by extracting twice with EtOAc. The aqueous layer was acidified with 4M 
aq. HCl to pH 2 and extracted with EtOAc (3×). The latter organic layers were combined, dried 
over MgSO4 and concentrated under reduced pressure. The title compound was purified by 
column chromatography (30% EtOAc/PE → 100% EtOAc) and obtained as a white solid (yield: 
1.35 g, 3.80 mmol, 95%). 1H NMR (200 MHz, CDCl3):  = 10.57 (bs, 1H), 5.14 (d, J = 8.4 Hz, 1H), 
4.63-4.43 (m, 1H), 3.40-3.11 (m, 2H), 1.37 (s, 9H) ppm. 13C NMR (50 MHz, CDCl3):  = 173.88, 
156.68, 148.35, 143.16, 139.83, 134.88, 110.11, 82.43, 53.38, 27.94, 26.61 ppm. = +22.3º (c 
= 1 in CHCl3). HRMS: calcd. for C14H14F5NO4 [M + H]








butoxycarbonylamino)propanoic acid (10b) 
This compound was prepared by the same method described for compound 10a. 
The product was obtained as a colourless solid (yield: 1.47 g, 3.67 mmol, 96%). 
Spectroscopic data are given for a mixture of rotamers. 1H NMR (400 MHz, 
CDCl3):  = 10.27 (s, 1H), 7.79 (s, 1H), 7.77 (s, 1H), 7.68 (s, 2H), 7.65 (s, 2H), 6.99 (d, J = 6.83 Hz, 
1H), 5.13 (d, J = 7.38 Hz, 1H), 4.66 (d, J = 6.05 Hz, 1H), 4.43 (d, J = 4.43 Hz, 1H), 3.45-3.30 (m, 
2H), 3.21-3.02 (m, 2H), 1.41 (s, 9H), 1.29 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 175.16, 
174.64, 156.69, 155.18, 139.21, 138.70, 131.84-131.51 (m), 129.69, 123.23 (q, J = 272.57 Hz), 
121.05, 121.02, 82.54, 80.85, 55.53, 53.91, 38.97, 37.55, 28.08, 27.86 ppm. HRMS: calcd. for 










bis(trifluoromethyl)phenyl) ethyl)-amide (2b) 
N,N’-Diisopropylcarbodiimide (1.3 eq., 0.41 mmol, 64 L) was added to 
a solution of BocPhe(m-(CF3)2)-OH (10b, 1 eq., 127 mg, 0.32 mmol) and 
N-hydroxysuccinimide (1.12 eq., 0.35 mmol, 41 mg) in DCM (5 mL) and 
the reaction mixture was stirred for 12 h yielding the crude BocPhe(m-(CF3)2)-OSu (11b) solution. 
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200 mg, 0.70 mmol) in THF (10 mL) at –78 °C. The reaction mixture was allowed to warm to RT and 
was stirred for 12 h before it was cooled to –78 °C. HCl (4.6 mmol, 1.15 mL 4M in 1,4-dioxane) was 
added and the reaction mixture was allowed to warm to RT, before being cooled to –78 °C. To the 
stirred solution DiPEA (8.0 mmol, 1.32 mL) and the crude BocPhe(m-(CF3)2)-OSu solution (0.32 
mmol) were added and the reaction mixture was allowed to warm to RT. The reaction mixture was 
stirred for an additional 2 h before being filtered over Celite and the filtrate was concentrated 
under reduced pressure. Purification of the residue by column chromatography (10% → 20% 
EtOAc/PE) resulted in the dipeptide (yield: 40 mg, 61 mol, 19%). This compound was dissolved in 
a 1/1 (v/v) mixture of DCM/TFA (2 mL) and stirred for 30 min. before being coevaporated three 
times with toluene. The crude TFA salt was dissolved again in DCM (2 mL) and HCTU (1.5 eq., 92 
mol, 38 mg), 2-pyrazine carboxylic acid (1.5 eq., 92 mol, 115 mg) and DiPEA (4 eq., 0.25 mmol, 
41 L) were added and the mixture was stirred for 3 h before being concentrated under reduced 
pressure and purified by HPLC (linear gradient 80% → 100% ACN in H2O, 0.1% TFA, 15 min). The 
product was obtained as a colourless solid (yield: 7.4 mg, 11 mol, 18%). 1H NMR (400 MHz, 
CDCl3):  = 9.34 (s, 1H), 8.78 (s, 1H), 8.55 (s, 1H), 8.38 (d, J = 8.47 Hz, 1H), 7.75 (s, 3H), 6.04 (d, J 
= 4.24 Hz, 1H), 4.85 (dd, J = 14.30, 6.92 Hz, 1H), 4.28 (d, J = 8.48 Hz, 1H), 3.41-3.20 (m, 3H), 
2.34-2.28 (m, 1H), 2.23-2.14 (m, 1H), 2.01 (t, J = 5.19, 5.19 Hz, 1H), 1.94-1.88 (m, 1H), 1.81 (d, J = 
14.60 Hz, 1H), 1.57-1.46 (m, 1H), 1.45-1.41 (m, 2H), 1.40 (s, 3H), 1.28 (s, 3H), 1.15 (d, J = 10.88 
Hz, 1H), 0.89-0.81 (m, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 169.62, 163.01, 147.66, 144.19, 
142.85, 138.99, 131.77 (q, J = 33.23 Hz), 129.83, 129.80, 123.19 (q, J = 272.80 Hz), 121.07, 86.23, 
77.91, 53.60, 51.23, 39.87, 39.50, 37.97, 35.37, 28.38, 27.04, 26.26, 25.47, 24.00, 22.80, 22.05 
ppm. = –16.2° (c = 1 in CHCl3). LC-MS: system B, gradient 50% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 9.33. HRMS: calcd. for C31H37BF6N4O4 [M + H]






Prepared according to the procedure as described for compound 2b 
using BocPhe(F5)-OH. The product was obtained as a colourless solid 
(yield: 12 mg, 19.7 mol, 14%). 1H NMR (600 MHz, CDCl3):  = 9.31 (s, 1H), 8.77 (d, J = 2.20 Hz, 
1H), 8.56 (d, J = 1.29 Hz, 1H), 8.40 (d, J = 8.63 Hz, 1H), 6.07 (d, J = 4.53 Hz, 1H), 4.87 (dd, J = 
14.43, 8.57 Hz, 1H), 4.30 (d, J = 8.64 Hz, 1H), 3.38-3.31 (m, 2H), 3.23 (dd, J = 13.98, 8.84 Hz, 1H), 
2.36-2.31 (m, 1H), 2.23-2.17 (m, 1H), 2.02 (t, J = 5.41, 5.41 Hz, 1H), 1.94-1.90 (m, 1H), 1.82 (d, J = 
14.61 Hz, 1H), 1.65-1.54 (m, 3H), 1.40 (s, 3H), 1.29 (s, 3H), 1.16 (d, J = 10.87 Hz, 1H), 0.92-0.82 
(m, 9H) ppm. 13C NMR (150 MHz, CDCl3):  = 169.13, 163.14, 147.68, 144.24, 143.57, 142.85, 
86.32, 78.08, 51.98, 51.17, 40.03, 39.43, 38.18, 35.35, 29.69, 28.43, 27.03, 26.24, 25.44, 24.01, 
22.89, 22.09 ppm. = –18.9° (c = 1 in CHCl3). LC-MS: system B, gradient 10% → 90% 
ACN/(0.1% TFA/H2O): Rt (min): 12.15. HRMS: calcd. for C29H34BF5N4O4 [M + H]


















TMS-diazomethane (3.0 mL as a 2M solution in hexanes, 6.0 mmol, 4 eq.) was 
added dropwise to a solution of BocPhe(F5)-OH (10a, 0.52 g, 1.5 mmol) in 
MeOH/toluene (1/1 (v/v), 8 mL) and the mixture was stirred until TLC analysis revealed a 
completed reaction after 2 h. The mixture was concentrated to obtain the product (yield: 0.54 g, 
1.5 mmol, quant.) as a white solid without further purification. 1H NMR (400 MHz, CDCl3):  = 5.27 
(d, J = 7.6 Hz, 1H), 4.60 (d, J = 4.4 Hz, 1H), 3.79 (s, 3H), 3.34 (dd, J = 13.2, 3.6 Hz, 1H), 3.08 (dd, J 
= 13.6, 6.8 Hz, 1H), 1.40 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  171.19, 154.79, 146.75, 
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52.54, 27.91, 25.94 ppm. = +37.8º (c = 1 in CHCl3). HRMS: calcd. for C15H16F5NO4 [M + H]+ 





This compound was prepared by the same method described for compound 12a. 
The product was obtained as a colourless solid (yield: 623 mg, 1.5 mmol, quant.). 
1H NMR (400 MHz, CDCl3):  = 7.77 (s, 1H), 7.59 (s, 2H), 5.14 (d, J = 7.09 Hz, 
1H), 4.63 (d, J = 6.25 Hz, 1H), 3.75 (s, 3H), 3.26 (ddd, J = 72.60, 13.71, 5.68 Hz, 2H), 1.42 (s, 9H) 
ppm. 13C NMR (100 MHz, CDCl3):  = 171.42, 154.82, 138.85, 131.63 (q, J = 32.67 Hz), 129.59, 
123.22 (q, J = 272.66 Hz), 120.98, 80.33, 54.08, 52.46, 37.92, 28.11 ppm 23]D = +45.2° (c = 1 in 
CHCl3). HRMS: calcd. for C17H19F6NO4 [M + H]








General procedure A: peptide coupling 
The Boc-protected amine (1 eq.) was treated with TFA (5 mL/mmol) for 30 min. followed by 
coevaporation of the mixture three times with toluene. The resulting TFA salt of the deprotected 
amine was dissolved in DCM (5 mL/mmol) followed by addition of the carboxylic acid (1 eq.) and 
HCTU (1.2 eq.). The pH was set to pH 9 by addition of DiPEA (~3.5 eq.) and the mixture was 
stirred until TLC analysis revealed complete consumption of either of the starting compounds 
(usually after 1 h). Next, the DCM layer was washed with aq. 1M HCl (2×), saturated aq. Na2CO3 
(2×) and brine, dried over MgSO4 and concentrated under reduced pressure. Peptides were 





Prepared via general procedure A using Boc-protected amine 12a and 
BocPheOH. The product was obtained as a colourless solid (yield: 759 mg, 
1.47 mmol, 95%). 1H NMR (400 MHz, CDCl3):  = 7.30-7.19 (m, 3H), 7.17 (d, J = 6.68 Hz, 2H), 6.62 
(d, J = 7.58 Hz, 1H), 4.95 (d, J = 7.80 Hz, 1H), 4.79 (dd, J = 13.52, 7.00 Hz, 1H), 4.36-4.29 (m, 1H), 
3.73 (s, 3H), 3.27 (dd, J = 14.06, 5.85 Hz, 1H), 3.06 (dd, J = 15.68, 6.89 Hz, 2H), 2.98-2.89 (m, 1H), 
1.39 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.33, 170.45, 155.28, 145.44 (dd, J = 237, 
11.0 Hz), 140.17 (dt, J = 251, 11.0 Hz), 137,30 (dt, J = 251, 11.0 Hz), 136.37, 129.08, 128.56, 
126.87, 109.60 (t, J = 19.0 Hz), 80.29, 55.77, 52.73, 51.21, 38.06, 28.05, 25.55 ppm. = 
+2.45° (c = 1 in CHCl3). LC-MS: system A, gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 
9.68. HRMS: calcd. for C24H25F5N2O5 [M + H]













Prepared via general procedure A using Boc-protected amine BocPheOMe and 
carboxylic acid 10a. The product was obtained as a colourless solid (yield: 497 
mg, 0.96 mmol, 91%). 1H NMR (400 MHz, CDCl3):  = 7.30-7.20 (m, 3H), 7.10 
(d, J = 6.62 Hz, 2H), 6.72 (d, J = 7.23 Hz, 1H), 5.24 (d, J = 8.58 Hz, 1H), 4.86 (td, J = 7.88, 6.08, 
6.08 Hz, 1H), 4.47-4.39 (m, 1H), 3.71 (s, 3H), 3.19 (dd, J = 14.17, 5.27 Hz, 1H), 3.10 (dd, J = 7.87, 
6.29 Hz, 2H), 2.95 (dd, J = 14.02, 8.91 Hz, 1H), 1.37 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 
171.54, 169.72, 155.09, 145.44 (dd, J = 237, 11.0 Hz), 140.17 (dt, J = 251, 11.0 Hz), 137,30 (dt, J 
= 251, 11.0 Hz), 135.50, 129.15, 128.52, 127.13, 110.49 (t, J = 19.0 Hz), 80.27, 53.16, 52.30, 
37.87, 27.97, 25.87 ppm. = +28.5° (c = 1 in CHCl3). LC-MS: system A, gradient 10% → 90% 
ACN/(0.1% TFA/H2O): Rt (min): 9.67. HRMS: calcd. for C24H25F5N2O5 [M + H]















Prepared via general procedure A using Boc-protected amine 12a and 
carboxylic acid 10a. The product (yield: 1.18 g, 1.9 mmol, 79%) was obtained 
as a white solid after purification by column chromatography (1% - 13% 
EtOAc/toluene). 1H NMR (400 MHz, MeOD):  = 4.77 (dd, J = 9.6, 5.2 Hz, 1H), 4.37-4.25 (m, 1H), 
3.79 (s, 3H), 3.43 (dd, J = 14.4, 5.2 Hz, 1H), 3.23 (dd, J = 14.0, 9.6 Hz, 1H), 3.15-3.08 (m, 1H), 
2.98-2.91 (m, 1H), 1.29 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 170.63, 170.09, 155.15, 
146.70 (m), 144.25 (m), 141.61 (m), 139.25-138.66 (m), 136.15 (m), 110.32, 80.68, 53.40, 52.98, 
51.58, 27.90, 25.54, 25.07 ppm. = +6.5º (c = 1 in CHCl3). LC-MS analysis: Rt 10.43 min 
(linear gradient 10-90% ACN in H2O, 0.1% TFA, 15 min). HRMS: calcd. for C24H20F10N2O5 [M +H]
+ 














Prepared via general procedure A using Boc-protected amine 12b and 
BocPheOH. The product was obtained as a colourless solid (yield: 823 mg, 
1.46 mmol, 96%). 1H NMR (400 MHz, (CDCl3):  = 7.76 (s, 1H), 7.53 (s, 2H), 
7.31-7.21 (m, 3H), 7.18 (d, J = 6.87 Hz, 2H), 6.64 (d, J = 7.24 Hz, 1H), 4.97 (d, J = 7.52 Hz, 1H), 
4.82 (dd, J = 12.66, 5.98 Hz, 1H), 4.37-4.30 (m, 1H), 3.67 (s, 3H), 3.21 (dq, J = 13.89, 13.88, 13.88, 
5.88 Hz, 2H), 3.10-2.97 (m, 2H), 1.38 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.30, 170.61, 
155.37, 138.59, 136.25, 131.64 (q, J = 33.0 Hz), 129.54, 129.11, 128.66, 127.02, 123.14 (q, J = 271 
Hz), 121.03, 80.35, 55.97, 52.95, 52.40, 37.63, 28.03 ppm. = +26.1° (c = 1 in CHCl3). LC-
MS: system A, gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 10.41. HRMS: calcd. for 
C26H28F6N2O5 [M + H]













Prepared via general procedure A using Boc-protected amine BocPheOMe and 
carboxylic acid 10b. The product was obtained as a colourless solid (yield: 551 
mg, 0.98 mmol, 93%). 1H NMR (400 MHz, CDCl3):  = 7.73 (s, 1H), 7.64 (s, 2H), 
7.28-7.17 (m, 3H), 7.05 (d, J = 6.55 Hz, 2H), 6.70 (d, J = 7.15 Hz, 1H), 5.33 (d, J = 7.66 Hz, 1H), 
4.83 (dd, J = 13.80, 6.14 Hz, 1H), 4.51-4.43 (m, 1H), 3.69 (s, 3H), 3.21 (dd, J = 13.92, 5.89 Hz, 1H), 
3.13-2.99 (m, 3H), 1.38 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.53, 170.17, 155.18, 
139.25, 135.47, 131.48 (q, J = 33 Hz), 129.69, 129.13, 128.56, 127.17, 123.24 (q, J = 271 Hz), 
120.76, 80.34, 54.82, 53.19, 52.55, 37.77, 28.05 ppm. = +28.2° (c = 1 in CHCl3). LC-MS: 
system A, gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 9.88. HRMS: calcd. for C26H28F6N2O5 















Prepared via general procedure A using Boc-protected amine 12b and 
carboxylic acid 10b. The product was obtained as a colourless solid (yield: 
971 mg, 1.39 mmol, 93%). 1H NMR (400 MHz,CDCl3):  = 7.77 (s, 1H), 7.76 
(s, 1H), 7.65 (s, 2H), 7.54 (s, 2H), 6.67 (d, J = 7.28 Hz, 1H), 4.98 (d, J = 7.51 Hz, 1H), 4.87-4.78 (m, 
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(100 MHz, CDCl3):  = 170.610, 170.322, 138.987, 138.367, 131.79 (q, J = 33.31 Hz), 129.513, 
123.15 (q, J = 267.69 Hz), 121.220, 80.940, 53.013, 52.634, 37.592, 27.985 ppm. LC-MS: system 
A, gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 10.94. HRMS: calcd. for C28H26F12N2O5 [M 




Prepared via general procedure A using Boc-protected amine 
BocPhePheOMe and azidophenylalanine. The product was obtained as a 
colourless solid (yield: 217 mg, 0.43 mmol, 87%). 1H NMR (400 MHz, 
CDCl3):  = 7.32-7.12 (m, 9H), 7.07-6.94 (m, 6H), 4.95 (dd, J = 14.23, 6.97 Hz, 1H), 4.81 (dd, J = 
12.13, 5.88 Hz, 1H), 3.87 (dd, J = 4.76, 3.55 Hz, 1H), 3.64 (s, 3H), 3.17 (dd, J = 13.84, 2.01 Hz, 
1H), 3.08-2.96 (m, 2H), 2.92 (d, J = 6.47 Hz, 2H), 2.81 (dd, J = 13.87, 8.70 Hz, 1H) ppm. 13C NMR 
(100 MHz, CDCl3):  = 171.04, 169.96, 168.22, 135.96, 135.89, 135.52, 129.32, 129.28, 129.06, 
128.40, 128.26, 127.03, 126.90, 126.76, 64.80, 53.45, 53.16, 52.02, 38.43, 38.20, 37.77 ppm. 
= +55.2° (c = 1 in CHCl3). LC-MS: system A, gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt 
(min): 8.96. HRMS: calcd. for C28H29N5O4 [M + H]















Prepared via general procedure A using Boc-protected amine 
BocPhePhe(F5)OMe and azidophenylalanine. The product was obtained 
as a colourless solid (yield: 205 mg, 0.35 mmol, 71%). 1H NMR (400 MHz, CDCl3):  = 7.34-7.18 
(m, 8H), 7.05 (dd, J = 7.64, 1.44 Hz, 2H), 6.92 (d, J = 8.00 Hz, 1H), 6.87 (d, J = 8.34 Hz, 1H), 4.77 
(ddd, J = 19.50, 14.54, 7.08 Hz, 2H), 4.19 (dd, J = 8.47, 3.99 Hz, 1H), 3.72 (s, 3H), 3.28-3.19 (m, 
2H), 3.03 (dd, J = 14.05, 7.07 Hz, 1H), 2.92-2.89 (m, 2H), 2.85 (dd, J = 14.12, 8.49 Hz, 1H) ppm. 
13C NMR (100 MHz, CDCl3):  = 170.23, 170.17, 168.52, 145.44 (dd, J = 237, 11.0 Hz), 140.17 (dt, J 
= 251, 11.0 Hz), 137,30 (dt, J = 251, 11.0 Hz), 135.84, 135.75, 129.34, 129.12, 128.52, 128.41, 
127.15, 126.89, 109.51 (dt, J = 18.60, 3.47 Hz), 65.07, 53.81, 52.66, 51.15, 38.33, 37.75, 25.37 
ppm. = +13.7° (c = 1 in CHCl3). LC-MS: system A, gradient 10% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 9.58. HRMS: calcd. for C28H24F5N5O4 [M + H]
















Prepared via general procedure A using Boc-protected amine 
BocPhe(F5)PheOMe and azidophenylalanine. The product was obtained 
as a colourless solid (yield: 117 mg, 0.20 mmol, 62%). 1H NMR (400 MHz, CDCl3):  = 7.45 (d, J = 
8.00 Hz, 1H), 7.30-7.20 (m, 8H), 7.11 (d, J = 8.80 Hz, 1H), 7.03 (d, J = 6.85 Hz, 2H), 5.09 (dd, J = 
15.60, 7.20 Hz, 1H), 4.93 (dd, J = 12.66, 5.98 Hz, 1H), 3.72 (s, 3H), 3.55 (dd, J = 8.47, 3.99 Hz, 
1H), 3.18 (dd, J = 14.00, 3.60 Hz, 1H), 3.13-3.08 (m, 3H), 2.93 (dd, J = 13.20, 6.00 Hz, 1H), 2.78 
(dd, J = 13.80, 9.00 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.14, 169.18, 168.72, 145.44 
(dd, J = 237, 11.0 Hz), 140.17 (dt, J = 251, 11.0 Hz), 137,30 (dt, J = 251, 11.0 Hz), 135.96, 135.62, 
129.41, 129.26, 128.43, 128.39, 127.21, 127.10, 109.65 (dt, J = 18.57, 3.61 Hz), 64.74, 53.36, 
52.27, 51.24, 38.31, 37.95, 25.86 ppm. 23][ D +18.0° (c = 1 in CHCl3). LC-MS: system A, gradient 
10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 9.84. HRMS: calcd. for C28H24F5N5O4 [M + H]
+ 


















Prepared via general procedure A using Boc-protected amine 15 and 
azidophenylalanine. The product was obtained as a colourless solid 
(yield: 0.22 g, 0.32 mmol, 61%). 1H NMR (400 MHz, CDCl3):  = 7.31-7.21 (m, 5H), 4.90-4.85 (m, 
1H), 4.83-4.77 (m, 1H), 4.21 (dd, J = 8.0, 3.2 Hz, 1H), 3.80 (s, 3H), 3.35-3.23 (m, 2H), 3.12-3.08 (m, 
2H), 2.99-2.90 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3):  = 170.47, 169.22, 169.02, 146.69 (m), 
144.17 (m), 141.69 (m), 138.60 (m), 136.08, 135.64, 129.39, 128.69, 126.01, 109.57 (m), 65.05, 
52.93, 51.70, 51.38, 38.21, 25.58, 24.81 ppm. = +12.6º (c = 1 in CHCl3). LC-MS: system A, 
gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 10.59. HRMS: calcd. for C24H19F10N5O4 [M + 

















Prepared via general procedure A using Boc-protected amine 
BocPhePhe(F6)OMe and azidophenylalanine. The product was 
obtained as a colourless solid (yield: 149 mg, 0.23 mmol, 48%). 1H 
NMR (400 MHz, CDCl3):  = 7.74 (s, 1H), 7.52 (s, 2H), 7.34-7.19 (m, 8H), 7.05 (d, J = 6.25 Hz, 2H), 
6.84 (d, J = 7.90 Hz, 1H), 6.67 (d, J = 7.37 Hz, 1H), 4.76 (dd, J = 13.42, 6.17 Hz, 1H), 4.67 (dd, J = 
14.62, 7.20 Hz, 1H), 4.15 (dd, J = 8.15, 4.04 Hz, 1H), 3.66 (s, 3H), 3.22 (dd, J = 14.19, 3.92 Hz, 
1H), 3.16 (dd, J = 14.08, 6.13 Hz, 2H), 3.00-2.84 (m, 3H) ppm. 13C NMR (100 MHz, CDCl3):  =  
170.49, 170.15, 168.57, 138.52, 135.77, 135.67,  131.61 (q, J = 33.29, Hz), 129.44, 129.14, 128.60, 
127.26, 127.13, 123.12 (q, J = 272.76 Hz), 121.04, 65.04, 54.24, 53.10, 52.42, 38.33, 38.04, 37.63 
23][ D = +37.5° (c = 1 in CHCl3). LC-MS: system A, gradient 10% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 10.14. HRMS: calcd. for C30H27F6N5O4 [M + H]


















Prepared via general procedure A using Boc-protected amine 
BocPhe(F6)PheOMe and azidophenylalanine. The product was obtained 
as a colourless solid (yield: 193 mg, 0.30 mmol, 93%). 1H NMR (400 MHz, 
CDCl3):  = 7.73 (s, 1H), 7.55 (s, 2H), 7.33-7.16 (m, 9H), 7.13 (d, J = 8.65 Hz, 1H), 6.99 (dd, J = 
6.92, 2.33 Hz, 2H), 5.10 (dd, J = 15.02, 6.46 Hz, 1H), 4.85 (td, J = 7.62, 5.62, 5.62 Hz, 1H), 3.77 
(dd, J = 8.95, 3.78 Hz, 1H), 3.72 (s, 3H), 3.24 (dd, J = 14.00, 3.68 Hz, 1H), 3.06 (dd, J = 14.03, 5.99 
Hz, 4H), 2.80 (dd, J = 14.00, 8.99 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.14, 169.20, 
168.77, 138.47, 135.89, 135.48, 131.47 (q, J = 33.21 Hz), 129.77 (d, J = 2.42 Hz), 129.37, 129.13, 
128.58, 128.45, 127.25, 127.21, 123.18 (q, J = 272.74 Hz), 121.01, 64.89, 53.15, 52.84, 52.23, 
38.53, 38.31, 37.78 ppm. = +41.8° (c = 1 in CHCl3). LC-MS: system A, gradient 10% → 90% 
ACN/(0.1% TFA/H2O): Rt (min): 10.20. HRMS: calcd. for C30H27F6N5O4 [M + H]






























N3 Prepared via general procedure A using Boc-protected amine 
BocPhe(F6)Phe(F6)OMe and azidophenylalanine. The product was 
obtained as a colourless solid (yield: 0.34 g, 0.44 mmol, 88%). 1H NMR 
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(400 MHz, CDCl3):  = 7.76 (s, 2H), 7.51 (s, 2H), 7.49 (s, 2H), 7.34-7.23 (m, 5H), 4.81-4.75 (m, 1H), 
4.70 (dd, J = 14.0, 7.2 Hz, 1H), 4.19 (dd, J = 8.0, 4.0 Hz, 1H), 3.70 (s, 3H), 3.30-3.24 (m, 2H), 3.20 
(dd, J = 16.8, 5.9 Hz, 2H), 3.00-2.93 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3):  = 170.48, 169.18, 
168.72, 138.26, 135.50, 131.81 (q, J = 11.0 Hz), 129.62, 129.51, 129.25, 128.73, 123.12 (q, J = 127 
Hz), 121.27, 64.97, 53.56, 53.03, 52.66, 38.41, 37.59, 37.48 ppm. = +2.2º (c = 1 in MeOH). 
LC-MS: system A, gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 11.66. HRMS: calcd. for 
C32H25F12N5O4 [M + H]
+ 772.17877; found 772.17899. 
23][ D
 
General procedure B: azide coupling of the peptidehydrazides to the epoxyketone 
warhead (18) 
Hydrazine hydrate (20 eq.) was added to the peptide methyl ester (1 eq.) in MeOH (20 mL/mmol) 
and refluxed until TLC analysis revealed complete consumption of the starting material (usually 
after 3 h). Toluene was added and the mixture was concentrated under reduced pressure followed 
by coevaporation with toluene (2×). The resulting acylhydrazide (1 eq.) was dissolved in a 1:1 
mixture of DCM/DMF (10 mL/mmol) and cooled to –35 °C. To this were added tert-butylnitrite (1.1 
eq.) and HCl (2.8 eq. as a 4M solution in 1,4-dioxane) and the mixture was stirred for 3 h at –35 
°C. Next, a mixture of the deprotected amine (18, 1.1 eq., as a TFA salt) and DiPEA (5 eq.) in DMF 
(1 mL) were added. The reaction was slowly warmed to RT and stirred for another 12 h before 
being diluted with DCM and washed with 1M HCl (2×), saturated Na2CO3 (2×) and brine. After 
drying (MgSO4) and concentrating the obtained crude product was purified by column 






phenylpropanamide, N3PhePhePheLeu-EK (3) 
Prepared via general procedure B. The product was obtained as a 
colourless solid (yield: 157 mg, 0.25 mmol, 77%). 1H NMR (400 MHz, CDCl3):  = 7.33-7.12 (m, 
12H), 7.04 (d, J = 6.38 Hz, 1H), 7.00 (d, J = 7.69 Hz, 3H), 6.94 (d, J = 7.93 Hz, 1H), 6.63 (d, J = 
8.15 Hz, 1H), 4.80 (dd, J = 14.46, 6.89 Hz, 1H), 4.74 (dd, J = 14.29, 6.80 Hz, 1H), 4.59-4.53 (m, 
1H), 4.03 (dd, J = 8.63, 4.02 Hz, 1H), 3.21-3.15 (m, 2H), 3.03-2.87 (m, 4H), 2.87-2.79 (m, 2H), 1.56-
1.50 (m, 2H), 1.49 (s, 3H), 1.22 (dd, J = 16.68, 7.16 Hz, 1H), 0.90 (dd, J = 9.10, 6.22 Hz, 6H) ppm. 
13C NMR (100 MHz, CDCl3):  = 207.96, 170.12, 168.61, 135.96, 135.87, 129.35, 129.27, 129.19, 
128.62, 128.56, 128.52, 128.39, 128.33, 127.18, 127.01, 126.82, 64.96, 58.80, 53.91, 53.86, 52.10, 
49.74, 40.13, 38.25, 37.88, 25.01, 23.20, 21.38, 16.50 ppm. = +47.5° (c = 1 in CHCl3). LC-
MS: system A, gradient 50% → 90% ACN/(0.1% TFA/H2O): Rt (min): 5.82. HRMS: calcd. for 
C36H42N6O5 [M + H]

















2-yl)-3-phenylpropanamide, N3PhePhePhe(F5)Leu-EK (4a) 
Prepared via general procedure B. The product was obtained as a 
colourless solid (yield: 234 mg, 0.32 mmol, quant.). 1H NMR (400 MHz, CDCl3):  = 7.38 (d, J = 
8.10 Hz, 1H), 7.33-7.13 (m, 10H), 7.03 (d, J = 6.67 Hz, 2H), 4.91 (dd, J = 12.63, 6.05 Hz, 2H), 4.67 
(t, J = 7.71, 7.71 Hz, 1H), 4.21 (dd, J = 8.55, 3.74 Hz, 1H), 3.23 (dd, J = 13.85, 3.76 Hz, 2H), 3.12 
(dd, J = 13.58, 5.98 Hz, 1H), 3.00-2.81 (m, 5H), 1.71-1.54 (m, 2H), 1.52 (s, 3H), 1.31-1.21 (m, 1H), 
0.93 (dd, J = 10.64, 6.35 Hz, 6H) ppm. 13C NMR (100 MHz, CDCl3):  = 208.71, 170.74, 169.26, 
168.84, 145.4 (dd, J = 246.15, 11.0 Hz), 140.32 (dt, J = 253.22, 11.0 Hz), 137.43 (dt, J = 246.40, 
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3.28 Hz), 65.09, 58.88, 53.85, 52.13, 51.90, 50.02, 40.67, 38.33, 38.18, 26.03, 25.20, 23.31, 21.51, 
16.50 ppm. = +8.7° (c = 1 in CHCl3). LC-MS: system B, gradient 50% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 7.73. HRMS: calcd. for C36H37F5N6O5 [M + H]






yl)-3-phenylpropanamide, N3PhePhePhe(F6)Leu-EK (4b) 
Prepared via general procedure B. The product was obtained as a 
colourless solid (yield: 156 mg, 0.20 mmol, 95%). 1H NMR (400 MHz, 
CDCl3):  = 7.71 (s, 1H), 7.53 (s, 2H), 7.34-7.16 (m, 8H), 7.05 (d, J = 7.63 Hz, 1H), 7.00 (d, J = 6.14 
Hz, 3H), 6.93 (d, J = 7.75 Hz, 1H), 4.76 (dd, J = 13.13, 6.42 Hz, 1H), 4.68 (dd, J = 14.27, 7.10 Hz, 
1H), 4.54 (dd, J = 13.00, 5.25 Hz, 1H), 4.15 (dd, J = 8.35, 3.84 Hz, 1H), 3.24-3.14 (m, 2H), 3.07 (dd, 
J = 13.92, 5.77 Hz, 2H), 2.92 (d, J = 6.64 Hz, 2H), 2.84 (d, J = 4.68 Hz, 2H), 1.67-1.57 (m, 1H), 
1.53 (dd, J = 13.48, 2.57 Hz, 1H), 1.49 (s, 3H), 1.30-1.22 (m, 1H), 0.95-0.91 (m, 6H) ppm. 13C NMR 
(100 MHz, CDCl3):  = 208.28, 170.34, 169.28, 168.61, 162.53, 138.62, 135.86, 135.66, 131.27 (q, J 
= 33.14 Hz), 129.80, 129.39, 129.03, 128.57, 128.54, 127.20, 127.06, 123.19 (q, J = 272.84 Hz), 
120.84, 64.98, 59.02, 54.20, 53.43, 52.14, 50.21, 39.79, 38.23, 38.00, 37.84, 36.44, 31.36, 25.07, 
23.24, 21.14, 16.39 ppm. = +41.9° (c = 1 in CHCl3). LC-MS: system B, gradient 50% → 90% 
ACN/(0.1% TFA/H2O): Rt (min): 8.73. HRMS: calcd. for C38H40F6N6O5 [M + H]





















2-yl)-3-phenylpropanamide, N3PhePhe(F5)PheLeu-EK (5a) 
Prepared via general procedure B. The product was obtained as a 
colourless solid (yield: 135 mg, 0.18 mmol, 92%). 1H NMR (400 MHz, CDCl3):  = 7.69 (d, J = 6.88 
Hz, 1H), 7.31-7.15 (m, 9H), 7.09 (d, J = 6.46 Hz, 2H), 7.04 (d, J = 6.34 Hz, 1H), 6.73 (d, J = 6.27 
Hz, 1H), 5.03 (dd, J = 14.61, 7.19 Hz, 1H), 4.83 (dd, J = 13.94, 6.69 Hz, 1H), 4.59 (dd, J = 12.37, 
5.10 Hz, 1H), 3.91 (dd, J = 8.90, 3.47 Hz, 1H), 3.22 (dd, J = 13.83, 3.23 Hz, 1H), 3.13-3.06 (m, 2H), 
3.02-2.97 (m, 3H), 2.83 (dd, J = 13.94, 9.17 Hz, 1H), 2.76 (d, J = 4.71 Hz, 1H), 1.64-1.52 (m, 2H), 
1.50 (s, 3H), 1.29-1.22 (m, 1H), 1.00-0.82 (m, 6H) ppm. 13C NMR (100 MHz, CDCl3):  = 208.27, 
169.95, 169.31, 168.94, 145.44 (dd, J = 237, 11.0 Hz), 140.17 (dt, J = 251, 11.0 Hz), 137,30 (dt, J 
= 251, 11.0 Hz), 135.98, 129.33, 128.46, 128.27, 127.09, 127.04, 126.91, 109.66 (dt, J = 19.00, 
2.82 Hz), 64.79, 58.83, 54.07, 52.04, 51.48, 49.82, 40.22, 38.73, 38.21, 25.62, 25.06, 23.10, 21.30, 
16.45 ppm. = +27.0° (c = 1 in CHCl3). LC-MS: system B, gradient 50% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 7.86. HRMS: calcd. for C36H37F5N6O5 [M + H]


















yl)-3-phenylpropanamide, N3PhePhe(F6)PheLeu-EK (5b) 
Prepared via general procedure B. The product was obtained as a 
colourless solid (yield: 220 mg, 0.28 mmol, 95%). 1H NMR (400 MHz, 
CDCl3):  = 7.85 (d, J = 7.85 Hz, 1H), 7.71 (s, 1H), 7.60 (s, 2H), 7.40 (d, J = 8.60 Hz, 1H), 7.32-7.08 
(m, 9H), 7.05 (d, J = 6.92 Hz, 2H), 5.13 (dd, J = 13.66, 7.60 Hz, 1H), 4.87 (dd, J = 13.75, 6.59 Hz, 
1H), 4.62 (dd, J = 12.45, 5.05 Hz, 1H), 4.04 (dd, J = 9.31, 3.45 Hz, 1H), 3.25-3.15 (m, 2H), 3.11-
2.96 (m, 4H), 2.79 (d, J = 4.02 Hz, 1H), 2.76 (dd, J = 13.05, 8.88 Hz, 1H), 1.63-1.52 (m, 2H), 1.51 
(s, 3H), 0.91 (dd, J = 8.50, 6.71 Hz, 6H) ppm. 13C NMR (100 MHz, CDCl3):  = 208.30, 170.16, 
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128.51, 128.16, 127.07, 126.72, 123.11 (q, J = 272.74 Hz), 120.75, 65.00, 58.77, 53.95, 52.89, 
51.99, 49.81, 40.08, 38.53, 38.39, 37.86, 25.04, 23.01, 21.32, 16.37 ppm. = +43.4° (c = 1 in 
CHCl3). LC-MS: system B, gradient 50% → 90% ACN/(0.1% TFA/H2O): Rt (min): 8.73. HRMS: calcd. 
for C38H40F6N6O5 [M + H]





















Prepared via general procedure B from 16. Purification by HPLC (linear gradient 72 → 82% ACN in 
H2O, 0.1% TFA, 15 min) furnished the title compound (yield: 16.4 mg, 20.1 mol, 10%) as a white 
solid. 1H NMR (400 MHz, MeOD):  = 7.31-7.23 (m, 5H), 4.63 (dd, J = 14.4, 6.8 Hz, 2H), 4.54 (dd, J 
= 10.0, 3.2 Hz, 1H), 4.04 (dd, J = 8.8, 5.2 Hz, 1H), 3.28 (d, J = 5.2 Hz, 1H), 3.17-3.09 (m, 3H), 
3.01-2.98 (m, 1H), 2.96-2.83 (m, 3H), 1.74-1.60 (m, 1H), 1.44 (s, 3H), 1.38-1.34 (m, 1H), 1.32-1.31 
(m, 1H), 0.93 (t, J = 6.8 Hz, 6H) ppm. 13C NMR (100 MHz, MeOD):  = 209.55, 171.41, 171.12, 
148.20, 145.78, 143.0-142.50 (m), 140.15-139.8 (m), 137.75, 137.68, 130.36, 129.60, 128.06, 
111.54 (q, J = 18 Hz), 65.49, 59.95, 53.09, 52.77, 51.27, 40.46, 38.69, 26.33, 26.02, 23.70, 21.58, 
16.73 ppm. = +5.5º (c = 1 in MeOH). LC-MS: system A, gradient 50% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 8.63. HRMS: calcd. for C36H32F10N6O5 [M + H]








Prepared via general procedure B. The product was obtained by 
HPLC purification (linear gradient 62 → 69% ACN in H2O, 0.1% TFA, 
15 min) as a yellowish oil (yield: 29.3 mg, 32.1 mol, 7%). 1H NMR (400 MHz, MeOD):  = 7.84 (s, 
2H), 7.79 (s, 4H), 7.25-7.14 (m, 5H), 4.76-4.59 (m, 2H), 4.49 (dd, J = 10.8, 2.8 Hz, 1H), 3.97 (dd, J 
= 8.8, 2.8 Hz, 1H), 3.28 (d, J = 5.7 Hz, 1H), 3.25 (d, J = 4.8 Hz, 1H), 3.21 (d, J = 5.2 Hz, 1H), 3.04-
2.98 (m, 3H), 2.91 (d, J = 4.8 Hz, 1H), 2.74 (dd, J = 13.9, 9.1 Hz, 1H), 1.74-1.70 (m, 1H), 1.51-1.47 
(m, 1H), 1.45 (s, 3H), 1.39-1.31 (m, 1H), 0.95 (d, J = 6.4 Hz, 3H), 0.91 (d, J = 6.4 Hz, 3H) ppm. 13C 
NMR (100 MHz, MeOD):  = 209.65, 172.28, 171.92, 171.25, 141.46, 137.81, 132.60 (q, J = 33.0 
Hz), 131.20, 130.25, 129.57, 128.07, 124.90 (q, J = 332 Hz), 121.77, 65.51, 60.18, 55.05, 54.78, 
52.98, 51.94, 40.08, 38.88, 38.33, 26.32, 23.73, 21.47, 16.95 ppm. = +29.4º (c = 1 in 
MeOH). LC-MS: system A, gradient 50% → 90% ACN/(0.1% TFA/H2O): Rt (min): 10.09. HRMS: 
calcd. for C40H38F12N6O5 [M + H]




















Compound 4a (70.7 mg, 97 mol) was dissolved in a 
mixture of toluene/tBuOH/H2O (1/1/1 v/v/v, 2 mL) and to this 
were added Bodipy-alkyne18 (1 eq., 97 mol, 32 mg), CuSO4 
(10 mol%, 9.7 mol, 9.7 L; 1M in H2O) and sodium 
ascorbate (15 mol%, 14.5 mol, 14.5 L; 1M in H2O). The 
mixture was stirred at 80 ºC for 2.5 h after which TLC analysis indicated complete consumption of 
the starting material. The mixture was concentrated under reduced pressure and the compound 
was purified by column chromatography (DCM → 2.5% MeOH/DCM) and obtained as a brownish 
solid (yield: 89.2 mg, 84.4 mol, 87%). 1H NMR (400 MHz, CDCl3)  = 8.07 (d, J = 5.49 Hz, 1H), 
7.62 (s, 1H), 7.52 (d, J = 8.17 Hz, 1H), 7.19 (d, J = 5.94 Hz, 1H), 7.08 (d, J = 4.92 Hz, 4H), 7.03-
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7.40 Hz, 1H), 5.30-5.24 (m, 1H), 4.82 (dd, J = 13.07, 6.73 Hz, 1H), 4.75 (dd, J = 12.64, 5.94 Hz, 
1H), 3.44-3.32 (m, 2H), 3.24 (d, J = 4.58 Hz, 1H), 3.05 (dd, J = 13.96, 6.43 Hz, 1H), 3.00-2.63 (m, 
8H), 2.50 (s, 6H), 2.37 (s, 6H), 1.95-1.86 (m, 2H), 1.73-1.58 (m, 4H), 1.54 (s, 3H), 1.31 (dd, J = 6.89, 
3.54 Hz, 1H), 0.92 (dd, J = 21.75, 6.16 Hz, 6H) ppm. 13C NMR (150 MHz, CDCl3):  = 208.40, 
170.33, 169.33, 167.56, 153.79, 147.36, 145.92, 140.22, 135.57, 135.24, 131.33, 129.02, 128.72, 
128.42, 128.23, 127.09, 126.60, 121.56, 120.54, 64.65, 58.79, 54.28, 52.03, 51.56, 49.92, 40.50, 
38.83, 38.64, 31.29, 29.58, 28.06, 25.43, 25.13, 23.19, 21.44, 16.46, 16.27, 14.35 ppm. 23][ D = 
+27.5° (c = 1 in CHCl3). LC-MS: system A, gradient 50% → 90% ACN/(0.1% TFA/H2O): Rt (min): 
8.95. HRMS: calcd. for C55H60BF7N8O5 [M + H]
+ 1057.47407; found 1057.47562. 
Competition assays 
Whole cell lysates of HEK-293T or EL4 were made by sonication in 3 volumes of lysis buffer 
containing 50 mM Tris pH 7.5, 1 mM DTT, 5 mM MgCl2, 250 mM sucrose, 2 mM ATP. Protein 
concentration was determined by the Bradford assay. Cell lysates (13.5 g total protein for HEK-
293T lysates and 9 g total protein for EL4 lysates) were exposed to the inhibitors for 1 h prior to 
incubation with MV151 (0.5 M) for 1 h at 37 °C. Reaction mixtures were boiled with Laemmli’s 
buffer containing -mercaptoethanol for 5 min. before being resolved by 12.5% SDS-PAGE. In-gel 
detection of residual proteasome activity was performed in the wet gel slabs directly on the 
Typhoon Variable Mode Imager (Amersham Biosciences) using the Cy3/Tamra settings (ex 532nm, 
em 560 nm) to detect MV151 and Cy2/Fam settings (ex 488 nm, em 520 nm) to detect compound 
19. 
IC50 determinations 
Purified 26S proteasome (~10 ng/mL) was incubated with various concentrations of inhibitors at 
37 ºC for 30 min. in the assay buffer (50 mM Tris-HCl, pH 7.5, 40 mM KCl, 2 mM EDTA, 1 mM DTT, 
100 M ATP, 50 g/mL BSA). In the meantime, 100 M solution of the fluorogenic peptide 
substrates (Suc-LLVY-7-amido-4-methyl-coumarin (amc) for the 5 site, Ac-nLPnLD-amc for the 
1 site and Ac-RLR-amc or Ac-RQR-amc for the 2 site) in the assay buffer were pre-incubated at 
37 °C. Immediately after the end of this incubation, an aliquot of the inhibitor-treated proteasome 
was mixed with the substrate, and fluorescence of released amc was measured continuously for 
30 min. at 37 °C. The rate of reaction was determined from the slope of the reaction progress 
curves. Mock-treated proteasomes served as control. Residual activity in inhibitor treated samples 
were plotted against concentration of inhibitors and IC50 values were determined from these plots. 
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The mammalian 20S proteasome catalytic core contains two sets of three 
catalytically active  subunits, which display a different substrate specificity, namely 1 
(caspase-like) cleaves after acidic residues, 2 (trypsin-like) cleaves after basic residues 
and 5 (chymotrypsin-like) cleaves after bulky, hydrophobic residues.1-3 In specific cell 
types involved in the immune surveillance system four additional active subunits can be 
expressed. In the so-called immunoproteasome the 1i, 2i and 5i replace their 
corresponding constitutive counterparts4 and, in addition to that, 5 is replaced by 5t 
in cortical thymic epithelial cells.5 To study the role of each individual catalytic subunit 
in the generation of oligopeptides, the development of cell permeable inhibitors that 
target one specific subunit has become an important field of research. Peptide-based 
inhibitors targeting the 5 subunit can be created by introduction of hydrophobic amino 
acids,6,7 as was, for example, shown in Chapter 4. In addition, Van Swieten et al.8 
reported on the development of a cell permeable 1 selective inhibitor containing 
hydrophobic amino acids as well. In contrast, the search for highly selective inhibitors 
for the 2 and/or 2i active sites with good cell permeability remains a challenging task. 
One reason for this might be that introduction of basic amino acids is often required to 
target the trypsin-like site more selectively. These basic amino acids (Arg, Lys) are 
positively charged at neutral pH, making it very difficult to cross the cell membrane. A 
second problem is the synthesis of inhibitors bearing an electrophilic trap (for instance 
the epoxy ketone) in combination with basic amino acids (especially at the P1 position, 
next to the warhead), for they are susceptible to c
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the 
ition to 
the vinyl sulfone electrophilic trap, the epoxyketone featured by natural proteasome 
inhibitor epoxomicin was incorporated as well (4b, 5b), since it displays a specific 
reactivity towards proteasome active sites (see also Chapter 4).3,13 The N-terminal 
benzyloxycarbonyl group was replaced by the structurally related azidophenylalanine, 
which opens the possibility for additional modifications,14-16 yet it does not significantly 
influence the inhibitory properties compared to the benzyloxycarbonyl group.17  
 
2 subunit selectively have been described in the literature (see Figure 1A). In a P2-
P4 side chain positional scanning study Bogyo et al.9 found the 2 selective inhibitor Ac-
YRLN-VS 1 and showed that the P3 substituent (Arg) is of considerable importance in 
selectivity enhancement. In addition, the group of Tomatis10,11 reported on the vinyl 
ethyl ester tripeptide HMB-VSL-VE 2, which was able to selectively target the 2 active 
site, both in purified proteasome and in living cells. 
This chapter describes the development of inhibitors targeting the trypsin-like 
subunits (2 and 2i) by modification of the P1 site, which plays a key role in subunit 
binding, with basic residues. The initial set of inhibitors synthesized and studied is 
shown in Figure 1C. The general structure is based on the tripeptide vinyl sulfone Z-L3VS 
3, which targets all proteasome active sites (Figure 1B).12 The P1 leucine side chain was 
replaced by either a panel of phenylalanine derivatives containing an amine with varying 
basicity (benzyl amine 4a, aniline 5a, pyridine 6) or a lysine (7) side chain. In add
 
Figure 1. (A) Examples of two published 2 selective proteasome inhibitors. (B) Modifications of broad-
spectrum proteasome inhibitor ZL3VS at the basis of the here presented inhibitors. (C) Initial panel of 
inhibitors prepared and studied in this chapter. 
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5.2 Results and Discussion 
Retro-synthetically, the modified oligopeptides can be prepared from tripeptide 
hydrazide N3Phe-Leu-Leu-NHNH2 and the properly protected warhead amines in an 
(epimerization free) azide coupling.18 The synthesis of P1-benzyl amine containing vinyl 
sulfone and epoxyketone warheads leading to inhibitors 4a and 4b is shown in Scheme 
1. The synthetic scheme commenced with the introduction of the aminomethylene 
substituent on L-phenylalanine 8, by performing an electrophilic aromatic substitution 
with N-(hydroxymethyl)trichloroacetamide under acidic conditions.19,20 In this reaction 
both the ortho and the para substituted isomers were formed, which could be separated 
by column chromatography. The desired para substituted isomer was obtained in 35% 
yield. After Cbz-protection of the -amine compound 9 was obtained. Basic removal of 
the trichloroacetamide group followed by Boc protection of the formed amine gave 10, 
which was coupled to N,O-dimethylhydroxylamine to give Weinreb-amide 11. Upon a 
reaction with 2-lithiumpropene the ’,’-unsaturated ketone 12 was obtained. 
Stereoselective reduction to the allylic alcohol 13 and subsequent asymmetric 
 resulted in epoxyketone 14.21 This compound 
was -amine deprotected by hydrogenation, which finalized the synthesis of compound 
15. The vinyl sulfone analogue was created by -amine deprotection of compound 11, 
followed by tritylation (16). Reduction of the Weinreb-amide, followed by a Horner-
Wadworth-Emmons reaction and de-tritylation finally resulted in compound 18. 
Scheme 1. Synthesis of warheads 15 and 18. 





























17 R = Tr
18 R = H
15 R = H TFA
11







9 R = Cl3Ac









Reagents and conditions: (a) i) N-(hydroxymethyl)trichloroacetamide, H2SO4, H2O; ii) benzyl chloroformate, 
Na2CO3, H2O, 1,4-dioxane, 35%; (b) i) 20% NaOH, EtOH/H2O 1:1; ii) Boc2O, Na2CO3, THF, H2O, 75%; (c) 
NH(Me)OMe·HCl, HCTU, DiPEA, DCM, 98%; (d) 2-bromopropene, tBuLi, THF, –78 °C, 94%; (e) NaBH4, 
CeCl3·7H2O, MeOH, 0 °C, 92%; (f) i) tBuOOH, VO(Acac)2, DCM, 0 °C; ii) Dess-Martin periodinane, DCM, 56%; (g) 
H2, Pd black, TFA, MeOH; (h) i) H2, Pd/C, AcOH, EtOH; ii) TrCl, Et3N, DMAP, DCM, 38%; (i) i) LiAlH4, Et2O, 0 °C; 
ii) diethyl ((methylsulfonyl)methyl)phosphonate, NaH, THF, 0 °C, 85%; (j) 1% TFA/DCM. 
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Aniline containing warheads 24 and 29 (Scheme 2) were made from Weinreb-
amide 21 by following a similar reaction sequence as described for 18 and 15 
respectively (see Scheme 1). Compound 21 was made from Fmoc protected para-
nitrophenylalanine 19. Reduction of the nitro group followed by Boc-protection of the 
formed amine and formation of the Weinreb-amide gave fully protected 20, which was 
converted into free -amine 21 by removal of the Fmoc group. 
Scheme 2. Synthesis of warheads 24 and 29. 
 
Reagents and conditions: (a) i) NH4HCO2H, Pd/C, MeOH; ii) Boc2O, NaHCO3, H2O, 1,4-dioxane; iii) 
NH(Me)OMe·HCl, HCTU, DiPEA, DCM, 99%; (b) DBU, THF, 85%; (c) TrCl, Et3N, DMAP, DCM, 96%; (d) i) LiAlH4, 
Et2O, 0 °C; ii) diethyl ((methylsulfonyl)methyl)phosphonate, NaH, THF, 0 °C, 85%; (e) 1% TFA/DCM; (f) benzyl 
chloroformate, DiPEA, THF, 85%; (g) 2-bromopropene, tBuLi, THF, –78 °C, 94%; (h) NaBH4, CeCl3·7H2O, MeOH, 
0 °C, 92%; (i) i) tBuOOH, VO(Acac)2, DCM, 0 °C; ii) Dess-Martin periodinane, DCM, 56%; (j) H2, Pd black, TFA, 
MeOH. 
The synthesis of lysine (33) and pyridine (37) functionalized vinyl sulfones is 
depicted in Scheme 3. These compounds were produced in a procedure similar to that 
for 18, from -amine-Boc-protected Weinreb-amide 3022 and commercially available 
Boc--(4-pyridyl)-L-alanine 34 respectively. 
Scheme 4 shows the azide coupling of amine warheads 18 and 24 with tripeptide 
hydrazide 38, giving, after TFA mediated deprotection and RP-HPLC purification, 
inhibitors 4a and 5a. The other inhibitors were made in a similar reaction from the 
appropriate amines in varying yields of 7-48% after RP-HPLC. LC-MS and NMR analysis 
showed for neither compound any sign of epimerization of the final products. 
The inhibition potential of the inhibitors for each of the catalytically active 
subunits was assessed in competition assays employing extracts of human embryonic 
kidney cells (HEK-293T) and mouse lymphoma cells (EL-4) in combination with the 
fluorescent broad spectrum proteasome probe MV15123 (see also Chapter 4). The gel 
images are shown in Figure 2. Competitive inhibition of a proteasome active site is 
reflected by the disappearance of the corresponding band. 
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Scheme 3. Synthesis of warheads 33 and 37. 
 
Reagents and conditions: (a) TrCl, DiPEA, DCM, 68%; (b) i) LiAlH4, Et2O, 0 °C; ii) diethyl 
((methylsulfonyl)methyl)phosphonate, NaH, THF, 0 °C, 64%; (c) 1% TFA/DCM; (d) NH(Me)OMe·HCl, HCTU, 
DiPEA, DCM, quant.; (e) TFA, DCM. 
Scheme 4. Azide coupling towards the target inhibitors.  
 
Reagents and conditions: (a) i) tBuONO, HCl, DMF, DCM, –30 °C; ii) compound 18 or 24, DiPEA; iii) TFA, 
DCM, then RP-HPLC, yields: 7-48%. 
It is apparent from these results (Figure 2) that the selectivity for 2 decreases with 
decreasing basicity (compare compounds 4a and 7 with 5a and 6). When the 
substituent becomes less basic the inhibitor targets both 5 and 2. This phenomenon 
can be explained by the fact that the nature of the substituent becomes more 
hydrophobic and is therefore more favoured by 5. In general, the 1 subunit is not 
affected by any compound and is even upregulated at higher concentrations (a related 
effect was also seen in Chapter 4 in case 5-specific inhibitors were employed).24 There 
appears to be little difference between the experiments in HEK-293T and EL-4 lysate 
with respect to the potency towards 2, however the selectivity for 2 over 5 is difficult 
to determine since the 5(i) and 1(i) bands are overlapping. Apparently, the inhibitors 
do not distinguish between the constitutive subunits and their immuno counterparts. 
Interestingly, the vinyl sulfones seem to display better characteristics, in terms of 
selectivity and potency, compared to the epoxyketones (compare compounds 4a and 
5a with 4b and 5b). This observation is remarkable since epoxyketones are generally 
more active than their vinyl sulfone counterparts (in a head-to-head comparison).16 
Benzyl amine derivative 4a and lysine derivative 7 are the most 2 selective inhibitors in 
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this series, however in terms of potency, compound 4a is about a 10 fold more potent 
than 7. Capable of (almost) complete inhibition of 2(i) at a concentration of 0.5 M, 
while leaving the other subunits untouched, compound 4a is the most valuable 
compound derived from this series. 
 











Figure 2. Characterization of the specificity of the inhibitors shown in Figure 1C. Competition assay in (A) 
HEK-293T cell lysate and (B) EL-4 cell lysate. Lysates were incubated with the inhibitors at the indicated final 
concentrations. Residual proteasome activity was labelled with 0.5 M MV151. 
Three inhibitors were selected from this panel and tested for their capability to 
cross the cell membrane. Primary amine containing compounds 4a and 7 were selected 
because of their enhanced preference for 2 and compound 5a was tested for its ability 
to target both 2 and 5. Living HEK-293T cells were incubated with each of the three 
inhibitors at 0.5, 5 and 50 M final concentrations for 4 hours, after which all residual 
proteasome activity was labelled with cell permeable probe MV151. The cells were lysed, 
all proteins denatured and resolved by SDS-PAGE. As a control the broad-spectrum 
proteasome inhibitor AdaAhx3L3VS,
25 which is known to be able to cross the cell 
membrane, was used. From the results shown in Figure 3 it follows that the primary 
amine in compound 4a does not result in inpermeability towards the cell membrane 
and is still able of inhibiting (almost) all 2 activity at 5 M. Aniline containing 
compound 5a was also able to cross the cell membrane, after which it targets both 2 
and 5. Lysine derived inhibitor 7 appears to be unable of crossing the cell membrane 
as evidenced from Figure 3. 
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Figure 3. Competition assay in live HEK-293T cells. The cells were treated with compounds 4a, 5a and 7 at 
the indicated final concentrations for 4 hours, followed by incubation with MV151 (5 M final concentration) 
for 2 hours. After cell lysis and denaturation the samples were resolved by SDS-PAGE and analyzed by 
fluorescence scanning. Controls used: 0 = no inhibitor, D = DMSO, Ada = AdaAhx3L3VS (20 M). 
For direct labelling of 2 a new fluorescent probe was made by reacting compound 
4a with a green fluorescent Bodipy-alkyne18 in a ‘click’ reaction (see Figure 4A). This 
reaction however was not as straightforward as could be expected from earlier results 
(see Chapter 4). Upon reaction of both compounds with CuSO4 and sodium ascorbate in 
an aqueous medium compound 4a was completely consumed, however the formed 
product had a mass of 1 Da less compared to the expected product mass and it was 
dramatically more hydrophobic compared to the starting material, as evidenced from 
LC-MS measurements. It was reasoned that the free benzylic amine was oxidized and 
hydrolyzed into its corresponding benzaldehyde (Figure 4A). This reaction has been 
previously observed by Srogl and Voltrova,26 who describe a copper/ascorbic acid dyad 
catalytic system for the selective aerobic oxidation of amines (both benzylic and 
aliphatic). Indeed, upon addition of ammonium acetate and NaCNBH3 a reductive 
amination took place, resulting in the desired product 39. 
The ability of compound 39 to label proteasome actives both in HEK-293T cell 
lysate and living cells was assessed in a competition assay as described above. A dual-
wavelength fluorescence read-out was performed allowing visualisation of one of the 
two fluorescent dyes at a time. The results are shown in Figure 4B. From this it becomes 
clear that the introduction of the bulky, hydrophobic bodipy moiety has resulted in the 
loss of the inhibitor’s selectivity for 2 over 5. Both subunits are inhibited equally well, 
leaving only 1 untouched. Probably the large hydrophobic moiety is too close to the 
active site and introduction of a spacer between tag and warhead may reinstall 2 
selectivity. Interestingly, introduction of the bodipy has had a detrimental effect on cell 
permeability. At a concentration of 5 M both subunits (2 and 5) seem not to be 
competed away at all, although a faint band for each subunit is visible in the lower gel. 
Even at a concentration of 50 M not all proteasome activity is silenced. This 
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observations must come from the cell penetrating properties of the probe, since all 2 
and 5 proteasomal activity is inhibited at a 5 M concentration in cell lysate. 
 






[Compound 39] (μM) [39] (μM)controls




Figure 4. (A) Synthesis of fluorescent probe 39 in a ‘click’ reaction with inhibitor 4a and Bodipy-alkyne. As a 
side reaction the benzylamine was converted to the corresponding benzaldehyde. Reagents and conditions: 
(a) Bodipy-alkyne, CuSO4, sodium ascorbate, H2O/tBuOH/toluene 1:1:1, 80 °C; (b) NH4OAc, NaCNBH4, MeOH, 
RP-HPLC, 29%. (B) Competition assay in HEK-293T cell lysate (left) and living cells (right) with compound 39 at 
the indicated final concentrations. Residual proteasome activity was labelled with MV151. Fluorescence read-
out at ex 532 nm, em 560 nm (MV151, upper panels) and ex 488 nm, em 520 nm (compound 39, lower 
panels). Controls used: Ada = AdaAhx3L3VS (20 M final concentration), D = DMSO, 0 = no inhibitor. 
As discussed in the introduction of this Chapter vinyl ethyl ester tripeptide HMB-
VSL-VE 2 was identified as a potent, cell permeable 2 selective inhibitor.10,11 Other 
inhibitors containing the vinyl ethyl ester warhead have been made, which are known to 
target other subunits as well.27 It is therefore likely that the majority of the 2 selectivity 
comes from the unique HMB-Val-Ser peptide sequence. For this reason, a combination 
of the HMB-Val-Ser peptide sequence and the P1-functionalized warheads discussed so 
far may result in inhibitors with an even enhanced preference for the 2(i) subunit. To 
this end compounds 40 and 41 (see Figure 5A) were synthesized via the method 
outlined above from HMB-Val-Ser(tBu)-NHNH2.28 First, both compounds were tested for 
their inhibitory activity in HEK-293T cell lysate in a competition assay as discussed 
earlier. The results are depicted in Figure 5A. When comparing compound 40 and 4a it 
becomes clear that substitution of the N3PheLeu2 for the HMB-Val-Ser motif the general 
potency is decreased by a factor two. In addition, the selectivity for 2 over 5 is 
substantially increased. Only a part of the 5 activity is inhibited at 50 M by 40, 
whereas compounds 4a completely blocks 5 at this concentration. This difference is 
even more pronounced for the inhibition in living cells by 40 (Figure 5B). The 2 band 
has almost disappeared at a concentration of 5 M and 5 is not affected at all at 
concentrations up to 50 M. The most striking result from this assay is the apparent 
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selectivity of compound 40 for 2 over 2i in EL-4 lysate (Figure 5A). At a concentration 
of 0.5 M 2 is almost completely blocked, whereas the compound starts to inhibit 2i 
only at 5 M. The attachment of the HMB-Val-Ser peptide sequence to the aniline 
derived vinyl sulfone (41) only resulted in a drop of potency of the inhibitor compared 
to 5a. The characteristics in terms of selectivity remain unchanged (it still targets both 
2 and 5). These observations invite the conclusion that the HMB-Val-Ser sequence on 
its own is not enough to active 2 selectivity, but that by selection of a suitable P1 
substituent this objective might be reached after all. 
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Figure 5. Competition assay of (A) compounds 40 and 41 in HEK-293T and EL-4 cell lysate and (B) 
compound 40 in HEK-293T living cells. Residual proteasome activity was labelled with MV151 as described 
above. Controls used: Ada = AdaAhx3L3VS (20 M final concentration), D = DMSO, 0 = no inhibitor. 
5.3 Conclusion 
In summary, the effect of introduction of different amines of varying basicity, at 
the P1 position in oligopeptide proteasome inhibitors with respect to the selectivity for 
proteasome’s trypsin-like sites was studied. As expected, it was found that the 2 
selectivity increases with increasing basicity of the side chain. All compounds were 
ineffective towards 1, but upon decreasing basic character of the substituent 5 was 
targeted. The most 2 selective compounds identified were lysine derived 7 and 4-
aminomethylene phenylalanine derived 4a, of which the latter one proved to be most 
potent. It was shown that 4a was capable of inhibiting 2 selectively both in cell lysate 
and in living cells. This demonstrates that the nature of the side chain amine is such, 
that it is basic enough to direct the inhibitor towards 2, yet it allows the inhibitor to 
cross the cell membrane. Introduction of a hydrophobic fluorescent tag into 4a, to label 
and visualize the 2 subunit selectively, resulted in a decreased selectivity for 2 over 
5. A good alternative would be the use of two-step labelling, in which a biological 
sample is first treated with inhibitor 4a, after which the construct is captured at the 
azide moiety via, for instance the Staudinger-Bertozzi ligation29 or ‘click’ chemistry.30 
Preliminary results however, showed that the azide in 4a is relatively inreactive towards 
 
108       Chapter 5  
a biotin-phosphane reagent.31 Therefore, improvements have to made, for instance by 
introduction of a more accessible azide or a spacer between warhead and modification 
site/tag.  
In addition, the 4-aminomethylene phenylalanine vinyl sulfone warhead was 
coupled to the HMB-Val-Ser peptide, of which a preference for 2 has been 
reported.10,11 This resulted in inhibitor 40, which is completely ineffective towards 5 up 
to 50 M in vivo and has a comparable potency towards 2. Interestingly, compound 40 
was found to be able to distinguish between the constitutive active subunit 2 and its 
immunoproteasome counterpart 2i, showing a ten fold higher preference for 2 in EL-4 
lysate. 
Experimental section 
General Procedures:  
Tetrahydrofuran was distilled over LiAlH4 prior to use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH), diisopropylethylamine (DiPEA) and 
trifluoroacetic acid (TFA) were of peptide synthesis grade, purchased at Biosolve, and used as 
received. All general chemicals (Fluka, Acros, Merck, Aldrich, Sigma) were used as received. O-(1H-
6-Chlorobenzotriazolyl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased 
at Iris Biotech (Marktrewitz, Germany). Traces of water were removed from reagents used in 
reactions that require anhydrous conditions by co-evaporation with toluene. Solvents that were 
used in reactions were stored over 4 Å molecular sieves, except methanol and acetonitrile which 
were stored over 3 Å molecular sieves. Column chromatography was performed on Screening 
Devices b.v. Silica Gel, with a particle size of 40-63 m and pore diameter of 60 Å. The eluents 
toluene, ethyl acetate and petroleum ether (40-60 °C boiling range) were distilled prior to use. TLC 
analysis was conducted on Merck aluminium sheets (Silica gel 60 F254). Compounds were 
visualized by UV absorption (254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) 
and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 
g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in ethanol, where appropriate, 
followed by charring at ca. 150 ºC. 1H- and 13C-NMR spectra were recorded on a Bruker AV-400 
(400 MHz) spectrometer. Chemical shifts are given in ppm () relative to tetramethylsilane, CD3OD 
or CDCl3 as internal standard. High resolution mass spectra were recorded by direct injection (2 
L of a 2 M solution in water/acetonitrile 50/50 (v/v) and 0.1% formic acid) on a mass 
spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source in 
positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 °C) with 
resolution R = 60,000 at m/z 400 (mass range m/z = 150-2,000) and dioctylpthalate (m/z = 
391.28428) as a “lock mass”. The high resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). Optical rotations  were 
recorded on a Propol automatic polarimeter. LC-MS analysis was performed on a Finnigan 
Surveyor HPLC system with a Gemini C18 50 × 4.60 mm column (detection at 200-600 nm), 
coupled to a Finnigan LCQ Advantage Max mass spectrometer with ESI. The applied buffers were 
H2O, ACN and 1.0% aq. TFA. HPLC purifications were performed on a Gilson HPLC system 
coupled to a Phenomenex Gemini 5 m 250 × 10 mm column and a GX281 fraction collector. The 
applied buffers were: 0.1% aq. TFA and ACN. 
23][ D
General procedure I: azide coupling of N3Phe-Leu-Leu-NHNH2 or HMB-Val-Ser(tBu)-
NHNH2 to an amine-warhead followed by acidic deprotection 
N3Phe-Leu-Leu-NHNH2 38 or HMB-Val-Ser(tBu)-NHNH2 (1 eq.) was dissolved in a 9:1 mixture of 
DCM/DMF (10 mL/mmol) and cooled to –35 °C. To this were added tert-butylnitrite (1.1 eq.) and 
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HCl (2.8 eq. as a 4 M solution in 1,4-dioxane) and the mixture was stirred for 3 h at –35 °C. Next, a 
mixture of the deprotected amine (1.1 eq.) and DiPEA (5 eq.) in DMF (1 mL) were added. The 
reaction was slowly warmed to room temperature and stirred for another 12 h before being diluted 
with DCM and extracted with 1M aq. HCl (2×), saturated aq. Na2CO3 (2×) and brine. After drying 
(MgSO4) and concentrating the obtained crude product was dissolved in DCM (2.5 mL/mmol). TFA 
(2.5 mL/mmol) was added and the mixture was stirred for 30 min, after which it was concentrated 




This compound was synthesized via general Boc-based peptide 
coupling procedures using HCTU from H-Leu-OMe, Boc-Leu-H and N3-
Phe-H. The last step involved the introduction of the hydrazide by 
stirring of a mixture containing tripeptide N3-Phe-Leu-Leu-OMe (1.51 g, 3.49 mmol) and hydrazine 
monohydrate (30 eq., 105 mmol, 5.1 mL) in MeOH (30 mL) for 15 h at RT. The title compound was 
obtained after coevaporation of the mixture with toluene (3×) as a colourless solid (yield: 1.51 g, 














trichloroacetamido)methyl)phenyl)propanoic acid (9)  
L-Phenylalanine (8, 8.26 g, 50.0 mmol) was added in portions to 
concentrated H2SO4 (35 mL) maintaining the temperature at 25 °C. N-
(hydroxymethyl)trichloroacetamide (1.05 eq., 52.5 mmol, 10.1 g) was added 
in portions while maintaining the temperature at 20-25 °C. The cooling bath was removed and the 
light-brown cloudy solution was stirred at room temperature for 1 h. The reaction mixture was 
added to ice (500 mL) and the pH was adjusted to pH 5.5 with 8 M aq. NaOH solution while 
maintaining the quench temperature at 15-20 °C. The white solid was filtered off and washed with 
ice-cold H2O. The residue was dissolved in a 1:1 mixture of H2O/dioxane (100 mL) and the pH was 
adjusted to pH 9 by addition of Na2CO3. Next, benzyl chloroformate (7.32 mL, 50.0 mmol) was 
added and the mixture was stirred for 4 h. Concentrated aq. HCl was added until pH 1 and the 
mixture was extracted twice with EtOAc. The combined organic layers were extracted with brine, 
dried (MgSO4) and concentrated under reduced pressure. The resulting crude product was purified 
by column chromatography (25% → 60% EtOAc/PE) and the title compound was obtained as a 
colourless solid (yield: 8.29 g, 17.5 mmol, 35%). 1H NMR (400 MHz, CDCl3):  = 10.16 (s, 1H), 7.31-
7.21 (m, 6H), 7.13 (d, J = 7.88 Hz, 2H), 7.09 (d, J = 7.97 Hz, 2H), 5.58 (d, J = 8.21 Hz, 1H), 5.05-
4.97 (m, 2H), 4.60 (dd, J = 13.68, 6.42 Hz, 1H), 4.40 (d, J = 5.54 Hz, 2H), 3.14 (dd, J = 13.57, 4.65 
Hz, 1H), 3.01 (dd, J = 13.81, 6.53 Hz, 1H) ppm. 13C NMR (100 MHz, CDCl3):  = 174.70, 162.06, 
155.85, 135.68, 135.31, 135.15, 129.57, 128.31, 128.28, 127.76, 127.57, 92.30, 66.91, 54.41, 









butoxycarbonyl)amino)methyl)phenyl)propanoic acid (10) 
Compound 9 (2.82 g, 5.94 mmol) was treated with 20% w/w NaOH in 
H2O/EtOH (1:1) for 1 h after which TLC analysis indicated complete conversion 
of starting material. Next, 3 M aq. HCl was added until pH 7 and the mixture was concentrated 
under reduced pressure. The resulting crude compound was dissolved in THF (40 mL) and cooled 
to 0 °C. Boc2O (1.5 eq., 8.91 mmol, 2.0 g) was added and the solution was basified by addition of 
Na2CO3 until pH 9. The mixture was stirred at RT for 3 h, after which it was acidified with 10% w/v 
aq. HCl until pH 2 and extracted with EtOAc (3×). The combined organic layers were extracted 
with brine, dried over MgSO4 and concentrated under reduced pressure. The resulting crude 
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was obtained as a colourless solid (yield: 1.90 g, 4.45 mmol, 75%). 1H NMR (400 MHz, CDCl3):  = 
9.32 (s, 1H), 7.36-7.28 (m, 5H), 7.16-7.02 (m, 4H), 5.33 (d, J = 7.64 Hz, 1H), 5.09 (q, J = 12.32, 
12.32, 12.29 Hz, 2H), 4.95 (s, 1H), 4.65 (d, J = 6.41 Hz, 1H), 4.26-4.19 (m, 2H), 3.20-3.04 (m, 2H), 
1.45 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 174.79, 156.16, 155.77, 137.47, 136.15, 134.80, 





Carboxylic acid 10 (4.45 g, 10.4 mmol) was dissolved in DCM (75 mL). To 
this were added NH(Me)OMe·HCl (1.5 eq., 15.6 mmol, 1.55 g), HCTU (1.5 eq., 15.6 mmol, 6.45 g) 
and DiPEA (4.5 eq., 46.7 mmol, 7.72 mL) and the mixture was stirred for 2 h until TLC analysis 
indicated a completed reaction. The solvent was evaporated under reduced pressure and the 
residue was dissolved in EtOAc. This was extracted with 1 M aq. HCl (2×), saturated aq. Na2CO3 
(2×) and brine, dried over MgSO4 and concentrated under reduced pressure. The product was 
purified by column chromatography (10% → 75% EtOAc/PE) and obtained as colourless oil (yield: 
4.81 g, 10.2 mmol, 98%). 1H NMR (400 MHz, CDCl3):  = 7.29-7.22 (m, 5H), 7.14 (d, J = 8.12 Hz, 
2H), 7.09 (d, J = 8.17 Hz, 2H), 6.02 (d, J = 8.49 Hz, 1H), 5.35 (s, 1H), 5.00 (dd, J = 28.51, 12.34 Hz, 
2H), 4.96-4.94 (m, 1H), 4.21 (d, J = 5.20 Hz, 2H), 3.62 (s, 3H), 3.10 (s, 3H), 3.02 (dd, J = 13.63, 
5.63 Hz, 1H), 2.85 (dd, J = 13.27, 7.70 Hz, 1H), 1.43 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 
171.54, 155.50, 137.23, 136.02, 135.04, 129.04, 127.92, 127.48, 127.42, 126.98, 78.64, 66.11, 
61.01, 51.78, 43.76, 37.46, 31.52, 27.96 ppm. = +10.1 (c = 1, CHCl3). HRMS: calcd. for 
C25H33N3O6 472.24421 [M+ H]









2-Bromopropene (3.5 eq., 14.0 mmol, 1.25 mL) was dissolved in THF (50 mL) 
and cooled to –78 °C. tBuLi (6.5 eq., 26.0 mmol, 16.3 mL; 1.6 M in hexane) 
was added slowly and the mixture was stirred for 1 h at –78 °C after which Weinreb amide 11 (1 
eq., 4.0 mmol, 1.89 g) was added in THF (5 mL). The mixture was allowed to warm to –20 °C in 6 h 
after which TLC analysis indicated complete consumption of the Weinreb amide. A saturated 
aqueous NH4Cl solution and EtOAc were added and the layers were separated. The organic layer 
was extracted with brine, dried over MgSO4 and concentrated under reduced pressure. The title 
compound was obtained after column chromatography (20% → 50% EtOAc/PE) as a colourless oil 
(yield: 1.71 g, 3.77 mmol, 94%). 1H NMR (400 MHz, CDCl3):  = 7.33-7.24 (m, 5H), 7.11 (d, J = 7.87 
Hz, 2H), 6.97 (d, J = 8.00 Hz, 2H), 6.03 (s, 1H), 5.85 (s, 1H), 5.77 (d, J = 8.18 Hz, 1H), 5.30 (dd, J = 
14.10, 6.11 Hz, 1H), 5.12-5.08 (m, 1H), 5.04 (dd, J = 26.54, 12.35 Hz, 2H), 4.21 (d, J = 5.41 Hz, 
2H), 3.09 (dd, J = 13.79, 5.88 Hz, 1H), 2.89 (dd, J = 13.76, 5.97 Hz, 1H), 1.84 (s, 3H), 1.44 (s, 9H) 
ppm. 13C NMR (100 MHz, CDCl3):  = 199.28, 155.66, 155.34, 141.99, 137.40, 136.13, 134.60, 
129.27, 128.17, 127.80, 127.71, 126.50, 79.01, 66.45, 55.13, 43.96, 38.76, 28.14, 17.44 ppm. 
HRMS: calcd. for C26H32N2O5 453.23840 [M+ H]







Ketone 12 (2.81 g, 4.30 mmol) was dissolved in MeOH (25 mL) and cooled to 
0 °C. To this were added CeCl3·7H2O (1.5 eq., 6.45 mmol, 2.43 g) and NaBH4 
(1.4 eq., 6.0 mmol, 227 mg) portionwise and the mixture was stirred for 5 min. after which TLC 
analysis indicated a complete conversion. Glacial acetic acid (10 mL) was added and the mixture 
was concentrated under reduced pressure. The resulting residue was dissolved in EtOAc and 
extracted with half saturated aq. NaHCO3 (2×) and brine, dried over MgSO4 and concentrated in 
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NMR (400 MHz, CDCl3):  = 7.31-7.01 (m, 9H), 5.30 (d, J = 9.18 Hz, 1H), 5.06 (s, 1H), 5.00 (d, J = 
5.19 Hz, 1H), 4.96-4.91 (m, 3H), 4.21 (d, J = 4.41 Hz, 1H), 4.16-4.11 (m, 1H), 4.07-3.98 (m, 1H), 
2.85 (d, J = 12.55 Hz, 1H), 2.65 (dd, J = 13.60, 10.41 Hz, 1H), 1.77 (s, 3H), 1.44 (s, 9H) ppm. 13C 
NMR (100 MHz, CDCl3):  = 155.96, 155.85, 144.44, 137.34, 136.44, 129.34, 128.19, 127.77, 
127.66, 127.25, 112.17, 79.25, 76.65, 66.27, 54.06, 44.15, 33.69, 28.22, 18.73 ppm. 23][ D = –18.7 




Allylic alcohol 13 (1.79 g, 3.94 mmol) was dissolved in DCM (25 mL) and 
cooled to 0 °C after which vanadyl acetylacetonate (0.1 eq., 0.4 mmol, 107 
mg) and tBuOOH (3 eq., 12.0 mmol, 2.18 mL; 5.5 M in decane) were added and the mixture was 
stirred at 0 °C until TLC analysis indicated complete consumption of starting material after 2 h. 
The mixture was concentrated under reduced pressure, redissolved in EtOAc and extracted with 
half sat. aq. NaHCO3, H2O and brine, dried over MgSO4 and concentrated under reduced pressure. 
The resulting product was quickly purified by column chromatography (20% → 60% EtOAc/PE) and 
immediately subjected to the next step because of the possible instability of the intermediate.  
The compound was dissolved in DCM (25 mL) and Dess-Martin periodinane (3 eq., 11.0 mmol, 
4.50 g) was added. The mixture was stirred at RT for 12 h after which TLC analysis indicated 
complete conversion. Next, a 1:4 (v/v) mixture (150 mL) of NaHCO3 (sat. aq.)/Na2S2O3 (1 M aq.) 
and the resulting emulsion was stirred vigorously for 30 min. after which the layers were separated 
and the aqueous layer extracted with DCM. The combined organic layers were extracted with sat. 
aq. NaHCO3, dried over MgSO4 and concentrated under reduced pressure. The title compound 
was obtained after column chromatography (20% → 30% EtOAc/PE) as a colourless oil (yield: 1.03 
g, 2.20 mmol, 56%). 1H NMR (400 MHz, CDCl3):  = 7.33-7.22 (m, 5H), 7.16 (d, J = 7.94 Hz, 2H), 
7.08 (d, J = 7.95 Hz, 2H), 5.51 (d, J = 8.19 Hz, 1H), 5.06-5.01 (m, 1H), 4.97 (d, J = 4.39 Hz, 2H), 
4.60 (dd, J = 12.65, 7.86 Hz, 1H), 4.24 (d, J = 4.36 Hz, 2H), 3.26 (d, J = 4.62 Hz, 1H), 3.08 (dd, J = 
13.96, 4.48 Hz, 1H), 2.87 (d, J = 4.53 Hz, 1H), 2.70 (dd, J = 13.88, 8.12 Hz, 1H), 1.49 (s, 3H), 1.44 
(s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 207.77, 155.74, 155.66, 137.61, 135.97, 134.62, 
129.32, 128.26, 127.91, 127.76, 127.44, 79.15, 66.62, 58.99, 54.07, 52.12, 44.07, 36.61, 28.21, 







oxopropyl)benzylcarbamate TFA salt (15) 
Cbz protected amine 14 (107 mg, 0.23 mmol) was dissolved in MeOH (5 mL) 
and to this was added TFA (1.2 eq., 0.27 mmol, 21 L). Argon was bubbled 
through the solution for 15 min., after which Pd black (10 mg) was added and the flask was 
charged with hydrogen gas. After 10 min, TLC analysis indicated complete conversion of starting 
material and all solids were removed by filtration over Celite. Toluene (10 mL) was added and the 
mixture was concentrated under reduced pressure followed by coevaporation with toluene (2×) in 
order to remove excess TFA. The purity of the deprotected amine (as TFA salt) was confirmed by 








Compound 11 (1.43 g, 3.04 mmol) was dissolved in a 50:1 mixture 
EtOH/AcOH (25 mL) and argon was bubbled through this solution for 15 
min. Next, Pd/C (10% w/w, 0.1 g) was added and hydrogen was bubbled through the mixture until 
TLC indicated complete consumption of starting material after 4 h. Argon was bubbled through for 
another 15 min. after which the mixture was filtered over Celite and the filtrate concentrated 
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1.21 g (max. 3.04 mmol) and was subsequently dissolved in DCM (20 mL). To this were added Et3N 
(2 eq., 6.08 mmol, 0.85 mL), DMAP (0.1 g) and tritylchloride (1.5 eq., 4.56 mmol, 1.30 g). The 
mixture was stirred for 6 h after which it was concentrated under reduced pressure, redissolved in 
EtOAc and extracted with 10 mM aq. HCl and brine, dried over MgSO4 and concentrated under 
reduced pressure. The resulting mixture was purified by column chromatography (10% → 50% 
EtOAc/PE) and the title compound was obtained as colourless foam (yield: 0.68 g, 1.17 mmol, 
38%). 1H NMR (400 MHz, CDCl3):  = 7.47 (s, 1H), 7.34 (d, J = 7.33 Hz, 6H), 7.26-7.20 (m, 4H), 
7.18-7.05 (m, 9H), 5.10 (s, 1H), 4.28 (s, 2H), 4.00 (t, J = 5.60, 5.60 Hz, 1H), 3.18 (s, 3H), 2.92 (dd, J 
= 13.24, 5.63 Hz, 1H), 2.77 (dd, J = 12.93, 7.51 Hz, 1H), 2.63 (s, 3H), 1.44 (s, 9H) ppm. 13C NMR 
(100 MHz, CDCl3):  = 174.80, 155.74, 145.92, 137.18, 137.13, 130.25, 128.70, 127.33, 127.15, 




Weinreb amide 16 (0.65 g, 1.12 mmol) was dissolved in Et2O (15 mL), put 
under an argon atmosphere and cooled to 0 °C. LiAlH4 (2 eq., 2.25 mmol, 
0.56 mL of a 4 M solution in Et2O) was added slowly and the mixture was stirred at 0 °C for 1 h 
after which TLC analysis indicated complete conversion of the starting compound. 0.1 M aq. HCl 
(15 mL) was slowly added and the layers were separated. The organic layer was extracted with 0.1 
M aq. HCl and brine, dried over MgSO4 and concentrated under reduced pressure. Diethyl 
((methylsulfonyl)methyl)phosphonate (1.5 eq., 1.68 mmol, 0.39 g) was dissolved in THF (20 mL) 
and cooled to 0 °C under an argon atmosphere. NaH (1.5 eq., 1.68 mmol, 67.2 mg, 60% w/w in 
mineral oil) was slowly added and the mixture was stirred at 0 ºC for 30 min. Next, the freshly 
obtained aldehyde (in THF (2 mL)) was slowly added and the mixture was stirred for 2 h while 
slowly warming it to RT. After this time TLC analysis indicated complete conversion of the 
aldehyde. EtOAc (20 mL) was added and the mixture was extracted with 10 mM aq. HCl (2×) and 
brine, dried over MgSO4 and concentrated under reduced pressure. The title compound was 
obtained after column chromatography (20% → 50% EtOAc/PE) as a colourless foam (yield: 0.57 
g, 0.95 mmol, 85%). 1H NMR (400 MHz, CDCl3):  = 7.46 (d, J = 7.6 Hz, 6H), 7.28 (t, J = 7.20, 6.80 
Hz, 6H), 7.20 (t, J = 7.20, 7.20 Hz, 3H), 7.13 (d, J = 7.60 Hz, 2H), 6.87 (d, J = 8.00 Hz, 2H), 6.57 
(dd, J = 14.80, 7.00 Hz, 1H), 5.96 (d, J = 14.80 Hz, 1H), 4.80 (s, 1H), 4.24 (d, J = 5.60 Hz, 2H), 3.49 
(q, J = 6.00 Hz, 1H), 2.61 (s, 3H), 2.54 (dd, J = 13.20, 5.20 Hz, 1H), 2.33 (dd, J = 13.20, 8.20 Hz, 
1H), 1.44 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 155.59, 150.21, 145.74, 137.42, 135.28, 
129.53, 128.35, 128.02, 127.70, 127.14, 126.44, 78.91, 71.05, 55.33, 43.79, 42.43, 41.86, 28.09 










Trityl protected amine 17 (0.54 g, 0.90 mmol) was treated with 1% v/v 
TFA/DCM (15 mL) at RT. To this yellow solution was added H2O (1 mL) which 
resulted in a colourless suspension. After stirring the mixture for 30 min., 10 mM aq. HCl (20 mL) 
was added and DCM was removed under reduced pressure. The aqueous layer was extracted with 
Et2O (3×) and basified with NaHCO3 until pH 9, after which it was extracted with DCM (3×). The 
latter combined organic layers were dried over MgSO4 and concentrated under reduced pressure. 
The resulting deprotected amine proved to be pure on LC-MS analysis and was subjected to the 
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N3Phe-Leu-Leu-Phe(4-CH2NH2)VS TFA salt (4a) 
This compound was synthesized according to General 
procedure I on a 100 mol scale by addition of amine 18. 
The title compound was obtained after RP-HPLC purification 
(gradient: 20% → 60% MeOH/0.1% aq. TFA) as a colourless 
solid (yield: 15.4 mg, 20.1 mol, 20%). 1H NMR (400 MHz, CD3OD):  = 7.39-7.21 (m, 9H), 6.78 
(dd, J = 15.20, 5.34 Hz, 1H), 6.55 (dd, J = 15.21, 1.52 Hz, 1H), 4.82-4.77 (m, 1H), 4.36-4.27 (m, 
2H), 4.17 (dd, J = 8.61, 4.80 Hz, 1H), 4.07 (s, 2H), 3.19 (dd, J = 14.05, 4.75 Hz, 1H), 3.02-2.95 (m, 
3H), 2.92 (s, 3H), 1.63-1.43 (m, 6H), 0.93 (t, J = 5.65, 5.65 Hz, 6H), 0.88 (d, J = 6.24 Hz, 6H) ppm. 
13C NMR (100 MHz, CD3OD):  = 174.45, 174.27, 171.95, 146.65, 139.63, 137.85, 133.01, 131.90, 
131.30, 130.47, 130.26, 129.67, 128.13, 65.56, 53.74, 53.49, 52.46, 44.11, 42.83, 41.80, 41.61, 
40.29, 38.71, 25.95, 25.86, 23.47, 23.46, 21.96, 21.94 ppm. LC-MS: Rt (min): 6.99 (ESI-MS (m/z): 
654.20 (M + H+)). HRMS: calcd. for C33H47N7O5S 654.34321 [M+ H]













N3Phe-Leu-Leu-Phe(4-CH2NH2)EK TFA salt (4b) 
This compound was synthesized according to General 
procedure I on a 100 mol scale by addition of amine 15. 
The title compound was obtained after RP-HPLC purification 
(gradient: 20% → 60% MeOH/0.1% aq. TFA) as a colourless 
solid (yield: 17.6 mg, 23.5 mol, 24%). 1H NMR (400 MHz, CD3OD):  = 7.36-7.20 (m, 9H), 4.68 
(dd, J = 9.34, 4.20 Hz, 1H), 4.38-4.28 (m, 2H), 4.12 (dd, J = 8.58, 4.79 Hz, 1H), 4.05 (s, 2H), 3.21 
(d, J = 4.97 Hz, 1H), 3.15 (dd, J = 14.18, 4.69 Hz, 1H), 3.08 (dd, J = 13.84, 4.06 Hz, 1H), 2.95-2.87 
(m, 2H), 2.72 (dd, J = 13.90, 9.34 Hz, 1H), 1.52-1.43 (m, 6H), 1.41 (s, 3H), 0.94-0.83 (m, 12H) ppm. 
13C NMR (100 MHz, CD3OD):  = 208.54, 174.48, 174.13, 171.69, 139.71, 137.87, 132.95, 131.15, 
130.47, 130.14, 129.65, 128.10, 65.59, 60.25, 54.51, 53.40, 53.15, 52.79, 44.14, 42.13, 41.79, 
38.73, 37.11, 25.83, 23.49, 22.03, 21.94, 16.81 ppm. LC-MS: Rt (min): 7.36 (ESI-MS (m/z): 634.20 
(M + H+)). HRMS: calcd. for C34H47N7O5 634.37114 [M+ H]

















To a suspension of Fmoc-Phe(4-NO2)-OH (19, 1.27 g, 2.93 mmol) in MeOH (60 
mL) was added ammonium formate (10 eq., 30.0 mmol, 1.95 g) which resulted in a clear solution. 
Pd/C (10% w/w, 0.5 g) was added and the mixture was stirred at RT for 14 h after which TLC 
analysis indicated complete consumption of starting material. All solids were removed by filtration 
over Celite and the filtrate was concentrated under reduced pressure. In order to remove excess 
ammonium formate the resulting product was coevaporated with a 3:1 (v/v) mixture of MeOH/H2O 
(5×). Next, the residue was dissolved in H2O (40 mL) containing NaHCO3 (11.7 mmol, 0.99 g) and 
cooled to 0 °C. To this was added Boc2O (4.40 mmol, 0.99 g) in 1,4-dioxane (20 mL) and the 
mixture was allowed to stir at RT for 14 h. The mixture was acidified with 10% w/v aq. HCl until pH 
1 and extracted three times with EtOAc. The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. Finally the Weinreb amide was created in a peptide 
couplings procedure similar to that for 11. The title compound was obtained after column 
chromatography (10% → 50% EtOAc/PE) as a colourless oil (yield: 1.59 g, 2.91 mmol, 99%). 1H 
NMR (400 MHz, CDCl3):  = 7.70-7.66 (m, 2H), 7.53 (dd, J = 12.68, 7.49 Hz, 2H), 7.33 (dd, J = 
13.74, 6.75 Hz, 4H), 7.27-7.21 (m, 2H), 7.11 (d, J = 8.33 Hz, 2H), 6.17 (d, J = 8.85 Hz, 1H), 5.06-
4.98 (m, 1H), 4.32 (dd, J = 10.25, 7.60 Hz, 1H), 4.25-4.19 (m, 1H), 4.14 (t, J = 7.25, 7.25 Hz, 1H), 
3.60 (s, 3H), 3.13 (s, 3H), 3.05 (dd, J = 13.68, 5.45 Hz, 1H), 2.90 (dd, J = 13.46, 7.49 Hz, 1H), 1.47 
(s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.76, 155.65, 152.62, 143.49, 143.42, 140.78, 





4.81, 119.51, 118.14, 79.76, 66.61, 61.13, 
51.93, 46.66, 37.40, 31.64, 27.96 ppm.  
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(S)-tert-butyl (4-(2-amino-3-(methoxy(methyl)amino)-3-
oxopropyl)phenyl)carbamate  (21) 
To a solution of compound 20 (1.50 g, 2.75 mmol) in THF (20 mL) was added 
DBU (1.5 mmol, 229 L). After 10 min. TLC analysis indicated complete 
consumption of starting material. 1 M aq. HCl (30 mL) and EtOAc (25 mL) were added and the 
layers were separated. The organic layer was extracted with 1 M aq. HCl and the combined 
aqueous layers were basified with Na2CO3 until pH 10. This layer was extracted with EtOAc (3×) 
and the latter combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. The title compound was obtained as a colourless oil (yield: 0.75 g, 2.34 mmol, 85%). 1H 
NMR (400 MHz, CDCl3)  = 7.62 (s, 1H), 7.33 (d, J = 8.14 Hz, 2H), 7.09 (d, J = 8.43 Hz, 2H), 4.02-
3.95 (m, 1H), 3.57 (s, 3H), 3.16 (s, 3H), 2.98 (dd, J = 13.30, 5.56 Hz, 1H), 2.65 (dd, J = 13.25, 7.71 
Hz, 1H), 1.93 (s, 2H), 1.49 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3)  = 175.13, 152.66, 137.04, 
131.64, 129.29, 118.28, 79.54, 60.96, 52.38, 40.41, 31.82, 27.94 ppm. = +19.6 (c = 1, 
CHCl3). HRMS: calcd. for C16H25N3O4 324.19178 [M+ H]









To a solution of amine 21 (0.38 g, 1.16 mmol) in DCM (15 mL) was added Et3N 
(1.2 eq., 1.40 mmol, 195 L), and tritylchloride (1.2 eq., 1.40 mmol, 0.40 g) 
and the mixture was stirred for 14 h. DCM was evaporated under reduced pressure and the 
residue was dissolved in EtOAc, extracted with 10 mM aq. HCl (2×) and brine, dried over MgSO4 
and concentrated under reduced pressure. The title compound was obtained after column 
chromatography (10% → 50% EtOAc/PE) as a colourless foam (yield: 0.61 g, 1.11 mmol, 96%). 1H 
NMR (400 MHz, CDCl3):  = 7.46 (s, 1H), 7.36 (d, J = 7.55 Hz, 6H), 7.22-7.02 (m, 13H), 6.95 (s, 
1H), 4.01-3.95 (m, 1H), 3.10 (s, 3H), 2.88 (dd, J = 13.31, 5.95 Hz, 1H), 2.73 (dd, J = 13.03, 7.26 Hz, 
1H), 2.61 (s, 3H), 1.49 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 174.86, 152.68, 145.93, 
136.93, 132.49, 130.36, 128.66, 127.31, 125.82, 118.18, 79.91, 70.58, 59.93, 41.63, 31.92, 28.15 










This compound was prepared from Weinreb amide 22 (0.61 g, 1.11 mmol) in a 
synthetic procedure similar to that for compound 17 and obtained after 
column chromatography (10% → 40% EtOAc/PE) as a colourless foam (yield: 0.24 g, 0.41 mmol, 
37%). 1H NMR (400 MHz, CDCl3):  = 7.45 (d, J = 7.49 Hz, 6H), 7.28-7.15 (m, 12H), 6.81 (d, J = 
8.38 Hz, 2H), 6.58 (s, 1H), 6.56 (dd, J = 15.04, 6.90 Hz, 1H), 5.92 (d, J = 15.11 Hz, 1H), 3.45 (dd, J 
= 12.80, 6.98 Hz, 1H), 2.58 (s, 3H), 2.51 (dd, J = 13.36, 5.25 Hz, 1H), 2.28 (dd, J = 13.33, 7.86 Hz, 
1H), 1.49 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 152.59, 150.70, 145.91, 137.06, 130.81, 
130.06, 128.55, 127.91, 126.64, 118.38, 80.34, 71.26, 55.55, 42.73, 41.68, 28.22 ppm. = –








This compound was prepared from trityl protected amine 23 in a synthetic 
procedure similar to that for compound 18. The purity was checked by LC-MS 
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(S)-benzyl (3-(4-(tert-butyloxycarbonylamino)phenyl)-1-
(methoxy(methyl)amino)-1-oxopropan-2-yl)carbamate (25) 
To a solution of amine 21 (0.79 g, 2.43 mmol) in THF (20 mL) was added 
DiPEA (1.2 eq., 2.91 mmol, 482 L), and benzylchloroformate (1.1 eq., 2.67 
mmol, 392 L) and the mixture was stirred for 4 h in which a colourless solid precipitated. EtOAc 
was added and the mixture was extracted with 1 M aq. HCl (2×), sat. aq. NaHCO3 and brine, dried 
over MgSO4 and concentrated under reduced pressure. The title compound was obtained after 
column chromatography (10% → 75% EtOAc/PE) as a colourless foam (yield: 0.95 g, 2.06 mmol, 
85%). 1H NMR (400 MHz, CDCl3):  = 7.33-7.23 (m, 7H), 7.14 (s, 1H), 7.05 (d, J = 8.21 Hz, 2H), 
5.80 (d, J = 8.71 Hz, 1H), 5.04 (dd, J = 26.77, 12.39 Hz, 2H), 4.98-4.94 (m, 1H), 3.62 (s, 3H), 3.13 
(s, 3H), 3.01 (dd, J = 13.65, 5.91 Hz, 1H), 2.85 (dd, J = 13.58, 7.35 Hz, 1H), 1.49 (s, 9H) ppm. 13C 
NMR (100 MHz, CDCl3):  = 171.72, 155.64, 152.64, 137.21, 136.07, 130.35, 129.52, 128.13, 
127.69, 127.64, 118.18, 79.88, 66.41, 61.21, 51.95, 37.53, 31.7 .05 ppm. 23][ D = +8.1 (c = 1, 












This compound was prepared from Weinreb amide 25 (0.90 g, 1.96 mmol) in a 
synthetic procedure similar to that for compound 12 and obtained after column 
chromatography (10% → 25% EtOAc/PE) as a colourless oil (yield: 0.70 g, 1.58 mmol, 81%). 1H 
NMR (400 MHz, CDCl3):  = 7.37-7.20 (m, 7H), 6.92 (d, J = 8.47 Hz, 2H), 6.81 (s, 1H), 6.00 (s, 1H), 
5.86 (d, J = 1.20 Hz, 1H), 5.66 (d, J = 8.15 Hz, 1H), 5.30 (dd, J = 14.10, 6.04 Hz, 1H), 5.07 (q, J = 
12.28, 12.28, 12.25 Hz, 2H), 3.07 (dd, J = 13.85, 6.11 Hz, 1H), 2.89 (dd, J = 13.86, 5.86 Hz, 1H), 
1.84 (s, 3H), 1.49 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 199.48, 155.44, 152.61, 142.11, 
137.24, 136.17, 129.91, 129.69, 128.31, 127.92, 127.84, 126.73, 118.22, 80.17, 66.63, 55.33, 
38.83, 28.16, 17.54 ppm. = +77.1 (c = 1, CHCl3). HRMS: calcd. for C25H30N2O5 439.22275 








This compound was prepared from ketone 26 (0.70 g, 1.85 mmol) in a synthetic 
procedure similar to that for compound 13 and obtained after column 
chromatography (10% → 25% EtOAc/PE) as a colourless oil (yield: 0.71 g, 1.85 mmol, quant.). 1H 
NMR (400 MHz, CDCl3):  = 7.32-7.18 (m, 7H), 7.04 (d, J = 8.15 Hz, 2H), 6.77 (s, 1H), 5.17 (d, J = 
9.01 Hz, 1H), 5.05-4.91 (m, 4H), 4.14-4.10 (m, 1H), 4.05-3.97 (m, 1H), 3.01 (s, 1H), 2.86-2.78 (m, 
1H), 2.64 (dd, J = 14.18, 9.64 Hz, 1H), 1.76 (s, 3H), 1.50 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  
= 156.03, 152.82, 144.45, 136.48, 136.33, 132.60, 129.65, 128.24, 127.79, 127.70, 118.49, 112.28, 
80.17, 76.61, 66.37, 54.06, 33.46, 28.20, 18.71 ppm. = –13.8 (c = 1, CHCl3). HRMS: calcd. 
for C25H32N2O5 441.23840 [M+ H]








This compound was prepared from allylic alcohol 27 (0.70 g, 1.58 mmol) in a 
synthetic procedure similar to that for compound 14 and obtained after 
column chromatography (10% → 30% EtOAc/PE) as a colourless oil (yield: 0.35 g, 0.76 mmol, 
48%). 1H NMR (400 MHz, CDCl3):  = 7.28-7.17 (m, 7H), 7.10 (s, 1H), 6.96 (d, J = 8.42 Hz, 2H), 
6.50 (s, 1H), 5.27 (d, J = 8.21 Hz, 1H), 5.00-4.87 (m, 2H), 4.51 (dt, J = 7.98, 7.96, 4.96 Hz, 1H), 
3.19 (d, J = 4.85 Hz, 1H), 2.98 (dd, J = 14.06, 4.82 Hz, 1H), 2.82 (d, J = 4.81 Hz, 1H) 2.62 (dd, J = 
14.04, 7.84 Hz, 1H), 1.47 (s, 3H), 1.43 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  =. 207.87, 
155.70, 155.61, 137.34, 136.02, 129.93, 129.78, 128.40, 128.04, 127.91, 118.53, 112.31, 82.57, 
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tert-butyl (4-((S)-2-amino-3-((R)-2-methyloxiran-2-yl)-3-
oxopropyl)phenyl)carbamate TFA salt (29) 
This compound was prepared from Cbz protected amine 28 in a synthetic 
procedure similar to that for compound 15. The purity was checked by LC-MS 







This compound was synthesized according to General procedure 
I on a 100 mol scale by addition of amine 24. The title 
compound was obtained after RP-HPLC purification (gradient: 
10% → 90% ACN/0.1% aq. TFA) as a colourless solid (yield: 8.2 
mg, 10.8 mol, 11%). 1H NMR (400 MHz, CD3OD):  = 8.25 (d, J = 8.29 Hz, 1H), 7.93 (d, J = 7.42 
Hz, 1H), 7.32 (d, J = 8.47 Hz, 2H), 7.26-7.19 (m, 8H), 6.77 (dd, J = 15.20, 5.35 Hz, 1H), 6.53 (dd, J 
= 15.21, 1.52 Hz, 1H), 4.81-4.73 (m, 1H), 4.33-4.27 (m, 1H), 4.27-4.22 (m, 1H), 4.14 (dd, J = 8.58, 
4.82 Hz, 1H), 3.16 (dd, J = 14.07, 4.83 Hz, 1H), 2.99-2.90 (m, 3H), 2.89 (s, 3H), 1.59-1.38 (m, 6H), 
0.89 (dd, J = 6.13, 3.43 Hz, 6H), 0.85 (d, J = 6.11 Hz, 6H) ppm. 13C NMR (100 MHz, CD3OD):  = 
174.55, 174.47, 171.98, 146.53, 138.54, 137.85, 132.22, 132.01, 130.48, 129.68, 128.14, 123.43, 
65.57, 53.73, 53.70, 52.53, 42.79, 41.83, 41.60, 39.97, 38.72, 25.94, 25.86, 23.48, 23.46, 21.94 
















This compound was synthesized according to General procedure I 
on a 100 mol scale by addition of amine 29. The title compound 
was obtained after RP-HPLC purification (gradient: 30% → 50% 
ACN/0.1% aq. TFA) as a colourless solid (yield: 4.1 mg, 6.60 mol, 
6.6%). 1H NMR (400 MHz, CD3OD):  = 7.36 (d, J = 8.47 Hz, 2H), 
7.28-7.16 (m, 9H), 4.66 (dd, J = 9.33, 4.29 Hz, 1H), 4.35-4.27 (m, 2H), 4.10 (dd, J = 8.46, 4.68 Hz, 
1H), 3.19 (d, J = 4.88 Hz, 1H), 3.15-3.10 (m, 2H), 2.98-2.88 (m, 2H), 2.73 (dd, J = 8.77, 5.04 Hz, 
1H), 1.56-1.42 (m, 8H), 1.38 (s, 3H), 0.90-0.82 (m, 12H) ppm. LC-MS: Rt (min): 7.37 (ESI-MS (m/z): 















tert-butyl ester (31) 
H-Lys(Boc)-N(Me)OMe (30) (2.72 g, 6.44 mmol) was dissolved in DCM (40 mL) and 
to this were added DiPEA (2 eq., 12.9 mmol, 2.13 mL) and tritylchloride (1.1 eq., 
7.08 mmol, 1.97 g). The reaction mixture was stirred for 15 h, after which TLC 
analysis indicated complete consumption of starting material, extracted with H2O (4×) and dried 
over MgSO4. The title compound was obtained after purification by column chromatography (DCM 
→ 3% MeOH/DCM) as a colourless foam (yield: 2.30 g, 4.32 mmol, 68%). 1H NMR (400 MHz, 
CDCl3):  = 7.49 (d, J = 7.47 Hz, 6H), 7.23 (t, J = 7.60, 7.60 Hz, 6H), 7.14 (t, J = 7.25 Hz, 3H), 4.63 
(s, 1H), 3.81 (s, 1H), 3.31 (s, 3H), 3.15-3.03 (m, 2H), 2.70 (s, 3H), 1.81-1.68 (m, 1H), 1.61-1.29 (m, 
14H) ppm. 13C NMR (100 MHz, CDCl3):  = 175.06, 155.58, 145.92, 128.52, 127.17, 125.77, 78.26, 








This compound was prepared from Weinreb amide 31 (0.81 g, 1.52 mmol) in a 
synthetic procedure similar to that for compound 17 and obtained after column 
chromatography (0% → 30% EtOAc/PE) as a colourless foam (yield: 0.53 g, 0.97 
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3H), 6.62 (dd, J = 15.05, 6.98 Hz, 1H), 6.22 (d, J = 15.06 Hz, 1H), 4.68-4.61 (m, 1H), 3.28-3.20 (m, 
1H), 2.98-2.89 (m, 2H), 2.71-2.67 (m, 3H), 1.42 (s, 9H), 1.30-0.81 (m, 6H) ppm. 13C NMR (100 MHz, 
CDCl3):  = 155.64, 150.93, 145.89, 128.38, 128.01, 127.69, 126.42, 78.62, 71.06, 53.72, 42.56, 
39.77, 35.29, 29.54, 28.14, 22.08 ppm. 
 




This compound was prepared from trityl protected amine 32 in a synthetic 
procedure similar to that for compound 18. The purity was checked by LC-MS 
analysis and the amine was subjected to the next step without further purification. 
 
N3Phe-Leu-Leu-LysVS TFA salt (7) 
This compound was synthesized according to General procedure 
I on a 360 mol scale by addition of amine 33. The title 
compound was obtained after RP-HPLC purification (gradient: 
20% → 65% ACN/0.1% aq. TFA) as a colourless solid (yield: 96.5 
mg, 134 mol, 37%). 1H NMR (400 MHz, CD3OD):  = 7.16-7.04 
(m, 5H), 6.65 (dd, J = 15.20, 5.10 Hz, 1H), 6.46 (dd, J = 15.21, 1.40 Hz, 1H), 4.44 (td, J = 9.60, 
4.87, 4.87 Hz, 1H), 4.17 (td, J = 9.78, 4.95, 4.95 Hz, 2H), 4.04 (dd, J = 8.56, 4.80 Hz, 1H), 3.05 (dd, 
J = 14.05, 4.77 Hz, 1H), 2.82 (dd, J = 16.0, 8.00 Hz, 1H), 2.82 (s, 3H), 2.76 (t, J = 7.42, 7.42 Hz, 
2H), 1.65-1.22 (m, 12H), 0.81 (d, J = 6.25 Hz, 3H), 0.76 (d, J = 6.04 Hz, 6H), 0.72 (d, J = 5.77 Hz, 
3H) ppm. 13C NMR (100 MHz, CD3OD):  = 174.72, 174.64, 171.90, 147.77, 137.79, 131.19, 
130.46, 129.64, 128.10, 65.47, 53.82, 53.67, 50.53, 42.83, 41.56, 41.44, 40.54, 38.66, 33.76, 27.89, 
25.97, 25.80, 23.77, 23.42, 21.99, 21.93 ppm. LC-MS: Rt (min): 5.73 (ESI-MS (m/z): 606.5 (M + 

















To a mixture of Boc--(4-pyridyl)-L-alanine (34, 300 mg, 1.08 mmol) and 
NH(Me)OMe·HCl (1.2 eq., 1.30 mmol, 129 mg) in DCM (10 mL) was added HCTU 
(1.2 eq., 1.30 mmol, 536 mg) and DiPEA (3.5 eq., 3.78 mmol, 625 L) and the mixture was stirred 
for 1 h after which TLC analysis indicated complete conversion of starting material. The solvent 
was evaporated under reduced pressure en the residue was taken up in EtOAc, extracted with sat. 
aq. NaHCO3 (2×) and brine, dried over MgSO4 and concentrated in vacuo. The title compound 
was obtained after purification by column chromatography  (EtOAc → 2% MeOH/EtOAc) as a pale 
yellow solid (yield: 334 mg, 1.08 mmol, quant.). 1H NMR (400 MHz, CD3OD):  = 8.40 (d, J = 4.59 
Hz, 2H), 7.29 (d, J = 4.88 Hz, 2H), 6.97 (d, J = 7.26 Hz, 1H), 4.77-4.68 (m, 1H), 3.76 (s, 3H), 3.15 
(s, 3H), 3.02 (dd, J = 13.59, 4.85 Hz, 1H), 2.83-2.77 (m, 1H), 1.32 (s, 9H) ppm. 13C NMR (100 MHz, 
CD3OD):  = 173.49, 157.58, 149.88, 149.50, 126.48, 80.55, 62.25, 52.71, 38.03, 32.49, 28.66 










Weinreb amide 35 (0.33 g, 1.08 mmol) was dissolved in THF (15 mL), put under an 
argon atmosphere and cooled to 0 °C. LiAlH4 (1.5 eq., 1.68 mmol, 1.68 mL of a 1 M 
solution in THF) was added slowly and the mixture was stirred at 0 °C for 1 h after which TLC 
analysis indicated complete conversion of the starting compound. 0.1 M aq. HCl (1 mL) was slowly 
added and the mixture was stirred vigorously for 5 min. The organic layer was extracted with sat. 
aq. NaHCO3 (2×) and brine, dried over MgSO4 and concentrated under reduced pressure. Diethyl 
((methylsulfonyl)methyl)phosphonate (1.5 eq., 1.68 mmol, 0.39 g) was dissolved in THF (20 mL) 
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mineral oil) was slowly added and the mixture was stirred at 0 °C for 30 min. Next, the freshly 
obtained aldehyde (in THF (2 mL)) was slowly added and the mixture was stirred for 2 h while 
slowly warming it to RT. After this time TLC analysis indicated complete conversion of the 
aldehyde. The reaction was quenched by addition of 1 M aq. HCl (1 mL) after which the mixture 
was diluted with EtOAc and extracted with sat. aq. NaHCO3 (2×) and brine, dried over MgSO4 and 
concentrated under reduced pressure. The title compound was obtained after column 
chromatography (40% → 80% Acetone/PE) as a colourless solid (yield: 117 mg, 0.36 mmol, 32%). 
1H NMR (400 MHz, CDCl3):  = 8.50 (d, J = 5.28 Hz, 2H), 7.15 (d, J = 5.90 Hz, 2H), 6.92 (dd, J = 
15.10, 4.76 Hz, 1H), 6.53 (d, J = 15.10 Hz, 1H), 5.56 (d, J = 8.99 Hz, 1H), 4.80-4.72 (m, 1H), 3.02-
2.84 (m, 2H), 2.93 (s, 3H), 1.39 (s, 9H) ppm. 13C NMR (100 MHz, CDCl3):  = 154.87, 149.59, 
146.40, 145.41, 130.04, 124.51, 80.10, 51.10, 42.58, 39.48, 28.06 ppm. =  –6.0 (c = 1, 
MeOH). HRMS: calcd. for C15H22N2O4S [M+ H]




This compound was synthesized according to General procedure I 
on a 300 mol scale by addition of amine 36 (after Boc 
deprotection with TFA/DCM 1:1 v/v, 37). The title compound was 
obtained after RP-HPLC purification (gradient: 25% → 45% 
ACN/0.1% aq. TFA) as a colourless syrup (yield: 89.0 mg, 142 mol, 48%). 1H NMR (400 MHz, 
CD3OD):  = 8.62 (d, J = 6.12 Hz, 2H), 7.85 (d, J = 6.16 Hz, 2H), 7.21-7.06 (m, 5H), 6.81 (dd, J = 
15.13, 5.03 Hz, 1H), 6.62 (dd, J = 15.23, 1.46 Hz, 1H), 5.00-4.93 (m, 1H), 4.20-4.14 (m, 1H), 4.10-
4.04 (m, 2H), 3.31 (dd, J = 13.99, 4.46 Hz, 1H), 3.11-3.03 (m, 2H), 2.88 (s, 3H), 2.86-2.82 (m, 1H), 
1.51-1.08 (m, 6H), 0.80 (dd, J = 7.81, 6.26 Hz, 6H), 0.75 (d, J = 6.00 Hz, 6H) ppm. 13C NMR (100 
MHz, CD3OD):  = 174.63, 174.48, 171.74, 160.53, 145.75, 142.38, 137.86, 132.60, 130.47, 
129.63, 129.45, 128.07, 65.49, 53.64, 53.55, 50.74, 42.76, 41.57, 41.45, 40.32, 38.64, 25.92, 25.80, 
23.49, 23.37, 21.86, 21.80 ppm. LC-MS: Rt (min): 6.86 (ESI-MS (m/z): 626.2 (M + H+)). HRMS: 
calcd. for C31H43N7O5S [M+ H]














CH2NH2)VS TFA salt (39) 
3545; found 982.53653. 
Compound 4a (5.68 mg, 8.69 mol) and Bodipy-
alkyne (1.5 eq., 13.0 mol, 4.28 mg) were dissolved 
in a 1:1:1 mixture of H2O/tBuOH/Tol (1.5 mL) and to 
this were added CuSO4 (0.1 eq., 0.87 mol, 0.87 L of a 1M solution in H2O) and sodium 
ascorbate (0.15 eq., 1.3 mol, 1.3 L of a 1M solution in H2O) and the reaction was stirred at 80 
°C for 4 h. LC-MS analysis revealed complete consumption of the azide and formation of a single 
product (Rt (min.): 10.41 (ESI-MS (m/z): 981.20 (M + H+))), which was assigned to be the 
corresponding benzaldehyde. The mixture was concentrated under reduced pressure and 
dissolved in MeOH (1.5 mL). To this were added NH4OAc (10 eq., 70 mol, 5.4 mg) and NaCNBH4 
(2 eq., 15 mol, 1.0 mg) and the reaction was stirred for 15 h, after which LC-MS analysis 
indicated a complete disappearance of the aldehyde peak. The reaction was quenched by 
addition of aqueous HCl (100 L, 1M) and the mixture was concentrated under reduced pressure. 
The title compound was obtained after RP-HPLC purification (gradient: 30% → 70% ACN/0.1% aq. 
TFA) as a red/brown solid (yield: 2.1 mg, 2.14 mol, 29%). 1H NMR (400 MHz, CD3OD):  = 7.77 (s, 
1H), 7.31 (d, J = 7.91 Hz, 2H), 7.25 (d, J = 8.08 Hz, 2H), 7.03-6.97 (m, 5H), 6.75 (dd, J = 15.17, 
5.40 Hz, 1H), 6.50 (dd, J = 15.26, 1.28 Hz, 1H), 6.08 (s, 2H), 5.52 (dd, J = 10.52, 5.15 Hz, 1H), 
4.85-4.81 (m, 1H), 4.29-4.22 (m, 2H), 3.95 (s, 2H), 3.37-3.34 (m, 2H), 2.97-2.91 (m, 4H), 2.87 (s, 
3H), 2.72-2.67 (m, 2H), 2.40 (s, 6H), 2.33 (s, 6H), 1.88-1.79 (m, 2H), 1.64-1.41 (m, 8H), 0.93-0.75 





























 (ESI-MS (m/z): 561.07 (M + H+)). HRMS: calcd. for C27H36N4O7S [M+ H]+ 561.23775; 
und 561.23775. 
Biological evaluation 
60 nm) to detect MV151 and Cy2/Fam settings (ex 488 nm, em 520 nm) 
to detect compound 39. 
This compound was synthesized according to General 
procedure I on a 245 mol scale by addition of amine 18. 
The title compound was obtained after RP-HPLC purification (gradient: 10% → 25% ACN/0.1% aq. 
TFA) as a colourless solid (yield: 57.3 mg, 83.2 mol, 34%). 1H NMR (400 MHz, CD3OD):  = 7.22 
(d, J = 8.48 Hz, 2H), 7.19 (d, J = 8.45 Hz, 2H), 6.95 (t, J = 7.80 Hz, 1H), 6.77-6.69 (m, 3H), 6.65 
(dd, J = 15.17, 1.46 Hz, 1H), 4.81-4.76 (m, 1H), 4.29 (t, J = 5.53 Hz, 1H), 4.17 (d, J = 7.16 Hz, 1H), 
3.90 (d, J = 5.45 Hz, 2H), 3.69 (dd, J = 10.78, 5.01 Hz, 1H), 3.60 (dd, J = 10.76, 6.19 Hz, 1H), 2.92 
(dd, J = 13.83, 6.47 Hz, 1H), 2.84-2.80 (m, 1H), 2.82 (s, 3H), 2.10-2.01 (m, 1H), 2.06 (s, 3H), 0.89 
(dd, J = 6.67, 4.95 Hz, 6H) ppm. 13C NMR (100 MHz, CD3OD):  = 174.00, 173.61, 171.83, 157.08, 
146.95, 139.62, 139.11, 132.93, 131.78, 131.18, 130.18, 127.60, 123.26, 119.16, 117.19, 62.90, 
61.62, 56.49, 52.60, 44.04, 42.84, 40.16, 31.40, 19.89, 19.06, 13.06 ppm. LC-MS: Rt (min): 4.19 

















This compound was synthesized according to General procedure 
I on a 100 mol scale by addition of amine 24. The title 
compound was obtained after RP-HPLC purification (gradient: 10% → 25% ACN/0.1% aq. TFA) as a 
colourless solid (yield: 14.2 mg, 21.0 mol, 21%). 1H NMR (400 MHz, CD3OD):  = 7.33 (d, J = 8.45 
Hz, 2H), 7.19 (d, J = 8.46 Hz, 2H), 7.00 (t, J = 7.81 Hz, 1H), 6.84-6.70 (m, 4H), 4.88-4.80 (m, 1H), 
4.33 (dd, J = 6.11, 5.13 Hz, 1H), 4.22 (d, J = 7.14 Hz, 1H), 3.72 (dd, J = 10.74, 5.01 Hz, 1H), 3.64 
(dd, J = 10.75, 6.27 Hz, 1H), 3.03 (dd, J = 13.89, 5.94 Hz, 1H), 2.90-2.85 (m, 1H), 2.88 (s, 3H), 2.11 
(s, 3H), 2.10-2.06 (m, 1H), 0.94 (t, J = 6.28 Hz, 6H) ppm. 13C NMR (100 MHz, CD3OD):  = 174.12, 
173.55, 171.89, 157.13, 146.75, 139.97, 139.12, 132.23, 131.98, 130.63, 127.60, 124.19, 123.27, 




Competition assays in cell-lysate 
Whole cell lysates of HEK-293T or EL-4 were made by sonication in 3 volumes of lysis buffer 
containing 50 mM Tris pH 7.5, 1 mM DTT, 5 mM MgCl2, 250 mM sucrose, 2 mM ATP, 0.025% 
digitonin. Protein concentration was determined by the Bradford assay. Cell lysates (13.5 g total 
protein for HEK lysates and 9 g total protein for EL-4 lysates) were exposed to the inhibitors for 
1 h at 37 °C prior to incubation with MV151 (0.5 M) for 1 h at 37 °C. Reaction mixtures were 
boiled with Laemmli’s buffer containing -mercaptoethanol for 5 min. before being resolved by 
12.5% SDS-PAGE. In-gel detection of residual proteasome activity was performed in the wet gel 
slabs directly on the Typhoon Variable Mode Imager (Amersham Biosciences) using the Cy3/Tamra 
settings (ex 532nm, em 5
Competition assays in living cells 
Human embryonic kidney cells (some 1 × 106) were cultured in 6-well plates in DMEM containing 
10% fetal calf serum, 10 units/mL penicillin and 10 g/mL streptomycin in a 7% CO2 humidified 
incubator at 37 °C overnight. Part of the medium was taken and to this was added the appropriate 
inhibitor in DMSO (1 L of a 1,000× stock solution), after which the medium was added to the 
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addition of MV151 (1 L of a 5 mM stock solution in DMSO) and incubation for 2 h at 37 °C. Next, 
the medium was removed and the cells were washed with PBS and harvested. After flash freezing 
in liquid N2, the cells were resuspended in 4 volumes of homogenation buffer (50 mM Tris pH 7.5, 
250 mM sucrose, 5 mM MgCl2, 1 mM DTT, 2 mM ATP, 0.025% digitonin) containing 10 M 
AdaKBio, sonicated (12 W, 1 min.) and centrifuged at 16,000 rcf at 0 °C for 20 min. The 
supernatant was collected and the protein concentration was determined by the Bradford assay. 
All samples were normalized to the same protein concentration with lysis buffer. After boiling the 
samples with Laemmli’s buffer containing -mercaptoethanol for 5 min. and resolving by 12.5% 
SDS-PAGE the residual proteasome activity was detected as described above. 
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Probing the 20S Proteasome 
Cavity with Photoreactive 
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inhib ors. This assumption invites a new application of extended proteasome activity-





Inhibitors and activity-based probes have proven their value in the study of 
proteasomal functioning and the role of the individual catalytic subunits (1, 2 and 
5).1 Some prominent proteasome inhibitors (Figure 1) are the peptide boronic acid 
Bortezomib (1, PS-341, Velcade),2 the natural product epoxomicin (2)3 and peptide vinyl 
sulfone ZL3VS (3).
4 Other examples comprise the 5 and 2 subunit specific inhibitors 
discussed in Chapters 4 and 5 respectively. Somewhat surprising, given its involvement 
in the multitude of physiological processes, the proteasome has been found to be a 
valid drug target, and Bortezomib is now used in the clinic as a last resort treatment for 
multiple myeloma.5 The small proteasome inhibitors 1-3 have in common that they are 
not selective for one specific catalytic subunit, but neither are capable of disabling all 
three subunits with equal efficiency. Kessler et al.6 hypothesized that an extended 
version of the hydrophobic peptide vinyl sulfones would result in a better mimic of the 
natural substrates and an increased mean residence time of the inhibitor at the active 
centre. Indeed they found that Ada(Ahx)3L3VS (4) and analogues thereof are much more 
potent and less selective proteasome inhibitors than their tri- or tetrapeptide vinyl 
sulfone counterparts. Arguably, extended peptide-like inhibitors such as 4 resemble the 
manner in which polypeptidic proteasome substrates are positioned in the inner 
proteasome cavity more closely, when compared to
it
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distal to the active site-reactive group. With this aim in mind, a panel of bifunctional 
ABPs was developed. These ABPs bind active proteasome subunits via their C-terminal 
vinyl sulfone warhead and can successively be crosslinked, via the N-terminal 
photocrosslinker, to residues it associates with (Figure 2A), providing information on the 
orientation the inhibitor adapts within the 20S cavity. 
 
 
Figure 1. Some proteasome inhibitors known in literature. 
The target extended peptide vinyl sulfones, equipped with three different 
photoreactive moieties (6-8) are shown in Figure 2B. They are analogues of proteasome 
probe 5 (Figure 1) described by Ovaa et al.,7 which differs from 4 in the azide, 
introduced in the Ahx moiety closest to the N-terminus. This azide allows two-step 
label g of proteasome activity (in living cells). For this, a biological sample is incubated 
with ABP 5 and subsequently treated with a biotin-phosphane reagent, which reacts 
with the azido moiety in a Staudinger-Bertozzi ligation.8 Here, the synthesis of 
compounds 6-8 and the result of incubating purified human erythrocyte 20S 
proteasome with these, followed by photolysis of the photocrosslinking moiety and 










Figure 2. (A) The bifunctional ABP binds an active site subunit and is subsequently photo-crosslinked to 
another subunit. X = C, N, O, S. (B) Proteasome probes discussed in this chapter. 
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6.2 Results and Discussion 
The target compounds were synthesized via a solution-phase Boc-based peptide 
synthesis protocol as shown in Scheme 1. The Boc protecting group in Boc-Ahx2-OMe 
(9)9 was removed and the resulting amine (10) was coupled to -azido--Boc-lysine 
(11),10 yielding tripeptide 12. Saponification of the methyl ester followed by coupling to 
tripeptide vinyl sulfone TFA·H-Leu3-VS
4 gave hexapeptide 13. Acidic removal of the N-
terminal Boc protecting group followed by a final HCTU mediated peptide coupling with 
4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoic acid11 resulted in proteasome probe 6 in 
72% yield. Compound 7 was synthesized in a similar fashion, employing 4-
benzoylbenzoic acid in the final coupling step, resulting in 77% yield. 
The synthesis of compound 8 proved to be less straightforward. Boc- deprotection 
of compound 13 and coupling to 4-azido-2-hydroxybenzoic acid12 gave only a small 
amount of the desired product. The main product formed was the N-terminal trifluoro-
acetylated version of 13 (as evidenced from LC-MS analysis). In order to circumvent this 
undesired reaction, compound 13 was deprotected with dry HCl in 1,4-dioxane and the 
final coupling step was executed with 4-azido-2-hydroxybenzoic acid N-
hydroxysuccinimide ester,13 which allowed formation of target compound 8 in a yield of 
53%. To prevent light initiated decomposition of the photocrosslinking moieties, all final 
compounds were stored in the dark. 
Scheme 1. Synthesis of photoreactive proteasome probes 6 and 8.  
 
Reagents and conditions: (a) TFA, DCM, quant.; (b) HCTU, DiPEA, DCM, 81%; (c) i) LiOH, MeOH; ii) TFA·H-Leu3-
VS,4 HCTU, DiPEA, DCM, 71%; (d) i) TFA, DCM; ii) 4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoic acid,11 HCTU, 
DiPEA, DCM, 72%; (e) i) HCl, 1,4-dioxane; ii) 4-azido-2-hydroxybenzoic acid N-hydroxysuccinimide ester,13 
DMF, 53%. 
The ability of each probe to label the proteasome active sites was assessed in 
competition assays employing mouse lymphoma cell extracts (EL-4) in combination with 
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the fluorescent broad spectrum proteasome probe MV15114 (see also Chapter 4). The 
three probes display approximately equal characteristics in terms of the overall potency 
and the lack of selectivity towards the individual active subunits (Figure 3). In general, 
they appear to be slightly less active compared to pan-reactive inhibitor 4.6,14 At a 
concentration of 10 M (almost) all proteasome activity is blocked by each of the three 
compounds and for this reason all succeeding experiments were conducted at this 
concentration. 
 







Figure 3. Competition studies of proteasome probes 6-8. Extracts of EL-4 cells (10 g) were incubated with 
increasing concentrations of the probes for 1 hour at 37 °C. Residual proteasome activity was labelled with 
MV151 (0.5 M final concentration). After denaturation and resolving by 12.5% SDS-PAGE, the gels were 
analyzed by fluorescence scanning. Inhibition of a proteasome active site is reflected by disappearance of the 
corresponding band.  
n a two-fold increase in intensity. A 
combination of these effects can not be excluded. 
At this stage, three sets of three samples containing purified human 20S 
proteasome were treated with either one of the three probes for two hours at 37 °C in 
the dark. Next, the samples were either kept in the dark or exposed to UV light (365 nm) 
for 30 minutes or 60 minutes at 0 °C, prior to treatment with biotin-phosphane 1415 for 
one hour at 37 °C. After denaturation and separation of the protein contents by gel-
electrophoresis, all biotinylated proteins were visualized by Western blotting. 
AdaK(biotin)Ahx3L3VS (Ada)
6 was used as a positive control for labelling of all 
proteasome active subunits. The results are shown in Figure 4. As expected from the 
previous results (Figure 3), all three peptide vinyl sulfones efficiently label the three 
catalytic activities (1, 2 and 5) present in the constitutive 20S proteasome. An 
interesting observation is the difference in signal intensity for probe 8 compared to 6 
and 7 (compare the non-exposed samples to the corresponding Ada labelled samples), 
which can be caused by several factors. An explanation might be a difference in potency 
between the probes, however, with the results from the competition assays in mind 
(Figure 3), this seems highly unlikely. Another possibility arises from the fact that 
compound 8 contains two azides, instead of one as in 6 and 7. The difference in 
labelling intensity is especially substantial for the non-UV light-exposed samples, in 
which case the azide present in the photocrosslinker is still intact and is very well 
capable of participating in the Staudinger-Bertozzi ligation.16 Therefore, either the aryl 
azide is much more reactive compared to the aliphatic azide, which results in a more 
efficient reaction and hence, a bigger signal intensity, or two biotin-phosphane reagents 
have reacted with this probe, which would result i
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Figure 4. Labelling of purified 20S proteasome with probes 6-8, followed by light activation of the 
photoreactive moiety. Purified 20S proteasome (200 ng) was incubated with compounds 6, 7 or 8 (10 M final 
concentration) for two hours at 37 °C, followed by irradiation of the samples with UV light ( = 365 nm) at 0 °C 
for 0, 30 or 60 minutes. After denaturing and resolving by 12.5% SDS-PAGE all biotinylated proteins were 
visualized by Western blotting. PS: pre-stained marker low range (Bio-Rad). Ada: samples were incubated with 
AdaK(biotin)Ahx3L3VS (10 M final concentration). 
The formation of a new construct with a higher molecular weight is the expected 
result when effective photocrosslinking of the covalently bound probe to another 
proteasome subunit occurs. This would be reflected by the appearance of a new band, 
which corresponds to a higher molecular weight polypeptide. The samples labelled with 
probes 6 and 7 and exposed to UV light do not show any difference compared to the 
non-exposed samples, which indicates that photocrosslinking efficiency of these 
compounds to other proteasome subunits is at most marginal. Either the 
photocrosslinking moiety was not activated at all, or the reactive species (after UV light 
mediated activation) was unable to react with another proteasome subunit. 
Interestingly, the photocrosslinking moiety in 8 is able to crosslink other subunits, 
which is shown by the appearance of two new bands with a mass of approximately 50 
kDa. Indeed, these bands are within the expected mass range corresponding to either 
1 or 5 attached to another proteasome subunit.17 
The successive labelling-photocrosslinking properties of compound 8 were further 
explored in an experiment in which the samples (obtained after incubation as described 
above) were irradiated at various durations (Figure 5A). Again, two new bands, 
corresponding to an increased molecular weight (~50 kDa), appear upon exposure to 
light. Remarkably, after five minutes of irradiation the bands are already slightly visible 
and maximal intensity is reached after ten minutes. 
To assess the nature of the newly formed bands, four samples of purified 20S 
proteasome were incubated with compound 8 and irradiated for 0, 15, 30 or 60 minutes. 
Subsequent Staudinger-Bertozzi ligation, SDS-PAGE and silver staining allowed 
visualization of all proteins. The results are shown in Figure 5B. All 14 distinct 20S 
constitutive proteasome proteins (1-7 and 1-7) are now visible. Those samples that were 
exposed to UV light reveal one additional band (indicated by the arrows) corresponding 
to a higher molecular weight polypeptide. This is in contrast to the results shown in 
Figure 5A, in which two bands were visible, however it might be possible that other 
bands are present, but are invisible because of the high intensity background at higher 
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MW. Nonetheless, this one band was cut from the gel (in each of the three lanes) and 
analyzed by LC-MS/MS after in-gel tryptic digest. The results were identical for each of 
the three lanes and multiple characteristic peptides for both the 5 and 6 subunits 
were identified (Table 1). This can only be the result of the formation of a covalent 
linkage between these two subunits and the molecular weight of the construct 
(calculated MW is 49.8 kDa) correlates well with the expected mass of the, via 
compound 8, crosslinked subunits. 
 
Ada



















Figure 5. Labelling of purified 20S proteasome with probe 8, followed by light initiated photocrosslinking. 
Purified 20S proteasome (200 ng) was incubated with 8 (10 M final concentration) for two hours at 37 °C, 
after which the samples were irradiated with UV light ( = 365 nm) for increasing amounts of time (0-60 
minutes). The samples were denatured and resolved by 12.5% SDS-PAGE. Visualization of (A) all biotinylated 
proteins by Western blotting and (B) the total protein content by silver stain. The arrows in (B) indicate the 
excised bands analyzed by LC-MS/MS after in-gel tryptic digest. BM: biotinylated marker low range (Bio-Rad). 
Ada: samples were incubated with AdaK(biotin)Ahx3L3VS (10 M final concentration). 











5 IPI00479306 22.4 6 36.3% 
6 IPI00025019 26.5 4 25.7% 
a np = number of identified peptides. 
This result raises the question in what way the crosslinked probe is orientated 
within the proteasome cavity. There are two possibilities: either a neighbouring 5 and 
6 subunit, within the same  ring, were crosslinked or the subunits from two different  
rings were covalently attached to each other. The calculated maximum length of 
compound 8 is approximately 38 Å.18 In comparison, the distance between two active 
sites of neighbouring  subunits (within the same  ring) is 28 Å and that of the subunits 
from two separate  rings 65 Å (determined from X-ray analysis of the yeast 
proteasome).19-21  It must be noted that the 6 subunit does not contain an active site, 
but photocrosslinking can take place at any subunit site, therefore the minimal distance 
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the probe needs to span is from the 5 active site to the edge of 6 and is probably 
shorter than the distance between two active sites. Although no solid conclusions can 
be drawn from this, it is unlikely that the probe spans the entire distance between 5 
and 6 from two different  rings. 
An interesting observation from the results presented here is the appearance of 
only two bands (of which only one could be further analyzed) of higher molecular 
weight, whereas many more are possible. An explanation might be that the overall 
photocrosslinking efficiency is low, so that only a small, undetectable, percentage of the 
subunits has been crosslinked. In addition to that, it might also be possible that the 
majority of the crosslinking takes place within the same subunit, which excludes the 
formation of higher molecular weight polypeptides. Finally, a third possibility might be 
that the probe is orientated relatively rigid in the 20S cavity and can therefore only be 
crosslinked to a limited number of subunits or is ‘solvent exposed’. 
6.3 Conclusion 
In summary, the synthesis of three photoreactive peptide vinyl sulfones is 
described. They can be used to label the proteasome active sites in a two step fashion, 
however only 4-azidophenyl containing probe 8 was capable of crosslinking to other 
subunits. The labelling-photocrosslinking approach in combination with two step 
ligation and LC-MS/MS analysis may become an alternative for existing methods (for 
instance X-ray crystallography)20-24 in proteasome research, although considerable 
optimizations are needed to extrapolate this methodology to a study towards an 
inhibitor’s mode of action and orientation within the 20S core particle. For example, 
improvements can be made in the photocrosslinking efficiency, or visualization 
methods. Also, the introduction of elongated spacers between nucleophilic trap and 




Acetonitrile (ACN), dichloromethane (DCM), N,N-dimethylformamide (DMF), methanol (MeOH), 
diisopropylethylamine (DiPEA) and trifluoroacetic acid (TFA) were of peptide synthesis grade, 
purchased at Biosolve, and used as received. All general chemicals (Fluka, Acros, Merck, Aldrich, 
Sigma) were used as received. O-(1H-6-Chlorobenzotriazolyl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate (HCTU) was purchased at Iris Biotech (Marktrewitz, Germany). Traces of 
water were removed from reagents used in reactions that require anhydrous conditions by 
coevaporation with toluene. Solvents that were used in reactions were stored over 4 Å molecular 
sieves, except methanol and acetonitrile which were stored over 3 Å molecular sieves. Column 
chromatography was performed on Screening Devices b.v. Silica Gel, with a particle size of 40-63 
m and pore diameter of 60 Å. The eluents toluene, ethyl acetate and petroleum ether (40-60 °C 
boiling range) were distilled prior to use. TLC analysis was conducted on Merck aluminium sheets 
(Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by spraying with a 
solution of (NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a 
solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid 
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(12.5 mL/L) in ethanol, where appropriate, followed by charring at ca. 150 °C. 1H- and 13C-NMR 
spectra were recorded on a Bruker AV-400 (400 MHz) spectrometer. Chemical shifts are given in 
ppm () relative to CD3OD as internal standard. High resolution mass spectra were recorded by 
direct injection (2 L of a 2 M solution in water/acetonitrile 50/50 (v/v) and 0.1% formic acid) on a 
mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion source in 
positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 °C) with 
resolution R = 60,000 at m/z 400 (mass range m/z = 150-2,000) and dioctylpthalate (m/z = 
391.28428) as a “lock mass”. The high resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). Optical rotations  were 
recorded on a Propol automatic polarimeter. LC-MS analysis was performed on a Finnigan 
Surveyor HPLC system with a Gemini C18 50 × 4.60 mm column (detection at 200-600 nm), 
coupled to a Finnigan LCQ Advantage Max mass spectrometer with ESI. The applied buffers were 
H2O, ACN and 1.0% aq. TFA. HPLC purifications were performed on a Gilson HPLC system 
coupled to a Phenomenex Gemini 5 m 250 × 10 mm column and a GX281 fraction collector. The 
applied buffers were: 0.1% aq. TFA and ACN. 
23][ D
General procedure I: peptide coupling 
The Boc-protected amine was treated with a 1:1 (v/v) mixture of DCM/TFA (5 mL/mmol) for 30 min. 
followed by addition of toluene and concentration of the mixture under reduced pressure. In order 
to remove excess TFA the mixture was coevaporated with toluene twice. The deprotected amine 
TFA salt (1 eq.) was dissolved in DCM (5 mL/mmol) and to this were added the carboxylic acid (1 
eq.), HCTU (1.1 eq.) and DiPEA (3.5 eq.). The mixture was stirred until TLC analysis revealed a 
complete conversion (usually after 2 h). The organic layer was washed with 1M aq. HCl (2×), sat. 
aq. NaHCO3 (2×) and brine, dried over MgSO4 and concentrated under reduced pressure. 
 
(S)-2-azido-6-((tert-butoxycarbonyl)amino)hexanoic acid (11) 
This compound was synthesized from H-Lys(Boc)-OH according to the 
procedure described by R. Stick et al.25 In short: H-Lys(Boc)-OH (1.325 g, 5.38 
mmol) was dissolved in MeOH (30 mL) and to this were added K2CO3 (3.2 eq., 17.21 mmol, 2.37 g), 
CuSO4·5H2O (1 mol%, 54.0 mol, 13.0 mg) and imidazole-1-sulfonyl azide hydrochloride (1.2 eq., 
6.46 mmol, 1.35 g). The mixture was stirred for 15 h after which TLC analysis indicated a complete 
conversion. The mixture was concentrated under reduced pressure, redissolved in EtOAc and 
washed with 1M aq. HCl. The aqueous layer was extracted twice with EtOAc followed by washing 
of the combined organic layers with brine, drying over MgSO4 and concentration under reduced 
pressure. The title compound was obtained after purification by column chromatography (25% → 
50% EtOAc/PE) as a colourless oil (yield: 524 mg, 1.92 mmol, 36%). The spectroscopic data 







This compound was synthesized according to general procedure I 
from 11 (1.92 mmol) and Boc-Ahx2-OMe 9
9 (2.0 mmol). The title 
compound was purified by column chromatography (75% EtOAc/PE → 5% MeOH/EtOAc) and 
obtained as a colourless oil (yield: 0.80 g, 1.55 mmol, 81%). 1H NMR (400 MHz, CD3OD):  = 8.14 
(t, J = 5.58 Hz, 1H), 7.88 (t, J = 5.39 Hz, 1H), 3.79 (dd, J = 11.98, 4.97 Hz, 1H), 3.64 (s, 3H), 3.21 
(dd, J = 13.06, 7.28 Hz, 2H), 3.16 (dd, J = 12.84, 7.02 Hz, 2H), 3.04 (t, J = 6.73 Hz, 2H), 2.32 (t, J 
= 7.40 Hz, 2H), 2.18 (t, J = 7.44 Hz, 2H), 1.87-1.70 (m, 2H), 1.62 (td, J = 15.35, 7.53 Hz, 4H), 1.57-
1.47 (m, 6H), 1.43 (s, 9H), 1.39-1.27 (m, 6H) ppm. 13C NMR (100 MHz, CD3OD):  = 175.63, 
175.54, 175.44, 172.03, 171.95, 158.22, 79.61, 64.17, 64.12, 51.98, 40.00, 40.31, 40.17, 40.04, 
36.94, 34.59, 32.40, 30.45, 30.02, 29.98, 28.86, 27.42, 27.36, 26.57, 25.58, 23.91 ppm.  = 
+9.7° (c = 1 in MeOH). LC-MS: gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 7.47. HRMS: 
calcd. for C24H44N6O6 [M + H]
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Boc-Ahx(-N3)-Ahx2-Leu3-VS (13) 
Compound 12 (0.80 g, 1.55 mmol) was dissolved in MeOH (8 mL) and cooled to 0 °C, after which 
LiOH (2 mL of a 1M aq. solution) was added slowly. The mixture was slowly warmed to RT and 
stirred for 15 h, after which TLC analysis indicated complete consumption of starting material. 
Next, 1M aq, HCl (3.6 mL) was added to neutralize the solution (~pH 5) and the mixture was 
concentrated under reduced pressure. The product was dissolved in DCM and dried over MgSO4 
to remove all traces of water. The resulting carboxylic acid was coupled to Boc-Leu3-VS
4 (1.61 
mmol) according to general procedure I and the title compound was obtained after purification by 
column chromatography (75% EtOAc/PE → 10% MeOH/EtOAc) as a colourless solid (yield: 0.99 g, 
1.10 mmol, 71%). 1H NMR (400 MHz, CD3OD):  = 8.15 (t, J = 5.61 Hz, 1H), 8.06 (d, J = 8.14 Hz, 
2H), 7.88 (t, J = 5.40 Hz, 2H), 6.80 (dd, J = 15.16, 5.09 Hz, 1H), 6.63 (dd, J = 15.18, 1.19 Hz, 1H), 
4.70-4.64 (m, 1H), 4.42-4.34 (m, 2H), 3.79 (t, J = 6.72 Hz, 1H), 3.21 (t, J = 6.98 Hz, 2H), 3.15 (t, J = 
6.92 Hz, 2H), 3.04 (t, J = 6.73 Hz, 2H), 2.98 (s, 3H), 2.26 (dt, J = 7.12, 3.26 Hz, 2H), 2.18 (t, J = 
7.44 Hz, 2H), 1.87-1.73 (m, 2H), 1.71-1.45 (m, 22H), 1.43 (s, 9H), 1.39-1.30 (m, 3H), 0.97-0.89 (m, 
18H) ppm. 13C NMR (100 MHz, CD3OD):  = 176.06, 175.62, 174.81, 174.04, 172.03, 158.30, 
148.36, 130.77, 79.68, 79.23, 64.19, 53.37, 53.26, 49.03, 43.22, 42.90, 41.62, 41.46, 41.00, 40.22, 
40.13, 36.91, 36.59, 32.42, 30.45, 30.08, 29.98, 28.86, 27.53, 27.43, 26.59, 26.50, 25.87, 25.82, 
25.74, 23.90, 23.49, 23.46, 22.20, 22.11, 22.01 ppm.  = –29.5° (c = 1 in MeOH). LC-MS: 
→gradient 10%  90% ACN/(0.1% TFA/H2O): Rt (min): 8.50. HRMS: calcd. for C43H79N9O9S [M + H]
+ 




This compound was synthesized according to general procedure I from compound 13 (0.21 mmol) 
and 4-(3-(trifluoromethyl)-3H-diazirin-3-yl)benzoic acid11 (0.23 mmol). The title compound was 
purified by crystallization from MeOH/Et2O and obtained as a colourless solid (yield: 155 mg, 0.15 
mmol, 72%). 1H NMR (400 MHz, CD3OD):  = 8.60 (t, J = 5.33 Hz, 1H), 8.17 (t, J = 5.41 Hz, 2H), 
8.06 (t, J = 7.59 Hz, 3H), 7.90 (d, J = 8.48 Hz, 2H), 7.33 (d, J = 8.21 Hz, 2H), 6.79 (dd, J = 15.17, 
5.08 Hz, 1H), 6.61 (dd, J = 15.19, 1.12 Hz, 1H), 4.72-4.62 (m, 1H), 4.42-4.30 (m, 2H), 3.81 (t, J = 
6.69 Hz, 1H), 3.40 (dd, J = 12.09, 6.52 Hz, 2H), 3.23-3.12 (m, 4H), 2.97 (s, 3H), 2.25 (t, J = 7.18 Hz, 
2H), 2.17 (t, J = 7.42 Hz, 2H), 1.93-1.75 (m, 2H), 1.72-1.40 (m, 22H), 1.39-1.27 (m, 3H), 0.93 (ddd, J 
= 9.86, 9.32, 5.12 Hz, 18H) ppm. 13C NMR (100 MHz, CD3OD):  = 176.38, 175.88, 175.15, 
174.39, 172.30, 168.78, 148.50, 137.35, 133.01, 130.85, 129.05, 127.67, 123.4 (q, J = 273.92 Hz), 
64.41, 53.56, 49.29, 43.33, 42.86, 41.65, 41.60, 40.91, 40.79, 40.43, 40.31, 40.24, 36.98, 36.66, 
32.50, 30.16, 30.07, 29.99, 27.63, 27.51, 26.67, 26.59, 25.98, 25.95, 25.85, 24.13, 23.46, 22.11, 
22.02, 21.96 ppm.  = –28.2° (c = 1 in MeOH). LC- →MS: gradient 10%  90% ACN/(0.1% 
TFA/H2O): Rt (min): 9.16. HRMS: calcd. for C47H74F3N11O8S [M + H]





This compound was synthesized according to general procedure I from compound 13 (0.22 mmol) 
and commercially available 4-benzoylbenzoic acid (0.24 mmol). The title compound was purified 
by crystallization from MeOH/Et2O and obtained as a colourless solid (yield: 170 mg, 0.17 mmol, 
77%). 1H NMR (400 MHz, CD3OD):  = 7.97 (d, J = 8.30 Hz, 2H), 7.83 (d, J = 8.31 Hz, 2H), 7.78 (d, 
J = 7.17 Hz, 2H), 7.66 (t, J = 7.41 Hz, 1H), 7.54 (t, J = 7.66 Hz, 2H), 6.80 (dd, J = 15.17, 4.97 Hz, 
1H), 6.62 (dd, J = 15.18, 1.26 Hz, 1H), 4.66 (td, J = 8.85, 4.85 Hz, 1H), 4.41-4.29 (m, 2H), 3.83 (t, J 
= 6.73 Hz, 1H), 3.48-3.41 (m, 2H), 3.20 (t, J = 7.03 Hz, 2H), 3.14 (t, J = 7.02 Hz, 2H), 2.98 (s, 3H), 
2.29-2.24 (m, 2H), 2.17 (t, J = 7.42 Hz, 2H), 1.94-1.77 (m, 2H), 1.74-1.43 (m, 22H), 1.38-1.28 (m, 
3H), 0.97-0.88 (m, 18H) ppm. 13C NMR (100 MHz, CD3OD):  = 197.64, 176.49, 175.82, 175.24, 
174.37, 172.20, 169.06, 148.50, 141.22, 139.33, 138.34, 134.18, 131.06, 130.98, 129.67, 128.43, 
64.30, 53.81, 53.54, 49.90, 49.17, 43.22, 42.88, 41.57, 41.41, 40.80, 40.29, 40.21, 36.97, 36.67, 
32.48, 30.13, 30.03, 29.98, 27.62, 27.50, 26.65, 26.56, 25.97, 25.93, 24.13, 23.48, 23.44, 22.08, 
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21.94 ppm.  = –26.8° (c = 1 in MeOH). LC- →MS: gradient 10%  90% ACN/(0.1% TFA/H2O): Rt 
(min): 8.69. HRMS: calcd. for C52H79N9O9S [M + H]




Compound 13 (0.23 g, 0.25 mmol) was Boc-deprotected with HCl (3 mL of a 4M solution in 1,4-
dioxane), followed by coevaporation with toluene (3×) and the resulting amine HCl salt was 
dissolved in DMF (2 mL). To this were added DiPEA (1 eq., 0.25 mmol, 43.0 L) and 4-azido-2-
hydroxybenzoic acid N-hydroxysuccinimide ester13 (1.3 eq., 91.0 mg, 0.33 mmol) and the reaction 
mixture was stirred for 15 h, after which LC-MS analysis indicated complete consumption of the 
amine. DCM (10 mL) was added and the mixture was washed with 1M aq. HCl (2×), sat. aq. 
NaHCO3 (2×) and brine, dried over MgSO4 and concentrated under reduced pressure. The title 
compound was obtained after purification by column chromatography (100% DCM → 6% 
MeOH/DCM) as a colourless solid (yield: 130 mg, 0.14 mmol, 53%). 1H NMR (400 MHz, CD3OD):  
= 7.75 (d, J = 8.32 Hz, 1H), 6.79 (dd, J = 15.17, 5.08 Hz, 1H), 6.61 (dd, J = 15.19, 1.27 Hz, 1H), 
6.57-6.52 (m, 2H), 4.65 (td, J = 9.10, 4.93 Hz, 1H), 4.35 (ddd, J = 14.62, 8.85, 6.09 Hz, 2H), 3.80 (t, 
J = 6.69 Hz, 1H), 3.38 (t, J = 6.95 Hz, 2H), 3.20-3.12 (m, 4H), 2.97 (s, 3H), 2.24 (dd, J = 8.01, 6.18 
Hz, 2H), 2.16 (t, J = 7.43 Hz, 2H), 1.89-1.74 (m, 2H), 1.71-1.39 (m, 22H), 1.38-1.25 (m, 3H), 0.97-
0.86 (m, 18H) ppm. 13C NMR (100 MHz, CD3OD):  = 176.27, 175.79, 174.96, 174.18, 172.11, 
170.31, 162.90, 148.43, 146.49, 130.83, 130.43, 113.88, 110.89, 108.23, 79.29, 64.31, 53.52, 
53.38, 49.15, 43.27, 42.88, 41.62, 41.51, 40.28, 40.21, 40.16, 36.96, 36.64, 32.44, 30.12, 30.00, 
27.59, 27.47, 26.61, 26.53, 25.94, 25.90, 25.81, 24.07, 23.45, 22.14, 22.04, 21.98 ppm.  = –
27.1° (c = 1 in MeOH). LC- →MS: gradient 10%  90% ACN/(0.1% TFA/H2O): Rt (min): 8.95. HRMS: 
calcd. for C45H74N12O9S [M + H]
+ 959.54952; found 959.55103. 
23][ D
Competition assays 
Whole cell lysates of EL4 were made by sonication of cell pellets in 3 volumes of lysis buffer 
containing 50 mM Tris pH 7.5, 1 mM DTT, 5 mM MgCl2, 250 mM sucrose, 2 mM ATP. Protein 
concentration was determined by the Bradford assay. Cell lysate (9 g total protein) was exposed 
to the inhibitors 6, 7 or 8 for 1 hour prior to incubation with MV15114 (0.5 M) for 1 hour at 37 °C. 
Reaction mixtures were boiled with Laemmli’s buffer containing -mercaptoethanol for 5 min. 
before being resolved by 12.5% SDS-PAGE. In-gel detection of residual proteasome activity was 
performed in the wet gel slabs directly on the Typhoon Variable Mode Imager (Amersham 
Biosciences) using the Cy3/Tamra settings (ex 532nm, em 560 nm) to detect MV151. 
Photocrosslinking in purified 20S proteasome 
Purified 20S proteasome (human erythrocyte, 1 mg/mL, Enzo life sciences) was diluted with lysis 
buffer (50 mM Tris pH 7.5, 1 mM DTT, 5 mM MgCl2, 250 mM sucrose, 2 mM ATP) to a 
concentration of 20 ng/L. From this, 10 L (200 ng 20S proteasome) was incubated with 
compound 6, 7 or 8 (10 M final concentration) for 2 h at 37 °C in the dark. The samples were 
irradiated with UV light ( 365 nm) for the appropiate time at 0 °C, by placing the lamp 
(Spectroline® ENF-260C/FE, 6W) directly on top of the opened Eppendorff tubes (distance from 
light source to sample ~4 cm). After irradiation, the samples were stored at 4 °C in the dark. Next, 
the samples were treated with a Biotin-phospane reagent15 (200 M final concentration) for 1 h at 
37 °C. After boiling the mixture with Laemmli’s buffer containing -mercaptoethanol for 5 min., 
the samples were resolved by 12.5% SDS-PAGE and all biotinylated proteins were visualized by 
Western blotting. The blots were blocked with 1% BSA in TBS-Tween 20 (0.1 % Tween 20) for 30 
min. at RT, hybridized for 1 h with Streptavidin-HRP (1:10,000) in blocking buffer, washed and 
visualized using an ECL+ kit (Amersham Biosciences). Also, in a different gel, the total protein 
content was visualized by silverstain. The appropriate bands were cut from the gel and an in-gel 
digestion was performed according to the procedure described in literature.26 
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LC-MS/MS analysis 
Tryptic peptides were analyzed on a Surveyor nanoLC system (Thermo) hyphenated to a LTQ-
Orbitrap mass spectrometer (Thermo). Gold and carbon coated emitters (OD/ID = 360/25 m tip 
ID = 5 m), trap column (OD/ID = 360/100 m packed with 25 mm robust Poros®10R2/15 mm 
BioSphere C18 5 m 120 Å) and analytical columns (OD/ID = 360/75 m packed with 20 cm 
BioSphere C18 5 m 120 Å) were from Nanoseparations (Nieuwkoop, The Netherlands). The 
mobile phases (A: 0.1% formic acid/H2O, B: 0.1% formic acid/ACN) were made with ULC/MS grade 
solvents (Biosolve). The emitter tip was coupled end-to-end with the analytical column via a 15 
mm long TFE teflon tubing sleeve (OD/ID 0.3 × 1.58 mm, Supelco, USA) and installed in a 
stainless steel holder mounted in a nanosource base (Upchurch scientific, Idex, USA). General 
mass spectrometric conditions were: an electrospray voltage of 1.8 kV was applied to the emitter, 
no sheath and auxiliary gas flow, ion transfer tube temperature 150 °C, capillary voltage 41 V, tube 
lens voltage 150 V. Internal mass calibration was performed with air-borne protonated 
polydimethylcyclosiloxane (m/z = 445.12002) and the plasticizer protonated dioctyl phthalate 
ions (m/z = 391.28429) as lock mass.27 For shotgun proteomics analysis, 10 L of the samples 
was pressure loaded on the trap column with a 10 L/min flow for 5 min. followed by peptide 
separation with a gradient of 35 min. 5 → 30% B, 15 min. 30 → 60% B, 5 min. A, at a flow of 300 
L/min. split to 250 nL/min. by the LTQ divert valve. For each data dependent cycle, one full MS 
scan (300-2000 m/z) acquired at high mass resolution (60,000 at 400 m/z, AGC target 1 × 106, 
maximum injection time 1,000 ms) in the Orbitrap was followed by 3 MS/MS fragmentations in the 
LTQ linear ion trap (AGC target 5 × 103, max injection time 120 ms) from the three most 
abundant ions.28 MS/MS settings were: collision gas pressure 1.3 mT, normalized collision energy 
35%, ion selection threshold of 500 counts, activation q = 0.25 and activation time of 30 ms. 
Fragmented precursor ions that were measured twice within 10 s were dynamically excluded for 60 
s and ions with z < 2 or unassigned were not analyzed. Data from MS/MS was validated manually.  
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A Levulinoyl Ester-Based 
Cleavable Linker for Activity-




-step activity-based protein profiling strategies.8-10 
Visua






Activity-based protein profiling has become an attractive strategy to report on 
enzyme activity in the context of complex biological samples (see Chapter 1).1,2 An 
activity-based profiling probe (ABP) normally consists of a recognition element targeted 
at a specific enzyme (family), and is equipped with a reactive group through which the 
targeted enzymes are covalently and irreversibly modified. Enzymes that use an amino 
acid side-chain nucleophile in their catalytic process can be made to react with an 
electrophilic trap, or suicide substrate,3,4 whereas activity-based profiling strategies of 
enzymes that do not employ such active site residues normally rely on the use of photo-
activatable groups.5-7 A third essential element of ABPs is the affinity/identification tag, 
which can be either incorporated into the ABP directly or alternatively installed via a 
bioorthogonal process in two
Geurink, B. I. Florea, N. Li, M. D. Witte, J. Verasdonck, C.-L. Kuo, G. A. van der Marel, H. S. 
Overkleeft, Angew. Chem. Int. Ed. 2010, accepted for publication. 
lization/identification tags come in several flavours, including fluorophores and 
immune epitope tags. The most popular tag in this context is the biotin group. It is 
relatively small, easy to install in a wide variety of differently functionalized activity-
based probes and has strong binding affinity to (strept)avidin. As a consequence a range 
of biochemical tools have become available over the decades for either the visualization 
of biotinylated biomolecules or their pull-down. As such, biotin is both an identification 
tag and visualizatio
The strong affinity of streptavidin for biotin makes that the release of biotinylated 
proteins captured by, for instance, streptavidin-coated beads can be difficult. Most 
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effective procedures rely on relatively harsh conditions, such as boiling of the sample in 
denaturing conditions and often in the presence of unmodified biotin. As a 
consequence, next to (denatured) streptavidin, the eluted protein pool is often 
contaminated with endogenously biotinylated biomolecules, present in the initial 
biological sample. 
The introduction of a specific linker between biotin and the ABP reactive group, 
which can be cleaved chemoselectively so that only the ABP bound material is released, 
is an attractive strategy to circumvent this problem (Figure 1A). Examples of such 
cleavable linkers (CL) are the disulfide linkage,11 enzymatically (Tev) cleavable,12 acid 
cleavable,13,14 diazobenzene derived (cleavable with Na2S2O4),
15 and hydrazone-based 
linkers.16,17 An ideal cleavable linker is stabile towards the various conditions (acidic, 
basic, reductive, including generally applied buffer systems) to which the biological 
sample may be exposed, depending on the nature of the experiment, and can also 
withstand the reactive (nucleophilic) species that are present in a cell extract. At the 
same time, the linker should be susceptible to mild cleavage conditions which are 
selective with respect to functional groups inherent to the biological sample. With this 
reasoning in mind, attention was focussed on the levulinoyl ester, a versatile protective 
group often applied in synthetic organic chemistry. It is acid stabile and can be removed 
selectively with respect to other esters by treatment with hydrazine. The levulinoyl ester 
thus meets to considerable extend the demands outlined above. A shortcoming is its 
intrin c base-lability and it was reasoned that this drawback can be rectified by 
choosing the alcohol, with which the levulinolate group is condensed, such that it is 
both electron-rich (to reduce its leaving group properties) and sterically congested (to 
minimize intermolecular nucleophilic attack). Altogether, epoxomicin based,18 
levulinolate modified activity-based proteasome probe 1 (Figure 1B) was designed. This 
chapter describes its synthesis and application in the activity-based enrichment and 




















Figure 1. (A) Schematic representation of an activity-based enrichment experiment using the levulinoyl ester 
based cleavable linker. After labelling of the target enzyme and pull-down the linker is (chemo)selectively 
cleaved with hydrazine. (B) Structure of target proteasome probe 1 containing the levulinoyl ester based 
cleavable linker. 
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7.2 Results and Discussion 
The synthesis of ABP 1 is shown in Scheme 1. Commercially available 2,6-
diisopropylphenol 2 was converted into benzaldehyde 3 in a Duff reaction19 and the 
alcohol was subsequently protected as the benzyl ether (4). The ensuing Horner-
Wadsworth-Emmons reaction with phosphonate 5 proceeded smoothly to give 6. 
Hydrogenation and concomitant benzyl deprotection led to alcohol 7. Next, the ketone 
in diethyl 4-oxopimelate (8) was protected as ketal (9)20 and one of the ethyl esters was 
), 
which was converted into azide 12 via its tosylate (11). Saponification followed by 
acidic hydrolysis gave compound 14, which was condensed with 7 to produce levulinoyl 
ester 15. The tert-butyl ester was removed and the resulting carboxylic acid (16) was 
transformed into its activated NHS ester (17). Condensation with the epoxomicin 
peptide sequence 18 gave compound 19, which was reacted with alkyne 20 to give 
target compound 1. 
Scheme 1. Synthesis of two-step labelling probe 19 followed by a ‘click’ reaction leading to target probe 1. 
selectively saponificated. The obtained carboxylate was reduced to the alcohol (10
 
Reagents and conditions: (a) hexamine, AcOH, H2O, reflux, 97%; (b) BnBr, K2CO3, acetone, 93%; (c) 5, NaH, 
THF, 0 °C, quant.; (d) Pd/C, H2, MeOH, 94%; (e) ethylene glycol, PPTS, toluene, reflux, quant.; (f) i) KOH, EtOH, 
50 °C; ii) ethyl chloroformate, Et3N, THF; iii) NaBH4, H2O, 37%; (g) TsCl, Et3N, DMAP, DCM, 85%; (h) NaN3, DMF, 
75 °C, 99%; (i) NaOH, MeOH, 89%; (j) HCl, H2O, THF, quant.; (k) 7, DIC, DMAP, DCM, 73%; (l) TFA, DCM, 
quant.; (m) HOSu, EDC, DCM, 95%; (n) 18, DiPEA, DMF, 63%; (o) 20, CuSO4, sodium ascorbate, DMF, 41%. 
The linker system present in 1 was designed after conducting a number of studies 
(see Scheme 2). Initially, compound 23 was synthesized in order to test the possibility 
of hydrazine mediated cleavage in a Tris buffer in general. Cleavage of the ester 
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appeared to be fast (within 30 minutes at room temperature), however the ester linkage 
was also easily hydrolyzed in a Tris buffer system at pH 7.5. In addition, the synthesis 
from 5-aminolevulinic acid hydrochloric acid (22) is cumbersome due to its lability 
under basic conditions. Next, a panel of compounds derived from levulinic acid coupled 
to different alcohols (primary, secondary, tertiary alcohols and phenols) or secondary 
amines (Scheme 2) was studied for their synthetic viability, cleavage properties and 
stability towards hydrolysis. The primary and secondary alcohols derived esters proved 
e tertiary alcohol and 2,6-di-
tert-butylphenol derived esters could not be constructed under the commonly applied 
condensation conditions. Furthermore, the secondary amides, although being stabile to 
hydrolysis, could not be cleaved with hydrazine. The optimal results, in terms of 
synthesis, cleavage and stability, were obtained for the 2,6-dimethyl- and 2,6-
diisopropyl phenols. 
Scheme 2. Design of the levulinoyl ester-based cleavable linker system. 
to be substantially susceptible towards hydrolysis. Both th
 
 
Based on these results compound 24 was created, in which the -amine 
functionality (in 23) was replaced by an azide. Although this compound showed 
improved properties, compared to 23, it still suffered from two issues. The ester linkage 
was still a little prone to hydrolysis in Tris buffer and the -azide moiety was too labile 
to allow for a clean ‘click’ reaction. The third generation designed was compound 25. 
The isopropyl groups ortho to the ester appeared sterically sufficiently bulky to avoid 
hydrolysis under basic conditions. Yet they allow intramolecular cyclization of the 
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hydrazone, which is formed after condensation of the ketone with hydrazine. The 4-alkyl 
substituent proved to be favourable compared to a 4-carbonyl substituent in that this 
more electron rich phenol makes the ester less prone to hydrolysis. Also, the additional 
ethylene moiety introduced between azide and ketone allowed for a smooth click 
reacti
ptured construct from streptavidin-coated beads was marginal. It was 
reasoned that the cleavable linker was in too close proximity to the streptavidin-bound 
ign (1) an 
additional Ahx spacer was placed between the cleavable linker and biotin, which allowed 
an easier release from the beads (vide infra). 
The stability and cleavability of the linker system under several conditions was 
studied by LC-MS analysis of a test-substrate containing the linker. The results are 
shown in Table 1. 
Table 1. Stability/cleavage of the indicated test-substrate (10 mM) under different conditions.a 
on with biotin propargyl amide. Although the ester linkage was completely 
optimized, a preliminary pull-down experiment showed that hydrazine mediated 
cleavage of the ca
biotin and hence inaccessible for hydrazine. Therefore in the final des
NH2 NH2
 
E y B  H2NNH2 Tem °C) Time ) Clea ge ntr uffer (pH) p. ( (h Additive va
1 Tris (7.5) – 23 15 – – 
2 Tris (7.5) – 37 15 – – 
3 Tris (7.5) + 23 15 – + 
4 Tris (7.5) + 37 1 – + 
5 Tris (7.5) + 37 15 – + 
6 Tris (7.5) NH H 37 
0.4% SDS 
23 15 – – 
12 MI (4.0) – 23 15 – – 
2O 15 – – 
7 Tris (7.5) – 23 15 – 
8 Tris (7.5) – 100 5 min. 4×SB – 
9 HEPES (5.8) – 23 15 – – 
10 PBS (7.4) – 23 15 – – 
11 MI (3.0) – 
13 MI (5.0) – 23 15 – – 
14 MI (6.0) – 23 15 – – 
a Concentrations used: [H2NNH2] = 100 mM; [NH2OH] = 100 mM; [Tris] = 100 mM; [HEPES] = 50 mM. PBS 
(phosphate buffered saline): 10 mM Na2HPO4, 1.8 mM KH PO , 0.14 M NaCl, 2.7 mM KCl. MI (McIlvaine’s 
buffer): combination of 0.1 M citric acid and 0.
2 4
2 M Na HPO . SB (sample buffer): 20 mM Tris, 1% SDS, 10% 
glycer
2 4
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From this, it can be seen that the cleavable linker is stabile towards a wide variety 
of conditions to which a biological sample may be exposed, including different buffer 
systems, strong denaturing conditions and pH 3-7.5. Only upon addition of hydrazine 
the linker is cleaved (entries 3-5) into the two expected products. Hydroxyl amine was 
unable to cleave the linkage (entry 6). 
The efficacy of compound 1 to select and identify proteasome catalytic activities 
from cell extracts in an activity-based labelling experiment followed by hydrazine 
mediated linker cleavage was investigated as follows. Incubation of HEK-293T cell lysate 
with  in a Tris buffer followed by treatment with or without hydrazine under different 
conditions and visualization by streptavidin Western blotting revealed that all three 
active subunits (1, 2 and 5) are labelled (see Figure 2A). Cleavage of the linker 
appears to be hydrazine concentration dependent (lanes 3-7) and full cleavage was 
achieved after exposure to 50 mM hydrazine for 15 h. A second experiment, in which 
samples of HEK-293T cell lysate, incubated with 1, were denatured and exposed to 100 
mM hydrazine for different amounts of time, revealed that full cleavage was achieved 
within three to five hours (Figure 2B). 
 
1
Lane 1 2 3 4 5 6 7 8 9
[H2NNH2] (mM)
PS
100 0 1 10 50 100 100 0
T (ºC) 23 23 23 23 23 23 23 37
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1 (2.5 M final concentration) for 1 h at 37 °C followed by denaturation. (A) Samples were treated with 
the indicated hydrazine concentration for 15 h, resolved by SDS-PAGE and all biotinylated proteins were 
visualized by anti-biotin Western blotting. Cleavage of the linker is shown by disappearance of the bands. PS: 
prestained marker low range. Lane 2: sample was pre-boiled with 1% SDS prior to incubation as a negative 
control. Lane 8: 20 mM SDS without denaturing. Lane 9: pH 8.5 is the pH value for a combination of 100 mM 
Tris and 100 mM hydrazine and was reached by addition of 1 L 1 M Tris to the sample. (B) Samples were 
treated with 100 mM hydrazine for the indicated amounts of time and subsequently analyzed as described 
above. Lane 1: compound 21 (vide infra). BM: Biotinylated marker low range. 
To evaluate the use of 1 for protein capture and release, HEK-293T cell lysate was 
treated with this compound followed by denaturation, cysteine bridge reduction (DTT) 
and capping (iodoacetamide), and capturing with streptavindin coated magnetic beads. 
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The beads were divided into equal aliquots and the elutes from each sample after 
treatment with or without hydrazine under different conditions were resolved by SDS-
PAGE and visualized by silver stain (see Figure 3A). As a control experiment, biotinylated 
probe AdaLys(biotin)Ahx3Leu3VS (21)
21 was added to the lysate which was then treated 
with either standard (non-selective) elution conditions (1% SDS, 10 M biotin, 100 °C, 
lanes 1 and 7) or hydrazine (lanes 2 and 8). These results show that the captured 
proteins from 1 can be released chemoselectively with hydrazine both at RT and at 37 
°C (lanes 4 and 10), whereas the captured construct derived from 21 is resistant towards 
these conditions (lanes 2 and 8). The steptavidin blots of the same samples in Figure 3B 
show a complete absence of biotin for the with compound 1 captured proteins, which 
proves that the cleavable linker is indeed cleaved. In addition it appears that a small 
amount of SDS (0.05%) is necessary during cleavage (compare lanes 3 and 9 with 4 and 
10), whereas SDS at this concentration solely does not sustain cleavage (lane 5 and 11). 
Cleavage in HEPES buffer at pH 5.8 occurs as well, but is accompanied by a higher 
release of undesired material (compare lane 10 with 12). The cleavage efficiency was 
determined by extensive washing of the beads from Figure 3, eluting all captured 
leftovers with SDS boiling and silver staining after SDS-PAGE (see Figure 4). For the 
samples of lanes 6, 10 and 12 (Figure 2) the cleavage efficiency appears to be (near) 
quantitative (no proteasome characteristic bands are present) and for that of lane 4 only 
a small amount of active proteasome subunits is visible. 
 
Lane 1 2 3 4 5 6 7 8 9 10 11 12
Probe (20 µM) 21 21 1 1 1 1 PS 21 21 1 1 1 1
Buffera SB PD PD PD PD H SB PD PD PD PD H
H2NNH2 (100 mM) – + + + – + – + + + – +
SDS (0.05%) ++b + – + + + ++b + – + + +















Figure 3. Enriched proteins after pull-down with ABPs 1 and 21 and cleavage from streptavidin beads under 
the indicated conditions for 15 h. (A) Silver stain. (B) Streptavidin Western blot from the same samples. PS = 
prestained marker low range. a The applied buffers were: SB (30 mM Tris·HCl pH 6.8, 1% SD % glycerol, S, 9
bromophenolblue (BPB), 0.25 M -mercaptoethanol, 10 M biotin); PD (50 mM Tris·HCl pH 7.5, 150 mM NaCl); 
H (50 mM HEPES pH 5.8). b ++ refers to the 1% SDS present in SB. The arrows indicate the excised bands 
analyzed by LC-MS/MS after in-gel tryptic digest. 
 










Figure 4. Determination of the cleavage efficiency. The beads from the samples in Figure 3 after hydrazine 
media d cleavage were washed extensively and boiled for 5 min. with sample buffer (20 mM Tris, 1% SDS, 
10% glycerol, 0.05% BPB, 0.25 M -mercaptoethanol) containing 10 M biotin. Samples were resolved by SDS-
PAGE and all proteins were visualized by silver stain. a The numbers correspond to the same samples in the 
lanes in Figure 3. 
To establish that the visualized bands indeed correspond to the targeted 
proteasome subunits the indicated bands (arrows in Figure 3) were cut from the gel and 
analyzed by LC-MS/MS after in-gel tryptic digest. In this analysis multiple characteristic 
peptides for each of the indicated subunits were identified (see Figure 5A). Moreover, 
the expected modified active site fragment peptides derived from 2 and 5 were 






1 β2 6 42.7%
2 β1 5 39.0%
3 β5 7 54.4%
A B
 F re 3 
after i gel tryptic digest and LC-MS/MS analysis. np= number of identified peptides. (B) MS/MS spectrum of 
the 5 active site fragment attached to the expected cleaved probe. Insert: part of the LC-MS run showing the 
parent ion m/z (calc. m/z = 756.4704 for z = 2) for the peptide-inhibitor construct as shown at the bottom. 
Finally, the stability of compound 1 in serum and plasma was investigated. To this 
end, compound 1 was added to samples containing PBS, plasma or serum and 
incubated at 37 °C for 15 hours. LC-MS analysis (see Figure 6) indicated that compound 
1 was completely stabile in these environments, as evidenced by the fact that no 
products resulting from ester cleavage (hydrolysis) could be detected. These last results 
demonstrate the viability of the levulinoyl linker for ABP profiling of enzymes in vivo. 
 
 
Figure . (A) Table showing the proteasome active subunits identified from the indicated bands in igu 5
n-
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Figure 6. LC-MS traces of samples containing PBS, plasma or serum and treated with compound 1 for 15 
hours at 37 °C. The MS spectrum is shown for the peak at 8.47 minutes in the serum sample, indicating that 
compound 1 is intact. No products resulting from hydrolysis of the ester linkage could be detected. 
7.3 Conclusion 
In summary, a levulinoyl ester-based linker system for use in activity-based protein 
profiling was developed. Tuning the nature of the levulinoyl ester has produced a linker 
system that is robust enough to survive conditions commonly applied to cell extracts in 
biochemical experiments. The linker withstands aqueous, acidic and basic media 
(including the widely used Tris buffer) and is resistant towards disulfide reducing 
conditions. It is thus believed that the linker has some important advantages over the 
reported11-17 linker systems. The versatility of the linker in the ABP-mediated enrichment 
of the proteasome active sites was demonstrated and it was shown that the expected 
cleavage product is indeed found back on the active site peptides obtained after tryptic 
digestion. These results thus form the basis for the development of new activity-based 
profiling strategies, for instance two-step labelling strategies that include bio-orthogonal 
chemistry. From the synthetic scheme it is apparent that the linker is compatible with 
‘click’ chemistry. In a preliminary experiment HEK-293T cell lysates were exposed to 
azide-containing probe 19. Ensuing treatment with biotinylated Staudinger 
phosphane,22 SDS-PAGE resolving of the protein contain by SDS-PAGE and streptavidin 
blotting revealed a pattern characteristic for the proteasome catalytic activities. This last 
result demonstrates the viability of the levulinoyl linker for two-step ABP profiling of 
enzymes in general.  
Experimental section 
General 
Tetrahydrofuran was distilled over LiAlH4 prior to use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH), diisopropylethylamine (DiPEA) and 
trifluoroacetic acid (TFA) were of peptide synthesis grade, purchased at Biosolve, and used as 
received. All general chemicals (Fluka, Acros, Merck, Aldrich, Sigma) were used as received. O-(1H-
6-chlorobenzotriazolyl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was purchased 
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at Iris Biotech (Marktrewitz, Germany). Traces of water were removed from reagents used in 
reactions that require anhydrous conditions by co-evaporation with toluene. Solvents that were 
used in reactions were stored over 4 Å molecular sieves, except methanol and acetonitrile which 
were stored over 3 Å molecular sieves. Column chromatography was performed on Screening 
Devices b.v. Silica Gel, with a particle size of 40-63 m and pore diameter of 60 Å. The eluents 
toluene, ethyl acetate (EtOAc) and petroleum ether (PE) (40-60 °C boiling range) were distilled 
prior to use. TLC analysis was conducted on Merck aluminium sheets (Silica gel 60 F254). 
Compounds were visualized by UV absorption (254 nm), by spraying with a solution of 
(NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of 
KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and acetic acid (12.5 mL/L) in 
ethanol, where appropriate, followed by charring at ca. 150 °C. 1H- and 13C-NMR spectra were 
recorded on a Bruker AV-400 (400 MHz) spectrometer. Chemical shifts are given in ppm () relative 
to tetramethylsilane, CD3OD or CDCl3 as internal standard. IR spectra were recorded on a 
Shimadzu FTIR-8300 and absorptions are given in cm-1. High resolution mass spectra were 
recorded by direct injection (2 L of a 2 M solution in water/acetonitrile 50/50 (v/v) and 0.1% 
formic acid) on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an 
electrospray ion source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary 
temperature 250 °C) with resolution R = 60,000 at m/z 400 (mass range m/z = 150-2000) and 
dioctylpthalate (m/z = 391.28428) as a “lock mass”. The high resolution mass spectrometer was 
calibrated prior to measurements with a calibration mixture (Thermo Finnigan). Optical rotations 
 were recorded on a Propol automatic polarimeter. LC-MS analysis was performed on a Jasco 
HPLC system with a Phenomenex Gemini 3 m C18 50 × 4.60 mm column (detection 
simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI 
(System A) or a Finnigan Surveyor HPLC system with a Gemini C18 50 × 4.60 mm column 
(detection at 200-600 nm), coupled to a Finnigan LCQ Advantage Max mass spectrometer with ESI 
(System B). The applied buffers were H2O, ACN and 1.0% aq. TFA. Unless noted otherwise the 
gradient used was 10% → 90% ACN/0.1% aq. TFA. HPLC purifications were performed on a Gilson 
HPLC system coupled to a Phenomenex Gemini 5 m 250 × 10 mm column and a GX281 fraction 





2,6-diisopropylphenol (2, 18.4 g, 100 mmol) was dissolved in AcOH (83 mL) and H2O (17 mL). To 
this was added hexamine (2 eq., 200 mmol, 28.0 g) and the mixture was heated to reflux for 5 min. 
after which a distillation head was installed and ca. 9 mL distillate was collected at 110 °C. The 
distillation head was removed again and the mixture was refluxed for another 2.5 h after which 
TLC analysis indicated complete consumption of the phenol starting compound. Next, the mixture 
was cooled to RT and H2O (20 mL) was added. Upon further cooling to 0 °C a pale yellow solid 
precipitated. The mixture was allowed to stand at 0 °C for 1 h followed by filtration of the solid. 
The residue was washed two times with ice-cold water and dried at 60 °C under reduced pressure. 
The title compound was obtained without further purification as a pale yellow solid (yield: 20.1 g, 
97.6 mmol, 97%). 1H NMR (400 MHz, CDCl3):  = 9.79 (s, 1H), 7.62 (s, 2H), 4.14 (bs, 1H), 3.30 (p, J 
= 6.80 Hz, 2H), 1.28 (d, J = 6.80 Hz, 12H) ppm. 13C NMR (100 MHz, CDCl3):  = 192.35, 157.16, 
135.26, 128.67, 126.01, 26.47, 22.24 ppm. 
 
4-(benzyloxy)-3,5-diisopropylbenzaldehyde (4) 
Phenol 3 (4.14 g, 20.0 mmol) was dissolved in acetone (100 mL) and to this were added 
benzylbromide (1.01 eq., 20.2 mmol, 3.46 g) and K2CO3 (2 eq., 40.0 mmol, 5.53 g). The suspension 
was stirred vigorously for 14 h after which TLC analysis revealed a completed reaction. The 
mixture was concentrated under reduced pressure, redissolved in EtOAc (100 mL) and extracted 
with H2O and brine. After drying (MgSO4) and concentration in vacuo of the organic layer the title 
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compound was obtained as a colourless oil (yield: 5.50 g, 18.6 mmol, 93%). 1H NMR (400 MHz, 
CDCl3):  = 9.95 (s, 1H), 7.70 (s, 2H), 7.48 (d, J = 7.18 Hz, 2H), 7.41 (t, J = 7.30 Hz, 2H), 7.35 (t, J 
= 7.20 Hz, 1H), 4.86 (s, 2H), 3.41 (sept., J = 6.85 Hz, 2H), 1.27 (d, J = 6.96 Hz, 12H) ppm. 13C 
NMR (100 MHz, CDCl3):  = 191.68, 158.53, 143.13, 136.76, 133.13, 128.50, 128.07, 127.25, 
126.13, 76.42, 26.66, 23.74 ppm. 
 
(E)-tert-butyl 3-(4-(benzyloxy)-3,5-diisopropylphenyl)acrylate (6) 
To a stirred solution of aldehyde 4 (0.23 g, 0.76 mmol) and tert-butyl 2-
(diethoxyphosphoryl)acetate (5, 1.5 eq., 1.14 mmol, 0.29 g) in THF (10 mL) at 0 °C was added NaH 
(1.5 eq., 1.14 mmol, 46.0 mg). The reaction mixture was stirred for 1 h at RT after which TLC 
analysis indicated a completed reaction. EtOAc (10 mL) was added and the mixture was extracted 
with 0.1 M aq. HCl (2×), sat. aq. NaHCO3 and brine. The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. The title compound was obtained after purification by 
column chromatography (100% PE → 5% EtOAc/PE) as a colourless oil (yield: 0.31 g, 0.77 mmol, 
quant.). 1H NMR (400 MHz, CDCl3):  = 7.60 (d, J = 15.94 Hz, 1H), 7.47 (d, J = 7.08 Hz, 2H), 7.40 
(t, J = 7.31 Hz, 2H), 7.33 (t, J = 7.24 Hz, 1H), 7.30 (s, 2H), 6.33 (d, J = 15.93 Hz, 1H), 4.81 (s, 2H), 
3.38 (sept., J = 6.89 Hz, 2H), 1.54 (s, 9H), 1.24 (d, J = 6.91 Hz, 12H) ppm. 13C NMR (100 MHz, 
CDCl3):  = 166.38, 154.87, 143.78, 142.42, 137.20, 130.97, 128.47, 127.94, 127.26, 124.02, 




Tert-butyl 3-(4-hydroxy-3,5-diisopropylphenyl)propanoate (7) 
Compound 6 (0.30 g, 0.76 mmol) was dissolved in MeOH (10 mL) and the solution was bubbled 
through with argon for 15 min. before Pd/C 10% w/w (10 mg) was added. The flask was charged 
with hydrogen for 1 h, after which TLC analysis indicated complete reduction. Argon was bubbled 
through for another 15 min. and all solids were removed by filtration over Celite. The title 
compound was obtained after evaporation of the solvent under reduced pressure as a colourless 
oil (yield: 0.22 g, 0.71 mmol, 94%). 1H NMR (400 MHz, CDCl3):  = 6.87 (s, 2H), 5.09 (s, 1H), 3.17 
(sept., J = 6.80 Hz, 2H), 2.85 (t, J = 7.84 Hz, 2H), 2.52 (t, J = 7.86 Hz, 2H), 1.42 (s, 9H), 1.24 (d, J 
= 6.91 Hz, 12H) ppm. 13C NMR (100 MHz, CDCl3):  = 172.73, 148.26, 133.75, 132.36, 123.10, 




Diethyl 3,3'-(1,3-dioxolane-2,2-diyl)dipropanoate (9)20 
Diethyl-4-oxopimelate (8, 11.4 g, 48.4 mmol), ethylene glycol (436 mmol, 24.0 mL) and PPTS (7.26 
mmol, 1.82 g) were dissolved in toluene (50 mL) and the mixture was heated to reflux under Dean-
Stark conditions for 2 h, after which TLC analysis indicated complete consumption of the ketone. 
The mixture was cooled to RT and extracted twice with sat. aq. NaHCO3 (50 mL). The organic layer 
was dried over MgSO4 and concentrated under reduced pressure. The title compound was 
obtained as a colourless liquid (yield: 13.2 g, 48.4 mmol, quant.). 1H NMR (300 MHz, CDCl3):  = 
4.13 (q, J = 7.13 Hz, 4H), 3.94 (s, 4H), 2.37 (t, J = 7.65 Hz, 4H), 1.98 (t, J = 7.64 Hz, 4H), 1.25 (t, J 
= 7.14 Hz, 6H) ppm. 13C NMR (75.5 MHz, CDCl3):  = 173.24, 109.84, 65.02, 60.20, 32.07, 28.78, 
14.07 ppm. 
 
Ethyl 3-(2-(3-hydroxypropyl)-1,3-dioxolan-2-yl)propanoate (10) 
A solution of KOH (1 eq., 47.7 mmol, 47.7 mL; 1 M in EtOH) was added dropwise to diethyl ester 9 
(13.2 g, 47.7 mmol) at 50 °C in 4 h. The resulting mixture was stirred at 50 °C for 14 h after which 
all EtOH was evaporated under reduced pressure. The resulting residue was suspended in THF 
(250 mL) and Et3N (0.5 eq., 23.8 mmol, 3.31 mL) and ethyl chloroformate (1.5 eq., 71.5 mmol, 6.84 
mL) were added. After vigorously stirring for 2 h the mixture was added to a cooled (0 °C) solution 
of NaBH4 (1.5 eq., 71.5 mmol, 2.71 g) in H2O (250 mL) and the mixture was stirred at RT for 1 h. 
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The reaction was quenched by addition of 1 mM aq. HCl (100 mL) and the resulting mixture was 
extracted with Et2O (3×). The combined organic layers were extracted with brine, dried over 
MgSO4 and concentrated under reduced pressure. The title compound was obtained after 
purification by column chromatography (25% → 100% EtOAc/PE) as a colourless liquid (yield: 4.14 
g, 17.8 mmol, 37%). 1H NMR (300 MHz, CDCl3):  = 4.13 (q, J = 7.13 Hz, 2H), 3.96 (s, 4H), 3.64 (t, J 
= 5.83 Hz, 2H), 2.37 (t, J = 7.75 Hz, 2H), 2.01 (t, J = 7.65 Hz, 2H), 1.93 (bs, 1H), 1.76-1.62 (m, 
4H), 1.26 (t, J = 7.13 Hz, 3H) ppm. 13C NMR (75.5 MHz, CDCl3):  = 208.84, 110.72, 65.00, 62.84, 




Ethyl 3-(2-(3-(tosyloxy)propyl)-1,3-dioxolan-2-yl)propanoate (11) 
Alcohol 10 (4.14 g, 17.8 mmol) was dissolved in DCM (125 mL) and Et3N (2.1 eq., 37.4 mmol, 5.18 
mL), DMAP (0.25 eq., 4.45 mmol, 0.50 g) and TsCl (2.55 eq., 8.66 mmol, 45.4 g) were added. The 
mixture was stirred for 4 h after which TLC analysis indicated a complete consumption of the 
starting compound. DCM was evaporated under reduced pressure and the residue was dissolved 
in EtOAc, extracted with 1 mM aq. HCl (2×) and brine, dried over MgSO4 and concentrated under 
reduced pressure. The title compound was obtained after purification by column chromatography 
(25% → 50% EtOAc/PE) as a colourless liquid (yield: 5.87 g, 15.2 mmol, 85%). 1H NMR (400 MHz, 
CDCl3):  = 7.79 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 4.12 (q, J = 7.1 Hz, 2H), 4.04 (t, J = 
6.4 Hz, 2H), 3.9-3.8 (m, 4H), 2.45 (s, 3H), 2.31 (t, J = 7.6 Hz, 2H), 1.92 (t, J = 7.6 Hz, 2H), 1.8-1.7 
(m, 2H), 1.7-1.6 (m, 2H), 1.26 (t, J = 6.8 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3):  = 173.38, 
144.80, 133.30, 129.80, 127.86, 110.15, 70.53, 65.06, 60.36, 33.01, 32.07, 28.83, 23.39, 21.60, 
14.19 ppm. 
 
Ethyl 3-(2-(3-azidopropyl)-1,3-dioxolan-2-yl)propanoate (12) 
A solution of tosylate 11 (5.87 g, 15.2 mmol) and NaN3 (1.2 eq., 18.2 mmol, 1.19 g) in DMF (120 
mL) was stirred at 75 °C for 14 h, after which TLC analysis indicated a complete conversion. The 
mixture was concentrated under reduced pressure and the residue was dissolved in EtOAc, 
extracted with sat. aq. NaHCO3 (2×), H2O and brine, dried over MgSO4 and concentrated under 
reduced pressure. The title compound was obtained as a colourless liquid (yield: 3.86 g, 15.0 
mmol, 99%). 1H NMR (400 MHz, CDCl3):  = 4.13 (q, J = 7.14 Hz, 2H), 3.94 (s, 4H), 3.32-3.26 (m, 
2H), 2.36 (t, J = 7.60 Hz, 2H), 1.99 (t, J = 7.60 Hz, 2H), 1.71-1.65 (m, 4H), 1.26 (t, J = 7.15 Hz, 3H) 
ppm. 13C NMR (100 MHz, CDCl3):  = 173.23, 110.20, 64.93, 60.17, 51.29, 34.07, 31.94, 28.73, 
23.24, 14.04 ppm. HRMS: calcd. for C11H19N3O4 258.14483 [M + H]
+; found 258.14491. IR film 
(cm-1) 2954.7, 2885.3, 2090.7, 1728.1, 1450.4, 1257.5, 1180.3, 1134.1, 1033.8, 948.9, 910.3, 864.1. 
 
3-(2-(3-azidopropyl)-1,3-dioxolan-2-yl)propanoic acid (13) 
Ethyl ester 12 (3.86 g, 15.0 mmol) was dissolved in MeOH (80 mL) and to this was added NaOH (4 
eq., 60.0 mmol, 30 mL; 2 M in H2O) at 0 °C. The mixture was allowed to slowly warm to RT and was 
stirred for 14 h after which TLC analysis revealed complete conversion. The mixture was 
concentrated under reduced pressure and the residue was dissolved in sat. aq. NaHCO3/H2O (3:1 
v/v, 80 mL) and extracted twice with EtOAc. Next, the aqueous layer was acidified with 10% w/v 
aq. HCl until pH 2 and extracted again twice with EtOAc. The latter organic layers were combined, 
dried over MgSO4 and concentrated under reduced pressure, which yielded the title compound as 
a colourless liquid (yield: 3.05 g, 13.3 mmol, 89%). 1H NMR (300 MHz, CDCl3):  = 10.20 (bs, 1H), 
3.96 (s, 4H), 3.34-3.25 (m, 2H), 2.41 (t, J = 7.50 Hz, 2H), 2.00 (t, J = 7.51 Hz, 2H), 1.71-1.65 (m, 
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7-azido-4-oxoheptanoic acid (14) 
Concentrated aq. HCl (19 mL) was added to a solution of compound 13 (3.05 g, 13.3 mmol) in 
THF (60 mL) and the mixture was stirred for 3 h, after which TLC analysis showed complete 
consumption of starting material. Water (150 mL) was added carefully and the aqueous layer was 
extracted with EtOAc three times. The combined organic layers were extracted with brine, dried 
over MgSO4 and concentrated in vacuo. The title compound was obtained as a colourless oil 
(yield: 2.46 g, 13.3 mmol, quant.) without further purification necessary. 1H NMR (400 MHz, 
CDCl3):  = 9.26 (bs, 1H), 3.32 (t, J = 6.64 Hz, 2H), 2.73 (t, J = 6.20 Hz, 2H), 2.64 (t, J = 6.16 Hz, 
2H), 2.57 (t, J = 7.06 Hz, 2H), 1.88 (p, J = 6.86 Hz, 2H) ppm. 13C NMR (100 MHz, CDCl3):  = 
207.65, 178.28, 50.56, 39.10, 36.80, 27.68, 22.79 ppm. 
 
4-(3-(tert-butoxy)-3-oxopropyl)-2,6-diisopropylphenyl 7-azido-4-oxoheptanoate (15) 
To a solution of alcohol 7 (1 eq., 13.3 mmol, 4.08 g), carboxylic acid 14 (1 eq., 13.3 mmol, 2.46 g) 
and DMAP (0.1 eq., 1.33 mmol, 0.16 g) in DCM (100 mL) was added DIC (1.2 eq., 16.0 mmol, 2.51 
mL) and the mixture was stirred for 14 h. Next, the mixture was concentrated under reduced 
pressure, the residue dissolved in EtOAc (100 mL), extracted with 1 M aq. HCl (2×), sat. aq. 
NaHCO3 and brine, dried (MgSO4) and concentrated under reduced pressure. The title compound 
was obtained after purification by column chromatography (100% Tol → 10% EtOAc/Tol) as a 
colourless oil (yield: 4.41 g, 9.64 mmol, 73%). 1H NMR (400 MHz, CDCl3):  = 6.96 (s, 2H), 3.30 (t, J 
= 6.68 Hz, 2H), 2.93-2.80 (m, 8H), 2.58 (t, J = 7.06 Hz, 2H), 2.53 (t, J = 7.83 Hz, 2H), 1.87 (p, J = 
6.88 Hz, 2H), 1.42 (s, 9H), 1.17 (d, J = 6.91 Hz, 12H) ppm. 13C NMR (100 MHz, CDCl3):  = 207.21, 
172.21, 171.48, 143.67, 140.03, 138.61, 123.69, 80.15, 50.52, 39.19, 36.95, 36.88, 30.90, 27.95, 
27.65, 27.32, 22.85 ppm. HRMS: calcd. for C26H39N3O5 496.27819 [M + Na]
+; found 496.27775. 
 
3-(4-((7-azido-4-oxoheptanoyl)oxy)-3,5-diisopropylphenyl)propanoic acid (16) 
TFA (10 mL) was added to a solution of tert-butyl ester 15 (1.40 g, 3.06 mmol) in DCM (10 mL) and 
this mixture was stirred for 30 min. after which TLC analysis showed complete consumption of 
starting material. Toluene (25 mL) was added and the mixture was concentrated under reduced 
pressure. In order to remove traces of TFA the mixture was coevaporated with toluene three 
times. The title compound was obtained as a colourless oil (yield: 1.28 g, 3.06 mmol, quant.). 1H 
NMR (400 MHz, CDCl3):  = 9.40 (s, 1H), 6.98 (s, 2H), 3.29 (t, J = 6.69 Hz, 2H), 2.95-2.81 (m, 8H), 
2.67 (t, J = 7.91 Hz, 2H), 2.59 (t, J = 7.06 Hz, 2H), 1.87 (p, J = 6.92 Hz, 2H), 1.17 (d, J = 6.91 Hz, 
12H) ppm. 13C NMR (100 MHz, CDCl3):  = 207.43, 178.29, 171.58, 143.75, 140.18, 138.08, 
123.64, 50.44, 39.14, 36.82, 35.59, 30.48, 27.59, 27.27, 22.79 ppm. HRMS: calcd. for C22H31N3O5 




N-hydroxysuccinimide (1.5 eq., 1.30 mmol, 150 mg) and EDC (1.5 eq., 1.30 mmol, 249 mg) were 
added to a solution of carboxylic acid 16 (0.36 g, 0.87 mmol) in DCM (7 mL) and the mixture was 
stirred for 14 h, after which TLC analysis indicated complete consumption of starting material. The 
solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc (20 mL). 
This was extracted with 1 M aq. HCl (2×) and brine, dried over MgSO4 and concentrated under 
reduced pressure. The title compound was obtained after purification by column chromatography 
(30% → 60% EtOAc/PE) as a colourless oil (yield: 0.43 g, 0.83 mmol, 95%). 1H NMR (400 MHz, 
CDCl3):  = 6.99 (s, 2H), 3.31 (t, J = 6.67 Hz, 2H), 3.06-3.00 (m, 2H), 2.95-2.81 (m, 12H), 2.60 (t, J 
= 7.06 Hz, 2H), 1.88 (p, J = 6.90 Hz, 2H), 1.18 (d, J = 6.89 Hz, 12H) ppm. 13C NMR (100 MHz, 
CDCl3):  = 207.26, 171.53, 169.03, 167.90, 144.16, 140.59, 137.15, 123.75, 50.60, 39.28, 36.95, 
32.70, 30.35, 27.70, 27.44, 25.54, 22.91 ppm. LC-MS (System A): Rt (min): 9.38 (ESI-MS (m/z): 
515.4 (M + H+)). HRMS: calcd. for C26H34N4O7 515.25003 [M + H]
+; found 515.24963. 
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Scheme 3. Synthesis of compound 19. 
 
Reagents and conditions: (a) HCTU, DiPEA, DCM, 89%; (b) i) DBU, DMF; ii) HOBt; iii) HCTU, DiPEA; iv) 
NH2NH2·H2O, MeOH, 72%; (c) i) tBuONO, HCl, DCM, DMF, –30 °C; ii) TFA·H2N-Leu-EK, DiPEA, 89%; (d) i) TFA, 
DCM; ii) 17, DiPEA, DMF, 63%. 
Fmoc-Ile-Thr(tBu)-OMe (26) 
Fmoc-Ile-OH (1.2 eq., 13.3 mmol, 4.70 g) was dissolved in DCM (60 mL) and to this were added 
HCTU (1.2 eq., 13.3 mmol, 5.50 g), DiPEA (3.3 eq., 36.0 mmol, 6.0 mL) and HCl·H-Thr(tBu)-OMe (1 
eq., 11.0 mmol, 2.50 g) successively. The mixture was stirred for 2 h after which TLC analysis 
indicated a completed reaction. DCM was evaporated under reduced pressure and the residue 
was dissolved in EtOAc, extracted with 1 M aq. HCl (2×), sat. aq. NaHCO3 (2×) and brine, dried 
over MgSO4 and concentrated under reduced pressure. The title compound was obtained after 
purification by column chromatography (10% → 50% EtOAc/PE) as a colourless solid (yield: 5.16 
g, 9.83 mmol, 89%). 1H NMR (400 MHz, CDCl3):  = 7.76 (d, J = 7.48 Hz, 2H), 7.60 (d, J = 7.41 Hz, 
2H), 7.39 (t, J = 7.46 Hz, 2H), 7.31 (dt, J = 7.43, 0.98 Hz, 2H), 6.48 (d, J = 8.84 Hz, 1H), 5.58 (d, J 
= 8.70 Hz, 1H), 4.49 (dd, J = 9.00, 1.68 Hz, 1H), 4.44-4.33 (m, 2H), 4.28-4.21 (m, 2H), 4.18 (dd, J 
= 8.53, 6.39 Hz, 1H), 3.71 (s, 3H), 1.94-1.83 (m, 1H), 1.65-1.53 (m, 1H), 1.33-1.21 (m, 1H), 1.17 (d, 
J = 6.27 Hz, 3H), 1.11 (s, 9H), 1.02-0.94 (m, 6H) ppm. 13C NMR (100 MHz, CDCl3):  = 171.42, 
170.86, 156.07, 143.78, 141.24, 127.63, 127.01, 125.07, 119.90, 74.21, 67.19, 66.96, 59.30, 57.83, 
52.13, 47.17, 38.18, 28.27, 24.82, 21.04, 15.08, 11.52 ppm. LC-MS (System B): Rt (min): 10.87 (ESI-
MS (m/z): 525.0 (M + H+)). 
 
Boc-Ile-Ile-Thr(tBu)-NHNH2 (27) 
DBU (1.05 eq., 10.3 mmol, 1.57 mL) was added to a solution of Fmoc-Ile-Thr(tBu)-OMe (26, 5.16 g, 
9.83 mmol) in DMF (50 mL) and the mixture was stirred for 5 min. after which HOBt (1.5 eq., 14.7 
mmol, 1.98 g) was added. After stirring the mixture for another 30 min. Boc-Ile-OH (1.2 eq., 11.8 
mmol, 2.73 g), HCTU (1.2 eq., 11.8 mmol, 4.88 g) and DiPEA (3 eq., 29.5 mmol, 4.87 mL) were 
added. TLC analysis indicated sufficient product formation after 14 h and the mixture was 
concentrated under reduced pressure. The residue was redissolved in DCM and extracted with 1 M 
aq. HCl (2×), sat. aq. NaHCO3 (2×) and brine, dried over MgSO4 and concentrated in vacuo. The 
intermediate was purified by column chromatography (10% → 50% EtOAc/PE) and the obtained 
product (3.69 g, 7.15 mmol) was dissolved in MeOH (50 mL). Hydrazine monohydrate (30 eq., 215 
mmol, 10.4 mL) was added and the mixture was stirred for 14 h, after which TLC analysis indicated 
complete consumption of starting material. Toluene was added and the mixture was concentrated 
under reduced pressure. The title compound was obtained after coevaporation with toluene (3×) 
as a colourless solid (yield: 3.66 g, 7.10 mmol, 72%). 1H NMR (400 MHz, CD3OD):  = 4.34 (d, J = 
3.53 Hz, 1H), 4.29 (d, J = 8.12 Hz, 1H), 4.05-3.99 (m, 1H), 3.92 (d, J = 7.90 Hz, 1H), 1.90-1.70 (m, 
2H), 1.61-1.47 (m, 2H), 1.42 (s, 3H), 1.22-1.10 (m, 1H), 1.17 (s, 9H), 1.08 (d, J = 6.32 Hz, 3H), 0.92-
0.85 (m, 12H) ppm. 13C NMR (100 MHz, CD3OD):  = 174.83, 173.39, 171.30, 157.91, 80.56, 75.84, 
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68.52, 60.62, 59.22, 58.56, 37.94, 37.85, 28.77, 28.66, 25.94, 19.78, 16.23, 15.95, 11.39, 11.32 
ppm. LC-MS (System A): Rt (min): 6.08 (ESI-MS (m/z): 516.4 (M + H+)). HRMS: calcd. for 
C25H49N5O6 516.37556 [M + H]
+; found 516.37530. 
 
Boc-Ile-Ile-Thr(tBu)-Leu-EK (28) 
Boc-Ile-Ile-Thr(tBu)-NHNH2 (27, 1 eq., 3.87 mmol, 2.0 g) was dissolved in a 9:1 v/v mixture of 
DCM/DMF (40 mL) and cooled to –30 °C. To this were added tBuONO (1.1 eq., 4.25 mmol, 0.57 
mL) and HCl (2.8 eq., 10.8 mmol, 2.70 mL; 4 M in 1,4-dioxane). This mixture was stirred at –30 °C 
for 3 h, after which (S)-2-amino-4-methyl-1-((R)-2-methyloxiran-2-yl)pentan-1-one TFA salt23,24 (1.1 
eq., 4.25 mmol, 1.16 g) in DMF (5 mL) and DiPEA (5 eq., 20.0 mmol, 3.31 mL) were added. The 
reaction was allowed to warm to RT and stirred for 14 h. Next, DCM (15 mL) was added and the 
mixture was extracted with 0.1 M aq., HCl (2×) and H2O, dried over MgSO4 and concentrated 
under reduced pressure. The title compound was obtained after purification by column 
chromatography (20% → 50% EtOAc/PE) as a colourless solid (yield: 2.25 g, 3.43 mmol, 89%). 1H 
NMR (400 MHz, CDCl3):  = 7.64 (d, J = 7.47 Hz, 1H), 6.99 (d, J = 5.63 Hz, 1H), 6.45 (d, J = 8.22 
Hz, 1H), 5.22 (d, J = 7.84 Hz, 1H), 4.46 (ddd, J = 10.45, 7.55, 2.94 Hz, 1H), 4.41-4.32 (m, 2H), 
4.14-4.07 (m, 1H), 3.94 (t, J = 7.34 Hz, 1H), 3.38 (d, J = 5.07 Hz, 1H), 2.89 (d, J = 5.06 Hz, 1H), 
1.92-1.77 (m, 2H), 1.74-1.63 (m, 1H), 1.60-1.55 (m, 1H), 1.54-1.48 (m, 2H), 1.52 (s, 3H), 1.44 (s, 
9H), 1.33-1.24 (m, 1H), 1.28 (s, 9H), 1.19-1.08 (m, 2H), 1.06 (d, J = 6.44 Hz, 3H), 0.96 (d, J = 6.54 
Hz, 6H), 0.92-0.86 (m, 12H) ppm. 13C NMR (100 MHz, CDCl3):  = 208.06, 171.59, 170.73, 169.51, 
155.80, 79.76, 75.49, 66.14, 59.24, 57.68, 56.95, 52.39, 50.74, 39.80, 37.30, 36.97, 28.28, 28.08, 
25.42, 24.88, 24.69, 23.35, 21.35, 16.75, 16.33, 15.53, 15.40, 11.28 ppm. LC-MS (System B): Rt 




Compound 24 (165 mg, 0.25 mmol) was treated with a 1:1 v/v mixture of DCM/TFA (2 mL) for 1 h 
and subsequently coevaporated with toluene (3×). The resulting intermediate was dissolved in 
DMF (2 mL) and to this were added compound 17 (1.1 eq., 0.258 mmol, 144 mg) and DiPEA (2 eq., 
0.50 mmol, 83 L). The reaction was stirred for 14 h before being concentrated under reduced 
pressure. The residue was dissolved in DCM (10 mL) and extracted with 1 M aq. HCl (2×), sat. aq. 
NaHCO3 (2×) and brine, dried over MgSO4 and concentrated under reduced pressure. The title 
compound was obtained after purification by column chromatography (25% → 100% EtOAc/PE) 
as a colourless solid (yield: 141 mg, 0.16 mmol, 63%). 1H NMR (400 MHz, CDCl3):  = 8.75 (s, 1H), 
8.28 (s, 1H), 8.24 (s, 1H), 7.46 (s, 1H), 6.97 (s, 2H), 4.94-4.76 (m, 3H), 4.63-4.55 (m, 1H), 4.34 (s, 
1H), 4.09-4.01 (m, 1H), 3.31 (t, J = 6.64 Hz, 2H), 3.22 (s, 1H), 3.00-2.77 (m, 9H), 2.59 (t, J = 7.01 
Hz, 4H), 1.88 ( p, J = 6.89 Hz, 2H), 1.83-1.73 (m, 1H), 1.70-1.35 (m, 8H), 1.49 (s, 3H), 1.20-1.06 (m, 
15H), 0.91-0.71 (m, 18H) ppm. 13C NMR (100 MHz, CDCl3):  = 208.14, 207.22, 172.12, 171.40, 
170.57, 143.75, 140.05, 138.75, 123.71, 67.38, 58.99, 57.47, 57.44, 57.16, 52.12, 50.53, 50.41, 
39.22, 38.07, 37.77, 36.92, 31.56, 27.65, 27.37, 25.29, 25.14, 24.88, 23.12, 22.85, 21.09, 17.35, 
16.65, 15.20, 15.16, 11.51, 11.35 ppm.  = –0.57 (c = 1 in CHCl3). LC-MS (System B): Rt (min): 





Boc-Ahx-propargylamide25 (275 mg, 1.03 mmol) was treated with a 1:1 v/v mixture of DCM/TFA (6 
mL) for 1 h and subsequently coevaporated with toluene (3×). The resulting intermediate was 
dissolved in DMF (5 mL) and to this were added biotin-OSu (1.1 eq., 1.1 mmol, 375 mg) and DiPEA 
(1.5 eq., 1.50 mmol, 248 L). The reaction was stirred for 14 h before being concentrated under 
reduced pressure. The title compound was obtained after crystallisation from MeOH/Et2O as a 
colourless solid. The compound was sufficiently pure based on LC-MS analysis and subjected to 
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the next step without further purification. LC-MS (System B): Rt (min): 4.27 (ESI-MS (m/z): 395.13 
(M + H+)). 
 
Biotin-Ahx-triazole-Lev-phenol-epoxomicin (1) 
To a solution of compound 19 (45.0 mg, 50.1 mol) and biotin-Ahx-propargylamide (20, 1.5 eq., 
70.0 mol, 30.0 mg) in DMF (1.5 mL) were added CuSO4 (0.2 eq., 10.0 mol, 10.0 L; 1 M in H2O) 
and sodium ascorbate (0.3 eq., 15.0 mol, 15.0 L; 1 M in H2O) and the mixture was stirred for 14 
h at RT after which LC-MS analysis indicated a complete conversion of the azide. The mixture was 
concentrated under reduced pressure and the title compound was obtained after RP-HPLC 
purification (40% → 70% ACN/0.1% aq. TFA) as a colourless solid (yield: 26.3 mg, 20.4 mol, 41%). 
1H NMR (400 MHz, CD3OD):  = 7.76 (s, 1H), 6.92 (s, 2H), 4.45 (dd, J = 10.68, 3.02 Hz, 1H), 4.38 
(dd, J = 7.43, 5.04 Hz, 1H), 4.34-4.26 (m, 4H), 4.22 (d, J = 5.04 Hz, 1H), 4.19 (dd, J = 7.87, 4.49 
Hz, 1H), 4.15 (d, J = 7.99 Hz, 1H), 4.10 (d, J = 8.14 Hz, 1H), 3.93 (dd, J = 6.19, 5.28 Hz, 1H), 3.15 
(d, J = 5.07 Hz, 1H), 3.12-3.08 (m, 1H), 3.05 (t, J = 7.07 Hz, 2H), 2.87-2.70 (m, 10H), 2.59 (d, J = 
12.70 Hz, 1H), 2.51-2.39 (m, 4H), 2.15-2.01 (m, 6H), 1.81-1.70 (m, 1H), 1.69-1.37 (m, 12H), 1.36 (s, 
3H), 1.35-1.17 (m, 6H), 1.10-1.01 (m, 16H), 1.00-0.88 (m, 1H), 0.86-0.77 (m, 12H), 0.76-0.69 (m, 
6H) ppm. 13C NMR (100 MHz, CD3OD):  = 209.52, 209.43, 176.00, 175.27, 174.10, 173.71, 
173.61, 172.25, 145.32, 141.72, 140.24, 124.93, 68.57, 63.45, 61.69, 60.14, 59.84, 59.41, 59.32, 
57.06, 53.10, 51.85, 50.58, 41.09, 40.37, 40.23, 39.53, 38.73, 38.04, 37.88, 37.79, 36.85, 35.64, 
32.80, 30.16, 29.83, 29.54, 28.68, 28.61, 27.58, 26.98, 26.54, 26.26, 26.05, 25.46, 23.82, 21.53, 
20.06, 17.06, 16.01, 15.97, 11.49, 11.37 ppm.  = –1.28 (c = 1 in MeOH). LC-MS (System B): 
Rt (min): 8.42 (ESI-MS (m/z): 1292.53 (M + H+)). HRMS: calcd. for C66H105N11O13S 1292.76868 [M + 
H]+; found 1292.76980. 
23][ D
Stability/cleavage of the test-substrate 
The test-substrate N3-CL-Lys-Gly-OH was made from compound 17 and dipeptide Fmoc-
Lys(Boc)-Gly-OtBu via standard peptide chemistry. The test-substrate was dissolved (10 mM) in 
either 100 mM Tris pH 7.5, 100 mM HEPES pH 5.8, PBS (10 mM Na2HPO4, 1.8 mM KH2PO3, 0.14 M 
NaCl, 2.7 mM KCl) or McIlvaine’s buffers (combinations of 0.1 M citric acid and 0.2 M Na2HPO4, 
pH 3, 4, 5, 6). Hydrazine or hydroxylamine (100 mM final concentration) was added where 
appropriate. The samples were incubated for either 1 h or 15 h (o/n) at 23 °C or 37 °C. LC-MS 
samples were prepared by mixing 250 L H2O with 25 L of the reaction mixture and 1 drop of 
TFA. The samples were analyzed by LC-MS by injection of 20 L of the LC-MS sample and the 
applied gradient was 10% → 90% ACN/0.1% aq. TFA. LC-MS results: test-substrate: Rt (min.): 5.60 
(ESI-MS (m/z): 603.7 (M + H+)); cleavage product azide: Rt (min.): 2.71 (ESI-MS (m/z): 182.1 (M + 
H+)); cleavage product phenol: Rt (min.): 4.24 (ESI-MS (m/z): 436.4 (M + H
+)). No signals for 
hydrolyzed substrate was detected in either sample. 
Search for optimal cleavage conditions 
HEK-293T cell lysate (13.5 g protein) was incubated with compound 1 (2.5 M final 
concentration) for 1 h at 37 °C, after which the samples were denatured by addition of 4 L 4× SB 
and boiling for 5 min. The appropriate amount of hydrazine (0, 1, 10, 50, 100 mM final 
concentration) was added and the samples were incubated at 23 °C for 15 h (o/n). After resolving 
of the protein content by 12.5% SDS-PAGE all biotinylated proteins were visualized by Western 
blotting. The blots were blocked with 1% BSA in TBS-Tween 20 (0.1 % Tween 20) for 30 min. at RT, 
hybridized for 1 h with Streptavidin-HRP (1:10,000) in blocking buffer, washed and visualized using 
an ECL+ kit (Amersham Biosciences). 
Pull-down experiments 
HEK-293T cell lysate (containing some 1.3 mg of protein) was incubated with 20 M ABPs 1 or 21 
for 1 h at 37 °C, denatured by boiling for 5 min. with 1% SDS and precipitated with 
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chloroform/methanol (C/M).26 The protein pellet was rehydrated in 180 L 8 M urea/100 mM 
NH4HCO3, reduced with 10 L 90 mM DTT for 30 min. at 37 °C, alkylated with 15 L 200 mM 
iodoacetamide at RT in the dark, cleared by centrifugation at 13,000 g and desalted by C/M. The 
pellet was dispersed in 25 L pull down (PD) buffer (50 mM Tris·HCl pH 7.5, 150 mM NaCl) with 2% 
SDS in a heated (37 °C) sonic bath. Stepwise (3 × 25 L, 4 × 100 L, 1 × 500 L) addition of PD 
buffer afforded a clear solution that was incubated with 50 L MyOne T1 Streptavidin grafted 
magnetic beads (Invitrogen) at RT with vigorous shaking for 1 h. The beads were stringently 
washed with 2 × 300 L PD buffer with 0.1% SDS, 2 × 300 L PD buffer, 2 × 300 L wash buffer I 
(4 M urea/50 mM NH4HCO3), 2 × 300 L wash buffer II (50 mM Tris·HCl pH 7.5, 10 mM NaCl) and 
2 × 300 L water. All 5 samples from ABP 1 were mixed and divided over 8 equal portions. The 
same was done for the 2 samples from ABP 21, which were divided over 3 equal portions. To the 
samples was added 65 L of the appropriate cleavage cocktail (see Figure 3) and the samples were 
shaken for 15 h at RT or at 37 °C. Next, the supernatant was removed, diluted with 20 L 4× 
sample buffer and boiled at 100 °C for 5 min. One sample from ABP 21 was treated directly with 
85 L 1× sample buffer containing 10 M biotin, boiled at 100 °C for 5 min. and stored o/n at 4 
°C. The samples were resolved by 12.5% SDS-PAGE (25 L of each sample was loaded) and all 
proteins were visualized by silverstain. The appropriate bands were cut from the gel and an in-gel 
digestion was performed according to the procedure described in literature.27 
After removal of the supernatant all beads were stringently washed as described above, eluted 
with 85 L 1× sample buffer containing 10 M biotin at 100 °C for 5 min., resolved by SDS-PAGE 
and visualized by silverstain to determine the cleavage efficiency (see Figure 4). 
LC-MS/MS analysis 
Trytic peptides were analyzed on a Surveyor nanoLC system (Thermo) hyphenated to a LTQ-
Orbitrap mass spectrometer (Thermo). Gold and carbon coated emitters (OD/ID = 360/25 m tip 
ID = 5 m), trap column (OD/ID = 360/100 m packed with 25 mm robust Poros®10R2/15 mm 
BioSphere C18 5 m 120 Å) and analytical columns (OD/ID = 360/75 m packed with 20 cm 
BioSphere C18 5 m 120 Å) were from Nanoseparations (Nieuwkoop, The Netherlands). The 
mobile phases (A: 0.1% formic acid/H2O, B: 0.1% formic acid/ACN) were made with ULC/MS grade 
solvents (Biosolve). The emitter tip was coupled end-to-end with the analytical column via a 15 
mm long TFE teflon tubing sleeve (OD/ID 0.3 × 1.58 mm, Supelco, USA) and installed in a 
stainless steel holder mounted in a nanosource base (Upchurch scientific, Idex, USA). General 
mass spectrometric conditions were: an electrospray voltage of 1.8 kV was applied to the emitter, 
no sheath and auxiliary gas flow, ion transfer tube temperature 150 °C, capillary voltage 41 V, tube 
lens voltage 150 V. Internal mass calibration was performed with air-borne protonated 
polydimethylcyclosiloxane (m/z = 445.12002) and the plasticizer protonated dioctyl phthalate 
ions (m/z = 391.28429) as lock mass.28 For shotgun proteomics analysis, 10 L of the samples 
was pressure loaded on the trap column with a 10 L/min flow for 5 min. followed by peptide 
separation with a gradient of 35 min. 5 → 30% B, 15 min. 30 → 60% B, 5 min. A, at a flow of 300 
L/min. split to 250 nL/min. by the LTQ divert valve. For each data dependent cycle, one full MS 
scan (300-2000 m/z) acquired at high mass resolution (60,000 at 400 m/z, AGC target 1 × 106, 
maximum injection time 1,000 ms) in the Orbitrap was followed by 3 MS/MS fragmentations in the 
LTQ linear ion trap (AGC target 5 × 103, max injection time 120 ms) from the three most 
abundant ions.29 MS/MS settings were: collision gas pressure 1.3 mT, normalized collision energy 
35%, ion selection threshold of 500 counts, activation q = 0.25 and activation time of 30 ms. 
Fragmented precursor ions that were measured twice within 10 s were dynamically excluded for 60 
s and ions with z < 2 or unassigned were not analyzed. Data from MS/MS was validated manually. 
Stability of the cleavable linker in blood serum and plasma 
Plasma and serum were collected from blood voluntarily donated by a healthy person. For plasma 
collection: blood was extracted in an EDTA tube and centrifuged for 15 min. at 4,000 g. For serum 
 
152       Chapter 7  
collection no EDTA was used. All experiments were executed in duplo. A volume of 100 L plasma 
or serum was incubated with compound 1 (10 M final concentration) for 15 h at 37 °C. Next, 900 
L of cooled (–20 °C) acetone was added and the samples were kept at –20 °C for 2 h and an 
additional 1 h at –80 °C. This was followed by centrifuging of the samples for 10 min. at 14,000 g, 
after which all acetone was evaporated under reduced pressure. The resulting yellowish pellet was 
extracted with 100 L ACN/H2O/tBuOH (1:1:1) for 5 min. and the samples were analyzed by LC-MS 
(injection of 20 L of the extract, system B, 10% → 90% ACN/0.1% aq. TFA). 
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The research described in this Thesis aims at the development of chemical biology 
research tools to study proteolytic activities of metalloproteases (MMPs and ADAMs) 
and proteasomes. The common thread throughout the Thesis is the use of 
photocrosslinking in combination with activity-based protein profiling. Chapter 1 
describes the properties of the three most commonly applied photophores and 
examples of their use in chemical biology. 
A potent class of MMP/ADAM inhibitors comprise the peptide succinyl 
hydroxamates. Chapter 2 deals with the synthesis of N,O-diprotected succinyl 
hydroxamate building block 1 (Figure 1) and its use in the construction of enantiopure 
peptide hydroxamates in a highly efficient, linear solid-phase peptide synthesis (SPPS) 
protocol. With the aid of this building block, a biotinylated photoreactive probe was 
synthesized, which was applied in the covalent modification and visualization of ADAM-
10. In addition, a library containing 96 inhibitors with general structure 2 was created 
and used to study the inhibitor preference of three metalloproteases (MMP-9, MMP-12 
and ADAM-17) with respect to the substituents at the P2’ and P3’ positions. The 
presented highly efficient method for SPPS of peptide hydroxama
sion of the inhibitor library by incorporation of other (both proteinogenic and non-
proteinogenic) amino acids at all positions. Especially the modification of the P1’ 
substituent will be of great interest, since this position has a big influence on the 
enzyme’s substrate preference.1,2 It should however be noted that modification of this 
site will lead to a change in building block structure and hence a greater synthetic 
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challenge. Extension of the inhibitor arsenal will hopefully lead to more potent, but 
especially more selective inhibitors for the MMP/ADAM family. 
Another interesting modification is the change of the hydroxamic acid zinc binding 
group (ZBG) into a zinc coordinating electrophilic moiety, which would allow for the 
covalent capture of metalloproteases. This concept has proven to be useful in the 
covalent modification of histone deacetylases (HDACs), which represent another class 
of zinc dependent metalloenzymes. For example, it was shown that the epoxyketone 
moiet  is able to coordinate the Zn2+ ion in HDACs and can subsequently trap a nearby 
nucleophile in the active site.3,4 A possible mechanism of action for epoxyketone 
containing MMP inhibitors is shown in Figure 1 (insert).5 As a first attempt 
diastereoisomers 3a and 3b were synthesized. These compounds are analogues of a 
known potent MMP inhibitor, which contains the hydroxamic acid ZBG.6 Unfortunately, 
in a preliminary activity study it was shown that these compounds only display 
inhibitory activity in the millimolar range towards MMP-12. Therefore, variations in the 




Figure 1. Structure of building block 1, used for the construction of a library containing 96 metalloprotease 
inhibitors with general structure 2. The epoxyketone ZBG containing MMP inhibitors 3a,b are supposed to 
form a covalent adduct with the enzyme’s active site via the mechanism shown in the insert. 
The efficiency of photolabelling of ADAM-10 with the photoreactive probe 
described in Chapter 2 proved to be rather modest. Therefore, the effect of moving the 
photophore to the more tightly binding P1’ pocket was studied and this is outlined in 
Chapter 3. The synthesis of building block 4 (Figure 2) and its application in the 
preparation of activity-based probe 5 is described herein. It was further demonstrated 
that 5 is indeed the more efficient MMP/ADAM probe in a head to head comparison 
towards a range of recombinant, purified metalloproteases. It has been shown that the 
use of other photophores in related MMP probes can also lead to efficient labelling.7,8 
However, the structural differences between these probes make mutual comparisons 
difficult. It is therefore of interest to synthesize the aryl azide (6a) and benzophenone 
(6b) analogues of 5 and study the differences with respect to inhibitory potency and 
labelling efficiency. 
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problem is the use of mixed isotope labelling (see Chapter 1). 
For t is, the photoaffinity probe should be designed with incorporation of a stable 
isotope containing moiety. In this respect, a valuable set of stable isotope tags may be 
the 13C-labelled PEG reagents 7a-g (Figure 2),9 which were initially designed as labelling 
reagents for the quantitative analysis of low molecular weight metabolites (intracellular 
amino acids and glutathione) by LC-MS. They can be easily incorporated into an ABP by 
means of a reaction between the activated PFP ester and an amine, both in solution-
phase peptide chemistry and in SPPS. This would allow for the preparation of a set of 
structurally identical probes of different molecular weight, which can be used directly in 
mixed isotope labelling.  
 
One of the most challenging tasks in photoaffinity labelling is the determination of 
the crosslinking site(s). Indeed, despite many efforts, locating the modified fragment 
after incubation and photocrosslinking MMPs with 5 has proven very difficult so far. A 
possible solution to this 
h
 
Figure 2. Structure of photoreactive building block 4, used for the synthesis of MMP/ADAM probe 5. 
Incorporation of the aryl azide or benzophenone photophores will lead to 6a and 6b respectively. The set of 
13C-labelled PEG derivatives 7a-g was used for quantitative analysis of low molecular weight metabolites.9 
The research described in Chapter 4 entails the study towards the effect of 
fluorine incorporation into proteasome inhibitors on their specificity towards the 
differ
fluori e incorporation, especially at the P2 site, led to a large decrease in potency 
towards the 1 and 2 subunits and hence resulted in selectivity for 5. Tripeptide 
epoxyketone 10 was identified as one of the most 5 selective inhibitors known to date 
and was subsequently converted into fluorescent probe 11, which can be used for 
specific labelling and visualization of the 5 subunit. 
It will be of interest to study the effect of fluorine incorporation at the P1 position, 
since this substituent is of great importance for substrate specificity. Also, the use of 
other fluorinated amino acids can give rise to improved (5) selectivity. Especially 
fluorinated leucine (Hfl, Leu(F6), Figure 3)
10,11 will be of interest, since it serves as a good, 
 
ent subunits. It was found that substitution of non-fluorinated Phe in peptide 
boronic ester 8 (Figure 3) with fluorinated versions (see insert) does not affect the 
selectivity. In addition, a set of peptide epoxyketones 9 was prepared, in which either 
one or both of the P2 and P3 positions is fluorinated. Interestingly, it was shown that 
n
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Figure 3. Structures of fluorinated proteasome inhibitors. 
structurally similar, substitute for leucine, which is commonly used in proteasome 
inhibitors. 
The development of selective inhibitors for the proteasome’s trypsin-like sites (2) 
with good cell penetrating properties is outlined in Chapter 5. Selectivity for 2 was 
achieved by instalment of basic side chain residues in the P1 position of tripeptide 
vinylsulfones and epoxyketones. Incorporation of a 4-aminomethylene phenylalanine 
analogue at this position resulted in compound 12 (Figure 4), which showed high 
inhibitory potency and selectivity for 2, both in cell extracts and in living cells. 
Attachment of this 4-aminomethylene-Phe-vinylsulfone warhead to the 3-hydroxy-2-
methylbenzoyl-Val-Ser motif further increased 2 selectivity and even resulted in 
selectivity for 2 over its immuproteasome counterpart 2i. 
 
 
Figure 4. Structures of proteasome inhibitors functionalized with an amine at the P1 site and the use of this 
modification in SPPS. 
It will be of interest to study the effect of incorporating the 4-aminobenzyl moiety 
in other peptide inhibitors. For example, incorporating the 2 directing substituent into 
1,5 selective proteasome inhibitor Bortezomib (resulting in compound 13) can lead to 
interesting insights into the selectivity determining part of the inhibitor. In addition, 
incorporation of 4-aminomethylene-Phe at the P3 position, resulting in 14, can lead to 
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an even higher selectivity for 2, since it was shown that the substituent at the P3 
position is also of great importance in subunit selectivity.12 It should be noted that this 
added basic residue may interfere with cell permeability. An interesting feature of the 
side-chain amine functionality is that it allows for an easy, linear SPPS of inhibitor 
libraries. For example, vinyl sulfone 15 (Figure 4) can be attached to a solid support via 
its side-chain amine, giving 16, after which a peptide chain can be build up at the N-
terminus. A subsequent cleavage step will then result in inhibitors with general structure 
17. 
Chapter 6 deals with the study towards the orientation of extended peptide 
vinylsulfones inside the proteasome’s catalytically active cavity. The study combined 
activity-based modification, by means of a warhead, with photocrosslinking. A panel of 
bifunctional two-step probes, comprising of an extended peptide vinylsulfone equipped 
with a N-terminal photophore, was prepared. Of these probes, compound 18 (Figure 5) 
was able to establish a crosslink between the active 5 subunit and a neighbouring 6 
subunit, which could be identified by subsequent SDS-PAGE and LC-MS/MS analysis. 
Although these results showed the applicability of this approach, it still needs 
improvements in order to be used in studies towards an inhibitor’s orientation within 
the proteasome’s active 20S core particle. The use of longer photoreactive probes, for 
example compounds 19 and 20, may be of interest in this respect and can lead to a 
more complete picture of the interactions of an inhibitor with the proteasome’s internal 
structure in general. Besides the spacer length, also a change of its nature, for instance 
by introduction of a more hydrophilic (PEG) or a more rigid spacer, can lead to 
interesting structural insights. This may well be combined with stable isotope 
incorporation, for example 13C labelled PEG spacers (modified versions of the PEG 




Figure 5. Structures of photoreactive proteasome probes. 
The design and preparation of a novel cleavable linker system, based on the 
levulinoyl ester, is described in Chapter 7. The cleavable linker was incorporated into 
potent proteasome inhibitor epoxomicin and attachment of biotin resulted in ABP 21 
(Figure 6). The optimal characteristics, in terms of stability and cleavability, of this linker 
system were reflected by the use of 21 for pull-down of proteasome active subunits 
from a cell lysate. Subsequent treatment with hydrazine allowed a chemoselective 
release of 21-derived bound proteins. It was shown that the cleavable linker is well 
compatible with transformations often applied in chemical biology research, including 
click chemistry and Staudinger-Bertozzi ligation. In order to asses proteomics-wide 
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applicability of the system, it needs to be used for the enrichment of other enzymes as 
well. In this respect, compound 22 was synthesized, in which the cleavable linker moiety 
was incorporated into DCG-04, for the ABPP of cysteine proteases.13 However, this 
compound remains to be tested. 
 
 
Figure 6. Structures of proteasome probe 21 and cysteine protease probe 22 containing the levulinoyl ester-
based cleavable linker system. 
The ease of cleavage of this linker system under relatively mild conditions and the 
fact that excess hydrazine can be easily removed by evaporation make that the use of 
this cleavable linker is not limited to activity-based enrichment of enzymes. For 
example, the linker system may find its use in affinity-based chromatography, or solid-
phase extraction (SPE), of proteins. In addition, the synthetic strategy of the linker 
system allows for a straightforward modification of levulinic acid. A possible application 
of this can be in the field of (automated) solid-phase oligosaccharide synthesis.14,15 This 
technique is used for the synthesis of oligosaccharides from their monomeric building 
blocks on a solid support, analogous to SPPS. The levulinoyl ester is often used as a 
temporal protecting group herein, because of the possibility to be cleaved orthogonally 
in the presence of other (permanent) protecting groups. A major difficulty in solid-phase 
oligosaccharide synthesis is the lack of straightforward methods to determine the 
loading of the resin, which indicates the coupling efficiency or yield. A possible solution 
for this is shown in Scheme 1. A click reaction of 9H-fluorene alkyne 23, easily prepared 
from fluorene and the appropriate terminal alkyne halide,16 with azido modified levulinic 
acid 24 (see Chapter 7) results in compound 25 (termed FLev). Subsequent 
condensation with 26 gives fully protected monomeric sugar building block 27, which 
can be applied in solid-phase oligosaccharide synthesis. For example, a coupling 
between immobilized sugar 28 with donor 27 results in immobilized disaccharide 29. 
Treatment of this construct with hydrazine results in a FLev deprotection and 
concomitant formation of fluorene containing compound 31. Measuring the UV 
absorbance ( = 301 nm) of the filtrate leads to the determination of the concentration 
of this species and hence, the loading on the solid support, which is analogous to Fmoc 
determination in SPPS. 
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R = permanent protecting group  
Experimental section 
General  
Tetrahydrofuran was distilled over LiAlH4 before use. Acetonitrile (ACN), dichloromethane (DCM), 
N,N-dimethylformamide (DMF), methanol (MeOH), diisopropylethylamine (DiPEA) and 
trifluoroacetic acid (TFA) were of peptide synthesis grade, purchased at Biosolve, and used as 
received. All general chemicals (Fluka, Fischer, Merck, Sigma-Aldrich) were used as received. O-
(1H-6-Chlorobenzotriazolyl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HCTU) was 
purchased at Iris Biotech (Marktrewitz, Germany). [1-13C1]acetic acid and [1,2-
13C2]acetic acid were 
from Buchem b.v.. [1-13C1]bromoacetic acid and [1,2-
13C2]bromoacetic acid were prepared from [1-
13C1]acetic acid and [1,2-
13C2]acetic acid via a reported procedure.
17 Amberlite IR120 H resin 
(Acros) was rinsed with MeOH (4×) and Et2O (4×) before use. Traces of water were removed from 
reagents used in reactions that require anhydrous conditions by coevaporation with toluene. 
Solvents that were used in reactions were stored over 4 Å molecular sieves, except methanol and 
acetonitrile, which were stored over 3 Å molecular sieves. Column chromatography was performed 
on silicagel (Screening Devices b.v.) with a particle size of 40-63 m and a pore size of 60 Å. 
Automated column chromatography was performed on a CombiFlash Companion with a Silicycle 
FLH-R10030B-ISO12 Sillaflash 12 g cartridge. The eluents toluene, ethyl acetate and petroleum 
ether (40-60 °C boiling range) were distilled prior to use. TLC analysis was conducted on Merck 
aluminium sheets (Silica gel 60 F254). Compounds were visualized by UV absorption (254 nm), by 
spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L) and (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% 
sulfuric acid, a solution of KMnO4 (20 g/L) and K2CO3 (10 g/L) in water, or ninhydrin (0.75 g/L) and 
acetic acid (12.5 ml/L) in ethanol, where appropriate, followed by charring at ca. 150 °C. 1H- and 
13C-NMR spectra were recorded on a Jeol JNM-FX-200 (200 MHz), a Bruker AV-400 (400 MHz) or a 
Bruker DMX-600 (600 MHz) spectrometer. Chemical shifts are given in ppm () relative to 
tetramethylsilane, CDCl3 or CD3OD as internal standard. High resolution mass spectra were 
recorded by direct injection (2 L of a 2 M solution in water/acetonitrile; 1/1; v/v and 0.1% formic 
acid) on a mass spectrometer (Thermo Finnigan LTQ Orbitrap) equipped with an electrospray ion 
source in positive mode (source voltage 3.5 kV, sheath gas flow 10, capillary temperature 250 °C) 
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with resolution R = 60,000 at m/z = 400 (mass range m/z = 150-2,000) and dioctylpthalate (m/z 
= 391.28428) as a “lock mass”. The high resolution mass spectrometer was calibrated prior to 
measurements with a calibration mixture (Thermo Finnigan). Optical rotations  were recorded 
on a Propol automatic polarimeter at room temperature. LC-MS analysis was performed on a 
Jasco HPLC system with a Phenomenex Gemini 3 lm C18 50 × 4.60 mm column (detection 
simultaneously at 214 and 254 nm), coupled to a PE Sciex API 165 mass spectrometer with ESI 
(system A) or on a Finnigan Surveyor HPLC system with a Gemini C18 50 × 4.60 mm column 
(detection at 200-600 nm), coupled to a Finnigan LCQ Advantage Max mass spectrometer with ESI 
(system B). Chiral HPLC analysis was performed on a Spectroflow 757 system (ABI Analytical 
Kratos Division, detection at 254 nm) equipped with a Chiralcel OD column (150  4.6 mm). RP-
HPLC purification was performed on a Gilson HPLC system coupled to a Phenomenex Gemini 5 
m 250  10 mm column and a GX281 fraction collector. Chiral HPLC analysis was performed on a 
Spectroflow 757 system (ABI Analytical Kratos Division, detection at 254 nm) equipped with a 
Chiralcel OD column (150  4.6 mm). 
23][ D
Scheme 2. Synthesis of MMP inhibitors 3a,b equipped with an epoxyketone ZBG. 
 
Reagents and conditions: (a) i) (ClCO)2, cat. DMF, DCM; ii) Pd(PPh3)2Cl2, tributylvinyltin, toluene, 80°C, 81%; (b) 
H2O2, K2CO3, tBuOH, H2O, 45%; (c) i) Pd/C, H2, THF, 0°C; ii) TFA·MePheNHMe, HATU, DiPEA, DMF, 32%, 39%. 
(R)-benzyl 2-isobutyl-4-oxohex-5-enoate (33) 
Carboxylic acid 32 (2.65 g, 10 mmol) was dissolved in DCM (70 mL), put under an argon 
atmosphere and cooled to 0 °C. After addition of a few drops of DMF, oxalyl chloride (4 eq., 5.08 
g, 40 mmol, 3.38 mL) was added to the solution. The mixture was stirred for 15 min. at 0 °C, then 
allowed to warm to room temperature and stirred until CO2 formation seized after 1 h. Toluene 
was added and the solution was concentrated under reduced pressure followed by coevaporation 
three times with toluene. The resulting acyl chloride was dissolved in toluene (35 mL) before 
tributylvinyltin (1.05 eq, 3.07 mL, 3.33 g, 10.5 mmol) and Pd(PPh3)2Cl2 (1 mol%, 70.2 mg, 0.1 mmol) 
were added. The mixture was then stirred for 20 h at 80 °C, a black colour was observed and TLC 
analysis indicated a complete conversion. The solution was allowed to cool to room temperature 
before being concentrated under reduced pressure. The product was obtained after purification 
by column chromatography (0% → 13% Et2O/PE) as a clear yellow liquid (yield: 2.28 g, 8.32 mmol, 
81%) 1H NMR (400 MHz, CDCl3):  = 7.45-7.23 (m, 5H), 6.32 (dd, J = 17.7, 10.4 Hz, 1H), 6.20 (d, J 
= 17.6 Hz, 1H), 5.80 (d, J = 10.4 Hz, 1H), 5.11 (s, 2H), 3.07-2.98 (m, 2H), 2.71-2.62 (m, 1H), 1.69-
1.49 (m, 2H), 1.39-1.23 (m, 1H), 0.92 (d, J = 6.4 Hz, 3H), 0.86 (d, J = 6.3 Hz, 3H) ppm. 13C NMR 
(100 MHz, CDCl3):  = 198.3, 175.3, 136.1, 135.9, 128.3, 128.2, 127.9, 66.1, 41.5, 41.1, 38.2, 25.7, 




(R)-benzyl 4-methyl-2-(2-((S/R)oxiran-2-yl)-2-oxoethyl)pentanoate (34) 
Compound 33 (1.1 g, 4.0 mmol) was dissolved in a mixture of tert-butanol (7.0 mL), hydrogen 
peroxide (2.5 eq, 1 mL, 10 mmol, 30% in H2O) and H2O (3.0 mL), before being cooled to 0 °C. An 
aqueous saturated solution of K2CO3 (344 L) was added dropwise and the reaction was stirred for 
1 h at 0 °C. The mixture was then allowed to warm to room temperature and stirred until TLC 
analysis indicated complete conversion after 2.5 h. Water was added to dilute the solution before 
being extracted three times with Et2O. The organic layers were combined, dried over anhydrous 
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MgSO4 and concentrated under reduced pressure. The crude mixture was then purified by column 
chromatography (3% → 8% EtOAc/PE) yielding 316 mg (1.09 mmol) of one diastereoisomer and 
210 mg (0.72 mmol) of the other diastereoisomer. The total yield was 326 mg (1.81 mmol, 45.3%). 
Diastereoisomer A: 1H NMR (400 MHz, CDCl3):  = 7.42-7.28 (m, 5H), 5.16-4.99 (m, 2H), 3.42-3.33 
(m, 1H), 3.09-2.96 (m, 1H), 2.95-2.88 (m, 2H), 2.69 (dd, J = 18.2, 10.2 Hz, 1H), 2.37 (dd, J = 18.2, 
4.1 Hz, 1H), 1.63-1.49 (m, 2H), 1.35-1.21 (m, 1H), 0.91 (d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.2 Hz, 3H) 
ppm. 13C NMR (100 MHz, CDCl3):  = 206.2, 175.2, 135.8, 128.4, 128.1, 128.0, 66.3, 53.6, 45.8, 
41.0, 37.7, 37.6, 25.6, 22.3, 22.2 ppm.  = +56.6° (c = 1 in CHCl3). HRMS: calcd. for C17H22O4 
[M + H]+: 291.15909; found: 291.15917. Diastereoisomer B: 1H NMR (400 MHz, CDCl3):  = 7.39-
7.25 (m, 5H), 5.11(s, 2H), 3.42-3.38 (m, 1H), 3.02-2.81 (m, 3H), 2.79 (d, J = 5.7 Hz, 1H), 2.40 (dd, J 
= 17.9, 4.4 Hz, 1H), 1.63-1.47 (m, 2H), 1.33-1.21 (m, 1H), 0.90 (d, J = 5.8 Hz, 3H), 0.85 (d, J = 5.7 
Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3):  = 205.4, 174.9, 135.7, 128.3, 128.0, 127.9, 66.2, 53.1, 
46.0, 40.8, 38.9, 37.7, 25.6, 22.3, 22.1 ppm.  = –12.6° (c = 1 in CHCl3). HRMS: calcd. for 
C17H22O4 [M + H]





phenylpropanoic acid (3a) 
Compound 34 (156 mg, 0.54 mmol) was dissolved in THF (4 mL), put under an argon atmosphere 
and cooled to 0 °C. Next, 10% Pd/C was added and the mixture was subjected to hydrogen at 0 °C 
until TLC analysis indicated complete consumption of starting material after 4 h. The argon 
atmosphere was restored and the solution was diluted with 2 mL of DMF. HATU (1.2 eq., 246 mg, 
0.65 mmol) and DiPEA (3.2 eq., 285 L, 1.72 mmol) were added and the mixture was preactivated 
for 10 min. Next, a solution of Me-Phe-NHMe TFA salt (2 eq., 331 mg, 1.08 mmol) and DiPEA (2 
eq., 178 L, 1.08 mmol) in DMF (4 mL) was added and the mixture was stirred overnight while 
being allowed to slowly warm to room temperature. TLC analysis indicated the appearance of 
several spots, including one major spot at RF 0.44 (50% EtOAc/PE). The mixture was filtrated over 
glassfiber patches and concentrated under reduced pressure. The residue was dissolved in DCM 
and washed with aqueous 1 M HCl, three times with a saturated aqueous NaHCO3 solution and 
once with brine. The organic layer was dried over anhydrous MgSO4 and concentrated under 
reduced pressure. The product was isolated after purification by column chromatography (20% → 
40% EtOAc/toluene) yielding 64.7 mg (0.17 mmol, 32%) of the title compound. 1H NMR (400 MHz, 
CDCl3, exists as a mixture of two rotamers):  = 7.71 (d, J = 4.1 Hz, 0.5H), 7.35-7.08 (m, 5H), 6.08 
(d, J = 4.1 Hz, 0.5H), 4.82 (t, J = 7.1 Hz, 0.5H), 4.46 (dd, J = 10.3, 3.6 Hz, 0.5H), 3.62 (dd, J = 14.5, 
3.6 Hz, 0.5H), 3.41-3.28 (m, 1.5H), 3.15-3.04 (m, 1.5H), 3.01 (dd, J = 6.5, 3.9 Hz, 1H), 2.97 (s, 
1.5H), 2.95 (d, J = 4.6 Hz, 2.5H), 2.86 (s, 1.5H), 2.86-2.83 (m, 0.5H), 2.73 (d, J = 4.9 Hz, 2H), 2.64 
(dd, J = 18.4, 10.0 Hz, 0.5H), 2.34 (dd, J = 18.5, 3.4 Hz, 1H), 1.55-1.42 (m, 0.5H), 1.42-1.29 (m, 
0.5H), 1.29-1.18 (m, 1H), 0.89 (d, J = 6.6 Hz, 1.5H), 0.86-0.76 (m, 2H), 0.61 (d, J = 6.6 Hz, 1.5H), 
0.59 (d, J = 6.6 Hz, 1.5H), –0.19 (ddd, J = 14.2, 11.3, 1.5 Hz, 0.5H) ppm. 13C NMR (100 MHz, 
CDCl3, exists as a mixture of two rotamers):  = 210.6, 207.6, 176.1, 175.8, 170.4, 169.9, 138.3, 
137.7, 129.5, 129.1, 128.9, 128.4, 126.9, 126.4, 63.3, 60.6, 53.8, 53.6, 46.4, 46.0, 40.7, 38.7, 38.2, 
37.8, 34.4, 33.9, 33.8, 33.4, 29.8, 26.7, 26.1, 25.5, 24.5, 23.3, 23.3, 21.6, 19.9 ppm.  –65.8° (c 
= 1 in CHCl3). LC-MS: gradient 10% → 90% ACN(0.1% TFA/H2O): Rt (min): 7.49. HRMS: calcd. for 
C21H30N2O4 [M + H]




phenylpropanoic acid (3b) 
Synthesized from its other diastereoisomer following the procedure described for compound 3a. 
The compound was obtained in a yield of 114 mg (0.30 mmol, 39%). 1H NMR (400 MHz, CDCl3, 
exists as a mixture of rotamers):  = 7.75 (d, J = 3.9 Hz, 0.5H, 7.33-7.12 (m, 5H), 6.16 (d, J = 4.1 
Hz, 0.5H), 4.91 (t, J = 7.6 Hz, 0.5H), 4.46 (dd, J = 10.3, 3.5 Hz, 0.5H), 3.63 (dd, J = 14.5, 3.5 Hz, 
0.5H), 3.43 (ddd, J = 25.1, 4.6, 2.4 Hz, 1H), 3.38-3.32 (m, 0.5H), 3.17-3.02 (m, 1.5H), 2.98 (d, J = 
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3.2 Hz, 1.5H), 3.01-2.94 (m, 1.5H), 2.93 (d, J = 4.7 Hz, 1.5H), 2.89 (d, J = 5.9 Hz, 1.5H), 2.85-2.79 
(m, 0.5H), 2.79-2.75 (m, 1.5H), 2.74 (d, J = 4.9 Hz, 1.5H), 2.40 (ddd, J = 23.0, 18.8, 3.8 Hz, 1H), 
1.53-1.40 (m, 0.5H), 1.40-1.29 (m, 0.5H), 1.29-1.19 (m, 1H), 0.94-0.86 (m, 2H), 0.83 (d, J = 6.5 Hz, 
1.5H), 0.61 (d, J = 1.5 Hz, 1.5H), 0.59 (d, J = 1.5 Hz, 1.5H), –0.16 (ddd, J = 14.2, 11.3, 3.1 Hz, 
0.5H) ppm. 13C NMR (100 MHz, CDCl3, exists as a mixture of rotamers)  = 209.2, 176.1, 175.6, 
170.4, 169.9, 138.3, 137.6, 129.5, 129.1, 128.9, 128.4, 126.9, 126.5, 63.4, 53.0, 47.0, 46.5, 40.7, 
40.1, 39.9, 38.6, 34.5, 34.0, 33.9, 33.5, 29.9, 26.8, 26.1, 25.7, 24.6, 23.3, 23.2, 21.9, 19.9 ppm. 
 –100.9° (c = 1 in CHCl3). LC-MS: gradient 10% → 90% ACN(0.1% TFA/H2O): Rt (min): 7.28. 
HRMS: calcd. for C21H30N2O4 [M + H]
+: 375.22783; found: 375.22786. 
23][ D
Scheme 3. Synthesis of 13C-labelled PEG-OPFP derivatives 7a-g. 
 
The asterisks (*) indicate the positions of 13C atoms. Reagents and conditions: (a) i) 12C2, 1-13C1, 1,2-13C2-
BrAcOH, NaH, NaI, THF; ii) LiAlH4, 15 minutes, then 2M NaOH (aq.), 75-95%; (b) i) 12C2, 1-13C1, 1,2-13C2-
BrAcOH, NaH, NaI, THF; ii) Amberlite H+; (c) PFPOH, EDC, DCM, 55-60% over two steps. 
General procedure A: extension of the PEG chain by one ethyleneglycol unit 
To a solution of the alcohol (1 eq.), bromoacetic acid (either 12C2, 1-
13C1 or 1,2-
13C2, 1.2 eq.) and 
NaI (0.01 eq.) in THF (5 mL/mmol) was carefully added NaH (60% in mineral oil, 4 eq.) in portions. 
After complete conversion of the alcohol (monitored by TLC analysis, usually after 2 h) LiAlH4 (2.5 
eq.) was carefully added in portions. The reaction was stirred for 30 min. after which NaOH (as a 
2M aqueous solution, 2.5 eq.) was added dropwise. After 15 min. of stirring Et2O (5 mL/mmol) and 
MgSO4 were added. The reaction was stirred vigorously for another 5 min., after which the solid 
was filtrated over Celite. The filtrate was concentrated under reduced pressure and the resulting 
crude product was purified by column chromatography (100% EtOAc → 15% MeOH/EtOAc). 
General procedure B: reaction of a PEG chain alcohol with bromoacetic acid followed by 
acidic work-up 
To a solution of the alcohol (1 eq.), bromoacetic acid (either 12C2, 1-
13C1 or 1,2-
13C2, 1.2 eq.) and 
NaI (0.01 eq.) in THF (5 mL/mmol) was carefully added NaH (60% in mineral oil, 4 eq.) in portions. 
After complete conversion of the alcohol (monitored by TLC analysis, usually after 2 h) Amberlyte 
IR120 H resin and Et2O (2 mL/mmol) were added. After 30 min. of stirring all solids and the resin 
were filtered off over Celite and the filtrate was concentrated under reduced pressure. The crude 
product was subjected to the next step (general procedure C) without further purification. 
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General procedure C: conversion of the carboxylic acid to the pentafluorophenyl ester 
The obtained (crude) carboxylic acid (obtained in general procedure B, 1 eq.) was dissolved in 
DCM (5 mL/mmol). To this solution were added pentafluorophenol (2 eq.) and EDC (2 eq.) and the 
reaction was stirred for 2 h. The mixture was then concentrated under reduced pressure and the 
product was purified by automated column chromatography (10% → 80% EtOAc/PE). 
 
[13-13C]2,5,8,11-tetraoxatridecan-13-ol 
Prepared according to general procedure A, starting from 2-(2-(2-methoxyethoxy)ethoxy)ethanol 
(210 mg, 1.28 mmol). The product was obtained as a colourless liquid (yield: 199 mg, 0.95 mmol, 
74%). 1H-NMR (200 MHz, CDCl3):  = 3.70 (dt, J = 150, 4.5 Hz, 2H), 3.70-3.53 (m, 14H), 3.39 (s, 
3H), 2.61 (bs, 1H) ppm. 13C-NMR (50 MHz, CDCl3):  = 61.72 ppm. 
 
[12,13-13C2]2,5,8,11-tetraoxatridecan-13-ol 
Prepared according to general procedure A, starting from 2-(2-(2-methoxyethoxy)ethoxy)ethanol 
(210 mg, 1.28 mmol). The product was obtained as a colourless liquid (yield: 194 mg, 0.92 mmol, 
72%). 1H-NMR (200 MHz, CDCl3):  = 3.70 (dt, J = 150, 4.5 Hz, 2H), 6.67 (dt, J = 150, 4.5 Hz, 2H), 
3.70-3.53 (m, 12H), 3.40 (s, 3H), 2.72 (bs, 1H) ppm. 13C-NMR (50 MHz, CDCl3):  = 72.53 (d, J = 41 
Hz), 61.70 (d, J = 41 Hz) ppm.    
 
[1,2-13C2]2-(2-(2-methoxyethoxy)ethoxy)ethanol 
Prepared according to general procedure A, starting from 2-(2-methoxyethoxy)ethanol (310 mg, 
2.58 mmol). The product was obtained as a colourless liquid (yield: 398 mg, 2.39 mmol, 93%). 1H-
NMR (200 MHz, CDCl3):  = 3.73 (dt, J = 142, 4.7 Hz, 2H), 3.62 (dm, J = 139 Hz, 2H), 3.69-3.53 
(m, 8H), 3.38 (s, 3H), 2.68 (bs, 1H) ppm. 13C-NMR (50 MHz, CDCl3):  = 72.47 (d, J = 39 Hz), 61.61 
(d, J = 41 Hz) ppm. 
 
[9,10,12,13-13C4]2,5,8,11-tetraoxatridecan-13-ol 
Prepared according to general procedure A, starting from [1,2-13C2]2-(2-(2-
methoxyethoxy)ethoxy)ethanol (398 mg, 2.39 mmol). The product was obtained as a colourless 
liquid (yield: 444 mg, 2.09 mmol, 87%). 1H-NMR (200 MHz, CDCl3):  = 4.11-3.96 (m, 4H), 3.67-
3.53 (m, 8H), 3.40 (s, 3H), 3.38-3.24 (m, 4H), 2.61 (bs, 1H) ppm. 13C-NMR (50 MHz, CDCl3):  = 
72.30 (d, J = 41 Hz), 70.18, 61.45 (d, J = 39 Hz) ppm. 
 
[16-13C]2,5,8,11,14-pentaoxahexadecan-16-oic acid 
Prepared according to general procedure B, starting from 2,5,8,11-tetraoxatridecan-13-ol (206 mg, 
0.99 mmol). 1H-NMR (200 MHz, CDCl3):  = 4.10 (d, J = 4.0 Hz, 2H), 3.74-3.55 (m, 16H), 3.38 (s, 
3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 173.83 ppm. LC-MS (system B): gradient 0% → 20% 
ACN/(0.1% TFA/H2O): Rt (min): 8.35 (ESI-MS (m/z): 268.1 (M + H+)). 
   
[15,16-13C2]2,5,8,11,14-pentaoxahexadecan-16-oic acid 
Prepared according to general procedure B, starting from 2,5,8,11-tetraoxatridecan-13-ol (201 mg, 
0.97 mmol). 1H-NMR (200 MHz, CDCl3):  = 4.19 (dd, J = 145, 4.5 Hz, 2H), 3.80-3.57 (m, 16H), 
3.39 (s, 3H). 13C-NMR (50 MHz, CDCl3):  = 171.95 (d, J = 56 Hz), 68.78 (d, J = 56 Hz) ppm. LC-MS 




Prepared according to general procedure B, starting from [13-13C]2,5,8,11-tetraoxatridecan-13-ol 
(199 mg, 0.95 mmol). 1H-NMR (200 MHz, CDCl3):  = 4.15 (dt, J = 145, 4.4 Hz, 2H), 3.73 (dm, J = 
145 Hz, 2H), 3.72-3.54 (m, 14H), 3.39 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 172.13 (d, J = 
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58 Hz), 70.78, 68.86 (d, J = 59 Hz) ppm. LC-MS (system B): gradient 0% → 20% ACN/(0.1% 
TFA/H2O): Rt (min): 8.37 (ESI-MS (m/z): 270.3 (M + H+)). 
 
[12,13,15,16-13C4]2,5,8,11,14-pentaoxahexadecan-16-oic acid 
Prepared according to general procedure B, starting from [12,13-13C2]2,5,8,11-tetraoxatridecan-13-
ol (194 mg, 0.92 mmol). 1H-NMR (200 MHz, CDCl3):  = 4.21 (dt, J = 145, 4.4 Hz, 2H), 3.73 (dm, J 
= 144 Hz, 2H), 3.80-3.57 (m, 14H), 3.40 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 172.25 (d, J = 
58 Hz), 71.63, 69.90, 69.00 (d, J = 56 Hz) ppm. LC-MS (system B): gradient 0% → 20% ACN/(0.1% 
TFA/H2O): Rt (min): 8.37 (ESI-MS (m/z): 271.3 (M + H+)). 
 
[9,10,12,13,16-13C5]2,5,8,11,14-pentaoxahexadecan-16-oic acid 
Prepared according to general procedure B, starting from [9,10,12,13-13C4]2,5,8,11-
tetraoxatridecan-13-ol (222 mg, 1.04 mmol). 1H-NMR (200 MHz, CDCl3):  = 4.20-3.99 (m, 6H), 
3.67-3.57 (m, 8H), 3.48-3.33 (m, 4H), 3.39 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 172.31, 
71.88, 70.90, 70.33, 69.42 ppm. LC-MS (system A): gradient 0% → 20% ACN/(0.1% TFA/H2O): Rt 
(min): 7.59 (ESI-MS (m/z): 272.0 (M + H+)). 
 
[9,10,12,13,15,16-13C6]2,5,8,11,14-pentaoxahexadecan-16-oic acid 
Prepared according to general procedure B, starting from [9,10,12,13-13C4]2,5,8,11-
tetraoxatridecan-13-ol (222 mg, 1.04 mmol). 1H-NMR (200 MHz, CDCl3):  = 4.18 (dt, J = 145 Hz, 
4.4 Hz, 2H), 4.12-3.99 (m, 4H), 3.67-3.47 (m, 8H), 3.39 (s, 3H), 3.37-3.29 (m, 4H) ppm. 13C-NMR 
(50 MHz, CDCl3):  = 172.45 (d, J = 56 Hz), 71.88, 70.94, 70.36, 69.60 ppm. LC-MS (system A): 
gradient 0% → 20% ACN/(0.1% TFA/H2O): Rt (min): 7.63 (ESI-MS (m/z): 273.1 (M + H+)). 
 
Perfluorophenyl 2,5,8,11,14-pentaoxahexadecan-16-oate (7a) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 
230 mg, 0.53 mmol, 58% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (s, 2H), 3.85-3.55 (m, 
16H), 3.39 (s, 3H) ppm. 13C-NMR (150 MHz, CDCl3):  = 166.30, 140.75 (dd, J = 243, 12.0 Hz), 
139.28 (dt, J = 252, 13.5 Hz), 137.41 (dt, J = 256, 15.0 Hz), 124.15 (t, J = 14.0 Hz), 71.46, 70.76, 
70.12, 70.11, 70.01, 67.33, 51.18 ppm. LC-MS (system B):  gradient 10% → 90% ACN/(0.1% 
TFA/H2O): Rt (min): 7.05 (ESI-MS (m/z): 433.1 (M + H+)). HRMS: calcd. for C17H21F5O7 [M + H]+: 
433.12802; found: 433.12818. 
 
Perfluorophenyl [16-13C]2,5,8,11,14-pentaoxahexadecan-16-oate (7b) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 
226 mg, 0.52 mmol, 54% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (d, J = 4.4 Hz, 2H), 
3.84-3.52 (m, 16H), 3.38 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 166.67 ppm. LC-MS (system 
B): gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 7.32 (ESI-MS (m/z): 434.0 (M + H+)). 
HRMS: calcd. for C16
13CH21F5O7 [M + H]
+: 434.13138; found: 434.13145. 
 
Perfluorophenyl [15,16-13C2]2,5,8,11,14-pentaoxahexadecan-16-oate (7c) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 
223 mg, 0.51 mmol, 52% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (dd, J = 145, 4.7 Hz, 
2H), 3.86-3.52 (m, 16H), 3.38 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 166.64 (d, J = 64 Hz), 
67.87 (d, J = 64 Hz) ppm. LC-MS (system B): gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 
7.33 (ESI-MS (m/z): 435.0 (M + H+)). HRMS: calcd for C1513C2H21F5O7 [M + H]+: 435.13473; found: 
435.13482. 
 
Perfluorophenyl [13,15,16-13C3]2,5,8,11,14-pentaoxahexadecan-16-oate (7d) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 67 
mg, 0.15 mmol, 21% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (dt, J = 145, 4.8 Hz, 2H), 
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3.76-3.43 (m, 16H), 3.38 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 166.64 (d, J = 64 Hz), 71.27, 
67.84 (d, J = 64 Hz) ppm. LC-MS (system B): gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 
7.05 (ESI-MS (m/z): 436.0 (M + H+)). HRMS: calcd. for C1413C3H21F5O7 [M + H]+: 436.13808; found: 
436.13816. 
 
Perfluorophenyl [12,13,15,16-13C4]2,5,8,11,14-pentaoxahexadecan-16-oate (7e) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 
147 mg, 0.34 mmol, 37% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (dt, J = 146, 4.7 Hz, 
2H), 3.79 (dm, J = 145 Hz, 2H), 3.67-3.50 (m, 14H), 3.38 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  
= 166.67 (d, J = 63 Hz), 71.06, 70.84, 67.84 (d, J = 64 Hz) ppm. LC-MS (system B): gradient 10% 
→ 90% ACN/(0.1% TFA/H2O): Rt (min): 7.03 (ESI-MS (m/z): 437.1 (M + H+)). HRMS: calcd. for 
C13
13C4H21F5O7 [M + H]
+: 437.14144; found: 437.14157. 
 
Perfluorophenyl [9,10,12,13,16-13C5]2,5,8,11,14-pentaoxahexadecan-16-oate (7f) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 
230 mg, 0.53 mmol, 53% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (t, J = 4.7 Hz, 2H), 
4.19-3.93 (m, 4H), 3.66-3.32 (m, 12H), 3.38 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 166.64, 
71.06, 70.87, 70.60 ppm. LC-MS (system B): gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 
7.05 (ESI-MS (m/z): 438.1 (M + H+)). HRMS: calcd. for C1213C5H21F5O7 [M + H]+: 438.14479; found: 
438.14491. 
 
Perfluorophenyl [9,10,12,13,15,16-13C6]2,5,8,11,14-pentaoxahexadecan-16-oate (7g) 
Prepared according to general procedure C. The product was obtained as a colourless oil (yield: 
277 mg, 0.63 mmol, 63% over 2 steps). 1H-NMR (200 MHz, CDCl3):  = 4.55 (dt, J = 146, 4.7 Hz, 
2H), 4.16-4.01 (m, 4H), 3.66-3.32 (m, 12H), 3.38 (s, 3H) ppm. 13C-NMR (50 MHz, CDCl3):  = 
166.67 (d, J = 64 Hz), 71.06, 70.87, 70.60, 67.87 (d, J = 64 Hz) ppm. LC-MS (system B): gradient 
10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 7.05 (ESI-MS (m/z): 439.1 (M + H+)). HRMS: calcd. for 
C11
13C6H21F5O7 [M + H]
+: 439.14815; found: 439.14827. 
Scheme 3. Synthesis of cleavable linker containing cathepsin probe 22. 
 
Reagents and conditions: (a) DiPEA, DMF, 73%; (b) Biotin-Ahx-propargylamide, CuSO4, sodium ascorbate, 
DMF, 34%. 
 




DCG-04 amine 3618 (0.12 g, 0.15 mmol) was dissolved in DMF (3 mL). To this were added NHS 
activated ester 3519 (1.1 eq., 89.0 mg, 0.165 mmol) and DiPEA (1.5 eq., 0.225 mmol, 37 L) and 
the mixture was stirred for 15 h. LC-MS analysis showed complete consumption of starting 
material. The mixture was concentrated in vacuo. The remaining crude oil was crystallized in 
MeOH/Et2O, filtered off and washed with Et2O to give the title compound as a colourless solid 
(yield: 118 mg, 0.11 mmol, 73%). 1H NMR (400 MHz, MeOD):  = 7.02 (d, J = 8.4 Hz, 2H), 7.00 (s, 
2H), 6.69 (d, J = 8.4 Hz, 2H), 4.5-4.4 (m, 2H), 4.3-4.2 (m, 3H), 3.66 (d, J = 1.6 Hz, 1H), 3.58 (d, J = 
1.6 Hz, 1H), 3.14 (t, J = 6.8 Hz, 2H), 3.1-2.8 (m, 12H), 2.61 (t, J = 6.8 Hz, 2H), 2.44 (t, J = 7.6 Hz, 
2H), 2.23 (t, J = 7.4 Hz, 2H), 1.9-1.8 (m, 2H), 1.6-1.1 (m, 15H), 1.36 (t, J = 3.8 Hz, 3H), 1.55 (d, J = 
6.8 Hz, 12H), 0.91 (dd, J = 16.0, 6.0 Hz, 6H) ppm. 13C NMR (100 MHz, MeOD):  = 175.3, 173.7, 
157.3, 141.7, 140.3, 131.4, 128.9, 124.9, 116.2, 63.2, 56.5, 54.4, 54.3, 53.4, 53.2, 51.8, 41.6, 40.2, 
40.0, 39.2, 38.2, 37.8, 36.6, 32.9, 30.0, 29.8, 28.7, 28.5, 27.4, 26.5, 25.9, 24.3, 24.1, 23.3, 22.0, 
14.4 ppm. LC-MS (system B): gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt (min): 8.66 (ESI-MS 







Compound 37 (118 mg, 0.11 mmol) was dissolved in DMF (2 mL). To this were added Biotin-Ahx-
propargylamide19 (1.4 eq., 0.154 mmol, 61.0 mg), 1 M CuSO4 in H2O (22 L) and 1 M sodium 
ascorbate in H2O (33 L) and the mixture was stirred for 15 h, after which LC-MS analysis showed 
complete consumption of starting material. The mixture was concentrated in vacuo and purified 
by RP-HPCL (10% → 90% ACN/0.1% aqueous TFA), which afforded the title compound as a 
colourless solid (yield: 55.0 mg, 38.5 mol, 35%). 1H NMR (400 MHz, MeOD):  = 6.87 (d, J = 8.4 
Hz, 2H), 6.85 (s, 2H), 6.55 (d, J = 8.4 Hz, 2H), 4.4-4.2 (m, 6H), 4.2-4.0 (m, 2H), 3.52 (d, J = 1.6 Hz, 
1H), 3.43 (d, J = 2.0 Hz, 1H), 3.2-2.9 (m, 7H), 2.8-2.6 (m, 15H), 2.55 (d, J = 12.8 Hz, 1H), 2.41 (t, J 
= 6.8 Hz, 2H), 2.30 (t, J = 7.6 Hz, 2H), 1.7-1.1 (m, 28H), 1.16 (t, J = 7.0 Hz, 3H), 1.00 (d, J = 6.8 
Hz, 12H), 0.76 (dd, J = 16.0, 6.0 Hz, 6H) ppm. 13C NMR (100 MHz, MeOD):  = 209.4, 177.2, 
176.2, 176.1, 176.0, 175.2, 173.8, 173.7, 173.1, 168.8, 168.4, 166.1, 160.1, 159.7, 157.3, 145.2, 
141.7, 140.3, 131.4, 128.9, 124.9, 124.5, 116.3, 63.4, 63.2, 61.7, 57.0, 56.5, 54.4, 53.4, 53.2, 50.6, 
41.7, 41.0, 40.2, 39.5, 39.1, 38.2, 37.8, 36.8, 36.7, 35.5, 32.9, 32.8, 30.1, 30.0, 29.8, 29.8, 29.5, 
28.7, 28.5, 27.5, 27.4, 26.9 ppm. LC-MS (system B): gradient 10% → 90% ACN/(0.1% TFA/H2O): Rt 
(min): 7.08 (ESI-MS (m/z): 1470.47 (M + H+)). 
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Moleculair gereedschap om de werking van matrix 










Het in dit proefschrift beschreven onderzoek richt zich op de ontwikkeling van 
moleculair gereedschap of “probes”, waarmee de aanwezigheid en/of de activiteit van 
enzymen in biologische monsters kan worden vastgesteld. In het bijzonder is aandacht 
besteed aan het bestuderen van metalloproteinases (MMPs en ADAMs) en 
proteasomen. Een probe bestaat doorgaans uit drie belangrijke onderdelen: een 
herkennings element om de probe specifiek één enzymfamilie te laten herkennen, een 
label voor de visualisatie/analyse van het gebonden enzym en een reactieve groep voor 
het covalent binden van het enzym. Zogenaamde “activiteitsgebaseerde probes” 
bevatten een reactieve (electrofiele) groep die reageert met een nucleofiel in het actieve 
centrum van het enzym, waarbij een covalente binding ontstaat. Enzymen die voor hun 
katalytische werking onafhankelijk zijn van een nucleofiele groep kunnen niet met 
activiteitsgebaseerde probes worden bestudeerd, omdat er geen covalent gebonden 
constructie ontstaat. Voor dit type enzymen kunnen zongenaamde “affiniteits-
gebaseerde probes” of “fotoreactieve probes” worden gebruikt. Deze probes bevatten 
een speciale groep die door middel van fotochemie een covalente binding kan 
bewerkstelligen, ook wel een fotofoor genoemd. Hoofdstuk 1 beschrijft de 
eigenschappen van de drie meest gebruikte fotoforen alsmede enkele voorbeelden van 
het gebruik ervan in chemisch-biologisch onderzoek. 
Een potente klasse van MMP/ADAM remmers wordt gevormd door de peptide 
succiniyl hydroxamaten. Hoofdstuk 2 behandelt de synthese van een volledig 
beschermde succinyl hydroxamaat bevattende bouwsteen. Deze bouwsteen werd 
gebruikt voor de constructie van chiraal zuivere peptide hydroxamaten in een efficiënt, 
lineair vaste drager peptide synthese protocol. Hiermee werd onder anderen een 
biotine-gekoppelde, fotoreactieve probe (fotolabiele groep op de P2’ positie) 
gesynthetiseerd, welke gebruikt werd voor het covalent modificeren en visualiseren van 
ADAM-10. Daarnaast werd er een bibliotheek, bestaande uit 96 peptide hydroxamaat 
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gebaseerde remmers, gemaakt waarbij de zijgroepen op de P2’ en de P3’ posities van de 
remmers zijn gevarieerd. Deze set van remmers werd vervolgens gebruikt voor het 
bestuderen van de voorkeur van MMP-9, MMP-12 en ADAM-17 voor de verschillende 
type remmers. 
De efficiëntie van het lichtgeactiveerde koppelen van ADAM-10 met de 
fotoreactieve probe beschreven in Hoofdstuk 2 bleek zeer gering te zijn. Om die reden 
werd het verplaatsen van de fotolabiele groep naar de P1’ positie bestudeerd, zoals 
uiteengezet wordt in Hoofdstuk 3. Hiervoor werd eerst een bouwsteen gemaakt, 
analoog aan die beschreven in Hoofdstuk 2, maar voorzien van een 3-aryl-3-
(trifluoromethyl)-3H-diazirine groep. Vervolgens werd deze bouwsteen gebruikt voor de 
synthese van een biotine-gekoppelde, fotoreactieve probe (fotolabiele groep op de P1’ 
positie). De hypothese dat het verplaatsen van de fotolabiele groep naar de P1’ positie 
een efficiëntere labeling zou bewerkstelligen bleek juist te zijn. De beschreven probe 
bleek superieur in het covalent modificeren van verschillende MMPs en ADAMs in 
vergelijking met de eerder beschreven probe (Hoodstuk 2). Een interessante uitkomst 
van deze studie is dat de efficiëntie van het fotogeactiveerde koppelen van een probe 
niet altijd evenredig samenhangt met zijn enzymremmende capaciteiten. 
Het onderzoek beschreven in Hoofdstuk 4 omvat een studie naar het effect van 
het opnemen van fluor in proteasoom remmers op hun specificiteit voor de 
verschillende, katalytisch actieve subunits. Er is gebleken dat het vervangen van 
fenylalanine in een boorester bevattende, potente proteasoom remmer door 
gefluoreerde fenylalanine derivaten geen invloed had op de potentie en de selectiviteit 
van de remmer. Verder werd er een set van tripeptide epoxyketonen vervaardigd, waarbij 
één van beide of beide P2 en P3 posities werden voorzien van een gefluoreerd 
fenylalanine derivaat. Een interessante bevinding bij het analyseren van de 
enzymremmende capaciteiten van deze verbinding, was dat het invoeren van fluor, met 
name op de P2 positie, leidde tot een sterke daling van de affiniteit voor de ‘caspase-
achtige’ (1) en ‘trypsine-achtige’ (2) subunits. Dit resulteerde uiteindelijke in een 
verhoogde selectiviteit voor de ‘chymotrypsine-achtige (5) subunit. Eén specifieke 
verbinding uit deze set kon worden aangemerkt als één van de meest 5 selectieve 
remmers die er vandaag de dag bekend zijn. Deze verbinding werd omgezet in een probe 
door middel van de ‘click’ reactie met een fluorescent bodipy-alkyn groep op het, in de 
verbinding aanwezige, N-terminale azide. Deze probe kon worden gebruikt voor het 
specifiek binden en visualiseren van de 5 subunit. 
De ontwikkeling van selectieve remmers voor de trypsine-achtige site van het 
proteasoom (2) met goede celpenetrerende eigenschappen staat beschreven in 
Hoofdstuk 5. De selectiviteit voor 2 werd bereikt door het installeren van basische 
zijketen residuen in de P1 positie van tripeptide vinylsulfonen en epoxyketonen. Het 
invoeren van een 4-aminomethyleen fenylalanine analoog op deze positie in een 
vinylsulfon resulteerde in een proteasoom remmer met een hoge selectiviteit voor 2, 
zowel in celextracten als in levende cellen. Het koppelen van dit 4-aminomethyleen 
fenylalanine vinylsulfon aan de 2 sturende peptide sequentie (3-hydroxy-2-
methylbenzoyl)-valine-serine zorgde voor een verdere verhoging van de selectiviteit voor 
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2 en resulteerde zelfs in selectiviteit voor 2 ten opzichte van zijn immunoproteasoom 
pendant 2i. 
Hoofdstuk 6 behandelt een studie naar de oriëntatie van verlengde peptide 
vinylsulfonen binnen in de katalytisch actieve holte van het proteasoom. In deze studie 
is het activiteitsgebaseerde modificeren van een enzym met behulp van een reactive, 
electrofiele groep gecombineerd met fotochemisch koppelen. Hiervoor werden in eerste 
instantie drie probes, bestaande uit een verlengd peptide vinylsulfon gekoppeld aan een 
N-terminale fotofoor (diazirine, arylazide en benzofenon), gemaakt. Van deze drie 
verbindingen bleek de arylazide variant als enige in staat om een koppeling tussen de 
actieve 5 subunit en een naburige 6 subunit te bewerkstelligen. Het gehele construct 
kon geïdentificeerd worden door middel van gel electroforese gevolgd door LC-MS/MS 
analyse. 
Het ontwerp en de synthese van een nieuwe selectief splitsbare linker, gebaseerd 
op de levuline ester, is beschreven in Hoofdstuk 7. Een speciaal ontworpen ester van 
levulinezuur en 2,6-diisopropylphenol werd ingebouwd in een activiteitsgebaseerde 
probe, gebaseerd op de potente proteasoom remmer epoxomicin en voorzien van 
biotine. De optimale eigenschappen van deze splitsbare linker, in termen van stabiliteit 
en splitsbaarheid, werden gedemonstreerd aan de hand van het gebruik ervan voor het 
selectief immobiliseren van proteasoom actieve subunits uit een celextract. Een directe 
behandeling van de vaste drager met hydrazine leidde vervolgens tot de selectieve elutie 
van de aan deze probe gebonden eiwitten. Verder bleek de nieuwe splitsbare linker zeer 
goed te combineren met transformaties die veelvuldig toegepast worden in chemisch 
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